<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2608002T3 - 
  Methods and compositions for treating and detecting SOD1 mediated diseases misfolded
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2608002T3/en">
    <meta name="description" content="
   
    A composition suitable for treating amyotrophic lateral sclerosis (ALS), said composition comprising a pharmaceutically acceptable carrier and an agent selected from: (1) an exogenous antibody or a fragment thereof that selectively binds to an epitope consisting of: (a ) IKGLTEGLHGF [DSE5]; (b) GLHGFHVH [DSE7]; or (c) an analog consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration; and (2) an immunogen comprising a peptide of less than 20 residues of SOD1 comprising: a) IKGLTEGLHGF [DSE5]; or b) GLHGFHVH [DSE7]; or c) an analog of a) or b), the analog comprising a modification of an amino acid by oxidation or nitration.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Methods and compositions for treating and detecting SOD1 mediated diseases misfolded
 
     ">
    <meta name="DC.date" content="2007-03-05" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    A composition suitable for treating amyotrophic lateral sclerosis (ALS), said composition comprising a pharmaceutically acceptable carrier and an agent selected from: (1) an exogenous antibody or a fragment thereof that selectively binds to an epitope consisting of: (a ) IKGLTEGLHGF [DSE5]; (b) GLHGFHVH [DSE7]; or (c) an analog consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration; and (2) an immunogen comprising a peptide of less than 20 residues of SOD1 comprising: a) IKGLTEGLHGF [DSE5]; or b) GLHGFHVH [DSE7]; or c) an analog of a) or b), the analog comprising a modification of an amino acid by oxidation or nitration.
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:12161575.1T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/36/68/26/6d7a3599ceed40/ES2608002T3.pdf">
    <meta name="citation_patent_number" content="ES:2608002:T3">
    <meta name="DC.date" content="2017-04-05" scheme="issue">
    <meta name="DC.contributor" content="Neil Cashman" scheme="inventor">
    <meta name="DC.contributor" content="Avijit Chakrabartty" scheme="inventor">
    <meta name="DC.contributor" content="Rishi Rakhit" scheme="inventor">
    <meta name="DC.contributor" content="Joachim Bernhard Ostermann" scheme="inventor">
    <meta name="DC.contributor" content="University Health Network" scheme="assignee">
    <meta name="DC.contributor" content="University of Health Network" scheme="assignee">
    <meta name="DC.contributor" content="Promis Neurosciences Inc" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Methods and compositions for treating and detecting SOD1 mediated diseases misfolded
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA194222092" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composicin adecuada para tratar la esclerosis lateral amiotrfica (ALS), comprendiendo dicha composicin un vehculo farmacuticamente aceptable y un agente seleccionado de: (1) un anticuerpo exgeno o un fragmento del mismo que se une selectivamente a un eptopo que consiste en: (a) IKGLTEGLHGF [DSE5]; (b) GLHGFHVH [DSE7]; o (c) un anlogo que consiste en IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7], comprendiendo el anlogo una modificacin de un aminocido por oxidacin o nitracin; y (2) un inmungeno que comprende un pptido de menos de 20 restos de SOD1 que comprende: a) IKGLTEGLHGF [DSE5]; o b) GLHGFHVH [DSE7]; o c) un anlogo de a) o b), comprendiendo el anlogo una modificacin de un aminocido por oxidacin o nitracin.</span>A composition suitable for treating amyotrophic lateral sclerosis (ALS), said composition comprising a pharmaceutically acceptable carrier and an agent selected from: (1) an exogenous antibody or a fragment thereof that selectively binds to an epitope consisting of: (a ) IKGLTEGLHGF [DSE5]; (b) GLHGFHVH [DSE7]; or (c) an analog consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration; and (2) an immunogen comprising a peptide of less than 20 residues of SOD1 comprising: a) IKGLTEGLHGF [DSE5]; or b) GLHGFHVH [DSE7]; or c) an analog of a) or b), the analog comprising a modification of an amino acid by oxidation or nitration.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result" hidden="">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Peptides Or Proteins"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Peptides Or Proteins
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Medicines That Contain Protein Lipid Enzymes And Other Medicines"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Medicines That Contain Protein Lipid Enzymes And Other Medicines
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Preparation Of Compounds By Using Micro-Organisms"><a id="link" href="/?q=Preparation+Of+Compounds+By+Using+Micro-Organisms&amp;peid=61bc01a919c08%3Ac%3A4e669f4f" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Preparation Of Compounds By Using Micro-Organisms
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Micro-Organisms Or Cultivation Processes Thereof"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Micro-Organisms Or Cultivation Processes Thereof
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Pharmaceuticals Containing Other Organic And Inorganic Compounds"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Pharmaceuticals Containing Other Organic And Inorganic Compounds
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline" style="" hidden="">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2608002T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/36/68/26/6d7a3599ceed40/ES2608002T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;sod1&quot;,&quot;antibody&quot;,&quot;disease&quot;,&quot;specific&quot;,&quot;antibodies&quot;]" data-before="20060303"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2608002T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2608002T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Neil Cashman"><a id="link" href="#" class="style-scope state-modifier">Neil Cashman</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Avijit Chakrabartty"><a id="link" href="#" class="style-scope state-modifier">Avijit Chakrabartty</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Rishi Rakhit"><a id="link" href="#" class="style-scope state-modifier">Rishi Rakhit</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Joachim Bernhard Ostermann"><a id="link" href="#" class="style-scope state-modifier">Joachim Bernhard Ostermann</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    University Health Network
  
                  </dd><dd class="style-scope patent-result">
                    
    University of Health Network
  
                  </dd><dd class="style-scope patent-result">
                    
    Promis Neurosciences Inc
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2007</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2608002T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES12161575.1T</div>
                <div class="style-scope application-timeline">Filing date: 2007-03-05</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK1989308T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK07710682.1T</div>
                <div class="style-scope application-timeline">Filing date: 2007-03-05</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2680020T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES12161564.5T</div>
                <div class="style-scope application-timeline">Filing date: 2007-03-05</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2012</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2013091648A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2012275632A</div>
                <div class="style-scope application-timeline">Filing date: 2012-12-18</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES12161575.1T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2006-03-03</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7439324B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from US11/367,609</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2006-12-01</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7794692B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from US11/565,967</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2007-03-05</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="University Health Network"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by University Health Network, University of Health Network, Promis Neurosciences Inc</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2017-04-05</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2017-04-05</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2608002T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2608002T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2027-03-05</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (1)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (1)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2608002T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2608002/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2608002T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES115220982" lang="EN" load-source="google" class="style-scope patent-text">
  <p id="p00001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00002" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00004" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCION</span>DESCRIPTION</span>
  </p>
  <p id="p00014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodos y composiciones para tratar y detectar enfermedades mediadas por SOD1 mal plegada Campo de la invencion</span>Methods and compositions for treating and detecting SOD1 mediated diseases misfolded Field of the invention</span>
  </p>
  <p id="p00015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencion se refiere a composiciones y su uso en el tratamiento de esclerosis lateral amiotrofica.</span>The invention relates to compositions and their use in the treatment of amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antecedentes de la invencion</span>Background of the invention</span>
  </p>
  <p id="p00017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mal plegamiento y agregacion de protefnas</span>Bad folding and protein aggregation</span>
  </p>
  <p id="p00018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las protefnas pueden plegarse en estructuras complejas y muy compactadas. El plegamiento no es solamente crucial para la actividad biologica, sino que el fallo de las protefnas en plegarse apropiadamente o en permanecer plegadas puede dar lugar a enfermedades (revisado en 48). El mal plegamiento puede causar, en algunos casos, la agregacion de protefnas, que puede dar lugar adicionalmente a depositos concretos extracelularmente (por ejemplo, placas) o intracelularmente (por ejemplo, inclusiones en el citosol o en el nucleo).</span>Proteins can be folded into complex and highly compacted structures. Folding is not only crucial for biological activity, but the failure of proteins to fold properly or remain folded can lead to disease (reviewed in 48). Misfolding can cause, in some cases, the addition of proteins, which can additionally result in specific deposits extracellularly (eg, plates) or intracellularly (for example, inclusions in the cytosol or nucleus).</span>
  </p>
  <p id="p00019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las enfermedades neurodegenerativas, tales como enfermedad de Alzheimer (AD), enfermedad de Parkinson (PD), enfermedad de Huntington (HD), esclerosis lateral amiotrofica (ALS) y enfermedades por priones se caracterizan por depositos neurales de protefna agregada mal plegada (revisado en 49).</span>Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and prion diseases are characterized by neural deposits of misfolded aggregate protein (reviewed in 49).</span>
  </p>
  <p id="p00020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las enfermedades neurodegenerativas, tales como enfermedad de Alzheimer (AD), enfermedad de Huntington, esclerosis lateral amiotrofica (ALS) y enfermedad de Parkinson/demencia con cuerpos de Lewy (PD, LBD) tambien plantean grandes desaffos para nuestra poblacion envejecida y para el sistema de asistencia sanitaria.</span>Neurodegenerative diseases, such as Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosis (ALS) and Parkinson's disease / dementia with Lewy bodies (PD, LBD) also pose major challenges for our aging population and for the system Healthcare</span>
  </p>
  <p id="p00021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AD, ALS y PD/LBD esporadica estan asociadas con acumulacion neural de multfmeros patologicos de polipeptidos mal plegados (estos podrfan ser preferentemente fibrillas, protofilamentos y agregados amorfos), incluyendo el fragmento amiloide beta (Abeta) de la protefna precursora amiloide (APP) en AD; la superoxido dismutasa-1 (SOD1) en ALS, AD y PD, y la alfa-sinuclefna en PD y LBD. Adicionalmente la polineuropatfa amiloidotica familiar (FAP) resulta de la agregacion de transtiretina para formar depositos amiloides. Como con las enfermedades por priones, mutaciones en genes que codifican estos polipeptidos estan asociadas con formas familiares dominantes autosomicas de AD, ALS y PD.</span>AD, ALS and sporadic PD / LBD are associated with neural accumulation of pathological multfomers of misfolded polypeptides (these could preferably be amorphous fibrils, protofilaments and aggregates), including the amyloid beta (Abeta) fragment of the amyloid precursor protein (APP) in AD; superoxide dismutase-1 (SOD1) in ALS, AD and PD, and alpha-synuclefna in PD and LBD. Additionally, familial amyloid polyneuropathy (FAP) results from the addition of transthyretin to form amyloid deposits. As with prion diseases, mutations in genes encoding these polypeptides are associated with autosomal dominant family forms of AD, ALS and PD.</span>
  </p>
  <p id="p00022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ALS y mal plegamiento de protefnas</span>ALS and poor protein folding</span>
  </p>
  <p id="p00023" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La esclerosis lateral amiotrofica (ALS) es una enfermedad neuromuscular mortal que afecta a aproximadamente 30.000 pacientes en Norte America, con 5.000 nuevos casos por ano. En ALS, tambien conocida como "enfermedad de Lou Gehrig", los musculos de las extremidades, para hablar y tragar, y la respiracion se debilitan y atrofian, debido a la degeneracion de las celulas nerviosas motoras que los alimentan desde la medula espinal y el cerebro. La mitad de los pacientes afectados mueren en 3 anos, siendo la supervivencia de mas de 5 anos de menos del 20 %.</span>Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease that affects approximately 30,000 patients in North America, with 5,000 new cases per year. In ALS, also known as "Lou Gehrig's disease", the limb muscles, to talk and swallow, and breathing become weak and stunted, due to the degeneration of motor nerve cells that feed them from the spinal cord and the brain. Half of the affected patients die in 3 years, with survival of more than 5 years of less than 20%.</span>
  </p>
  <p id="p00024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ALS pertenece a una familia de trastornos neurodegenerativos mortales, que incluye enfermedades por priones, enfermedades de Alzheimer y Parkinson, y en que se cree que las protefnas mal plegadas agregadas causan eliminacion progresiva de las celulas cerebrales. Aproximadamente el 20 % de ALS familiar (hereditaria) esta asociada con mutaciones en el gen que codifica la superoxido dismutasa-1 (SOD1), una enzima de defensa de radicales libres intracelular (vease 73 y la Tabla 1 para la lista de mutaciones conocidas). Los depositos intracelulares de SOD1 mal plegada agregada se han observado en ALS familiar, y tambien en la ALS no familiar mas comun (esporadica), que sugiere que la agregacion de SOD1 puede subyacer a todas las ALS.</span>ALS belongs to a family of fatal neurodegenerative disorders, which includes prion diseases, Alzheimer's and Parkinson's diseases, and in which it is believed that poorly folded aggregated proteins cause progressive elimination of brain cells. Approximately 20% of familial (hereditary) ALS is associated with mutations in the gene encoding superoxide dismutase-1 (SOD1), an intracellular free radical defense enzyme (see 73 and Table 1 for the list of known mutations) . Intracellular deposits of poorly folded SOD1 have been observed in family ALS, and also in the more common non-family ALS (sporadic), which suggests that the aggregation of SOD1 may underlie all ALS.</span>
  </p>
  <p id="p00025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los experimentos realizados en cultivo celular y ratones transgenicos para SOD1 mutante humana han establecido que SOD1 mal plegada extracelular es muy toxica para las neuronas motoras (1), en parte por activacion de las rutas de eliminacion por celulas inmunitarias locales (microglia). Recientemente, tambien ha quedado claro que SOD1 mal plegada se exporta de la celula por mecanismos tanto secretores como constitutivos (1, 2).</span>Experiments in cell culture and transgenic mice for human mutant SOD1 have established that extracellular folded SOD1 is very toxic to motor neurons (1), in part by activation of local immune cell elimination pathways (microglia). Recently, it has also become clear that poorly folded SOD1 is exported from the cell by both secretory and constitutive mechanisms (1, 2).</span>
  </p>
  <p id="p00026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La agregacion de SOD1 puede progresar a traves de un mecanismo de mal plegamiento dirigido por molde basado en protefna (3) similar al propuesto para las enfermedades por priones (4). Por tanto, SOD1 mal plegada en el espacio extracelular no solamente es directamente toxica para las neuronas motoras, sino que tambien participa en la propagacion de una celula a otra de la enfermedad en todo el sistema nervioso por un proceso de mal plegamiento con un molde tipo prion.</span>The aggregation of SOD1 can be progressed through a protein-directed mold-directed misfolding mechanism (3) similar to that proposed for prion diseases (4). Therefore, SOD1 misfolded in the extracellular space is not only directly toxic to motor neurons, but also participates in the spread of one cell to another of the disease throughout the nervous system by a process of misfolding with a type mold prion</span>
  </p>
  <p id="p00027" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00030" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00031" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00032" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00033" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00034" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00035" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 1. Mutaciones detectadas en SOD1 en FALS.</span>TABLE 1. Mutations detected in SOD1 in FALS.</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Aminoacidos </span>&nbsp;Amino acids</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Mutacion   Aminoacidos   Mutacion   Aminoacidos   Mutacion </span>&nbsp;Amino Acid Mutation Amino Acid Mutation Mutation</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4 </span>&nbsp;4</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> A -&gt; S (en FALS).  67  L -&gt; R (en FALS).  112  I -&gt; M (en FALS). </span>&nbsp;A -&gt; S (in FALS). 67 L -&gt; R (in FALS). 112 I -&gt; M (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4 </span>&nbsp;4</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> A -&gt; T (en FALS).  72  G -&gt; S (en FALS).  112  I -&gt; T (en FALS). </span>&nbsp;A -&gt; T (in FALS). 72 G -&gt; S (in FALS). 112 I -&gt; T (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4 </span>&nbsp;4</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> A -&gt; V (en FALS).  76  D -&gt; Y (en FALS).  113  I -&gt; T (en FALS). </span>&nbsp;A -&gt; V (in FALS). 76 D -&gt; Y (in FALS). 113 I -&gt; T (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6 </span>&nbsp;6</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> C -&gt; F (en FALS).  80  H -&gt; A (en ALS).  114  G -&gt; A (en FALS). </span>&nbsp;C -&gt; F (in FALS). 80 H -&gt; A (in ALS). 114 G -&gt; A (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7 </span>&nbsp;7</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> V -&gt; E (en FALS).  84  L -&gt; F (en FALS).  115  R -&gt; G (en FALS). </span>&nbsp;V -&gt; E (in FALS). 84 L -&gt; F (in FALS). 115 R -&gt; G (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8 </span>&nbsp;8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> L -&gt; Q (en FALS).  84  L -&gt; V (en FALS).  118  V -&gt; VFLQ (en FALS). </span>&nbsp;L -&gt; Q (in FALS). 84 L -&gt; V (in FALS). 118 V -&gt; VFLQ (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8 </span>&nbsp;8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> L -&gt; V (en FALS).  85  G -&gt; R (en FALS).  124  D -&gt; V (en FALS). </span>&nbsp;L -&gt; V (in FALS). 85 G -&gt; R (in FALS). 124 D -&gt; V (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 12 </span>&nbsp;12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> G -&gt; R (en FALS).  86  N -&gt; S (en FALS).  125  D -&gt; H (en FALS). </span>&nbsp;G -&gt; R (in FALS). 86 N -&gt; S (in FALS). 125 D -&gt; H (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 14 </span>&nbsp;14</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> V -&gt; G (en FALS).  89  A -&gt; V (en FALS).  126  L -&gt; S (en FALS). </span>&nbsp;V -&gt; G (in FALS). 89 A -&gt; V (in FALS). 126 L -&gt; S (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 14 </span>&nbsp;14</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> V -&gt; M (en FALS).  90  D -&gt; A (en FALS).  133  Ausente (en ALS). </span>&nbsp;V -&gt; M (in FALS). 90 D -&gt; A (in FALS). 133 Absent (in ALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 16 </span>&nbsp;16</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> G -&gt; S (en ALS).  90  D -&gt; V (en FALS).  134  S -&gt; N (en FALS). </span>&nbsp;G -&gt; S (in ALS). 90 D -&gt; V (in FALS). 134 S -&gt; N (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 21 </span>&nbsp;twenty-one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> E -&gt; G (en FALS).  93  G -&gt; A (en FALS).  139  N -&gt; K (en FALS). </span>&nbsp;E -&gt; G (in FALS). 93 G -&gt; A (in FALS). 139 N -&gt; K (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 21 </span>&nbsp;twenty-one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> E -&gt; K (en FALS).  93  G -&gt; C (en FALS).  144  L -&gt; F (en FALS). </span>&nbsp;E -&gt; K (in FALS). 93 G -&gt; C (in FALS). 144 L -&gt; F (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 37 </span>&nbsp;37</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> G -&gt; R (en FALS.  93  G -&gt; D (en FALS).  144  L -&gt; S (en FALS). </span>&nbsp;G -&gt; R (in FALS. 93 G -&gt; D (in FALS). 144 L -&gt; S (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 38 </span>&nbsp;38</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> L -&gt; R (en FALS).  93  G -&gt; R (en FALS).  145  A -&gt; T (en FALS). </span>&nbsp;L -&gt; R (in FALS). 93 G -&gt; R (in FALS). 145 A -&gt; T (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 38 </span>&nbsp;38</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> L -&gt; V (en FALS).  93  G -&gt; V (en FALS).  146  C -&gt; R (en FALS). </span>&nbsp;L -&gt; V (in FALS). 93 G -&gt; V (in FALS). 146 C -&gt; R (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 41 </span>&nbsp;41</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> G -&gt; D (en FALS).  100  E -&gt; G (en FALS).  148  V -&gt; G (en FALS). </span>&nbsp;G -&gt; D (in FALS). 100 E -&gt; G (in FALS). 148 V -&gt; G (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 41 </span>&nbsp;41</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> G -&gt; S (en FALS).  100  E -&gt; K (en FALS).  148  V -&gt; I (en FALS). </span>&nbsp;G -&gt; S (in FALS). 100 E -&gt; K (in FALS). 148 V -&gt; I (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 43 </span>&nbsp;43</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> H -&gt; R (en FALS).  101  D -&gt; G (en FALS).  149  I -&gt; T (en FALS). </span>&nbsp;H -&gt; R (in FALS). 101 D -&gt; G (in FALS). 149 I -&gt; T (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 45 </span>&nbsp;Four. Five</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> F -&gt; C (en FALS).  101  D -&gt; N (en FALS).  151  I -&gt; T (en FALS). </span>&nbsp;F -&gt; C (in FALS). 101 D -&gt; N (in FALS). 151 I -&gt; T (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 46 </span>&nbsp;46</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> H -&gt; R (en FALS).  104  I -&gt; F (en FALS).     </span>&nbsp;H -&gt; R (in FALS). 104 I -&gt; F (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 48 </span>&nbsp;48</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> H -&gt; Q (en FALS).  105  S -&gt; L (en FALS).     </span>&nbsp;H -&gt; Q (in FALS). 105 S -&gt; L (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 49 </span>&nbsp;49</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> E -&gt; K (en FALS).  106  L -&gt; V (en FALS).     </span>&nbsp;E -&gt; K (in FALS). 106 L -&gt; V (in FALS).</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 65 </span>&nbsp;65</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> N -&gt; S (en FALS).  108  G -&gt; V (en FALS).     </span>&nbsp;N -&gt; S (in FALS). 108 G -&gt; V (in FALS).</span>
      </dd>
    </dl>
  
  <p id="p00186" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Enfermedad de Alzheimer</span>Alzheimer disease</span>
  </p>
  <p id="p00187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AD es una enfermedad neurodegenerativa de demencia comun (memoria y cognicion alteradas) asociada con la acumulacion en el cerebro de placas extracelulares compuestas predominantemente de los peptidos Abeta (1-40), Abeta (1-42) y Abeta (1-43), todos los cuales son productos proteolfticos de APP (revisado en 50). Ademas, los haces neurofibrilares, compuestos principalmente de protefna tau fosforilada de forma anormal (una protefna asociada con microtubulos neuronales), se acumulan de forma intracelular en neuronas que mueren (revisado en 49). Las formas familiares de AD pueden estar causadas por mutaciones en el gen APP, o en los genes de presenilina 1 o 2 (revisado en 51), cuyos productos proteicos estan implicados en el procesamiento de APP en Abeta. Las variantes alelicas de Apolipoprotefna E tambien influyen en la edad de la aparicion de las formas tanto esporadica como familiar de AD (revisado en 52). Abeta, tau y tau fosforilada se han detectado en la sangre y CSF de pacientes con AD y en controles normales (53 - 55). La inmunizacion de pacientes con enfermedad de Alzheimer con Abeta ha demostrado algunos resultados de tratamiento preliminares prometedores, aunque limitados por meningoencefalitis autoinmunitaria en seres humanos (56 - 58).</span>AD is a neurodegenerative disease of common dementia (altered memory and cognition) associated with the accumulation in the brain of extracellular plaques predominantly composed of Abeta (1-40), Abeta (1-42) and Abeta (1-43) peptides, all of which are APP proteolytic products (reviewed in 50). In addition, neurofibrillary bundles, mainly composed of abnormally phosphorylated tau protein (a protein associated with neuronal microtubules), accumulate intracellularly in dying neurons (reviewed in 49). Familiar forms of AD may be caused by mutations in the APP gene, or in the presenilin 1 or 2 genes (reviewed in 51), whose protein products are involved in the processing of APP in Abeta. The allelic variants of Apolipoprotefna E also influence the age of occurrence of both sporadic and familial forms of AD (reviewed in 52). Abeta, tau and phosphorylated tau have been detected in the blood and CSF of patients with AD and in normal controls (53-55). Immunization of patients with Alzheimer's disease with Abeta has shown some promising preliminary treatment results, although limited by autoimmune meningoencephalitis in humans (56-58).</span>
  </p>
  <p id="p00188" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Enfermedad de Parkinson</span>Parkinson's disease</span>
  </p>
  <p id="p00189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PD es un trastorno neurodegenerativo del movimiento, el segundo solamente tras AD en predominancia (-350 por 100.000 habitantes, revisado en 59). Se caracteriza clfnicamente por rigidez, lentitud de movimientos y temblores. La mayorfa de los casos de enfermedad de Parkinson son esporadicos, pero las formas tanto esporadicas como familiares de la enfermedad se caracterizan por cuerpos de Lewy intracelulares en neuronas que mueren de la sustancia negra, una poblacion de neuronas del mesencefalo (-60.000) que se han diezmado selectivamente en PD. Los cuerpos de Lewy estan compuestos predominantemente de alfa-sinuclefna (60). Las mutaciones en, y la duplicacion de, el gen que codifica la alfa-sinuclefna se han encontrado en pacientes con enfermedad de Parkinson familiar (revisado en 61). Otro gen asociado con PD recesiva autosomica es parkina, que esta implicada en la degradacion de la alfa-sinuclefna (61). Los cuerpos de Lewy corticales difusos compuestos de alfa-sinuclefna se observan en enfermedad con cuerpos de Lewy (LBD), un sfndrome de demencia asociado con cambios parkinsonianos de tono, alucinaciones y fluctuacion rapida de los sfntomas (62). LBD puede ser la segunda forma mas comun de demencia neurodegenerativa despues de AD, representando del 20 al 30 por ciento de los casos entre las personas por encima de la edad de 60 anos. Similar al enfoque de vacuna para la enfermedad de Alzheimer (58 - 60) se han obtenido resultados prometedores en un modelo de raton de enfermedad de Parkinson/con cuerpos de Lewy por inmunizacion con alfa-sinuclefna (63). Otros sfndromes de demencia incluyen demencias frontotemporales, enfermedad de Pick y demencia corticobasal, y otros conocidos para la medicina neurologica.</span>PD is a neurodegenerative movement disorder, the second only after AD in predominance (-350 per 100,000 inhabitants, reviewed in 59). It is clinically characterized by stiffness, slow movements and tremors. Most cases of Parkinson's disease are sporadic, but both sporadic and familial forms of the disease are characterized by intracellular Lewy bodies in neurons that die of the black substance, a population of mesencephalic neurons (-60,000) that are have decimated selectively in PD. Lewy bodies are predominantly composed of alpha-synuclefna (60). Mutations in, and duplication of, the gene that encodes alpha-synuclefna have been found in patients with familial Parkinson's disease (reviewed in 61). Another gene associated with autosomal recessive PD is parkin, which is involved in the degradation of alpha-synuclefna (61). Diffuse cortical Lewy bodies composed of alpha-synuclefna are observed in disease with Lewy bodies (LBD), a dementia syndrome associated with parkinsonian changes in tone, hallucinations and rapid fluctuation of symptoms (62). LBD may be the second most common form of neurodegenerative dementia after AD, accounting for 20 to 30 percent of cases among people over the age of 60. Similar to the vaccine approach for Alzheimer's disease (58-60), promising results have been obtained in a mouse model of Parkinson's disease / with Lewy bodies by immunization with alpha-synuclefna (63). Other dementia syndromes include frontotemporal dementias, Pick's disease and corticobasal dementia, and others known for neurological medicine.</span>
  </p>
  <p id="p00190" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SOD1 se ha detectado en agregados proteicos de AD y PD</span>SOD1 has been detected in protein aggregates of AD and PD</span>
  </p>
  <p id="p00191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El estres oxidativo se ha implicado en varias enfermedades neurodegenerativas, incluyendo ALS, PD y AD. Las</span>Oxidative stress has been implicated in several neurodegenerative diseases, including ALS, PD and AD. The</span>
  </p>
  <p id="p00192" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00194" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00196" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00198" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00200" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00202" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00204" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">especies reactivas de oxfgeno y nitrogeno (ROS y RNS respectivamente) generadas en estos entornos pueden participar en la lesion celular, incluyendo la oxidacion anormal de protefnas o lfpidos. Otras marcas distintivas patologicas de dicha enfermedad incluyen acumulaciones de desechos citoesqueleticos y muerte neuronal selectiva, frecuentemente atribuida a estres oxidativo y la protefna soluble acumulada (74-81). Varias enzimas, incluyendo SOD1, tienen papeles antioxidantes. Las alteraciones en la actividad de dichas enzimas pueden contribuir a un estado patologico neurodegenerativo.</span>reactive oxygen and nitrogen species (ROS and RNS respectively) generated in these environments may participate in cell injury, including abnormal oxidation of proteins or lipids. Other distinctive pathological marks of said disease include accumulations of cytoskeletal wastes and selective neuronal death, often attributed to oxidative stress and accumulated soluble protein (74-81). Several enzymes, including SOD1, have antioxidant roles. Alterations in the activity of these enzymes can contribute to a neurodegenerative pathological state.</span>
  </p>
  <p id="p00206" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Recientemente, Choi et al. (64) informo de que SOD1 es una diana principal del dano oxidativo en cerebros AD y PD. Apreciaron que el nivel total de SOD1 esta aumentado tanto en Ad como en PD y que SOD1 forma agregados proteicos que se asocian con placas seniles amiloides y haces neurofibrilares en cerebros AD. Choi et al. (64) han sugerido que AD, PD y ALS pueden compartir un mecanismo patogenico comun. Tambien se ha demostrado recientemente que SOD1 se secreta en el espacio extracelular, en una forma que es toxica para las neuronas, pero mas accesible por agentes terapeuticos extracelulares (1).</span>Recently, Choi et al. (64) reported that SOD1 is a major target of oxidative damage in AD and PD brains. They appreciated that the total level of SOD1 is increased in both Ad and PD and that SOD1 forms protein aggregates that are associated with senile amyloid plaques and neurofibrillar bundles in AD brains. Choi et al. (64) have suggested that AD, PD and ALS may share a common pathogenetic mechanism. It has also recently been shown that SOD1 is secreted in the extracellular space, in a form that is toxic to neurons, but more accessible by extracellular therapeutic agents (1).</span>
  </p>
  <p id="p00207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La implicacion de que SOD1 mal plegada extracelular desempena un papel en la patogenesis de ALS proporciona una oportunidad para el tratamiento con anticuerpos de enfermedades autodegenerativas, ya que este compartimento es accesible para la neutralizacion por anticuerpos. En seres humanos normales, las IgG pueden cruzar la barrera hematoencefalica hasta niveles entre 1/100 y 1/1000 de las concentraciones en circulacion; y una trasudacion de inmunoglobulinas a menudo esta aumentada en enfermedades que afectan a la barrera hematoencefalica. Sin embargo, el tratamiento de pacientes humanos con anticuerpos o vacunas dirigidas a epftopos extracelulares accesibles sobre protefnas ubicuas puede conducir a efectos autoinmunitarios nocivos tales como los observados con Abeta en enfermedad de Alzheimer. Por tanto, sigue existiendo una necesidad en la tecnica de composiciones y metodos para el diagnostico y tratamiento de enfermedades relacionadas con SOD1 mal plegada, tales como ALS, AD y PD.</span>The implication that extracellular folded SOD1 plays a role in the pathogenesis of ALS provides an opportunity for treatment with autodegenerative disease antibodies, since this compartment is accessible for antibody neutralization. In normal humans, IgGs can cross the blood-brain barrier to levels between 1/100 and 1/1000 of the circulating concentrations; and immunoglobulin transudation is often increased in diseases that affect the blood-brain barrier. However, the treatment of human patients with antibodies or vaccines targeting extracellular epftopos accessible on ubiquitous proteins can lead to harmful autoimmune effects such as those observed with Abeta in Alzheimer's disease. Therefore, there remains a need in the art of compositions and methods for the diagnosis and treatment of diseases related to misfolded SOD1, such as ALS, AD and PD.</span>
  </p>
  <p id="p00208" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Goldberg (2005) "SESSION 7A Protein Folding and Degradation Defects", Amyotrophic Lateral Sclerosis Vol. 6, N. 4, Supl. 1: paginas 33-35 describe una SOD1 monomerica/mal plegada C45detectada en modelos de raton de ALS usando un anticuerpo disenado.</span>Goldberg (2005) "SESSION 7A Protein Folding and Degradation Defects", Amyotrophic Lateral Sclerosis Vol. 6, No. 4, Suppl. 1: pages 33-35 describe a C45 monomeric / misfolded SOD1 detected in ALS mouse models using a designed antibody.</span>
  </p>
  <p id="p00209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El documento WO 2007/025385 describe un anticuerpo que se une especfficamente a una superoxido dismutasa 1 (SOD1) anormal, y que neutraliza su efecto patologico cuando se administra a un animal tal como a un ser humano. El anticuerpo es un anticuerpo monoclonal producido por lfneas celulares de hibridoma depositadas en la International Depositary Authority of Canada el 29 de agosto de 2006 con los numeros de acceso ADI-290806-01, ADI-290806-02 y ADI-290806-03. Tambien se describe el uso del anticuerpo en el tratamiento, prevencion y diagnostico de enfermedades neurodegenerativas tales como esclerosis lateral amiotrofica, Parkinson y Alzheimer en un animal tal como en un ser humano.</span>WO 2007/025385 describes an antibody that specifically binds to an abnormal superoxide dismutase 1 (SOD1) and that neutralizes its pathological effect when administered to an animal such as a human being. The antibody is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on August 29, 2006 with accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The use of the antibody in the treatment, prevention and diagnosis of neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's and Alzheimer's disease in an animal such as in a human being is also described.</span>
  </p>
  <p id="p00210" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El documento US 5.849.290 y la base de datos Geneseq (24 de febrero de 2009) "Human Cu/Zn SOD exon 2 protein fragment", recuperado del numero de acceso EBI GSP: AAW82448 describe la secuencia de aminoacidos del fragmento de la protefna SOD Cu/Zn humana codificado por el exon 2 del gen SOD1.</span>US 5,849,290 and the Geneseq database (February 24, 2009) "Human Cu / Zn SOD exon 2 protein fragment", retrieved from the EBI accession number GSP: AAW82448 describes the amino acid sequence of the protein fragment Human SOD Cu / Zn encoded by exon 2 of the SOD1 gene.</span>
  </p>
  <p id="p00211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sumario de la invencion</span>Summary of the invention</span>
  </p>
  <p id="p00212" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SOD1 mal plegada es toxica para las neuronas (1) y se cree que participa en la muerte celular neuronal y la disfuncion en esclerosis lateral amiotrofica y otras enfermedades neurodegenerativas. La presente invencion usa epftopos especfficos de enfermedad por SOD1 (DSE) como una diana para vacunas o inmunoterapia para esclerosis lateral amiotrofica. Tambien se describen DSE como una diana para vacunas o inmunoterapia para (ALS), enfermedad de Alzheimer (AD), enfermedad de Parkinson (PD) y enfermedades con cuerpos de Lewy (LBD). La invencion afsla y aborda epftopos que se presentan selectivamente por formas no nativas de SOD1 que estan asociadas con ALS. Estos epftopos no se presentan o estan accesibles en formas nativas de SOD1. Por ejemplo, los epftopos especfficos de enfermedad tales como especfficos de ALS, especfficos de AD y especfficos de PD, no se presentan por las formas dimericas nativas de SOD1. Sin embargo, los epftopos especfficos de enfermedad se presentan o estan accesibles cuando el monomero SOD1 no logra asociarse o se disocia de su estado homodimerico normal, y en otras formas no nativas de SOD1, incluyendo monomeros de SOD1 mal plegados, dfmeros de SOD1 mal plegados y agregados de SOD1. Estos epftopos se presentan selectivamente o estan accesibles en forman no nativas de SOD1, y son caracterfsticos de afecciones, enfermedades y trastornos relacionados con SOD1 no nativa.</span>SOD1 misfolded is toxic to neurons (1) and is believed to be involved in neuronal cell death and dysfunction in amyotrophic lateral sclerosis and other neurodegenerative diseases. The present invention uses specific episodes of SOD1 disease (DSE) as a target for vaccines or immunotherapy for amyotrophic lateral sclerosis. DSE is also described as a target for vaccines or immunotherapy for (ALS), Alzheimer's disease (AD), Parkinson's disease (PD) and Lewy body diseases (LBD). The invention afsla and addresses epftopos that occur selectively by non-native forms of SOD1 that are associated with ALS. These epftopos do not occur or are accessible in native forms of SOD1. For example, disease-specific epftopes such as ALS-specific, AD-specific and PD-specific, are not presented by the native dimeric forms of SOD1. However, disease-specific epftopos present or are accessible when the monomer SOD1 fails to associate or dissociates from its normal homodimeric state, and in other non-native forms of SOD1, including misfolded SOD1 monomers, misfolded SOD1 monomers and aggregates of SOD1. These epftopos occur selectively or are accessible in non-native forms of SOD1, and are characteristic of conditions, diseases and disorders related to non-native SOD1.</span>
  </p>
  <p id="p00213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En esta solicitud, epftopos "especfficos de ALS" se refiere a epftopos que se presentan en las formas asociadas a ALS de SOD1, epftopos "especfficos de AD" se refiere a epftopos que se presentan en las formas asociadas a AD de SOD1, y epftopos "especfficos de PD" se refiere a epftopos que se presentan en las formas asociadas a PD de SOD1 que surgen de procesos tales como mal plegamiento, agregacion o disociacion. SOD1 mal plegada presenta muchos de los mismos epftopos en cada uno de ALS, AD y PD, sin embargo, por conveniencia en este documento, los epftopos se describen como "especfficos" a esa enfermedad porque, dentro del organismo de un sujeto particular, los epftopos se presentan especfficamente solamente en la SOD1 toxica no nativa que causa, subyace o esta asociada con la enfermedad neurodegenerativa. Dichos epftopos especfficos de enfermedad, por tanto,</span>In this application, "ALS-specific epftopos" refers to epftopos that occur in the ALS-associated forms of SOD1, "AD-specific" epftopes refers to epftopos that occur in the AD-associated forms of SOD1, and epftopos "PD specific" refers to epftopos that occur in the PD-associated forms of SOD1 that arise from processes such as misfolding, aggregation or dissociation. SOD1 misfolded presents many of the same epftopos in each of ALS, AD and PD, however, for convenience in this document, epftopos are described as "specific" to that disease because, within the organism of a particular subject, the epftopos occur specifically only in non-native toxic SOD1 that causes, underlies or is associated with neurodegenerative disease. Such disease-specific epftopos, therefore,</span>
  </p>
  <p id="p00214" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00215" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00216" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00218" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00220" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00225" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">incluyen los epftopos sobre el monomero de SOD1 que se revelan cuando el monomero de SOD1 se disocia de su estado homodimerico normal, los epftopos se presentan selectivamente o estan accesibles en formas de SOD1 no nativas incluyendo monomero de SOD1 mal plegado, dfmero de SOD1 mal plegado y los epftopos se presentan selectivamente o estan accesibles en agregados de SOD1.</span>they include epftopos on the monomer of SOD1 that are revealed when the monomer of SOD1 dissociates from its normal homodimeric state, epftopes occur selectively or are accessible in non-native forms of SOD1 including monomer of SOD1 poorly folded, number of poorly folded SOD1 and epftopos are presented selectively or are accessible in aggregates of SOD1.</span>
  </p>
  <p id="p00228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La presente invencion proporciona composiciones, anticuerpos aislados, inmunogenos y usos de dichas composiciones, anticuerpos aislados e inmunogenos en el tratamiento de ALS, asf como hibridomas, kits y metodos para obtener dichos anticuerpos como se define en las reivindicaciones adjuntas.</span>The present invention provides compositions, isolated antibodies, immunogens and uses of said compositions, isolated antibodies and immunogens in the treatment of ALS, as well as hybridomas, kits and methods for obtaining said antibodies as defined in the appended claims.</span>
  </p>
  <p id="p00229" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen epftopos que se presentan por o estan accesibles en formas no nativas de SOD1, incluyendo:</span>Epftopes are presented that are presented by or are accessible in non-native forms of SOD1, including:</span>
  </p>
  <p id="p00230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DLGKGGNEESTKTGNAGS (DSE2) (documento WO 2005/019828);</span>DLGKGGNEESTKTGNAGS (DSE2) (WO 2005/019828);</span>
  </p>
  <p id="p00231" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NPLSRKHGGPKDEE (DSE3) (documento WO 2005/019828);</span>NPLSRKHGGPKDEE (DSE3) (WO 2005/019828);</span>
  </p>
  <p id="p00232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IKGLTEGLHGF (DSE5) (8);</span>IKGLTEGLHGF (DSE5) (8);</span>
  </p>
  <p id="p00233" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HCIIGRTLVVH (DSE 6) (8); y</span>HCIIGRTLVVH (DSE 6) (8); Y</span>
  </p>
  <p id="p00234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GLHGFHVH (DSE7),</span>GLHGFHVH (DSE7),</span>
  </p>
  <p id="p00235" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">asf como los epftopos adicionales que se presentan por o estan accesibles solamente en formas monomericas de SOD1, que incluyen:</span>as well as additional epftopos that are presented by or are accessible only in monomeric forms of SOD1, which include:</span>
  </p>
  <p id="p00236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (DSE1); y</span>RLACGVIGI (DSE1); Y</span>
  </p>
  <p id="p00237" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAVCVLK (DSE4).</span>KAVCVLK (DSE4).</span>
  </p>
  <p id="p00238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La presente solicitud describe estos epftopos y/o determinantes antigenicos contenidos dentro de estos epftopos, y asimismo cualquier epftopo presentado selectivamente o accesible en formas no nativas de SOD1, como dianas para intervencion inmunoterapeutica. Por ejemplo, los peptidos aislados correspondientes a estos epftopos son utiles para reducir o inhibir la participacion de SOD1 monomerica, dimerica o mal plegada en agregacion de SOD1, que es caracterfstica de trastornos relacionados con SOD1 mal plegada, tal como esclerosis lateral amiotrofica, enfermedad de Alzheimer y/o enfermedad de Parkinson. Por consiguiente, los peptidos aislados correspondientes a estos epftopos pueden usarse para tratar esclerosis lateral amiotrofica, enfermedad de Alzheimer y/o enfermedad de Parkinson y pueden usarse para provocar una respuesta inmunitaria selectiva en un animal contra las moleculas SOD1 monomericas, agregadas o mal plegadas, y para inhibir o neutralizar el efecto toxico de estas especies de SOD1 mal plegadas en neuronas. En el caso donde el peptido aislado correspondiente a un epftopo especffico de enfermedad se usa en una vacuna, el peptido aislado puede ser cualquier analogo de los peptidos aislados indicados que produce anticuerpos endogenos contra ese epftopo. Ademas, el inventor proporciona protefnas de union tales como anticuerpos y fragmentos que se unen a los epftopos especfficos de esclerosis lateral amiotrofica, anticuerpos y fragmentos que se unen a epftopos especfficos de enfermedad de Alzheimer y anticuerpos y fragmentos que se unen a epftopos especfficos de enfermedad de Parkinson. Estos anticuerpos pueden usarse para detectar o tratar la esclerosis lateral amiotrofica, la enfermedad de Alzheimer y la enfermedad de Parkinson.</span>The present application describes these epftopos and / or antigenic determinants contained within these epftopos, and also any epftopo presented selectively or accessible in non-native forms of SOD1, as targets for immunotherapeutic intervention. For example, isolated peptides corresponding to these epftopes are useful for reducing or inhibiting the participation of monomeric, dimeric or misfolded SOD1 in aggregation of SOD1, which is characteristic of disorders related to poorly folded SOD1, such as amyotrophic lateral sclerosis, disease of Alzheimer's and / or Parkinson's disease. Accordingly, isolated peptides corresponding to these epftopes can be used to treat amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease and can be used to elicit a selective immune response in an animal against monomeric, aggregated or misfolded SOD1 molecules. and to inhibit or neutralize the toxic effect of these poorly folded SOD1 species in neurons. In the case where the isolated peptide corresponding to a disease specific epftope is used in a vaccine, the isolated peptide can be any analogue of the indicated isolated peptides that produces endogenous antibodies against that epftopo. In addition, the inventor provides binding proteins such as antibodies and fragments that bind to specific episodes of amyotrophic lateral sclerosis, antibodies and fragments that bind to specific epftopes of Alzheimer's disease and antibodies and fragments that bind to disease-specific epftopes of Parkinson's. These antibodies can be used to detect or treat amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease.</span>
  </p>
  <p id="p00239" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, se describe una composicion util para inhibir la agregacion de SOD1 mediada por SOD1 monomerica o mal plegada, y por tanto para tratar trastornos de SOD1 incluyendo enfermedades neurodegenerativas tales como esclerosis lateral amiotrofica, enfermedad de Alzheimer y/o enfermedad de Parkinson. Por consiguiente, se describe una composicion para tratar una enfermedad neurodegenerativa tal como ALS, AD o PD en un sujeto, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 (opcionalmente mencionado como un epftopo especffico de enfermedad), o un inmunogeno que comprende dicho peptido, en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable. Tambien se describe una composicion para tratar ALS en un sujeto, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, o un analogo del mismo que provoca anticuerpos endogenos que se unen a ese epftopo o un inmunogeno que comprende dicho peptido aislado, en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable. Tambien se describe una composicion para tratar AD en un sujeto, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado selectivamente o asociado con formas no nativas de SOD1, o un analogo del mismo que provoca anticuerpos endogenos que se unen a ese epftopo o un inmunogeno que comprende dicho peptido aislado o analogo, en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable. Tambien se describe una composicion para tratar PD en un sujeto, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, o un inmunogeno que comprende dicho peptido, en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable.</span>Accordingly, a useful composition is described to inhibit the aggregation of SOD1 mediated by monomeric or poorly folded SOD1, and therefore to treat SOD1 disorders including neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease. Accordingly, a composition for treating a neurodegenerative disease such as ALS, AD or PD in a subject is described, comprising an effective amount of an isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 (optionally mentioned as a disease specific epftope), or an immunogen comprising said peptide, in admixture with a suitable diluent or carrier, such as a pharmaceutically acceptable one. A composition for treating ALS in a subject is also described, comprising an effective amount of an isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1, or an analog thereof that causes endogenous antibodies that bind to that epftopo or an immunogen comprising said isolated peptide, in admixture with a suitable diluent or carrier, such as a pharmaceutically acceptable one. A composition for treating AD in a subject is also described, comprising an effective amount of an isolated peptide corresponding to an epftope selectively presented or associated with non-native forms of SOD1, or an analog thereof that causes endogenous antibodies that bind to that epftopo or an immunogen comprising said isolated or analogous peptide, in admixture with a suitable diluent or carrier, such as a pharmaceutically acceptable one. A composition for treating PD in a subject is also described, comprising an effective amount of an isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1, or an immunogen comprising said peptide, in admixture with a diluent or suitable vehicle, such as a pharmaceutically acceptable one.</span>
  </p>
  <p id="p00240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, que se selecciona del grupo que consiste en los peptidos asilados de la Tabla 2 o de la Tabla 2A (descritas a continuacion) o un analogo de los mismos.</span>An isolated peptide corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 is described, which is selected from the group consisting of the isolated peptides of Table 2 or Table 2A (described below) or an analogue of the same.</span>
  </p>
  <p id="p00241" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00243" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00245" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00247" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00249" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00251" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00254" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 2. Peptidos aislados correspondientes a epftopos selectivamente accesibles en formas no nativas de</span>Table 2. Isolated peptides corresponding to selectively accessible epitopes in non-native forms of</span>
  </p>
  <p id="p00255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SOD1</span>SOD1</span>
  </p>
  <p id="p00256" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (SEQ ID NO: 1, DSE1):</span>RLACGVIGI (SEQ ID NO: 1, DSE1):</span>
  </p>
  <p id="p00257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DLGKGGNEESTKTGNAGS (SEQ ID NO: 2, DSE2);</span>DLGKGGNEESTKTGNAGS (SEQ ID NO: 2, DSE2);</span>
  </p>
  <p id="p00258" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NPLSRKHGGPKDEE; (SEQ ID NO: 3, DSE3):</span>NPLSRKHGGPKDEE; (SEQ ID NO: 3, DSE3):</span>
  </p>
  <p id="p00259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IKGLTEGLHGF; SEQ ID NO: 5, DSE5);</span>IKGLTEGLHGF; SEQ ID NO: 5, DSE5);</span>
  </p>
  <p id="p00260" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HCIIGRTLVVH; SEQ ID NO: 6, DSE6);</span>HCIIGRTLVVH; SEQ ID NO: 6, DSE6);</span>
  </p>
  <p id="p00261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLA[acido cisteico]GVIGI (DSE1a); SEQ ID NO: 8, DSE1a);</span>RLA [cysteic acid] GVIGI (DSE1a); SEQ ID NO: 8, DSE1a);</span>
  </p>
  <p id="p00262" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAVCVLK (DSE4); SEQ ID NO: 4, DSE4) y GLHGFHVH (DSE7) SEQ ID NO: 7, DSE7).</span>KAVCVLK (DSE4); SEQ ID NO: 4, DSE4) and GLHGFHVH (DSE7) SEQ ID NO: 7, DSE7).</span>
  </p>
  <p id="p00263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos peptidos aislados enumerados en la Tabla 2 se mencionan en este documento como los "peptidos aislados de la Tabla 2".</span>These isolated peptides listed in Table 2 are referred to herein as the "isolated peptides of Table 2".</span>
  </p>
  <p id="p00264" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion farmaceutica para tratar la esclerosis lateral amiotrofica en un sujeto, que comprende una cantidad eficaz de un epftopo especffico de esclerosis lateral amiotrofica aislado, o un inmunogeno que comprende dicho epftopo, en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable. En una descripcion, el epftopo o una forma inmunogenica del mismo se presenta selectivamente o es accesible en la forma monomerica de SOD1. Dichos epftopos incluyen aquellos que reconocen un epftopo del monomero SOD1 que descansa normalmente en la superficie de contacto del dfmero SOD1. Otro de dichos epftopos son aquellos accesibles en la superficie de SOD1 cuando lo monomeros de SOD1 estan en su estado asociado normal, por ejemplo, cuando SOD1 esta en su forma dimerica o cuando esta en su forma agregada. En descripciones particulares, el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica se selecciona del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A pharmaceutical composition for treating amyotrophic lateral sclerosis in a subject is described, which comprises an effective amount of a specific epitope of isolated amyotrophic lateral sclerosis, or an immunogen comprising said epftope, in admixture with a suitable diluent or carrier, such as one. pharmaceutically acceptable. In a description, the epftope or an immunogenic form thereof is presented selectively or is accessible in the monomeric form of SOD1. Such epftopes include those that recognize an epftope of the SOD1 monomer that normally rests on the contact surface of the SOD1 dimer. Another such epftopos is those accessible on the surface of SOD1 when the monomers of SOD1 are in their normal associated state, for example, when SOD1 is in its dimeric form or when it is in its aggregate form. In particular descriptions, the isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis is selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambien son utiles analogos de los peptidos aislados y peptidos aislados modificados. Los analogos y peptidos aislados modificados comprenden peptidos de origen in vivo y modificados por ingenierfa molecular correspondientes a los epftopos presentados o accesibles en formas no nativas de SOD1 que retienen la capacidad de provocar la produccion de anticuerpos que reconocen especfficamente los epftopos correspondientes en formas monomericas, mal plegadas o agregadas de SOD1. En una descripcion, el analogo peptfdico aislado comprende un acido cisteico. Se describe un peptido aislado analogo correspondiente a un epftopo que comprende RLAC*GVIGI (DSE1 a), donde * indica una cistefna oxidada, en forma de acido cisteico.</span>They are also useful analogs of isolated peptides and modified isolated peptides. Modified isolated analogs and peptides comprise peptides of in vivo origin and modified by molecular engineering corresponding to epftopos presented or accessible in non-native forms of SOD1 that retain the ability to cause the production of antibodies that specifically recognize corresponding epftopos in monomeric forms, misfolded or added SOD1. In a description, the isolated peptide analog comprises a cysteic acid. An isolated analogous peptide corresponding to an epftope comprising RLAC * GVIGI (DSE1 a) is described, where * indicates an oxidized cysteine, in the form of cysteic acid.</span>
  </p>
  <p id="p00266" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para tratar un trastorno, enfermedad o afeccion mediada por SOD1 que comprende una cantidad eficaz de un acido nucleico aislado que codifica un peptido o analogo correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado. Se describe una composicion para tratar la esclerosis lateral amiotrofica, que comprende una cantidad eficaz de un acido nucleico aislado que codifica un peptido correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con diluyente o vehfculo adecuado.</span>A composition for treating a disorder, disease or condition mediated by SOD1 is described which comprises an effective amount of an isolated nucleic acid encoding a peptide or analog corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a diluent. or suitable vehicle. A composition for treating amyotrophic lateral sclerosis is described, comprising an effective amount of an isolated nucleic acid encoding a peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with suitable diluent or carrier.</span>
  </p>
  <p id="p00267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, el acido nucleico codifica un peptido aislado correspondiente a un epftopo seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>In one description, the nucleic acid encodes an isolated peptide corresponding to an epitope selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00268" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para tratar la esclerosis lateral amiotrofica, que comprende una cantidad eficaz de un acido nucleico que codifica un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado, donde el peptido aislado correspondiente al epftopo especffico de esclerosis lateral amiotrofica se selecciona del grupo que consiste en los peptidos aislados de la Tabla 2 o de la tabla 2A, o un analogo de los mismos.</span>A composition for treating amyotrophic lateral sclerosis is described, which comprises an effective amount of a nucleic acid encoding an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a suitable diluent or vehicle, where the isolated peptide corresponding to the epftopo Amyotrophic lateral sclerosis specimen is selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estas composiciones pueden usarse para tratar la esclerosis lateral amiotrofica, la enfermedad de Alzheimer y/o la enfermedad de Parkinson y en metodos para tratar la esclerosis lateral amiotrofica, la enfermedad de Alzheimer y/o la enfermedad de Parkinson.</span>These compositions can be used to treat amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease and in methods to treat amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease.</span>
  </p>
  <p id="p00270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones son utiles particularmente para tratar una enfermedad neurodegenerativa usando inmunoterapia dirigida a un epftopo presentado en SOD1 mal plegada, donde el tratamiento comprende inmunoterapia activa, es decir, terapia basada en vacuna en que el peptido aislado correspondiente a un epftopo se usa en un inmunogeno para producir anticuerpos que reconocen SOD1 monomerica o mal plegada en el destinatario, o comprende inmunoterapia pasiva en que se administra un anticuerpo contra el peptido aislado correspondiente al epftopo al destinatario. La composicion tfpicamente es una composicion farmaceutica.</span>The compositions are particularly useful for treating a neurodegenerative disease using immunotherapy directed to an epftopo presented in poorly folded SOD1, where the treatment comprises active immunotherapy, that is, vaccine-based therapy in which the isolated peptide corresponding to an epftope is used in an immunogen to produce antibodies that recognize monomeric or poorly folded SOD1 in the recipient, or comprises passive immunotherapy in which an antibody is administered against the isolated peptide corresponding to the epftope to the recipient. The composition is typically a pharmaceutical composition.</span>
  </p>
  <p id="p00271" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado. La afeccion, enfermedad o trastorno medico incluye, aunque sin limitacion, esclerosis lateral amiotrofica, enfermedad de Alzheimer y enfermedad de Parkinson.</span>Accordingly, a composition for eliciting an immune response in an animal is described, which comprises an effective amount of an isolated peptide corresponding to an epitope presented in non-native forms of SOD1 in admixture with a suitable diluent or carrier. The medical condition, disease or disorder includes, but is not limited to, amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease.</span>
  </p>
  <p id="p00272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00273" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00275" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00277" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00279" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00281" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00283" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00285" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otra descripcion es una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado, donde el peptido aislado correspondiente al epftopo especffico de esclerosis lateral amiotrofica se selecciona del grupo que consiste en los peptidos asilados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>Another description is a composition for eliciting an immune response in an animal, which comprises an effective amount of an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a suitable diluent or vehicle, where the isolated peptide corresponding to the specific epftope of Amyotrophic lateral sclerosis is selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, la composicion es una composicion farmaceutica para tratar la esclerosis lateral amiotrofica en un sujeto por inmunizacion activa, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica, o un inmunogeno que comprende dicho peptido aislado correspondiente a dicho epftopo, en mezcla con un vehfculo adecuado, tal como un diluyente o vehfculo farmaceuticamente aceptable. En una descripcion, el peptido aislado o una forma inmunogenica del mismo corresponde a un epftopo presentado selectivamente o accesible en la forma monomerica de SOD1. Dichos epftopos incluyen aquellos epftopos en el monomero de SOD1 que normalmente descansa en la superficie de contacto del dfmero de SOD1. Otros de dichos epftopos son aquellos accesibles en la superficie de SOD1 cuando esta en forma dimerica, o cuando SOD1 esta en su forma agregada. Se describe el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica que se selecciona del grupo que consiste en los peptidos asilados de la Tabla o de la Tabla 2A, o un analogo de los mismos.</span>In one description, the composition is a pharmaceutical composition for treating amyotrophic lateral sclerosis in a subject by active immunization, which comprises an effective amount of an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis, or an immunogen comprising said isolated peptide. corresponding to said epitope, in admixture with a suitable vehicle, such as a pharmaceutically acceptable diluent or vehicle. In a description, the isolated peptide or an immunogenic form thereof corresponds to an epftope presented selectively or accessible in the monomeric form of SOD1. Such epftopos include those epftopos in the monomer of SOD1 that normally rests on the contact surface of the SOD1 dimer. Other such epftopos are those accessible on the surface of SOD1 when it is in dimeric form, or when SOD1 is in its aggregate form. The isolated peptide corresponding to a specific amyotrophic lateral sclerosis epftope that is selected from the group consisting of the asylated peptides of the Table or Table 2A, or an analogue thereof, is described.</span>
  </p>
  <p id="p00287" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un acido nucleico que codifica un peptido correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, en mezcla con un diluyente o vehfculo adecuado. La afeccion, enfermedad o trastorno medico es un trastorno de SOD1 tal como una enfermedad neurodegenerativa que incluye, aunque sin limitacion, esclerosis lateral amiotrofica, enfermedad de Alzheimer y enfermedad de Parkinson.</span>A composition for eliciting an immune response in an animal is described, comprising an effective amount of a nucleic acid encoding a peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1, in admixture with a suitable diluent or carrier. The medical condition, disease or disorder is an SOD1 disorder such as a neurodegenerative disease that includes, but is not limited to, amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease.</span>
  </p>
  <p id="p00288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una descripcion adicional es una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un acido nucleico que codifica un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado, donde el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica se selecciona del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A further description is a composition for eliciting an immune response in an animal, which comprises an effective amount of a nucleic acid encoding an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a suitable diluent or vehicle, where the peptide isolated corresponding to a specific epitope of amyotrophic lateral sclerosis is selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00289" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estas composiciones son utiles para provocar una respuesta inmunitaria en un animal y son utiles en metodos para provocar una respuesta inmunitaria en un animal contra formas no nativas de SOD1, incluyendo una respuesta inmunitaria contra epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer y/o epftopos especfficos de enfermedad de Parkinson.</span>These compositions are useful for eliciting an immune response in an animal and are useful in methods for eliciting an immune response in an animal against non-native forms of SOD1, including an immune response against specific episodes of amyotrophic lateral sclerosis, epftopos specific to Alzheimer's disease. and / or specific episodes of Parkinson's disease.</span>
  </p>
  <p id="p00290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estas composiciones son utiles para generar protefnas de union, tales como anticuerpos contra formas no nativas de SOD1, incluyendo anticuerpos que se unen a epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer y/o epftopos especfficos de enfermedad de Parkinson.</span>These compositions are useful for generating binding proteins, such as antibodies against non-native forms of SOD1, including antibodies that bind specific epitopes of amyotrophic lateral sclerosis, specific epftopes of Alzheimer's disease and / or specific epitopes of Parkinson's disease.</span>
  </p>
  <p id="p00291" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, se describen anticuerpos exogenos especfficos para formas no nativas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer y/o epftopos especfficos de enfermedad de Parkinson.</span>Accordingly, exogenous antibodies specific for non-native forms of SOD1 are described, including specific episodes of amyotrophic lateral sclerosis, epftopos specific for Alzheimer's disease and / or epftopos specific for Parkinson's disease.</span>
  </p>
  <p id="p00292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, los anticuerpos especfficos para formas no nativas de SOD1 se producen usando una composicion que comprende un peptido aislado correspondiente a un epftopo especffico de enfermedad seleccionado del grupo que consiste en los peptidos aislados de la Tabla o de la Tabla 2A, o un analogo de los mismos.</span>In one description, antibodies specific for non-native forms of SOD1 are produced using a composition comprising an isolated peptide corresponding to a disease-specific epftope selected from the group consisting of the isolated peptides of the Table or Table 2A, or a analog of them.</span>
  </p>
  <p id="p00293" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, el anticuerpo se une al epftopo RLACGVIGI. En otra descripcion, el anticuerpo se une al epftopo DLGKGGNEESTKTGNAGS. En otra descripcion, el anticuerpo se une al epftopo NPLSRKHGGPKDEE. En un aspecto de la invencion, el anticuerpo se une al epftopo IKGLTEGLHGF. En otra descripcion, el anticuerpo se une al epftopo HCIIGRTLVVH. En otra descripcion, el anticuerpo se une al epftopo RLAC*GVIGI. En otra descripcion, el anticuerpo se une al epftopo KAVCVLK. En un aspecto de la invencion, el anticuerpo se une al epftopo GLHGFHVH.</span>In one description, the antibody binds to the RLACGVIGI epftope. In another description, the antibody binds to the DLGKGGNEESTKTGNAGS epitope. In another description, the antibody binds to the NPLSRKHGGPKDEE epitope. In one aspect of the invention, the antibody binds to the IKGLTEGLHGF epitope. In another description, the antibody binds to the HCIIGRTLVVH epitope. In another description, the antibody binds to the epitope RLAC * GVIGI. In another description, the antibody binds to the KAVCVLK epitope. In one aspect of the invention, the antibody binds to the GLHGFHVH epitope.</span>
  </p>
  <p id="p00294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos de la invencion pueden ser anticuerpos policlonales, anticuerpos monoclonales, anticuerpos quimericos, anticuerpos humanizados, anticuerpos humanos y/o fragmentos de union a epftopo y analogos de los mismos. La invencion comprende adicionalmente hibridomas que producen anticuerpos contra DSE5. Las realizaciones de la presente invencion incluyen los hibridomas per se, asf como la descendencia de los mismos, fusiones posteriores con los mismos y ADN y ARN endogeno que codifica el anticuerpo contra SOD1. En aspectos relacionados, la invencion, por tanto, proporciona adicionalmente un metodo para producir anticuerpos que se unen selectivamente a DSE5, que comprende la etapa de cultivar los hibridomas. Estos anticuerpos son utiles para tratar la esclerosis lateral amiotrofica por inmunizacion pasiva. Por ejemplo, inhiben o neutralizan el efecto toxico de estas especies mal plegadas de SOD1 en las neuronas, y/o evitan la progresion de la enfermedad por eliminacion inmunologica de agregados toxicos de SOD, inhibiendo la agregacion de SOD1 mediada por SOD1 mal plegada, y/o bloqueando el proceso de mal plegamiento dirigido por molde SOD1. Por tanto, la invencion incluye composiciones utiles para tratar la esclerosis lateral amiotrofica en un sujeto, que comprende una cantidad eficaz de un anticuerpo</span>The antibodies of the invention can be polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies and / or epftope binding fragments and analogs thereof. The invention further comprises hybridomas that produce antibodies against DSE5. Embodiments of the present invention include hybridomas per se, as well as their offspring, subsequent fusions therewith and endogenous DNA and RNA encoding the antibody against SOD1. In related aspects, the invention, therefore, additionally provides a method for producing antibodies that selectively bind to DSE5, which comprises the step of culturing hybridomas. These antibodies are useful for treating amyotrophic lateral sclerosis by passive immunization. For example, they inhibit or neutralize the toxic effect of these poorly folded SOD1 species on neurons, and / or prevent disease progression by immunological elimination of toxic SOD aggregates, inhibiting SOD1 aggregation mediated by misfolded SOD1, and / or blocking the misfolding process directed by SOD1 mold. Thus, the invention includes compositions useful for treating amyotrophic lateral sclerosis in a subject, which comprises an effective amount of an antibody.</span>
  </p>
  <p id="p00295" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00297" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00299" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00301" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00303" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">especffico para DSE5 o DS7 en mezcla con un diluyente o vehfculo adecuado.</span>specific for DSE5 or DS7 in admixture with a suitable diluent or vehicle.</span>
  </p>
  <p id="p00309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ademas de los anticuerpos, tambien se describen otros agentes que se unen especfficamente a epftopos presentados o accesibles en formas no nativas de SOD1 y no presentados o accesibles en formas nativas de SOD1. Los agentes que se unen incluyen polipeptidos, moleculas pequenas, aptameros nucleicos o peptfdicos, aficuerpos y anticalinas.</span>In addition to the antibodies, other agents that specifically bind epftopos presented or accessible in non-native forms of SOD1 and not presented or accessible in native forms of SOD1 are also described. Binding agents include polypeptides, small molecules, nucleic or peptide aptamers, enzymes and anticalins.</span>
  </p>
  <p id="p00310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mas generalmente, se describe un metodo para tratar a un sujeto que tiene una afeccion, enfermedad o trastorno medico mediado por una forma no nativa de la superoxido dismutasa (SOD), comprendiendo el metodo la etapa de administrar al sujeto una composicion que comprende un vehfculo farmaceuticamente aceptable y un agente seleccionado de (1) una protefna en forma de un anticuerpo o fragmento del mismo que se une selectivamente a la forma monomerica o mal plegada de SOD1, y/o (2) un inmunogeno que provoca la produccion de dicho anticuerpo por dicho sujeto, y/o (3) una secuencia de acido nucleico que codifica (1) o (2).</span>More generally, a method for treating a subject having a medical condition, disease or disorder mediated by a non-native form of superoxide dismutase (SOD) is described, the method comprising the step of administering to the subject a composition comprising a vehicle. pharmaceutically acceptable and an agent selected from (1) a protein in the form of an antibody or fragment thereof that selectively binds to the monomeric or misfolded form of SOD1, and / or (2) an immunogen that causes the production of said antibody by said subject, and / or (3) a nucleic acid sequence encoding (1) or (2).</span>
  </p>
  <p id="p00311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los metodos descritos, por tanto, se refieren a aplicaciones inmunoterapeuticas de anticuerpos contra SOD1 que se unen selectivamente a epftopos accesibles en las formas monomericas o mal plagadas de SOD1 presentes en estados patologicos. El metodo puede realizarse como monoterapia, en que un anticuerpo cualquiera o un epftopo cualquiera se administra al sujeto. Como alternativa, el metodo puede realizarse como una terapia de combinacion, en que el sujeto se trata para recibir tanto un anticuerpo o peptido seleccionado correspondiente a un epftopo como otro agente util en el tratamiento o control de la enfermedad.</span>The methods described, therefore, refer to immunotherapeutic applications of antibodies against SOD1 that selectively bind accessible epftopes in the monomeric or poorly plagued forms of SOD1 present in pathological conditions. The method can be performed as monotherapy, in which any antibody or any epftope is administered to the subject. Alternatively, the method can be performed as a combination therapy, in which the subject is treated to receive both an antibody or selected peptide corresponding to an epftope and another agent useful in the treatment or control of the disease.</span>
  </p>
  <p id="p00312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos anticuerpos son utiles para detectar formas no nativas de formas monomericas, dimericas o agregadas de SOD1, y de ese modo son utiles para diagnosticar la esclerosis lateral amiotrofica. Se describe un metodo de deteccion o diagnostico de la esclerosis lateral amiotrofica en un sujeto, que comprende las etapas de:</span>These antibodies are useful for detecting non-native forms of monomeric, dimeric or aggregate forms of SOD1, and thus are useful for diagnosing amyotrophic lateral sclerosis. A method of detecting or diagnosing amyotrophic lateral sclerosis in a subject is described, comprising the steps of:</span>
  </p>
  <p id="p00313" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(a) poner en contacto una muestra de ensayo de dicho sujeto con un anticuerpo especffico para un epftopo especffico de esclerosis lateral amiotrofica, donde el anticuerpo se une a un epftopo especffico de esclerosis lateral amiotrofica para producir un complejo de anticuerpo-antfgeno;</span>(a) contacting a test sample of said subject with a specific antibody for a specific epitope of amyotrophic lateral sclerosis, where the antibody binds to a specific epftope of amyotrophic lateral sclerosis to produce an antibody-antigen complex;</span>
  </p>
  <p id="p00314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) medir la cantidad de complejo de anticuerpo-antfgeno en la muestra de ensayo; y</span>(b) measure the amount of antibody-antigen complex in the test sample; Y</span>
  </p>
  <p id="p00315" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(c) comparar la cantidad de complejo de anticuerpo-antfgeno en la muestra de ensayo con un control donde una diferencia en la cantidad del complejo de anticuerpo-antfgeno en la muestra de ensayo en comparacion con el control es indicativa de esclerosis lateral amiotrofica. Opcionalmente, y en el caso donde el epftopo SOD1 mal plegado esta enmascarado dentro de una agregacion de SOD1, el metodo proporciona la etapa de tratar la muestra para promover la disgregacion del agregado de SOD1 para exponer el epftopo diana antes de la etapa (a).</span>(c) comparing the amount of antibody-antigen complex in the test sample with a control where a difference in the amount of the antibody-antigen complex in the test sample compared to the control is indicative of amyotrophic lateral sclerosis. Optionally, and in the case where the badly folded SOD1 epftope is masked within an SOD1 aggregation, the method provides the step of treating the sample to promote the disintegration of the SOD1 aggregate to expose the target epftopo before stage (a) .</span>
  </p>
  <p id="p00316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos anticuerpos y/o fragmentos de union de los mismos se conjugan de forma util con marcadores para producir un agente de diagnostico.</span>These antibodies and / or binding fragments thereof are conjugated in a useful manner with markers to produce a diagnostic agent.</span>
  </p>
  <p id="p00317" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen kits que comprenden las composiciones y anticuerpos descritos para tratar enfermedades neurodegenerativas tales como esclerosis lateral amiotrofica, enfermedad de Alzheimer y enfermedad de Parkinson, por ejemplo para inhibir la agregacion de SOD1; para provocar una respuesta inmunitaria en un animal; o para detectar SOD1 mal plegada, y de ese modo diagnosticar una enfermedad neurodegenerativa tal como esclerosis lateral amiotrofica, enfermedad de Alzheimer o enfermedad de Parkinson.</span>Kits comprising the compositions and antibodies described for treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are described, for example to inhibit the aggregation of SOD1; to elicit an immune response in an animal; or to detect poorly folded SOD1, and thereby diagnose a neurodegenerative disease such as amyotrophic lateral sclerosis, Alzheimer's disease or Parkinson's disease.</span>
  </p>
  <p id="p00318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambien se describen novedosos peptidos aislados. En una descripcion los peptidos aislados novedosos comprenden peptidos que comprenden una secuencia de aminoacidos seleccionada del grupo que consiste en:</span>Novel isolated peptides are also described. In a description the novel isolated peptides comprise peptides comprising an amino acid sequence selected from the group consisting of:</span>
  </p>
  <p id="p00319" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (SEQ ID NO: 1, DSE1)</span>RLACGVIGI (SEQ ID NO: 1, DSE1)</span>
  </p>
  <p id="p00320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ACGVIGI (SEQ ID NO: 9, analogo de DSE1)</span>ACGVIGI (SEQ ID NO: 9, DSE1 analog)</span>
  </p>
  <p id="p00321" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ac-GG-RLACGVIG-GGKG (SEQ ID NO: 10, analogo de DSE1)</span>Ac-GG-RLACGVIG-GGKG (SEQ ID NO: 10, DSE1 analog)</span>
  </p>
  <p id="p00322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11, analogo de DSE2)</span>CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11, DSE2 analog)</span>
  </p>
  <p id="p00323" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CNPLSRKHGGPKDEE (SEQ ID NO: 12, analogo de DSE3)</span>CNPLSRKHGGPKDEE (SEQ ID NO: 12, DSE3 analog)</span>
  </p>
  <p id="p00324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CIKGLTEGLHGF (SEQ ID NO: 14, analogo de DSE5)</span>CIKGLTEGLHGF (SEQ ID NO: 14, DSE5 analogue)</span>
  </p>
  <p id="p00325" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLA[Acido cisteico]GVIGI (SEQ ID NO: 8, DSE1a)</span>RLA [Cysteic acid] GVIGI (SEQ ID NO: 8, DSE1a)</span>
  </p>
  <p id="p00326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A[Acido cisteico]GVIGI (sEq ID NO: 13, analogo de DSE1a)</span>A [Cysteic acid] GVIGI (sEq ID NO: 13, analogue of DSE1a)</span>
  </p>
  <p id="p00327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">C-GGG-RLA[Acido cisteico]GVIGI-GSG (SEQ ID NO: 15, analogo de DSE1a)</span>C-GGG-RLA [Cysteic acid] GVIGI-GSG (SEQ ID NO: 15, analogue of DSE1a)</span>
  </p>
  <p id="p00328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAVCVLK (SEQ ID NO: 4, DSE4);</span>KAVCVLK (SEQ ID NO: 4, DSE4);</span>
  </p>
  <p id="p00329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GSGKAVCLK (SEQ ID NO: 16, analogo de DSE 4); y GLHGFHVH (SEQ ID NO: 7, DSE7).</span>GSGKAVCLK (SEQ ID NO: 16, DSE analog 4); and GLHGFHVH (SEQ ID NO: 7, DSE7).</span>
  </p>
  <p id="p00330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra descripcion, la invencion comprende novedosos peptidos aislados modificados que comprenden RLA[Acido cisteico]GVIGI (SEQ ID NO: 8, DSE1a), donde el resto de cistefna es acido cisteico.</span>In another description, the invention comprises novel modified isolated peptides comprising RLA [Cysteic acid] GVIGI (SEQ ID NO: 8, DSE1a), wherein the rest of cystephine is cysteic acid.</span>
  </p>
  <p id="p00331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En descripciones relacionadas, estos peptidos se proporcionan en forma marcada, o como conjugados o fusiones, por ejemplo, "inmunogenos" utiles para producir anticuerpos o detectar SOD1 y para otros usos de diagnostico y</span>In related descriptions, these peptides are provided in a labeled form, or as conjugates or fusions, for example, "immunogens" useful for producing antibodies or detecting SOD1 and for other diagnostic uses and</span>
  </p>
  <p id="p00332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00333" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00335" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00337" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00339" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00341" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00342" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00343" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00344" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00345" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">terapeuticos. Dichos inmunogenos comprenden los peptidos acoplados, por ejemplo, a KLH o a antfgeno MAP.</span>therapeutic Such immunogens comprise peptides coupled, for example, to KLH or to MAP antigen.</span>
  </p>
  <p id="p00346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ciertas descripciones se refieren a un metodo de i) provocar una respuesta inmunitaria en un sujeto y/o ii( tratar una afeccion, enfermedad o trastorno medico mediado por una forma mal plegada de la superoxido dismutasa (SOD) en un sujeto que necesita tratamiento, que comprende administrar una composicion que comprende un acido nucleico que codifica un inmunogeno aislado especffico de esclerosis lateral amiotrofica (por ejemplo, peptido) de la invencion en mezcla con un diluyente o un vehfculo adecuado al sujeto. Por supuesto, dichos acidos nucleicos codificaran solamente aquellas formas de los epftopos y peptidos que consisten en aminoacidos codificados geneticamente, pero los acidos nucleicos tambien pueden producir, de forma endogena, analogos de los epftopos codificados que, despues de expresarse tal cual, quedan modificados in vivo tal como por nitracion, oxidacion, carbonilacion y similares por el entorno endogeno. Las secuencias de nucleotidos adecuadas de ARN y de ADN se exponen en esta solicitud (otras secuencias de ADN que tienen identidad de secuencia o equivalente sinonimos de codones tambien son utiles en los metodos). Ejemplos de afecciones, enfermedades o trastornos medicos incluyen ALS, enfermedad de Parkinson, enfermedad con cuerpos de Lewy o enfermedad de Alzheimer.</span>Certain descriptions refer to a method of i) provoking an immune response in a subject and / or ii (treating a medical condition, disease or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment, which comprises administering a composition comprising a nucleic acid encoding a specific isolated amyotrophic sclerosis immunogen (eg, peptide) of the invention in admixture with a diluent or a suitable vehicle to the subject. Of course, said nucleic acids will encode only those forms of epftopos and peptides consisting of genetically encoded amino acids, but nucleic acids can also produce, endogenously, analogs of encoded epftopes that, after being expressed as such, are modified in vivo such as by nitration, oxidation, carbonylation and the like by the endogenous environment. Suitable nucleotide sequences of RNA and DNA are exposed n in this application (other DNA sequences that have sequence identity or equivalent synonymous with codons are also useful in the methods). Examples of medical conditions, diseases or disorders include ALS, Parkinson's disease, Lewy body disease or Alzheimer's disease.</span>
  </p>
  <p id="p00347" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para i) aumentar la eliminacion inmunologica de agregados de SOD, ii) reducir la agregacion de SOD1 mediada por SOD1 mal plegada, y/o iii) reducir el mal plegamiento dirigido por molde de SOD1, que comprende administrar al sujeto una composicion que comprende un vehfculo farmaceuticamente aceptable y un agente seleccionado de (1) un anticuerpo exogeno aislado que se une selectivamente a la forma mal plegada de SOD, y/o (2) un inmunogeno que provoca la produccion de un anticuerpo endogeno que se une selectivamente al monomero o a la forma mal plegada de SOD, y/o (3) una secuencia de acido nucleico que codifica (1) o (2).</span>A method is described for i) increasing the immunological elimination of SOD aggregates, ii) reducing the aggregation of SOD1 mediated by misfolded SOD1, and / or iii) reducing the misfolding directed by SOD1 mold, which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and an agent selected from (1) an isolated exogenous antibody that selectively binds to the misfolded form of SOD, and / or (2) an immunogen that causes the production of an endogenous antibody that binds selectively to the monomer or to the misfolded form of SOD, and / or (3) a nucleic acid sequence encoding (1) or (2).</span>
  </p>
  <p id="p00348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para tratar una afeccion, enfermedad o trastorno medico mediado por una forma mal plegada de la superoxido dismutasa (SOD) en un sujeto que necesita tratamiento, comprendiendo el metodo administrar al sujeto que necesita tratamiento un agente (tal como un anticuerpo exogeno o inmunogeno (por ejemplo, peptido)) descrito en este documento que i) causa eliminacion inmunologica de agregados de SOD, ii) reduce la agregacion de SOD1 mediada por SOD1 mal plegada y/o iii) reduce el mal plegamiento dirigido por molde de SOD1. Tambien se describen metodos de tratamiento de afecciones, enfermedades o trastornos medicos descritos en este documento administrando a un sujeto una cantidad eficaz de un anticuerpo especffico para epftopos descritos en este documento que se presentan selectivamente o estan accesibles en formas no nativas de SOD1.</span>A method for treating a medical condition, disease or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment is described, the method comprising administering to the subject in need of treatment an agent (such as an exogenous antibody or immunogen (eg, peptide)) described herein that i) causes immunological elimination of SOD aggregates, ii) reduces SOD1 aggregation mediated by misfolded SOD1 and / or iii) reduces mold-directed misfolding of SOD1 . Methods of treatment of medical conditions, diseases or disorders described herein are also described by administering to an individual an effective amount of a specific antibody for epitopes described herein that are selectively presented or accessible in non-native forms of SOD1.</span>
  </p>
  <p id="p00349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras caracterfsticas y ventajas de la presente invencion llegaran a ser evidentes a partir de la siguiente descripcion detallada.</span>Other features and advantages of the present invention will become apparent from the following detailed description.</span>
  </p>
  <p id="p00350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Breve descripcion de las figuras</span>Brief description of the figures</span>
  </p>
  <p id="p00351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las realizaciones de la invencion se describiran en relacion a los dibujos en que:</span>The embodiments of the invention will be described in relation to the drawings in which:</span>
  </p>
  <p id="p00352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 1 es un grafico que demuestra que el anticuerpo anti-DSE1a reconoce preferentemente DSE1a sobre DSE1.</span>Figure 1 is a graph showing that the anti-DSE1a antibody preferentially recognizes DSE1a over DSE1.</span>
  </p>
  <p id="p00353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 2 es un grafico que ilustra los datos de ELISA que muestran que el anticuerpo anti-DSE2 reconoce la protefna SOD1 oxidada.</span>Figure 2 is a graph illustrating the ELISA data showing that the anti-DSE2 antibody recognizes the oxidized SOD1 protein.</span>
  </p>
  <p id="p00354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 3A es un diagrama de antigenicidad de SOD1 usando el metodo de Hopp y Woods.</span>Figure 3A is an antigenicity diagram of SOD1 using the Hopp and Woods method.</span>
  </p>
  <p id="p00355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 3B es un diagrama de antigenicidad de SOD1 usando el metodo de Kolaskar y Tongaonkar.</span>Figure 3B is an antigenicity diagram of SOD1 using the Kolaskar and Tongaonkar method.</span>
  </p>
  <p id="p00356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 4A es una inmunotransferencia que muestra que DSE2 reconoce SOD1 humana y de raton desnaturalizada.</span>Figure 4A is an immunoblot showing that DSE2 recognizes human and denatured mouse SOD1.</span>
  </p>
  <p id="p00357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 4B es una inmunotransferencia de SOD1 inmunoprecipitada de cerebro humano y murino normal que demuestra que el anticuerpo anti-DSE2 no inmunoprecipita SOD1 nativa.</span>Figure 4B is an immunobrecipitated SOD1 immunoblot of normal human and murine brain demonstrating that the native anti-DSE2 antibody does not immunoprecipitate SOD1.</span>
  </p>
  <p id="p00358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 4C es una inmunotransferencia de SOD1 inmunoprecipitada de ratones transgenicos que sobreexpresan SOD1 humana de tipo silvestre y mutante.</span>Figure 4C is an immunobrecipitated SOD1 immunoblot of transgenic mice that overexpress wild and mutant human SOD1.</span>
  </p>
  <p id="p00359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 5A es una seccion de cerebro humano de hipocampo normal en una mujer de 52 anos de edad tenido con un anticuerpo contra DSE2.</span>Figure 5A is a section of the normal hippocampus human brain in a 52-year-old woman who had an antibody against DSE2.</span>
  </p>
  <p id="p00360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 5B es una composicion de las secciones del hipocampo humano de una mujer de 78 anos de edad con enfermedad de Alzheimer en fase final sondeadas con anticuerpo monoclonal anti-DSE2.</span>Figure 5B is a composition of the human hippocampus sections of a 78-year-old woman with late-stage Alzheimer's disease probed with anti-DSE2 monoclonal antibody.</span>
  </p>
  <p id="p00361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 6 (A-F) es una composicion de secciones cerebrales de una mujer de 79 anos de edad con demencia sondeadas con anticuerpo monoclonal anti-DSE2.</span>Figure 6 (A-F) is a composition of brain sections of a 79-year-old woman with dementia probed with anti-DSE2 monoclonal antibody.</span>
  </p>
  <p id="p00362" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Descripcion detallada de la invencion</span>Detailed description of the invention</span>
  </p>
  <p id="p00363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen composiciones inmunoterapeuticas y metodos que abordan especfficamente especies toxicas de SOD1, incluyendo a aquellos conformeros de SOD1 que puede asociarse con enfermedades neurodegenerativas, tales como ALS, AD y Pd, identificando y aprovechando la ventaja terapeutica de epftopos inmunologicos (sitios de union de anticuerpo) expuestos sobre la superficie molecular de SOD1 mal plegada y agregada. Estos epftopos no se presentan en SOD1 plegada normalmente nativa. Se describen epftopos previamente desconocidos que son utiles como dianas para disenar compuestos o para producir anticuerpos para terapia o para diagnostico. Tambien se describe el uso inmunoterapeutico de epftopos identificados previamente presentados en formas mal plegadas y</span>Immunotherapeutic compositions and methods that specifically address toxic SOD1 species are described, including those conforming to SOD1 that can be associated with neurodegenerative diseases, such as ALS, AD and Pd, identifying and exploiting the therapeutic advantage of immunological epftopos (antibody binding sites). ) exposed on the molecular surface of SOD1 misfolded and added. These epftopos do not occur in normally native folded SOD1. Previously unknown epftopos are described which are useful as targets for designing compounds or for producing antibodies for therapy or for diagnosis. The immunotherapeutic use of previously identified epftopes in misfolded forms and</span>
  </p>
  <p id="p00364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00369" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00376" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">agregadas de SOD1 pero no conservadas en formas nativas de SOD1 (vease 3 y el documento WO 2005/019828). Estos epftopos son dianas utiles para inmunoterapia pasiva o activa para prevenir la progresion de la enfermedad. Sin el deseo de limitarse a teorfa alguna, estos epftopos previenen la progresion de la enfermedad por eliminacion inmunologica o secuestro de agregados toxicos de SOD1, bloqueando el proceso de mal plegamiento dirigido por molde de SOD1, neutralizando el efecto toxico de estas especies mal plegadas de SOD1 en neuronas, y/o la inhibicion del estres oxidativo mediado por SOD1 mal plegada.</span>aggregates of SOD1 but not conserved in native forms of SOD1 (see 3 and WO 2005/019828). These epftopos are useful targets for passive or active immunotherapy to prevent disease progression. Without wishing to limit themselves to any theory, these epftopes prevent the progression of the disease by immunological elimination or sequestration of toxic aggregates of SOD1, blocking the process of misfolding directed by SOD1 mold, neutralizing the toxic effect of these poorly folded species of SOD1 in neurons, and / or inhibition of oxidative stress mediated by poorly folded SOD1.</span>
  </p>
  <p id="p00378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones y usos de los epftopos especfficos de enfermedad</span>Compositions and uses of disease-specific epftopes</span>
  </p>
  <p id="p00379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han determinado que hay epftopos presentados selectivamente por, o accesibles en, SOD1 monomerica o formas mal plegadas de SOD1 en formas monomericas, dimericas o agregadas, pero no en la forma nativa o homodimerica apropiadamente plegada de SOD1. Las formas mal plegadas de SOD1 se caracterizan por la adopcion de una conformacion, particularmente una conformacion secundaria o terciaria que es diferente de la conformacion adoptada por un dfmero de SOD1 de tipo silvestre, y/o participa en la formacion de agregados de SOD1 que son caracterfsticos de trastornos de SOD1 incluyendo enfermedades neurodegenerativas tales como esclerosis lateral amiotrofica, enfermedad de Alzheimer y enfermedad de Parkinson. Dicha SOD1 mal plegada puede tener una secuencia de tipo silvestre o una secuencia mutada. En ciertas realizaciones, los epftopos son aquellos presentados selectivamente por o accesibles en SOD1 mal plegada que tiene una secuencia de tipo silvestre o nativa. En otras realizaciones, los epftopos son estos presentados selectivamente por o accesibles en SOD1 mal plegada que tiene la secuencia mutada o no de tipo silvestre. En otras realizaciones, el epftopo se presenta por el monomero de SOD1 (en cualquier forma incluyendo de tipo silvestre, mutante, mal plegada y nativa), y se vuelve accesible en el monomero de SOD1 tras la disociacion del monomero del homodfmero de SOD1. El reconocimiento inmunologico de solamente SOD1 mal plegada reducira o eliminara las manifestaciones autoinmunitarias causadas por la union de anticuerpo a SOD1 nativa normal. El reconocimiento inmunologico de SOD1 mal plegada que es tipo silvestre, en particular, sera util particularmente en el tratamiento de ALS esporadica.</span>The inventors have determined that there are epftopes selectively presented by, or accessible in, monomeric SOD1 or misfolded forms of SOD1 in monomeric, dimeric or aggregated forms, but not in the properly folded native or homodimeric form of SOD1. Misfolded forms of SOD1 are characterized by the adoption of a conformation, particularly a secondary or tertiary conformation that is different from the conformation adopted by a wild-type SOD1 dimer, and / or participates in the formation of SOD1 aggregates that are Characteristics of SOD1 disorders including neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease. Said misfolded SOD1 may have a wild type sequence or a mutated sequence. In certain embodiments, epftopes are those selectively presented by or accessible in misfolded SOD1 having a wild or native type sequence. In other embodiments, epftopes are these presented selectively by or accessible in poorly folded SOD1 having the mutated or non-wild-type mutated sequence. In other embodiments, the epftope is presented by the monomer of SOD1 (in any form including wild-type, mutant, misfolded and native), and becomes accessible in the monomer of SOD1 after dissociation of the monomer of the homodimer of SOD1. Immunological recognition of only misfolded SOD1 will reduce or eliminate autoimmune manifestations caused by antibody binding to normal native SOD1. The immunological recognition of misfolded SOD1 which is wild type, in particular, will be particularly useful in the treatment of sporadic ALS.</span>
  </p>
  <p id="p00380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El termino "SOD1" como se usa en este documento significa la superoxido dismutasa 1 e incluye todas las formas analogas y mutantes de todas las especies, particularmente SOD1 humana (es decir, hSOD1) y menciona opcionalmente como SOD. La secuencia de aminoacidos de SOD1 humana (por ejemplo, numero de acceso UniProtKB/TrEMBL Q6NR85; numero de acceso a GenBank CAG46542; SEQ ID NO: 17) y la secuencia de nucleotidos de ARNm (por ejemplo, numero de acceso a GenBank NM_000454; SEQ ID NO: 18) de SOD1 humana se han caracterizado previamente.</span>The term "SOD1" as used herein means superoxide dismutase 1 and includes all analog and mutant forms of all species, particularly human SOD1 (ie, hSOD1) and optionally mentioned as SOD. The amino acid sequence of human SOD1 (e.g., UniProtKB / TrEMBL access number Q6NR85; GenBank accession number CAG46542; SEQ ID NO: 17) and the mRNA nucleotide sequence (e.g., GenBank accession number NM_000454; SEQ ID NO: 18) of human SOD1 have been previously characterized.</span>
  </p>
  <p id="p00381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Tipo silvestre" se refiere a la secuencia primaria de aminoacidos de una protefna nativa o no mutante, y SOD1 de tipo silvestre se refiere a SOD1, y particularmente SOD1 humana, que puede mencionarse opcionalmente como hSOD1, que tiene una secuencia de aminoacidos nativa o de origen natural. La secuencia de aminoacidos de SOD1 humana se proporciona en la SEQ ID NO: 17 y la secuencia de acido nucleico se proporciona en la SEQ ID NO: 18. "Tipo silvestre" tambien puede hacer referencia a la estructura nativa normal de una protefna especffica (por ejemplo, las coordenadas a nivel atomico de la estructura cristalina de la protefna SOD1 dimerica nativa estan disponibles en el numero de acceso del Protein Data Bank 1PUO). SOD1 plegada de tipo silvestre se menciona opcionalmente como SOD1 "plegada de forma nativa", SOD1 "plegada normalmente" y/o SOD1 "plegada apropiadamente".</span>"Wild type" refers to the primary amino acid sequence of a native or non-mutant protein, and wild-type SOD1 refers to SOD1, and particularly human SOD1, which may optionally be referred to as hSOD1, which has a native amino acid sequence or of natural origin. The amino acid sequence of human SOD1 is provided in SEQ ID NO: 17 and the nucleic acid sequence is provided in SEQ ID NO: 18. "Wild type" may also refer to the normal native structure of a specific protein ( for example, the atomic level coordinates of the crystalline structure of the native dimeric SOD1 protein are available in the accession number of the Protein Data Bank 1PUO). SOD1 folded in the wild type is optionally mentioned as SOD1 "folded natively", SOD1 "folded normally" and / or SOD1 "folded properly".</span>
  </p>
  <p id="p00382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SOD mutante" se refiere a formas de SOD, y particularmente formas endogenas de SOD, que aparecen como resultado de mutacion genetica que produce, por ejemplo, sustituciones de aminoacidos, tales como aquellas sustituciones caracterfsticas, por ejemplo, de ALS familiar. Dichas sustituciones incluyen las enumeradas en la Tabla 1.</span>"Mutant SOD" refers to forms of SOD, and particularly endogenous forms of SOD, that appear as a result of genetic mutation that produces, for example, amino acid substitutions, such as those characteristic substitutions, for example, of familiar ALS. Such substitutions include those listed in Table 1.</span>
  </p>
  <p id="p00383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Mal plegada" como se usa en este documento, se refiere a la estructura secundaria y terciaria de una protefna, e indica que la protefna ha adoptado una conformacion que no es normal para esa protefna en su estado de funcionamiento apropiado. Aunque el mal plegamiento puede estar causado por mutaciones en una protefna, tales como delecion, sustitucion o adicion de aminoacidos, la protefna de secuencia de tipo silvestre tambien puede estar mal plegada en enfermedad, y exponer epftopos especfficos de enfermedad, por ejemplo, como resultado de condiciones microambientales y/o modificacion de aminoacidos tales como nitracion, oxidacion, carbonilacion u otra modificacion.</span>"Misfolded" as used herein, refers to the secondary and tertiary structure of a protein, and indicates that the protein has adopted a conformation that is not normal for that protein in its proper functioning state. Although misfolding may be caused by mutations in a protein, such as deletion, substitution or addition of amino acids, the wild-type sequence protein may also be poorly folded in disease, and expose disease-specific epitopes, for example, as a result. of microenvironmental conditions and / or modification of amino acids such as nitration, oxidation, carbonylation or other modification.</span>
  </p>
  <p id="p00384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, en el caso donde SOD1 no nativa es SOD1 mutante tal como una forma de SOD1 que comprende variaciones de secuencia caracterfsticas de ALS familiar, el mutante de SOD1 no nativo es diferente a un mutante donde uno o mas de los aminoacidos A4, G37, G85, o G93 esta mutado.</span>In certain embodiments, in the case where non-native SOD1 is mutant SOD1 such as a form of SOD1 comprising sequence variations characteristic of familial ALS, the non-native SOD1 mutant is different from a mutant where one or more of the amino acids A4, G37, G85, or G93 is mutated.</span>
  </p>
  <p id="p00385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un "epftopo", como se usa en este documento, significa una region de una protefna que se reconoce por un receptor de celulas B o de celulas T, o un anticuerpo o un fragmento de union del mismo. El epftopo esta representado opcionalmente en este documento por la secuencia lineal de aminoacidos o la region de la protefna reconocida por el anticuerpo. Los "peptidos aislados correspondientes a un epftopo" opcionalmente se mencionan en sf mismos como un "epftopo".</span>An "epftope," as used herein, means a region of a protein that is recognized by a B cell or T cell receptor, or an antibody or a binding fragment thereof. The epftope is optionally represented herein by the linear amino acid sequence or the region of the protein recognized by the antibody. The "isolated peptides corresponding to an epftopo" are optionally mentioned in themselves as an "epftopo".</span>
  </p>
  <p id="p00386" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00387" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00389" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00391" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00393" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00395" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00396" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00397" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00398" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00399" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un epftopo es "accesible" en el contexto de la presente memoria descriptiva cuando esta accesible a la union por un anticuerpo o por un fragmento de union del mismo. Un epftopo especffico de enfermedad de la invencion puede estar parcial o completamente expuesto sobre la superficie molecular de una protefna mal plegada en una forma accesible para union del anticuerpo, y parcial o completamente oculto del reconocimiento por el anticuerpo en la isoforma plegada de forma nativa de la protefna. Dicho epftopo se presenta o esta accesible de forma selectiva en una conformacion mal plegada o no nativa de una protefna y no se presenta o esta accesible en la conformacion nativa de la protefna. "Presentada de forma selectiva o accesible" se usa contextualmente, para indicar que el epftopo mencionado esta disponible para la union a un anticuerpo u otra protefna de union en SOD1 mal plegada y no disponible para la union del anticuerpo en formas nativas de SOD1. El epftopo especffico de enfermedad es suficientemente diferente de una parte correspondiente de SOD1 nativa plegada apropiadamente (es decir, SOD1 que tiene actividad SOD1 no patogenica normal), habitualmente en terminos de su conformacion, de modo que un anticuerpo puede unirse selectivamente al epftopo.</span>An epftope is "accessible" in the context of the present specification when it is accessible to binding by an antibody or by a binding fragment thereof. A disease specific epftope of the invention may be partially or completely exposed on the molecular surface of a misfolded protein in an accessible way for antibody binding, and partially or completely hidden from recognition by the antibody in the natively folded isoform of The protein. Said epftope is presented or is selectively accessible in a poorly folded or non-native conformation of a protein and is not present or is accessible in the native conformation of the protein. "Presented in a selective or accessible manner" is used contextually, to indicate that the aforementioned epftope is available for binding to an antibody or other binding protein in SOD1 that is poorly folded and not available for binding of the antibody in native forms of SOD1. The disease specific epftope is sufficiently different from a corresponding part of properly folded native SOD1 (i.e., SOD1 having normal non-pathogenic SOD1 activity), usually in terms of its conformation, so that an antibody can selectively bind to the epftopo.</span>
  </p>
  <p id="p00400" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un epftopo comprende uno o mas determinantes antigenicos. Por ejemplo, un anticuerpo generado contra un peptido aislado correspondiente a un epftopo especffico de enfermedad especffica reconoce parte de o toda dicha secuencia epitopica. Por consiguiente, en una realizacion, una parte de un peptido aislado correspondiente a un epftopo presentado o accesible en SOD1 mal plegada que retiene un determinante antigenico se usa para crear anticuerpos contra dicho epftopo.</span>An epftopo comprises one or more antigenic determinants. For example, an antibody generated against an isolated peptide corresponding to a specific disease specific epitope recognizes part of or all said epitopic sequence. Accordingly, in one embodiment, a portion of an isolated peptide corresponding to an epftope presented or accessible in misfolded SOD1 that retains an antigenic determinant is used to create antibodies against said epftope.</span>
  </p>
  <p id="p00401" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando se hace referencia a epftopos de SOD1 presentados selectivamente en ALS, los epftopos se mencionan opcionalmente como epftopos especfficos de ALS; cuando se hace referencia a epftopos presentados selectivamente en enfermedad de Alzheimer, los epftopos se mencionan opcionalmente como epftopos especfficos de AD y asimismo cuando se hace referencia a epftopos presentados selectivamente en enfermedad de Parkinson, los epftopos se mencionan opcionalmente como epftopos especfficos de PD para facilitar la referencia de la enfermedad nombrada. Sin embargo, se entiende que los epftopos especfficos de ALS de SOD1 no estan limitados a ALS, sino que se presentan opcionalmente en otras enfermedades neurodegenerativas tales como AD y PD; los epftopos especfficos de AD de SOD1 no estan limitados a AD, sino que se presentan opcionalmente en otras enfermedades neurodegenerativas tales como ALS y PD; y los epftopos de SOD1 especfficos de PD no estan limitados a PD, sino que se presentan opcionalmente en otras enfermedades neurodegenerativas tales como AD y ALS. Los epftopos que estan accesibles selectivamente en formas de SOD1 que estan asociadas con afecciones, enfermedades y trastornos mediados con SOD1 se mencionan opcionalmente como epftopos especfficos de enfermedad.</span>When reference is made to SOD1 epftopos selectively presented in ALS, epftopos are optionally mentioned as specific episodes of ALS; when referring to epftopos selectively presented in Alzheimer's disease, epftopos are optionally mentioned as specific epftopos of AD and also when referring to epftopos selectively presented in Parkinson's disease, epftopos are optionally mentioned as specific epftopos of PD to facilitate the reference of the named disease. However, it is understood that SOD1-specific ALS epftopes are not limited to ALS, but optionally occur in other neurodegenerative diseases such as AD and PD; AD-specific episodes of SOD1 are not limited to AD, but optionally present in other neurodegenerative diseases such as ALS and PD; and PD-specific SOD1 epftopes are not limited to PD, but optionally present in other neurodegenerative diseases such as AD and ALS. Epftopes that are selectively accessible in forms of SOD1 that are associated with conditions, diseases and disorders mediated with SOD1 are optionally mentioned as disease-specific epftopos.</span>
  </p>
  <p id="p00402" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un epftopo puede reconocerse selectivamente por un anticuerpo en una conformacion de una protefna y no en una segunda conformacion de la protefna. "Selectivo" se usa contextualmente para caracterizar las propiedades de union de un anticuerpo. Un anticuerpo que se une selectivamente a un epftopo dado se unira a ese epftopo con mayor avidez o con mas especificidad, respecto a otros epftopos diferentes presentados por la misma molecula. Por ejemplo, un anticuerpo se une selectivamente a un epftopo especffico de enfermedad si se une a SOD1 mal plegada en que el epftopo especffico de enfermedad esta accesible, de forma dos veces mas eficaz de lo que se une a SOD1 nativa donde el epftopo especffico de enfermedad no esta accesible. En otras realizaciones, el anticuerpo se une de forma 3-5 veces, 5-7 veces, 7-10, 10-15, 5-15, o 5-30 veces mas eficaz.</span>An epftope can be selectively recognized by an antibody in a conformation of a protein and not in a second conformation of the protein. "Selective" is used contextually to characterize the binding properties of an antibody. An antibody that selectively binds to a given epftope will bind to that epftope with greater avidity or more specificity, relative to other different epftopes presented by the same molecule. For example, an antibody selectively binds to a disease-specific epftope if it binds to poorly folded SOD1 in which the disease-specific epftope is accessible, twice as effectively as it binds to native SOD1 where the specific epftope of disease is not accessible. In other embodiments, the antibody binds 3-5 times, 5-7 times, 7-10, 10-15, 5-15, or 5-30 times more effectively.</span>
  </p>
  <p id="p00403" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos que son "especfficos de enfermedad", en el contexto de la presente memoria descriptiva, son epftopos que se presentan o estan accesibles selectivamente por una o mas formas mal plegadas de SOD1 que son caracterfsticas de una enfermedad particular o de una categorfa de enfermedad.</span>Epftopos that are "disease specific", in the context of the present specification, are epftopos that are presented or are selectively accessible by one or more misfolded forms of SOD1 that are characteristic of a particular disease or of a disease category. .</span>
  </p>
  <p id="p00404" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A causa de la especificidad de enfermedad de SOD1 de estos epftopos, son dianas utiles para tratar trastornos, enfermedades y afecciones mediadas por SOD1 tales como esclerosis lateral amiotrofica, enfermedad de Alzheimer o enfermedad de Parkinson o para producir una respuesta inmunitaria en un animal. Por ejemplo, la vacunacion de sujetos diagnosticados con esclerosis lateral amiotrofica, enfermedad de Alzheimer o enfermedad de Parkinson con una composicion que comprende peptidos aislados correspondientes a los epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer o epftopos especfficos de enfermedad de Parkinson, respectivamente, inhibe la formacion de agregados de SOD1 en la enfermedad bloqueando la participacion de las especies moleculares de SOD1 mal plegadas en el proceso de agregacion y/o bloqueando el mal plegamiento dirigido por molde de SOD1, o induciendo la eliminacion basada en complejo inmunitario de formas unidas a anticuerpo de SOD1 neurotoxica mal plegada y/o agregados.</span>Because of the specificity of SOD1 disease of these epftopos, they are useful targets to treat disorders, diseases and conditions mediated by SOD1 such as amyotrophic lateral sclerosis, Alzheimer's disease or Parkinson's disease or to produce an immune response in an animal. For example, vaccination of subjects diagnosed with amyotrophic lateral sclerosis, Alzheimer's disease or Parkinson's disease with a composition comprising isolated peptides corresponding to specific episodes of amyotrophic lateral sclerosis, specific epftopos of Alzheimer's disease or specific epftopos of Parkinson's disease , respectively, inhibits the formation of SOD1 aggregates in the disease by blocking the participation of poorly folded SOD1 molecular species in the aggregation process and / or blocking the misfolding directed by SOD1 template, or inducing elimination based on immune complex of antibody-bound forms of misfolded and / or aggregated neurotoxic SOD1 antibody.</span>
  </p>
  <p id="p00405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 se encuentran en SOD1 asociada con enfermedades neurodegenerativas y son utiles para tratar, diagnosticar o prevenir enfermedades relacionadas con SOD1 mal plegada, incluyendo enfermedad de Alzheimer, enfermedad de Parkinson y/o esclerosis lateral amiotrofica.</span>Epftopes presented selectively or accessible in non-native forms of SOD1 are found in SOD1 associated with neurodegenerative diseases and are useful for treating, diagnosing or preventing diseases related to poorly folded SOD1, including Alzheimer's disease, Parkinson's disease and / or amyotrophic lateral sclerosis .</span>
  </p>
  <p id="p00406" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "epftopo presentado selectivamente o accesible en formas no nativas de SOD1" como se usa en este documento, se refiere a un epftopo que se presenta selectivamente o esta accesible en SOD1 monomerica o SOD1 mal plegada en formas monomericas, dimericas o agregadas, pero no sobre la superficie molecular de la forma homodimerica nativa, plegada correctamente de SOD1. En otros terminos, los epftopos pueden caracterizarse como</span>The expression "epftopo presented selectively or accessible in non-native forms of SOD1" as used herein, refers to an epftope that is selectively presented or is accessible in monomeric SOD1 or SOD1 misfolded in monomeric, dimeric or aggregated forms, but not on the molecular surface of the native homodimeric form, correctly folded from SOD1. In other terms, epftopes can be characterized as</span>
  </p>
  <p id="p00407" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00409" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00410" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00411" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00412" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00413" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00414" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00415" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00416" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00417" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00418" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00419" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00420" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aquellos que dan lugar a anticuerpos que se unen selectivamente a formas de SOD1 asociadas con enfermedades relacionadas con SOD1 mal plegada, incluyendo enfermedad de Alzheimer, enfermedad de Parkinson y/o esclerosis lateral amiotrofica, respecto a la forma homodimerica nativa de SOD1.</span>those that give rise to antibodies that selectively bind to SOD1 forms associated with poorly folded SOD1 related diseases, including Alzheimer's disease, Parkinson's disease and / or amyotrophic lateral sclerosis, relative to the native homodimeric form of SOD1.</span>
  </p>
  <p id="p00421" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los siguientes 7 epftopos se han identificado como epftopos presentados selectivamente o accesibles en formas no nativas de SOD1:</span>The following 7 epftopos have been identified as epftopos presented selectively or accessible in non-native forms of SOD1:</span>
  </p>
  <p id="p00422" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (SEQ ID NO: 1, DSE1);</span>RLACGVIGI (SEQ ID NO: 1, DSE1);</span>
  </p>
  <p id="p00423" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DLGKGGNEESTKTGNAGS (SEQ ID NO: 2, DSE2) (documento WO 2005/019828);</span>DLGKGGNEESTKTGNAGS (SEQ ID NO: 2, DSE2) (WO 2005/019828);</span>
  </p>
  <p id="p00424" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NPLSRKHGGPKDEE (SEQ ID NO: 3, DSE3) (documento WO 2005/019828);</span>NPLSRKHGGPKDEE (SEQ ID NO: 3, DSE3) (WO 2005/019828);</span>
  </p>
  <p id="p00425" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IKGLTEGLHGF (SEQ ID NO: 5, DSE5) (8);</span>IKGLTEGLHGF (SEQ ID NO: 5, DSE5) (8);</span>
  </p>
  <p id="p00426" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HCIIGRTLVVH (SEQ ID NO: 6, DSE6) (8)</span>HCIIGRTLVVH (SEQ ID NO: 6, DSE6) (8)</span>
  </p>
  <p id="p00427" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAVCVLK (SEO ID NO: 4, DSE4); y GLHGFHVH (SEQ ID NO: 7, DSE7).</span>KAVCVLK (SEO ID NO: 4, DSE4); and GLHGFHVH (SEQ ID NO: 7, DSE7).</span>
  </p>
  <p id="p00428" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que los epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 pueden ser la totalidad o parte de las secuencias anteriores. El termino "parte de" como se usa en este documento se refiere a la secuencia que retiene la actividad epitopica de union a un anticuerpo selectivo para formas no nativas de SOD1 y donde el anticuerpo se genera opcionalmente por inmunizacion con un peptido aislado correspondiente a dicho epftopo en un animal. Tambien se describen analogos de las secuencias anteriores, tales como RLA[Acido cisteico]GVIGI (DSE1a), que tiene una cistefna oxidada.</span>One skilled in the art will appreciate that epftopos presented selectively or accessible in non-native forms of SOD1 may be all or part of the above sequences. The term "part of" as used herein refers to the sequence that retains the epitopic activity of binding to a selective antibody for non-native forms of SOD1 and where the antibody is optionally generated by immunization with an isolated peptide corresponding to said Epftopo in an animal. Analogs of the above sequences are also described, such as RLA [Cysteic Acid] GVIGI (DSE1a), which has an oxidized cystephine.</span>
  </p>
  <p id="p00429" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "epftopo especffico de enfermedad de Alzheimer" como se usa en este documento, se refiere a un epftopo que esta selectivamente presente o accesible en SOD1 monomerica o SOD1 mal plegada en forma monomerica, dimerica o agregada, pero no en la forma homodimerica nativa de SOD1. En otros terminos, los epftopos pueden caracterizarse como aquellos donde la inmunizacion con un inmunogeno que comprende peptidos aislados correspondientes a dichos epftopos da lugar a anticuerpos que se unen selectivamente a formas asociadas a enfermedad de Alzheimer de SOD1, respecto a la forma homodimerica nativa de SOD1.</span>The expression "specific epftopo of Alzheimer's disease" as used herein, refers to an epftope that is selectively present or accessible in monomeric SOD1 or SOD1 misfolded in monomeric, dimeric or aggregated form, but not in the native homodynamic form of SOD1. In other terms, epftopos can be characterized as those where immunization with an immunogen comprising isolated peptides corresponding to said epftopes gives rise to antibodies that selectively bind to forms associated with Alzheimer's disease of SOD1, with respect to the native homodimeric form of SOD1 .</span>
  </p>
  <p id="p00430" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que el epftopo especffico de enfermedad de Alzheimer puede ser la totalidad o parte de las secuencias anteriores. El termino "parte de", como se usa en este documento, se refiere a la secuencia que retiene la actividad epitopica de union de un anticuerpo selectivo para formas no nativas de SOD1 donde el anticuerpo se genera opcionalmente por inmunizacion con un peptido aislado correspondiente a la totalidad o parte de dicho epftopo en un animal. Tambien se describen analogos de las secuencias anteriores.</span>One skilled in the art will appreciate that the specific epftopo of Alzheimer's disease may be all or part of the above sequences. The term "part of", as used herein, refers to the sequence that retains the epitopic binding activity of a selective antibody for non-native forms of SOD1 where the antibody is optionally generated by immunization with an isolated peptide corresponding to all or part of said epftopo in an animal. Analogs of the above sequences are also described.</span>
  </p>
  <p id="p00431" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "epftopo especffico de enfermedad de Parkinson", como se usa en este documento, se refiere a un epftopo que esta selectivamente presente o accesible en SOD1 monomerica o SOD1 mal plegada en forma monomerica, dimerica o agregada, pero no en la forma homodimerica nativa de SOD1. En otros terminos, los epftopos pueden caracterizarse como aquellos donde la inmunizacion con un inmunogeno que comprende peptidos aislados correspondientes a dichos epftopos da lugar a anticuerpos que se unen selectivamente a formas asociadas a enfermedad de Parkinson de SOD1, respecto a la forma homodimerica nativa de SOD1.</span>The term "Parkinson's disease-specific epftope", as used herein, refers to an epftope that is selectively present or accessible in monomeric SOD1 or SOD1 misfolded in monomeric, dimeric or aggregated form, but not in the homodimeric form. native of SOD1. In other terms, epftopos can be characterized as those where immunization with an immunogen comprising isolated peptides corresponding to said epftopes gives rise to antibodies that selectively bind to forms associated with Parkinson's disease of SOD1, relative to the native homodimeric form of SOD1 .</span>
  </p>
  <p id="p00432" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que el epftopo especffico de enfermedad de Parkinson puede ser la totalidad o parte de las secuencias anteriores. El termino "parte de", como se usa en este documento, se refiere a la secuencia que retiene la actividad epitopica de union de un anticuerpo selectivo para formas no nativas de SOD1, donde el anticuerpo se genera opcionalmente por inmunizacion con un peptido aislado correspondiente a la totalidad o parte de dicho epftopo en un animal. Tambien se describen analogos de las secuencias anteriores.</span>One skilled in the art will appreciate that the specific epitope of Parkinson's disease may be all or part of the above sequences. The term "part of", as used herein, refers to the sequence that retains the epitopic binding activity of a selective antibody for non-native forms of SOD1, where the antibody is optionally generated by immunization with a corresponding isolated peptide. to all or part of said epftopo in an animal. Analogs of the above sequences are also described.</span>
  </p>
  <p id="p00433" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "epftopo especffico de esclerosis lateral amiotrofica", como se usa en este documento, se refiere a un epftopo que esta selectivamente presente o accesible en SOD1 monomerica o SOD1 mal plegada en forma monomerica, dimerica o agregada, pero no en la forma homodimerica nativa de SOD1. En otros terminos, los epftopos pueden caracterizarse como aquellos que dan lugar a anticuerpos que se unen selectivamente a formas asociadas a ALS de SOD1, respecto a la forma homodimerica nativa de SOD1.</span>The expression "specific epitope of amyotrophic lateral sclerosis", as used herein, refers to an epftope that is selectively present or accessible in monomeric SOD1 or SOD1 misfolded in monomeric, dimeric or aggregated form, but not in the homodynamic form native of SOD1. In other terms, epftopes can be characterized as those that give rise to antibodies that selectively bind to ALS-associated forms of SOD1, relative to the native homodimeric form of SOD1.</span>
  </p>
  <p id="p00434" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que el epftopo especffico de esclerosis lateral amiotrofica puede ser la totalidad o parte de las secuencias anteriores. El termino "parte de", como se usa en este documento, se refiere a la secuencia que retiene la actividad epitopica de union de un anticuerpo selectivo para formas no nativas de SOD1, donde el anticuerpo se genera opcionalmente por inmunizacion con un peptido aislado correspondiente a la totalidad o parte de dicho epftopo en un animal. Tambien se describen analogos de las secuencias anteriores.</span>One skilled in the art will appreciate that the specific epitope of amyotrophic lateral sclerosis may be all or part of the above sequences. The term "part of", as used herein, refers to the sequence that retains the epitopic binding activity of a selective antibody for non-native forms of SOD1, where the antibody is optionally generated by immunization with a corresponding isolated peptide. to all or part of said epftopo in an animal. Analogs of the above sequences are also described.</span>
  </p>
  <p id="p00435" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El termino "analogo", como se usa en este documento, incluye partes, extensiones, sustituciones, variantes, modificaciones o equivalentes qufmicos y derivados de los mismos de las secuencias de aminoacidos y nucleotidos descritas en este documento que realizan sustancialmente la misma funcion que el peptido, protefna o moleculas de acido nucleico descritas en este documento sustancialmente del mismo modo. Por ejemplo, los analogos de peptidos y protefnas incluyen, sin limitacion, sustituciones conservativas de aminoacidos. Los analogos de peptidos tambien incluyen la modificacion de acido cisteico de un aminoacido, como en RLAC*GVIGI (DSE1 a). Por ejemplo,</span>The term "analog", as used herein, includes parts, extensions, substitutions, variants, modifications or chemical equivalents and derivatives thereof of the amino acid and nucleotide sequences described herein that perform substantially the same function as the peptide, protein or nucleic acid molecules described herein in substantially the same way. For example, peptide and protein analogs include, without limitation, conservative amino acid substitutions. Peptide analogs also include the modification of cysteic acid of an amino acid, as in RLAC * GVIGI (DSE1 a). For example,</span>
  </p>
  <p id="p00436" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00437" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00438" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00439" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00441" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00442" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00444" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00446" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00448" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">un aminoacido se acetila opcionalmente (Ac-). Los analogos de los peptidos y protefnas tambien incluyen adiciones y deleciones a los peptidos y protefnas descritos en este documento. Los analogos de acidos nucleicos incluyen sustituciones de nucleotidos degenerados que codifican un peptido aislado como se describe en este documento. Ademas, los peptidos analogos y secuencias nucleotfdicas analogas incluyen derivados de los mismos.</span>an amino acid is optionally acetylated (Ac-). Peptide and protein analogs also include additions and deletions to the peptides and proteins described herein. Nucleic acid analogs include degenerate nucleotide substitutions encoding an isolated peptide as described herein. In addition, analog peptides and analog nucleotide sequences include derivatives thereof.</span>
  </p>
  <p id="p00450" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una "sustitucion conservativa de aminoacido", como se usa en este documento, es una en que un resto de aminoacido se remplaza con otro resto de aminoacido sin anular las propiedades deseadas del peptido.</span>A "conservative amino acid substitution," as used herein, is one in which an amino acid residue is replaced with another amino acid residue without nullifying the desired properties of the peptide.</span>
  </p>
  <p id="p00451" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "derivado de un peptido" se refiere a un peptido que tiene uno o mas restos derivatizados qufmicamente por reaccion de un grupo lateral funcional. Dichas moleculas derivatizadas incluyen, por ejemplo, aquellas moleculas en que los grupos amino libres se han derivatizado para formar clorhidratos de amina, grupos p- tolueno sulfonilo, carbobenzoxi, grupos t-butiloxicarbonilo, grupos cloroacetilo o grupos formilo. Los grupos carboxilo libres pueden derivatizarse para formar sales, esteres metflicos y etflicos u otros tipos de esteres o hidracidas. Los grupos hidroxilo libres pueden derivatizarse para formar derivados O-acilo u O-alquilo. El nitrogeno de imidazol de histidina puede derivatizarse para formar N-im-bencilhistidina. Tambien se incluyen como derivados aquellos peptidos que contienen uno o mas derivados de aminoacido de origen natural de los veinte aminoacidos convencionales. Por ejemplo: puede sustituirse 4-hidroxiprolina en el lugar de la prolina; puede sustituirse 5- hidroxilisina en el lugar de lisina; puede sustituirse 3-metilhistidina en el lugar de histidina; puede sustituirse homoserina en el lugar de serina; y puede sustituirse ornitina en el lugar de lisina. Un derivado de un peptido tambien incluye opcionalmente peptidos que comprenden formas de aminoacidos que estan oxidadas.</span>The term "derivative of a peptide" refers to a peptide having one or more chemically derivatized moieties by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which the free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. The free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. Histidine imidazole nitrogen can be derivatized to form N-im-benzylhistidine. Also included as derivatives are those peptides that contain one or more naturally occurring amino acid derivatives of the twenty conventional amino acids. For example: 4-hydroxyproline can be substituted at the proline site; 5- hydroxylysine can be substituted at the lysine site; 3-methylhistidine may be substituted at the histidine site; homoserine may be substituted at the serine site; and ornithine can be substituted at the lysine site. A derivative of a peptide also optionally includes peptides comprising amino acid forms that are oxidized.</span>
  </p>
  <p id="p00452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El estres oxidativo puede conducir a danos en las protefnas, ADN y lfpidos celulares. Se ha informado de estres oxidativo en AD y PD (64). Los inventores han demostrado que anticuerpos selectivos para DSE1a que comprenden una cistefna oxidada en forma de acido cisteico, tienen alta afinidad por SOD1 mal plegada. Otros aminoacidos tambien pueden oxidarse o nitrarse como resultado del estres oxidativo. Por ejemplo, la histidina, arginina y lisina pueden formar grupos carbonilo, la metionina puede oxidarse en sulfoxido de metiona y la fenilalanina puede nitrarse en nitrotriptofano. Adicionalmente la cistefna puede oxidarse en acido cistefna sulffnico.</span>Oxidative stress can lead to damage to proteins, DNA and cell lipids. Oxidative stress has been reported in AD and PD (64). The inventors have shown that selective antibodies to DSE1a that comprise an oxidized cysteine in the form of cysteic acid have high affinity for poorly folded SOD1. Other amino acids can also be oxidized or nitrated as a result of oxidative stress. For example, histidine, arginine and lysine can form carbonyl groups, methionine can be oxidized in methiona sulfoxide, and phenylalanine can be nitrated in nitrotriptan. Additionally, cystefna can be oxidized in sulphonic cysteine acid.</span>
  </p>
  <p id="p00453" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, los epftopos en una realizacion comprenden uno o mas aminoacidos oxidados o nitrados. En realizaciones especfficas de la invencion, el epftopo de SOD1 puede comprender un aminoacido oxidado o nitrado, particularmente cistefna oxidada, es decir, acido cisteico.</span>Accordingly, epftopes in one embodiment comprise one or more oxidized or nitrated amino acids. In specific embodiments of the invention, the SOD1 epitope may comprise an oxidized or nitrated amino acid, particularly oxidized cysteine, that is, cysteic acid.</span>
  </p>
  <p id="p00454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos aislados correspondientes a epftopos presentados selectivamente en SOD1 no nativa, en una realizacion comprenden uno o mas aminoacidos oxidados o nitrados. En realizaciones especfficas de la invencion el epftopo de SOD1 puede comprender un aminoacido oxidado o nitrado, particularmente cistefna oxidada, es decir, acido cisteico.</span>Isolated peptides corresponding to epftopes selectively presented in non-native SOD1, in one embodiment comprise one or more oxidized or nitrated amino acids. In specific embodiments of the invention, the SOD1 epitope may comprise an oxidized or nitrated amino acid, particularly oxidized cysteine, that is, cysteic acid.</span>
  </p>
  <p id="p00455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos asilados correspondientes a epftopos que son utiles en la presente invencion, por tanto, son opcionalmente peptidos que incorporan secuencias correspondientes a tramos de aminoacidos contiguos dentro de la secuencia de SOD1 humana para formar epftopos selectivamente accesible solamente en formas monomericas de SOD1, o en cualquier forma de SOD1 que este mal plegada o sea no nativa. Los epftopos que se han identificado como selectivamente accesibles en SOD1 no nativa comprenden los siguientes tramos de aminoacidos de hSOD1:</span>Asylated peptides corresponding to epftopes that are useful in the present invention, therefore, are optionally peptides that incorporate sequences corresponding to contiguous amino acid stretches within the human SOD1 sequence to form selectively accessible epftopes only in monomeric forms of SOD1, or in any form of SOD1 that is misfolded or is not native. Epftopes that have been identified as selectively accessible in non-native SOD1 comprise the following amino acid stretches of hSOD1:</span>
  </p>
  <p id="p00456" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (SEQ ID NO: 1 en SOD1 SEQ ID NO: 17 restos 143-151) DLGKGGNEESTKTGNAGS (SEQ ID NO:</span>RLACGVIGI (SEQ ID NO: 1 in SOD1 SEQ ID NO: 17 residues 143-151) DLGKGGNEESTKTGNAGS (SEQ ID NO:</span>
  </p>
  <p id="p00457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 en SOD1 SEQ ID NO: 17 restos 125-142);</span>2 in SOD1 SEQ ID NO: 17 residues 125-142);</span>
  </p>
  <p id="p00458" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NPLSRKHGGPKDEE; (SEQ ID NO: 3 en SOD1 SEQ ID NO: 17 restos 65-78);</span>NPLSRKHGGPKDEE; (SEQ ID NO: 3 in SOD1 SEQ ID NO: 17 residues 65-78);</span>
  </p>
  <p id="p00459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IKGLTEGLHGF (SEQ ID NO: 5 en SOD1 SEQ ID NO: 17 restos 35-42);</span>IKGLTEGLHGF (SEQ ID NO: 5 in SOD1 SEQ ID NO: 17 residues 35-42);</span>
  </p>
  <p id="p00460" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HCIIGRTLVVH (SEQ ID NO: 6 en SOD1 SEQ ID NO: 17 restos 110-120);</span>HCIIGRTLVVH (SEQ ID NO: 6 in SOD1 SEQ ID NO: 17 residues 110-120);</span>
  </p>
  <p id="p00461" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAVCVLK (SEQ ID NO: 4 en SOD1 SEQ ID NO: 17 restos 3-9); y</span>KAVCVLK (SEQ ID NO: 4 in SOD1 SEQ ID NO: 17 residues 3-9); Y</span>
  </p>
  <p id="p00462" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GLHGFHVH (SEQ ID NO: 7 en SOD1 SEQ ID NO: 17 restos 41-48)</span>GLHGFHVH (SEQ ID NO: 7 in SOD1 SEQ ID NO: 17 remains 41-48)</span>
  </p>
  <p id="p00463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para servir como inmunogeno util para inmunoterapia activa o para crear anticuerpos para su uso, por ejemplo, en inmunoterapia pasiva, el peptido incorpora de forma deseable un mfnimo de aproximadamente 3, 4, 5, 6 o 7 restos del epftopos especffico de enfermedad de SOD1. En una realizacion, el peptido aislado correspondiente a un epftopo comprende de forma deseable al menos 8 restos de SOD1. El peptido se acomodara dentro de un tramo de SOD1 que es de menos de 20 restos. Se describe el uso de peptidos que comprenden una parte aun mas grande de SOD1, posiblemente produciendo multiples anticuerpos, que requiere la seleccion de aquellos que se unen selectivamente a un epftopo caracterfstico de SOD1 mal plegada.</span>To serve as a useful immunogen for active immunotherapy or to create antibodies for use, for example, in passive immunotherapy, the peptide desirably incorporates a minimum of about 3, 4, 5, 6 or 7 residues of the specific episodes of SOD1 disease . In one embodiment, the isolated peptide corresponding to an epitope desirably comprises at least 8 residues of SOD1. The peptide will be accommodated within a stretch of SOD1 that is less than 20 residues. The use of peptides comprising an even larger part of SOD1 is described, possibly producing multiple antibodies, which requires the selection of those that selectively bind to a poorly folded SOD1 characteristic epitope.</span>
  </p>
  <p id="p00464" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las secuencias de SOD1 utiles para abordarse de acuerdo con la presente descripcion incluyen las regiones de hSOD1 que incorporan los restos 3-9, los restos 35-45, los restos 41-48, los restos 65-78, los restos 125-142, los restos 143-151 y los restos 145-151. Como se aprecia, dicha secuencia peptfdica correspondiente a epftopos de SOD1 mal plegada puede truncarse para incorporar un mfnimo de cualquiera de 5, 6 o 7 restos de las regiones indicadas. Por ejemplo, DSE1 que tiene la secuencia RLACGVIGI, puede truncarse retirando los primeros dos aminoacidos "RL". Ademas, estas regiones pueden ampliarse, como se indica, para incorporar restos de SOD1 flanqueantes adicionales hasta una cantidad maxima de restos que impacte de alguna manera en el equilibrio</span>Useful SOD1 sequences to be addressed in accordance with the present description include the regions of hSOD1 incorporating residues 3-9, residues 35-45, residues 41-48, residues 65-78, residues 125-142, remains 143-151 and remains 145-151. As can be seen, said peptidic sequence corresponding to episodes of misfolded SOD1 can be truncated to incorporate a minimum of any of 5, 6 or 7 residues of the indicated regions. For example, DSE1, which has the sequence RLACGVIGI, can be truncated by removing the first two "RL" amino acids. In addition, these regions can be extended, as indicated, to incorporate additional flanking SOD1 residues to a maximum amount of residues that somehow impacts the balance</span>
  </p>
  <p id="p00465" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00466" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00467" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00468" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00469" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00470" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00471" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00472" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00473" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00474" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00475" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00476" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00477" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">deseado entre el coste de la produccion de peptido o vacuna y la especificidad deseada y otras propiedades del anticuerpo resultante.</span>desired between the cost of peptide or vaccine production and the desired specificity and other properties of the resulting antibody.</span>
  </p>
  <p id="p00479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, el peptido aislado correspondiente a un epftopo especffico de enfermedad comprende todo o parte de la secuencia de un peptido aislado seleccionado del grupo que cosiste en los peptidos de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>In a description, the isolated peptide corresponding to a disease-specific epitope comprises all or part of the sequence of an isolated peptide selected from the group that sewed on the peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00480" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos correspondientes a estos epftopos pueden comprender adicionalmente restos de aminoacido adicionales no de SOD1 particularmente en los extremos N y C-terminales de los mismos, que puede ser utiles en la conjugacion del peptido con un agente util, por ejemplo, para provocar una respuesta inmunitaria, o un agente que sirve como marca util en la produccion del peptido o para controlar su presencia. Por ejemplo, el peptido puede comprender adicionalmente un resto Cys N-terminal para ayudar con el acoplamiento a kLh o similares. El peptido puede comprender adicionalmente uno, dos, tres o mas restos de glicina flanqueantes, o una combinacion de glicina/serina o de glicina/lisina tal como GSG o GGKG, para mejorar la respuesta inmunitaria aumentando la longitud del peptido sin cambiar la especificidad de los anticuerpos que se forman. El peptido correspondiente al epftopo puede comprender adicionalmente un enlazador eficaz para acoplar el peptido en tandem con otra copia del mismo peptido o uno diferente correspondiente al mismo epftopo o uno diferente. Como alternativa, el peptido correspondiente a un epftopo puede comprender adicionalmente una marcad de polihistidina o Flag. En otra realizacion, los peptidos pueden comprender aminoacidos adicionales que potencian la inmunogenicidad o solubilidad del peptido. En una realizacion, el numero de aminoacidos adicionales es de 1 a aproximadamente 10, preferiblemente de 1 a 8, mas preferiblemente de 1 a 5. De forma importante, los restos adicionales no afectan de forma material a la conformacion del peptido. En una descripcion, el peptido aislado correspondiente al epftopo especffico de esclerosis lateral amiotrofica comprende 6 aminoacidos adicionales y comprende la secuencia GGRLACGVIGIGGKG. En otra descripcion, el peptido aislado correspondiente al epftopo especffico de esclerosis lateral amiotrofica comprende 4 aminoacidos adicionales y comprende la secuencia GGRLACGVIGIAQ.</span>The peptides corresponding to these epftopes may additionally comprise additional amino acid residues not of SOD1, particularly at the N and C-terminal ends thereof, which may be useful in conjugating the peptide with a useful agent, for example, to elicit a response. immune, or an agent that serves as a useful brand in the production of the peptide or to control its presence. For example, the peptide may additionally comprise an N-terminal Cys moiety to assist with coupling to kLh or the like. The peptide may additionally comprise one, two, three or more flanking glycine residues, or a combination of glycine / serine or glycine / lysine such as GSG or GGKG, to improve the immune response by increasing the length of the peptide without changing the specificity of the antibodies that form. The peptide corresponding to the epftope may additionally comprise a linker effective to couple the peptide in tandem with another copy of the same or a different peptide corresponding to the same or a different epftope. Alternatively, the peptide corresponding to an epftope may additionally comprise a polyhistidine or Flag tag. In another embodiment, the peptides may comprise additional amino acids that enhance the immunogenicity or solubility of the peptide. In one embodiment, the number of additional amino acids is from 1 to about 10, preferably from 1 to 8, more preferably from 1 to 5. Importantly, the additional residues do not materially affect the conformation of the peptide. In a description, the isolated peptide corresponding to the specific amyotrophic lateral sclerosis epftope comprises 6 additional amino acids and comprises the sequence GGRLACGVIGIGGKG. In another description, the isolated peptide corresponding to the specific epitope of amyotrophic lateral sclerosis comprises 4 additional amino acids and comprises the sequence GGRLACGVIGIAQ.</span>
  </p>
  <p id="p00481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, las secuencias de aminoacidos analogas del peptido aislado correspondiente a epftopos especfficos de enfermedad presentados selectivamente o accesibles en formas no nativas de SOD1 tfpicamente tienen al menos: el 60 %, 70 %, 80 % o 90 % de identidad de secuencia con las secuencias anteriores. En otra descripcion, las secuencias de aminoacidos analogas del peptido aislado correspondiente a epftopos especfficos de ALS, epftopos especfficos de PD o epftopos especfficos de AD tiene al menos: el 60 %, 70 %, 80 % o 90 % de identidad de secuencia con las secuencias anteriores. La expresion "identidad de secuencia" como se usa en este documento se refiere al porcentaje de identidad de secuencia entre dos secuencias polipeptfdicas. Para determinar el porcentaje de identidad entre dos secuencias polipeptfdicas, se alinean las secuencias de aminoacidos de esas dos secuencias, preferiblemente usando el algoritmo Clustal W (9), junto con la matriz de valores BLOSUM 62 (10) y una penalizacion por abertura de hueco de 10 y una penalizacion por extension de hueco de 0,1, de modo que se obtenga la coincidencia de mayor orden entre dos secuencias donde al menos el 50 % de la longitud total de una de las secuencias esta implicada en la alineacion. Otros metodos que pueden usarse para alinear secuencias son el metodo de alineacion de Needleman y Wunsch (11), revisado por Smith y Waterman (12) de modo que se obtenga la coincidencia de mayor orden entre las dos secuencias y se determine la cantidad de aminoacidos identicos entre las dos secuencias. Otros metodos para calcular el porcentaje de identidad entre dos secuencias de aminoacidos estan generalmente reconocidos en la tecnica e incluyen, por ejemplo, aquellos descritos por Carillo y Lipton (13) y aquellos descritos en Computational Molecular Biology (14). En lfneas generales, se emplearan programas informaticos para dichos calculos. Los programas informaticos que pueden usarse a este respecto incluyen, aunque sin limitacion, GCG (15) BLASTP, BLASTN y FASTA (16).</span>In one description, the analog amino acid sequences of the isolated peptide corresponding to disease-specific epftopes presented selectively or accessible in non-native forms of SOD1 typically have at least: 60%, 70%, 80% or 90% sequence identity with the above sequences. In another description, the analog amino acid sequences of the isolated peptide corresponding to specific episodes of ALS, specific epftopos of PD or specific epftopos of AD have at least: 60%, 70%, 80% or 90% sequence identity with the previous sequences. The expression "sequence identity" as used herein refers to the percentage of sequence identity between two polypeptide sequences. To determine the percentage of identity between two polypeptide sequences, the amino acid sequences of those two sequences are aligned, preferably using the Clustal W algorithm (9), together with the BLOSUM 62 value matrix (10) and a gap opening penalty. of 10 and a gap extension penalty of 0.1, so that the highest order match between two sequences is obtained where at least 50% of the total length of one of the sequences is involved in the alignment. Other methods that can be used to align sequences are the alignment method of Needleman and Wunsch (11), reviewed by Smith and Waterman (12) so that the highest order match between the two sequences is obtained and the amount of amino acids is determined. identical between the two sequences. Other methods for calculating the percentage of identity between two amino acid sequences are generally recognized in the art and include, for example, those described by Carillo and Lipton (13) and those described in Computational Molecular Biology (14). In general, computer programs will be used for these calculations. Computer programs that can be used in this regard include, but are not limited to, GCG (15) BLASTP, BLASTN and FASTA (16).</span>
  </p>
  <p id="p00482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, aunque las dianas epitopicas preferidas comprenden la secuencia que se encuentra en hSOD1, se describen analogos de estas secuencias epitopicas que, como se ha indicado anteriormente, incluyen derivados, extensiones, truncamientos, aminoacidos modificados y similares. Dichas formas de los peptidos aislados correspondientes a epftopos especfficos de enfermedad estan abarcadas por el termino "analogos". Dichos analogos tambien son utiles para crear anticuerpos que se uniran a los epftopos presentes en SOD mal plegada o monomerica, por ejemplo, a uno de los siete epftopos identificados anteriormente en este documento.</span>Therefore, although the preferred epitope targets comprise the sequence found in hSOD1, analogs of these epitope sequences are described which, as indicated above, include derivatives, extensions, truncations, modified amino acids and the like. Said forms of the isolated peptides corresponding to disease-specific epitopes are encompassed by the term "analogs." Such analogs are also useful for creating antibodies that will bind to epftopes present in poorly folded or monomeric SOD, for example, to one of the seven epftopes identified earlier in this document.</span>
  </p>
  <p id="p00483" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, respecto a los epftopos preferidos identificados anteriormente, los peptidos aislados utiles correspondientes a analogos epitopicos, incluyen peptidos aislados que comprenden, aunque sin limitacion:</span>Therefore, with respect to the preferred epftopes identified above, the isolated useful peptides corresponding to epitope analogs, include isolated peptides comprising, but not limited to:</span>
  </p>
  <p id="p00484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para RLACGVIGI:</span>For RLACGVIGI:</span>
  </p>
  <p id="p00485" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">truncamiento N-terminal de R o RL; extension N-terminal con G o GG o acetil-GG y/o extension C-terminal</span>N-terminal truncation of R or RL; N-terminal extension with G or GG or acetyl-GG and / or C-terminal extension</span>
  </p>
  <p id="p00486" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">con G, GG, GGK o GGKG, por ejemplo, para llegar a acetil-RLACGVIVIVGGKG; con o sin oxidacion de C</span>with G, GG, GGK or GGKG, for example, to reach acetyl-RLACGVIVIVGGKG; with or without C oxidation</span>
  </p>
  <p id="p00487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">para producir acido cisteico, para llegar a AC*GVIVIVG, incluyendo CGGGRLAC*GVIGIGSG;</span>to produce cysteic acid, to reach AC * GVIVIVG, including CGGGRLAC * GVIGIGSG;</span>
  </p>
  <p id="p00488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLAC*GVIGIGSG y CRLAC*GVIGIGSG; (donde C* indica acido cisteico)</span>RLAC * GVIGIGSG and CRLAC * GVIGIGSG; (where C * indicates cysteic acid)</span>
  </p>
  <p id="p00489" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para DLGKGGNEESTKTGNAGS;</span>For DLGKGGNEESTKTGNAGS;</span>
  </p>
  <p id="p00490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">truncamiento N-terminal de D, DL, DLG, DLGK y/o truncamiento C-terminal de S, GS, AGS, NAGS; extension</span>N-terminal truncation of D, DL, DLG, DLGK and / or C-terminal truncation of S, GS, AGS, NAGS; extension</span>
  </p>
  <p id="p00491" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">N-terminal con C o con G, GG o GGG; extension C-terminal con G, GG, GS o GSG; por ejemplo para llegar a</span>N-terminal with C or with G, GG or GGG; C-terminal extension with G, GG, GS or GSG; for example to get to</span>
  </p>
  <p id="p00492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00493" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00494" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00495" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00496" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00498" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00499" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00500" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00502" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00503" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00505" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CDLGKGGNEESTKTGNAGS, con o sin modificacion interna por carbonilacion de uno o dos restos de K, por ejemplo; e incluyendo peptidos tales como LGKGGNEESTKTGNAGS, DLGKGGNEESTKTGNAG, GKGGNEESTKTGNAGS, DLGKGGNEESTKTGNA, KGGNEESTKTGNAGS, DLGKGGNEESTKTGN, GGNEESTKTGNAGS, DLGKGGNEESTKTG, LGKGGNEESTKTGNAG, GKGGNEESTKTGNA, o KGGNEESTKTGN.</span>CDLGKGGNEESTKTGNAGS, with or without internal modification by carbonylation of one or two residues of K, for example; and including peptides such as LGKGGNEESTKTGNAGS, DLGKGGNEESTKTGNAG, GKGGNEESTKTGNAGS, DLGKGGNEESTKTGNA, KGGNEESTKTGNAGS, DLGKGGNEESTKTGN, GGNEESTKTGNAGS, DLGKGGNEESTKTG, LGKGGNEESTKTGNAG, GKGGNEESTKTGNA or KGGNEESTKTGN.</span>
  </p>
  <p id="p00506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para NPLSRKHGGPKDEE;</span>For NPLSRKHGGPKDEE;</span>
  </p>
  <p id="p00507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">truncamiento N-terminal de N, NP, NPL y/o truncamiento C-terminal de E, EE, DEE; extension N-terminal con C o con G, GG o GGG; extension C-terminal con G, GG, GS o GSG; por ejemplo para llegar a CNPLSRKHGGPKDEE, con o sin modificacion interna por carbonilacion de uno o dos restos de H, por ejemplo;</span>N-terminal truncation of N, NP, NPL and / or C-terminal truncation of E, EE, DEE; N-terminal extension with C or with G, GG or GGG; C-terminal extension with G, GG, GS or GSG; for example to arrive at CNPLSRKHGGPKDEE, with or without internal modification by carbonylation of one or two residues of H, for example;</span>
  </p>
  <p id="p00508" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para IKGLTEGLHGF;</span>For IKGLTEGLHGF;</span>
  </p>
  <p id="p00509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">adicion N-terminal de C, para llegar a CIKGLTEGLHGF Y para HCIIGRTLVVH;</span>N-terminal addition of C, to reach CIKGLTEGLHGF AND for HCIIGRTLVVH;</span>
  </p>
  <p id="p00510" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">truncamiento N-terminal de H o HC y/o truncamiento C-terminal de H, o VH, extension N-terminal para incluir la secuencia de SOD en los restos 109 o 108/109 y/o para incluir G, GG, o GGG y/o extension C-terminal por uno o dos restos de SOD tales como los restos 121 o 121/122, por ejemplo para llegar a GGGHCIIGRTLVVHGSG.</span>N-terminal truncation of H or HC and / or C-terminal truncation of H, or VH, N-terminal extension to include the SOD sequence in residues 109 or 108/109 and / or to include G, GG, or GGG and / or C-terminal extension by one or two SOD residues such as residues 121 or 121/122, for example to reach GGGHCIIGRTLVVHGSG.</span>
  </p>
  <p id="p00511" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos de los peptidos descritos anteriormente se resumen en la Tabla 2A Tabla 2A. Peptidos aislados de DSE y analogos</span>Examples of the peptides described above are summarized in Table 2A Table 2A. Isolated DSE peptides and analogs</span>
  </p>
  <p id="p00512" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ACGVIGI (SEQ ID NO: 9, analogo de DSE1);</span>ACGVIGI (SEQ ID NO: 9, analogue of DSE1);</span>
  </p>
  <p id="p00513" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ac-GG-RLACGVIG-GGKG (SEQ ID NO: 10, analogo de DSE1);</span>Ac-GG-RLACGVIG-GGKG (SEQ ID NO: 10, analogue of DSE1);</span>
  </p>
  <p id="p00514" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11, analogo de DSE2);</span>CDLGKGGNEESTKTGNAGS (SEQ ID NO: 11, DSE2 analog);</span>
  </p>
  <p id="p00515" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CNPLSRKHGGPKDEE (SEQ ID NO: 12; analogo de DSE3);</span>CNPLSRKHGGPKDEE (SEQ ID NO: 12; DSE3 analogue);</span>
  </p>
  <p id="p00516" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CIKGLTEGLHGF (SEQ ID NO: 14, analogo de DSE5);</span>CIKGLTEGLHGF (SEQ ID NO: 14, DSE5 analogue);</span>
  </p>
  <p id="p00517" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLA[Acido cisteico]GVIGI (SEQ ID NO: 8, DSE1a);</span>RLA [Cysteic acid] GVIGI (SEQ ID NO: 8, DSE1a);</span>
  </p>
  <p id="p00518" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A[Acido cisteico]GVIGI (SEQ ID NO: 13, analogo de DSE1a);</span>A [Cysteic acid] GVIGI (SEQ ID NO: 13, analogue of DSE1a);</span>
  </p>
  <p id="p00519" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">C-GGG-RLA[Acido cisteico]GVIGI-GSG (SEQ ID NO: 15, analogo de DSE1a); y GSGKAVCLK (SEQ ID NO: 16,</span>C-GGG-RLA [Cysteic acid] GVIGI-GSG (SEQ ID NO: 15, analogue of DSE1a); and GSGKAVCLK (SEQ ID NO: 16,</span>
  </p>
  <p id="p00520" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">analogo de DSE4).</span>analogue of DSE4).</span>
  </p>
  <p id="p00521" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se ha indicado anteriormente, se describe un epftopo de DSE1, un peptido aislado correspondiente al epftopo y un anticuerpo dirigido contra el epftopo. Los experimentos caracterizaron adicionalmente DSE1. Los inventores prepararon anticuerpos dirigidos contra epftopos encontrados en formas no nativas de SOD1. Los inventores detectaron SOD1 mal plegada de los tejidos medulares de modelos de raton de ALS G85R, G93A y G37R por inmunoprecipitacion usando el anticuerpo contra SED1. Los inventores tambien detectaron SOD1 mal plegada en secciones medulares de modelos de raton de ALS G93A, G37R y de un paciente humano con ALS, usando el anticuerpo contra SED1 como sonda. Los inventores usaron SED1 para determinar la localizacion subcelular de SOD1 mal plegada donde se determino que el sitio principal de deposicion de SOD1 mal plegada es las mitocondrias vacuoladas dentro de las neuronas motoras del asta ventral. Ademas, se detecto SOD1 mal plegada en las fracciones de medula espinal tanto mitocondrial como citoplasmatica, pero se inmunoprecipitaron solamente cantidades minoritarias de fracciones similares de tejidos de hfgado y cerebro del raton G93A. En ratones G85R, SOD1 mal plegada estaba enriquecido en mitocondrias de medula espinal y cerebro en comparacion con la cantidad recuperada del citosol. Los inventores tambien demostraron que SOD1 mal plegada estaba inicialmente ausente, pero se detectaba antes de la aparicion de la enfermedad y se correlaciona con perdida de neuronas motoras en ratones del modelo de ALS.</span>As indicated above, a DSE1 epftopo, an isolated peptide corresponding to the epftopo and an antibody directed against the epftopo are described. The experiments further characterized DSE1. The inventors prepared antibodies directed against epftopos found in non-native forms of SOD1. The inventors detected poorly folded SOD1 of the medullary tissues of mouse models of ALS G85R, G93A and G37R by immunoprecipitation using the antibody against SED1. The inventors also detected misfolded SOD1 in spinal sections of mouse models of ALS G93A, G37R and of a human patient with ALS, using the antibody against SED1 as a probe. The inventors used SED1 to determine the subcellular location of misfolded SOD1 where it was determined that the main site of deposition of misfolded SOD1 is the vacuolated mitochondria within the motor neurons of the ventral horn. In addition, poorly folded SOD1 was detected in both mitochondrial and cytoplasmic spinal cord fractions, but only minor amounts of similar fractions of liver and liver tissues of mouse G93A were immunoprecipitated. In G85R mice, poorly folded SOD1 was enriched in spinal cord and brain mitochondria compared to the amount recovered from the cytosol. The inventors also demonstrated that poorly folded SOD1 was initially absent, but was detected before the onset of the disease and correlated with loss of motor neurons in mice of the ALS model.</span>
  </p>
  <p id="p00522" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En el caso donde el peptido aislado correspondiente a un epftopo per se o su analogo no es suficientemente inmunogenico, incluso cuando se administra con adyuvantes convencionales, el peptido aislado o el analogo peptfdico aislado puede administrarse en forma de un "inmunogeno", en que el peptido aislado correspondiente al epftopo o a los analogos se fusiona a o se conjuga con un agente que potencia la inmunogenicidad del peptido. Por tanto, la inmunogenicidad o eficacia de la composicion para tratar la esclerosis lateral amiotrofica, la enfermedad de Alzheimer y/o la enfermedad de Parkinson o para provocar una respuesta inmunitaria tambien puede potenciarse conjugando el peptido aislado correspondiente a un epftopo especffico de enfermedad (por ejemplo, tal como un epftopo especffico de esclerosis lateral amiotrofica) directamente, tal como a traves de un enlace amida, o indirectamente a traves de un enlazador qufmico tal como carbodiimida o cualquier secuencia espaciadora peptfdica tal como una glicina o una secuencia de glicina-serina incluyendo Gly-4-S, a una molecula que potencia la inmunogenicidad del peptido correspondiente al epftopo. Por ejemplo, un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica puede conjugarse con el antfgeno MAP, o hemocianina de lapa californiana (KLH). KLH es una protefna respiratoria encontrada en moluscos. Su gran tamano la hace muy inmunogenica, y la gran cantidad de restos de lisina disponibles para la conjugacion la hacen muy util para unirse a un polipeptido, tal como un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica.</span>In the case where the isolated peptide corresponding to an epitope per se or its analogue is not sufficiently immunogenic, even when administered with conventional adjuvants, the isolated peptide or the isolated peptide analogue can be administered in the form of an "immunogen", in which the Isolated peptide corresponding to the epftope or analogs is fused to or conjugated with an agent that enhances the immunogenicity of the peptide. Therefore, the immunogenicity or efficacy of the composition to treat amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease or to elicit an immune response can also be enhanced by conjugating the isolated peptide corresponding to a disease specific epftope (by for example, such as a specific epitope of amyotrophic lateral sclerosis) directly, such as through an amide bond, or indirectly through a chemical linker such as carbodiimide or any peptidic spacer sequence such as a glycine or a glycine-serine sequence including Gly-4-S, to a molecule that enhances the immunogenicity of the peptide corresponding to the epftope. For example, an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis can be conjugated with the MAP antigen, or Californian limpet hemocyanin (KLH). KLH is a respiratory protein found in mollusks. Its large size makes it very immunogenic, and the large amount of lysine residues available for conjugation makes it very useful for binding to a polypeptide, such as an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00523" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00524" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00525" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00526" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00527" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00528" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00529" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00530" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00531" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00532" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00533" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00534" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00535" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00536" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La conjugacion de KLH puede hacerse a traves de restos de Cys N-terminales anadidos al peptido aislado correspondiente al epftopo, si no hay otro sitio conveniente disponible en el peptido para la conjugacion con KLH.</span>The conjugation of KLH can be done through N-terminal Cys moieties added to the isolated peptide corresponding to the epitope, if no other convenient site is available in the peptide for conjugation with KLH.</span>
  </p>
  <p id="p00537" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, la composicion para provocar una respuesta inmunitaria puede comprender un inmunogeno. Un "inmunogeno", como se usa en este documento, significa una sustancia que provoca una respuesta inmunitaria y/o causa produccion de un anticuerpo. Ademas de los peptidos aislados, los conjugados y fusiones descritas en este documento, son utiles peptido mimeticos que provocan anticuerpos de reaccion cruzada contra epftopos especfficos de enfermedad de SOD1 (vease 82).</span>Therefore, the composition for eliciting an immune response may comprise an immunogen. An "immunogen," as used herein, means a substance that elicits an immune response and / or causes the production of an antibody. In addition to the isolated peptides, the conjugates and fusions described herein, mimetic peptides are useful that elicit cross-reactive antibodies against specific episodes of SOD1 disease (see 82).</span>
  </p>
  <p id="p00538" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que puede haber otros epftopos presentados selectivamente o accesibles en formas no nativas de SOD1, tales como otros epftopos especfficos de esclerosis lateral amiotrofica, otros epftopos especfficos de enfermedad de Alzheimer y/u otros epftopos especfficos de enfermedad de Parkinson. Por ejemplo, otros epftopos especfficos de enfermedad pueden identificarse usando el ensayo de proteccion de epftopos descrito en el documento WO 2005/019828. En otro ejemplo, otros epftopos especfficos de enfermedad pueden identificarse el metodo descrito en Khare et al. (8). Ademas, los epftopos utiles pueden identificarse como aquellos que se presentan selectivamente en SOD1 que esta desnaturalizada o en SOD1 que esta sometida a condiciones desnaturalizantes tales como agentes caotropicos, calor, pH extremos o detergentes conocidos para los expertos en la materia, o tratada de otro modo para inducir la adopcion de una conformacion mal plegada, respecto a una SOD1 de control a pH neutro.</span>One skilled in the art will appreciate that there may be other epftopos selectively presented or accessible in non-native forms of SOD1, such as other specific episodes of amyotrophic lateral sclerosis, other specific epftopos of Alzheimer's disease and / or other specific epftopos of Parkinson's disease. For example, other disease-specific epftopos can be identified using the epftopos protection assay described in WO 2005/019828. In another example, other disease-specific epftopes can be identified by the method described in Khare et al. (8). In addition, useful epftopes can be identified as those that occur selectively in SOD1 that is denatured or in SOD1 that is subjected to denaturing conditions such as chaotropic agents, heat, extreme pH or detergents known to those skilled in the art, or treated by another mode to induce the adoption of a misfolded conformation, with respect to a control SOD1 at neutral pH.</span>
  </p>
  <p id="p00539" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo de identificacion de epftopos especfficos de enfermedad en protefnas no nativas asociadas a enfermedad. El fundamento de la seleccion de epftopos especfficos de enfermedad se basa en varias consideraciones. Los epftopos peptfdicos lineales seleccionados deben estar ocultos en un estado inaccesible al anticuerpo en la isoforma normal de la protefna diana, pero deben estar expuestos en la superficie de la isoforma mal plegada patologica de modo que los epftopos peptfdicos lineales puedan unirse por un anticuerpo especffico para el epftopo normalmente ocultado. Otras consideraciones incluyen el papel predicho o definido de forma experimental del epftopo especffico definido en la formacion de agregados, y la longitud e inmunogenicidad adecuadas de un peptido correspondiente al epftopo como una diana para inmunizacion o inmunoterapia. Los epftopos especfficos de enfermedad optimos se benefician de la seguridad de la respuesta inmunitaria contra un antfgeno no nativo, con minimizacion de autoinmunidad y la eficacia comparativa de regfmenes de adyuvante mfnimo para vacunas terapeuticas. Los epftopos especfficos de enfermedad optimos tambien se benefician de la eficacia de la neutralizacion e inhibicion de la actividad toxica y dirigida por molde de protefnas mal plegadas por union de anticuerpos. La neutralizacion tambien puede acelerar la degradacion de las especies proteicas mal plegadas por sistemas tales como el sistema retfculo-endotelial y por las celulas efectoras inmunitarias del SNC residentes tales como microglia.</span>A method of identifying disease specific epftopes in non-native proteins associated with disease is described. The rationale for the selection of disease-specific epftopes is based on several considerations. The selected linear peptide epftopes must be hidden in a state inaccessible to the antibody in the normal isoform of the target protein, but they must be exposed on the surface of the pathologically misfolded isoform so that the linear peptide epftopes can be bound by a specific antibody to The normally hidden epftope. Other considerations include the predicted or experimentally defined role of the specific epftope defined in the formation of aggregates, and the appropriate length and immunogenicity of a peptide corresponding to the epftope as a target for immunization or immunotherapy. Optimal disease-specific epftopos benefit from the safety of the immune response against a non-native antigen, with minimization of autoimmunity and the comparative efficacy of minimum adjuvant regimes for therapeutic vaccines. Optimal disease-specific epitopes also benefit from the efficacy of neutralization and inhibition of toxic and template-directed activity of misfolded proteins by antibody binding. Neutralization can also accelerate the degradation of poorly folded protein species by systems such as the reticulum-endothelial system and by resident CNS immune effector cells such as microglia.</span>
  </p>
  <p id="p00540" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden epftopos para tratar enfermedades neurodegenerativas mediadas por SOD1</span>Compositions comprising epftopos for treating neurodegenerative diseases mediated by SOD1</span>
  </p>
  <p id="p00541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para tratar la esclerosis lateral amiotrofica en un sujeto, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en una forma no nativa de SOD1 en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable. La expresion "peptido aislado" se refiere al peptido que se ha producido, por ejemplo, por tecnicas recombinantes o sinteticas, y se ha retirado de la fuente que produjo el peptido, tal como celulas recombinantes o reactivos residuales de sfntesis peptfdica. El peptido aislado esta opcionalmente "purificado", que significa al menos: un 80 %, un 85 %, un 90 %, un 95 %, un 98 % o un 99 % de pureza y opcionalmente pureza de calidad farmaceutica.</span>A composition for treating amyotrophic lateral sclerosis in a subject is described, comprising an effective amount of an isolated peptide corresponding to an epftope selectively presented or accessible in a non-native form of SOD1 in admixture with a suitable diluent or carrier, such as one. pharmaceutically acceptable. The term "isolated peptide" refers to the peptide that has been produced, for example, by recombinant or synthetic techniques, and has been removed from the source that produced the peptide, such as recombinant cells or residual peptide synthesis reagents. The isolated peptide is optionally "purified", which means at least: 80%, 85%, 90%, 95%, 98% or 99% purity and optionally pharmaceutical quality purity.</span>
  </p>
  <p id="p00542" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un "peptido aislado correspondiente a un epftopo", como se usa en este documento, se refiere al peptido producido que comprende el epftopo o una region del epftopo y es igual o similar en secuencia a un epftopo especffico de enfermedad en SOD1 no nativa. "Epftopo" se usa opcionalmente para hacer referencia al peptido aislado producido que corresponde al epftopo en SOD1 presentado selectivamente o accesible en formas no nativas de SOD1.</span>An "isolated peptide corresponding to an epftope", as used herein, refers to the peptide produced that comprises the epftopo or a region of the epftopo and is the same or similar in sequence to a disease specific epftope in non-native SOD1. "Epftopo" is optionally used to refer to the isolated peptide produced corresponding to the epftopo in SOD1 selectively presented or accessible in non-native forms of SOD1.</span>
  </p>
  <p id="p00543" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En el caso donde el peptido aislado correspondiente al epftopo especffico de enfermedad, per se no es suficientemente inmunogenico, incluso cuando se administra con adyuvantes convencionales, el peptido aislado puede administrarse en forma de un inmunogeno, en que el peptido aislado esta fusionado a o conjugado con un agente que potencia la inmunogenicidad de dicho peptido. Se describe el peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en una forma no nativa de SOD1, que comprende todo o parte de un peptido aislado de la Tabla 2 o de la Tabla 2A mencionado anteriormente en este documento.</span>In the case where the isolated peptide corresponding to the disease-specific epitope, per se is not sufficiently immunogenic, even when administered with conventional adjuvants, the isolated peptide can be administered in the form of an immunogen, in which the isolated peptide is fused to or conjugated to an agent that enhances the immunogenicity of said peptide. The isolated peptide corresponding to an epftope presented selectively or accessible in a non-native form of SOD1, comprising all or part of an isolated peptide of Table 2 or Table 2A mentioned hereinbefore, is described.</span>
  </p>
  <p id="p00544" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se usa en este documento, la propiedad de inhibir o reducir la formacion de agregados de SOD1 se revela como una reduccion en la tasa de formacion, cantidad o tamano de agregados neurotoxicos de SOD1, como se revela usando ensayos establecidos para este proposito, y como se ejemplifica en este documento.</span>As used herein, the property of inhibiting or reducing the formation of SOD1 aggregates is revealed as a reduction in the rate of formation, quantity or size of SOD1 neurotoxic aggregates, as disclosed using tests established for this purpose, and as exemplified in this document.</span>
  </p>
  <p id="p00545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion util para tratar la esclerosis lateral amiotrofica en un sujeto que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado, tal como uno farmaceuticamente aceptable, tal como vehfculos</span>A useful composition for treating amyotrophic lateral sclerosis is described in a subject comprising an effective amount of an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a suitable diluent or vehicle, such as a pharmaceutically acceptable carrier, such as vehicles.</span>
  </p>
  <p id="p00546" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00547" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00548" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00550" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00551" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00553" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00554" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00555" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00557" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00558" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00559" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">farmaceuticamente aceptables. En otras descripciones, el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica comprende la secuencia de un peptido aislado de la Tabla 2 o de la Tabla 2A mencionado anteriormente.</span>pharmaceutically acceptable. In other descriptions, the isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis comprises the sequence of an isolated peptide from Table 2 or Table 2A mentioned above.</span>
  </p>
  <p id="p00560" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se usa en este documento, la expresion "tratar la esclerosis lateral amiotrofica", como se usa en este documento, incluye inhibir la enfermedad, prevenir la enfermedad o reducir los sfntomas asociados con la enfermedad.</span>As used herein, the expression "treat amyotrophic lateral sclerosis", as used herein, includes inhibiting the disease, preventing the disease or reducing the symptoms associated with the disease.</span>
  </p>
  <p id="p00561" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden epftopos para provocar respuestas inmunitarias</span>Compositions comprising epftopos to elicit immune responses</span>
  </p>
  <p id="p00562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un epftopo aislado presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado. Se describe el epftopo presentado selectivamente o accesible en formas no nativas de SOD1, que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislado de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A composition for eliciting an immune response in an animal is described, comprising an effective amount of an isolated epftope presented selectively or accessible in non-native forms of SOD1 in admixture with a suitable diluent or carrier. The epftope presented selectively or accessible in non-native forms of SOD1, comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00563" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado, donde el epftopo especffico de esclerosis lateral amiotrofica comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A composition for eliciting an immune response in an animal is described, which comprises an effective amount of an isolated peptide corresponding to a specific amyotrophic sclerosis epitope in admixture with a suitable diluent or vehicle, where the amyotrophic lateral sclerosis specific epftope comprises a Isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "provocar una respuesta inmunitaria" se define como iniciar, desencadenar, causar, potenciar, mejorar o aumentar cualquier respuesta del sistema inmunitario, por ejemplo, de naturaleza humoral o mediada por celulas. El inicio o potenciacion de una respuesta inmunitaria puede evaluarse usando ensayos conocidos para los expertos en la materia incluyendo, aunque sin limitacion, ensayos de anticuerpos (por ejemplo, ensayos ELISA), ensayos de citotoxicidad especfficos de antfgeno y la produccion de citoquinas (por ejemplo, ensayos ELISPOT).</span>The expression "elicit an immune response" is defined as initiating, triggering, causing, enhancing, enhancing or enhancing any response of the immune system, for example, of a humoral or cell-mediated nature. The initiation or potentiation of an immune response can be assessed using assays known to those skilled in the art including, but not limited to, antibody assays (eg, ELISA assays), antigen-specific cytotoxicity assays and cytokine production (e.g. , ELISPOT trials).</span>
  </p>
  <p id="p00565" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicion para provocar una respuesta inmunitaria puede comprender un inmunogeno. Un "inmunogeno", como se usa en este documento significa una sustancia que provoca una respuesta inmunitaria y/o causa la produccion de un anticuerpo. Se describe el inmunogeno que comprende un peptido aislado seleccionado de los peptidos aislados proporcionados en la Tabla 2 o en la Tabla 2A. Se describe el peptido aislado que se conjuga a un vehfculo adecuado tal como KLH. Ademas de los peptidos aislados descritos en este documento, son utiles peptido mimeticos que provocan anticuerpos de reactividad cruzada contra epftopos especfficos de enfermedad de SOD1. El termino "animal" o "sujeto", como se usa en este documento, incluye todos los miembros del reino de animales incluyendo mamfferos, preferiblemente seres humanos.</span>The composition for eliciting an immune response may comprise an immunogen. An "immunogen," as used herein means a substance that elicits an immune response and / or causes the production of an antibody. The immunogen comprising an isolated peptide selected from the isolated peptides provided in Table 2 or Table 2A is described. The isolated peptide that is conjugated to a suitable vehicle such as KLH is described. In addition to the isolated peptides described herein, mimetic peptides that elicit cross-reactivity antibodies against SOD1 disease-specific epitopes are useful. The term "animal" or "subject", as used herein, includes all members of the animal kingdom including mammals, preferably humans.</span>
  </p>
  <p id="p00566" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se usa en este documento, la expresion "cantidad eficaz" significa una cantidad eficaz, a dosificaciones y periodos de tiempo necesarios para conseguir un resultado deseado. Las cantidades eficaces pueden variar de acuerdo con factores tales como la patologfa, edad, genero, peso del animal. El regimen de dosificacion puede ajustarse para proporcionar la respuesta terapeutica optima.</span>As used herein, the term "effective amount" means an effective amount, at dosages and periods of time necessary to achieve a desired result. The effective amounts may vary according to factors such as the pathology, age, gender, weight of the animal. The dosage regimen can be adjusted to provide the optimal therapeutic response.</span>
  </p>
  <p id="p00567" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones farmaceuticas que comprenden peptidos aislados correspondientes a epftopos especfficos de enfermedad</span>Pharmaceutical compositions comprising isolated peptides corresponding to disease-specific epftopes</span>
  </p>
  <p id="p00568" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones descritas en este documento pueden prepararse por metodos conocidos per se para la preparacion de composiciones farmaceuticamente aceptables que pueden administrarse a sujetos, opcionalmente como una vacuna, de modo que se combine una cantidad eficaz de la sustancia activa en una mezcla con un vehfculo farmaceuticamente aceptable. Los vehfculos adecuados se describen, por ejemplo, en Remington's Pharmaceutical Sciences (17). En esta base, las composiciones incluyen, aunque no exclusivamente, soluciones de las sustancias en asociacion con uno o mas vehfculos o diluyentes farmaceuticamente aceptables, y contenidas en soluciones tamponadas con un pH adecuado e iso-osmoticas con los fluidos fisiologicos.</span>The compositions described herein can be prepared by methods known per se for the preparation of pharmaceutically acceptable compositions that can be administered to subjects, optionally as a vaccine, so that an effective amount of the active substance is combined in a mixture with a pharmaceutically carrier. acceptable. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (17). On this basis, the compositions include, but are not limited to, solutions of the substances in association with one or more pharmaceutically acceptable carriers or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with physiological fluids.</span>
  </p>
  <p id="p00569" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones farmaceuticas incluyen, sin limitacion, polvos liofilizados o soluciones o suspensiones inyectables esteriles acuosas o no acuosas, que pueden contener adicionalmente antioxidantes, tampones, bacteriostaticos u solutos que vuelven a las composiciones sustancialmente compatibles con los tejidos o con la sangre de un destinatario pretendido. Otros componentes que pueden estar presentes en dichas composiciones incluyen agua, tensioactivos (tales como Tween), alcoholes, polioles, glicerina y aceites vegetales, por ejemplo. Las soluciones y suspensiones de inyeccion improvisada pueden prepararse a partir de polvos esteriles, granulos, comprimidos o soluciones o suspensiones concentradas. La composicion puede suministrarse, por ejemplo, pero a modo de limitacion, como un polvo liofilizado que se reconstituye con agua esteril o solucion salina antes de su administracion al paciente.</span>Pharmaceutical compositions include, without limitation, lyophilized powders or sterile aqueous or non-aqueous injectable solutions or suspensions, which may additionally contain antioxidants, buffers, bacteriostatic or solutes that make the compositions substantially compatible with the tissues or blood of an intended recipient. . Other components that may be present in said compositions include water, surfactants (such as Tween), alcohols, polyols, glycerin and vegetable oils, for example. Improvised injection solutions and suspensions can be prepared from sterile powders, granules, tablets or concentrated solutions or suspensions. The composition can be supplied, for example, but by way of limitation, as a lyophilized powder that is reconstituted with sterile water or saline solution before administration to the patient.</span>
  </p>
  <p id="p00570" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones farmaceuticas pueden comprender un vehfculo farmaceuticamente aceptable. Los vehfculos farmaceuticamente aceptables adecuados incluyen esencialmente composiciones qufmicamente inertes y no toxicas que no interfieren con la eficacia de la actividad biologica de la composicion farmaceutica. Ejemplos de vehfculos</span>The pharmaceutical compositions may comprise a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers essentially include chemically inert and non-toxic compositions that do not interfere with the efficacy of the biological activity of the pharmaceutical composition. Examples of vehicles</span>
  </p>
  <p id="p00571" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00572" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00573" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00574" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00575" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00576" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00577" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00578" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00579" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00580" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00581" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00582" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00583" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00584" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">farmaceuticamente aceptables incluyen, aunque sin limitacion, agua, soluciones salinas, soluciones de glicerol, etanol, cloruro de N-(1(2,3-dioleiloxi)propil)N,N,N-trimetilamonio (DOTMA), diolesilfosfatidil-etanolamina (DOPE), y liposomas. Dichas composiciones deben contener una cantidad terapeuticamente eficaz del compuesto, junto con una cantidad adecuada de vehfculo para proporcionar la forma para administracion directa al paciente.</span>Pharmaceutically acceptable include, but are not limited to, water, saline solutions, glycerol solutions, ethanol, N- (1 (2,3-dioleyloxy) propyl) N, N, N-trimethylammonium (DOTMA) chloride, diolesylphosphatidyl ethanolamine (DOPE) ), and liposomes. Such compositions must contain a therapeutically effective amount of the compound, together with an adequate amount of vehicle to provide the form for direct administration to the patient.</span>
  </p>
  <p id="p00585" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicion puede estar en forma de una sal farmaceuticamente aceptable que incluye, sin limitacion, aquellas formadas con grupos amino libres tales como los derivados de acido clorhfdrico, fosforico, acetico, oxalico, tartarico, etc., y aquellas formadas con grupos carboxilo libres tales como las derivadas de hidroxido de sodio, potasio, amonio, calcio, ferrico, isopropilamina, trietilamina, 2-etilamino etanol, histidina, procafna, etc.</span>The composition may be in the form of a pharmaceutically acceptable salt that includes, without limitation, those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acid, etc., and those formed with free carboxyl groups such such as those derived from sodium hydroxide, potassium, ammonium, calcium, ferric, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procafna, etc.</span>
  </p>
  <p id="p00586" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La inmunogenicidad puede mejorarse significativamente si el agente o agentes inmunizantes o inmunogenos (por ejemplo, peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica o una fusion o conjugado del mismo con un agente inmunopotenciador) y/o composicion se co-inmuniza, independientemente del formato de administracion, con un adyuvante. Habitualmente, se usan adyuvantes como una solucion al 0,05 al 1,0 % en solucion salina tamponada con fosfato. Los adyuvantes potencian la inmunogenicidad de un inmunogeno pero no son necesariamente inmunogenicos en si mismos. Los adyuvantes pueden actuar reteniendo el inmunogeno de forma local cerca del sitio de administracion para producir un efecto de deposito que facilita una liberacion lenta y sostenida del inmunogeno a las celulas del sistema inmunitario. Los adyuvantes tambien pueden atraer a celulas del sistema inmunitario hasta un deposito de inmunogeno y estimulan dichas celulas para provocar respuestas inmunitarias. Por tanto, realizaciones de esta invencion abarcan composiciones que comprenden adicionalmente adyuvantes.</span>The immunogenicity can be significantly improved if the immunizing agent or agents (for example, isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis or a fusion or conjugate thereof with an immunopotentiating agent) and / or composition is co-immunized, independently of the administration format, with an adjuvant. Typically, adjuvants are used as a 0.05 to 1.0% solution in phosphate buffered saline. Adjuvants enhance the immunogenicity of an immunogen but are not necessarily immunogenic in themselves. Adjuvants can act by retaining the immunogen locally near the site of administration to produce a deposit effect that facilitates a slow and sustained release of the immunogen to the cells of the immune system. The adjuvants can also attract immune system cells to an immunogen reservoir and stimulate said cells to elicit immune responses. Thus, embodiments of this invention encompass compositions that further comprise adjuvants.</span>
  </p>
  <p id="p00587" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se han usado adyuvantes durante muchos anos para mejorar las respuestas inmunitarias del hospedador para, por ejemplo, vacunas. Los adyuvantes intrfnsecos (tales como lipopolisacaridos) normalmente son los componentes de bacterias muertas o atenuadas usadas como vacunas. Los adyuvantes extrfnsecos son inmunomoduladores que se unen tfpicamente de forma no covalente a antfgenos y se formulan para potenciar las respuestas inmunitarias del hospedador. Por tanto, se han identificado adyuvantes que potencian la respuesta inmunitaria contra antfgenos suministrados de forma parenteral. Algunos de estos adyuvantes son toxicos, sin embargo, y pueden causar efectos secundarios indeseables haciendolos inadecuados para su uso en seres humanos y para muchos animales. De hecho, solamente el hidroxido de aluminio, el sulfato de aluminio y el fosfato de aluminio (mencionados habitualmente de forma colectiva como alumbre) se usan rutinariamente como adyuvantes en vacunas humanas y veterinarias. Puede usarse alumbre con agentes inmunoestimuladores tales como MPL o 3-DMP; QS21; y aminoacidos monomericos o polimericos tales como acido poliglutamico o polilisina. La eficacia del alumbre en respuestas crecientes de anticuerpos contra toxoide difterico y tetanico esta bien establecida. No obstante, tienen limitaciones. Por ejemplo, el alumbre es ineficaz para vacunacion contra la gripe y provoca de forma incoherente una respuesta inmunitaria mediada por celulas con otros inmunogenos. Los anticuerpos provocados por antfgenos con adyuvante de alumbre son principalmente del isotipo IgG1 en ratones, que puede no ser optimo para la proteccion por algunos agentes de vacuna.</span>Adjuvants have been used for many years to improve host immune responses for, for example, vaccines. Intrinsic adjuvants (such as lipopolysaccharides) are usually the components of dead or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators that typically bind non-covalently to antigens and are formulated to enhance host immune responses. Thus, adjuvants that enhance the immune response against parenterally delivered antigens have been identified. Some of these adjuvants are toxic, however, and can cause undesirable side effects making them unsuitable for use in humans and for many animals. In fact, only aluminum hydroxide, aluminum sulfate and aluminum phosphate (usually referred to collectively as alum) are routinely used as adjuvants in human and veterinary vaccines. Alum can be used with immunostimulatory agents such as MPL or 3-DMP; QS21; and monomeric or polymeric amino acids such as polyglutamic acid or polylysine. The efficacy of alum in increasing antibody responses against diphtheria and tetanic toxoid is well established. However, they have limitations. For example, alum is ineffective for vaccination against influenza and incoherently provokes an immune response mediated by cells with other immunogens. Antibodies raised by alum adjuvant antigens are primarily of the IgG1 isotype in mice, which may not be optimal for protection by some vaccine agents.</span>
  </p>
  <p id="p00588" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una amplia gama de adyuvantes extrfnsecos puede provocar respuestas inmunitarias potentes contra inmunogenos. Estos incluyen saponinas tales como Stimulons (QS21, Aquila, Worcester, Mass.) o partfculas generadas a partir de las mismas tales como ISCOM (complejos inmunoestimuladores) e ISCOMATRIX, en complejo con antfgenos proteicos de membrana (complejos inmunoestimuladores), polfmeros Pluronic con aceite mineral, micobacterias muertas y aceite mineral, adyuvante completo de Freund, productos bacterianos tales como muramil dipeptido (MDP) y lipopolisacarido (LPS), asf como lfpido A y liposomas.</span>A wide range of extrinsic adjuvants can elicit potent immune responses against immunogens. These include saponins such as Stimulons (QS21, Aquila, Worcester, Mass.) Or particles generated therefrom such as ISCOM (immunostimulatory complexes) and ISCOMATRIX, in complex with membrane protein antigens (immunostimulatory complexes), Pluronic polymers with oil mineral, dead mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A and liposomes.</span>
  </p>
  <p id="p00589" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto de esta invencion, los adyuvantes utiles en cualquiera de las realizaciones de la invencion descrita en este documento son los siguientes. Los adyuvantes para inmunizacion parenteral incluyen compuestos de aluminio (tales como hidroxido de aluminio, fosfato de aluminio e hidroxifosfato de aluminio). El antfgeno puede precipitarse con, o adsorberse sobre, el compuesto de aluminio de acuerdo con protocolos convencionales. Tambien pueden usarse otros adyuvantes tales como RIBI (ImmunoChem, Hamilton, MT) en administracion parenteral.</span>In one aspect of this invention, the adjuvants useful in any of the embodiments of the invention described herein are as follows. Adjuvants for parenteral immunization include aluminum compounds (such as aluminum hydroxide, aluminum phosphate and aluminum hydroxyphosphate). The antigen can be precipitated with, or adsorbed on, the aluminum compound according to conventional protocols. Other adjuvants such as RIBI (ImmunoChem, Hamilton, MT) may also be used in parenteral administration.</span>
  </p>
  <p id="p00590" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los adyuvantes para inmunizacion a la mucosa incluyen toxinas bacterianas (por ejemplo, la toxina colerica (CT), la toxina termo-inestable (LT) de E. coli, la toxina A de Clostridium difficile y la toxina pertussis (PT), o combinaciones, subunidades, toxoides o mutantes de las mismas). Por ejemplo, puede ser util una preparacion purificada de la subunidad B de la toxina colerica nativa (CTB). Tambien son adecuados fragmentos, homologos, derivados y fusiones con cualquiera de estas toxinas, con la condicion de que retengan la actividad adyuvante. Preferiblemente, se usa un mutante que tiene toxicidad reducida. Se han descrito mutantes adecuados (por ejemplo, en el documento WO 95/17211 (mutante Arg-7-Lys CT), en el documento WO 96/6627 (mutante Arg-192-Gly LT), y en el documento WO 95/34323 (mutante Arg-9-Lys y Glu-129-Gly PT)). Mutantes adicionales de LT que pueden usarse en los metodos y composiciones de la invencion incluyen, por ejemplo, mutantes Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, y Glu-112-Asp. Otros adyuvantes (tales como monofosforil lfpido A (MPLA) bacteriano de diversas fuentes (por ejemplo, E. coli, Salmonella minnesota, Salmonella typhimurium, o Shigella flexneri, saponinas, o microesferas de polilactido glicolido (PLGA)) tambien pueden usarse en administracion a la mucosa.</span>Adjuvants for mucosal immunization include bacterial toxins (for example, cholera toxin (CT), thermosetting toxin (LT) from E. coli, Clostridium difficile toxin A and pertussis toxin (PT), or combinations , subunits, toxoids or mutants thereof). For example, a purified preparation of subunit B of native cholera toxin (CTB) may be useful. Fragments, homologues, derivatives and fusions with any of these toxins are also suitable, with the proviso that they retain the adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants have been described (for example, in WO 95/17211 (mutant Arg-7-Lys CT), in WO 96/6627 (mutant Arg-192-Gly LT), and in WO 95 / 34323 (mutant Arg-9-Lys and Glu-129-Gly PT)). Additional mutants of LT that can be used in the methods and compositions of the invention include, for example, Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other bacterial adjuvants (such as monophosphoryl lipid A (MPLA) from various sources (e.g., E. coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri, saponins, or glycolide polylactide microspheres (PLGA)) can also be used in administration to the mucosa</span>
  </p>
  <p id="p00591" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otros adyuvantes incluyen citoquinas tales como interleuquinas, por ejemplo, IL-1, IL-2 e IL-12, quimioquinas, por</span>Other adjuvants include cytokines such as interleukins, for example, IL-1, IL-2 and IL-12, chemokines, by</span>
  </p>
  <p id="p00592" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00593" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00594" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00595" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00596" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00597" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00598" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00599" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00600" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00601" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00602" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00603" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00604" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00605" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ejemplo, CXCL10 y CCL5, factor estimulador de macrofagos y/o factor de necrosis tumoral. Otros adyuvantes que pueden usarse incluyen oligonucleotidos CpG (Davis. Curr Top Microbiol Immunol., 247:171-183, 2000).</span>example, CXCL10 and CCL5, macrophage stimulating factor and / or tumor necrosis factor. Other adjuvants that can be used include CpG oligonucleotides (Davis. Curr Top Microbiol Immunol., 247: 171-183, 2000).</span>
  </p>
  <p id="p00606" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las emulsiones de aceite en agua incluyen escualeno; aceite de cacahuete; MF59 (documento WO 90/14387); SAF (Syntex Laboratories, Palo Alto, Calif.); y Ribi (Ribi Immunochem, Hamilton, Mont.). Las emulsiones de aceite en agua pueden usarse con agentes inmunoestimuladores tales como muramil dipeptidos (por ejemplo, N- acetilmuramil-L-treonil-D-isoglutamina (thr-MDP), -acetil-normuramil-L-alanil-D-isoglutamina (nor-MDP), N- acetilmuramil-L-alanil-D-isoglutamil-L-alanina-2-(1'-2'dipalmitoil-sn-glicero-3-hidroxifosforiloxi)-etilamina (MTP-PE), N- acetilglucosaminil-N-acetilmuramil-L-Al-D-isoglu-L-Ala-di-palmitoxi propilamida (DTP-DPP) teramida (TM)), u otros componentes de la pared celular bacteriana.</span>Oil-in-water emulsions include squalene; peanut oil; MF59 (WO 90/14387); SAF (Syntex Laboratories, Palo Alto, Calif.); and Ribi  (Ribi Immunochem, Hamilton, Mont.). Oil-in-water emulsions can be used with immunostimulatory agents such as muramyl dipeptides (e.g., N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), -acetyl-normuramyl-L-alanyl-D-isoglutamine (nor -MDP), N- acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine-2- (1'-2dipalmitoyl-sn-glycerol-3-hydroxyphosphoryloxy) -ethylamine (MTP-PE), N- acetylglucosaminyl- N-acetylmuramyl-L-Al-D-isoglu-L-Ala-di-palmitoxy propylamide (DTP-DPP) teramide (TM)), or other components of the bacterial cell wall.</span>
  </p>
  <p id="p00607" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los adyuvantes utiles para inmunizacion a la mucosa y parenteral incluyen polifosfazeno (por ejemplo, documento WO 95/2415), DC-chol (3 b-(N-(N',N'-dimetil aminometano)-carbamoil) colesterol (por ejemplo, patente de Estados Unidos n. 5.283.185 y documento WO 96/14831) y QS-21 (por ejemplo, documento WO 88/9336).</span>Useful adjuvants for mucosal and parenteral immunization include polyphosphazene (for example, WO 95/2415), DC-chol (3 b- (N- (N ', N'-dimethyl aminomethane) -carbamoyl) cholesterol (for example , U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (for example, WO 88/9336).</span>
  </p>
  <p id="p00608" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un adyuvante puede acoplarse a un inmunogeno para administracion (Livingston. J Immunol., 159: 1383-1392, 1997). Por ejemplo, puede acoplarse directamente un lfpido tal como acido palmftico a uno o mas peptidos de modo que el cambio en la conformacion de los peptidos que comprenden el inmunogeno no afecte a la naturaleza de la respuesta inmunitaria contra el inmunogeno.</span>An adjuvant can be coupled to an immunogen for administration (Livingston. J Immunol., 159: 1383-1392, 1997). For example, a lipid such as palm keric acid can be directly coupled to one or more peptides so that the change in the conformation of the peptides comprising the immunogen does not affect the nature of the immune response against the immunogen.</span>
  </p>
  <p id="p00609" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La eleccion de un adyuvante puede depender de varios factores, incluyendo la via de administracion, la eficacia del adyuvante, el regimen de dosificacion, la estabilidad de la vacuna que contiene al adyuvante y la especie que se esta vacunando. El adyuvante puede administrarse con un inmunogeno como una composicion individual. Ademas, puede administrarse un adyuvante antes, de forma concurrente con o despues de la administracion del inmunogeno.</span>The choice of an adjuvant can depend on several factors, including the route of administration, the effectiveness of the adjuvant, the dosage regimen, the stability of the vaccine containing the adjuvant and the species being vaccinated. The adjuvant can be administered with an immunogen as an individual composition. In addition, an adjuvant can be administered before, concurrently with or after the administration of the immunogen.</span>
  </p>
  <p id="p00610" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La inmunogenicidad o eficacia de la composicion para tratar la esclerosis lateral amiotrofica, la enfermedad de Alzheimer y/o la enfermedad de Parkinson o provocar una respuesta inmunitaria tambien puede potenciarse conjugando el peptido aislado correspondiente a un epftopo especffico de enfermedad (por ejemplo, tal como un epftopo especffico de esclerosis lateral amiotrofica) directamente, tal como a traves de un enlace amida, o indirectamente a traves de un enlazador qufmico tal como carbodiimida o cualquier secuencia espaciadora peptfdica tal como una secuencia de glicina o glicina-serina incluyendo Gly4-S, a una molecula que potencia la inmunogenicidad del epftopo. Por ejemplo, un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica puede conjugarse a hemocianina de lapa californiana (KLH). KLH es una protefna respiratoria encontrada en moluscos. Su gran tamano la hace muy inmunogenica, y la gran cantidad de restos de lisina disponibles para conjugacion la hacen muy util para su fijacion a una protefna, tal como un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica.</span>The immunogenicity or efficacy of the composition for treating amyotrophic lateral sclerosis, Alzheimer's disease and / or Parkinson's disease or provoking an immune response can also be enhanced by conjugating the isolated peptide corresponding to a disease specific epftope (for example, such as a specific epitope of amyotrophic lateral sclerosis) directly, such as through an amide bond, or indirectly through a chemical linker such as carbodiimide or any peptide spacer sequence such as a glycine or glycine-serine sequence including Gly4-S, to a molecule that enhances epitope immunogenicity. For example, an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis can be conjugated to hemocyanin of California limpet (KLH). KLH is a respiratory protein found in mollusks. Its large size makes it very immunogenic, and the large amount of lysine residues available for conjugation makes it very useful for its fixation to a protein, such as an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00611" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se encuentran otras directrices sobre la tecnica de vacunacion de peptidos en el trabajo que muestra que un epftopo especffico de enfermedad para la protefna de prion mal plegada (6) proporciona una diana para celulas de neuroblastoma infectadas de priones in vitro (7), y que la vacunacion de peptidos de ratones con este epftopo es protectora contra la inoculacion de priones infecciosos.</span>Other guidelines on the technique of peptide vaccination are found at work showing that a disease-specific epftope for the misfolded prion protein (6) provides a target for in vitro prion-infected neuroblastoma cells (7), and that The vaccination of mouse peptides with this epftope is protective against the inoculation of infectious prions.</span>
  </p>
  <p id="p00612" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos aislados correspondientes a los epftopos o a los analogos de los mismos presentados selectivamente o accesibles en formas no nativas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, especfficos de enfermedad de Alzheimer o especfficos de enfermedad de Parkinson se preparan facilmente usando una diversidad de metodos conocidos para los expertos en la materia. Por consiguiente, los peptidos que corresponden a epftopos especfficos de enfermedad tales como epftopos especfficos de esclerosis lateral amiotrofica pueden prepararse por sfntesis qufmica usando tecnicas bien conocidas en la qufmica de protefnas, tales como sfntesis en fase solida (18) o sfntesis en solucion homogenea (19).</span>Isolated peptides corresponding to epftopes or analogs thereof presented selectively or accessible in non-native forms of SOD1, including epitopes specific for amyotrophic lateral sclerosis, specific for Alzheimer's disease or specific for Parkinson's disease are readily prepared using a variety of methods known to those skilled in the art. Accordingly, peptides corresponding to disease-specific epftopos such as specific episodes of amyotrophic lateral sclerosis can be prepared by chemical synthesis using techniques well known in protein chemistry, such as solid phase synthesis (18) or homogenous solution synthesis ( 19).</span>
  </p>
  <p id="p00613" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos correspondientes a los epftopos presentados selectivamente o accesibles en formas no nativas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, especfficos de enfermedad de Alzheimer o especfficos de enfermedad de Parkinson tambien producirse por tecnologfa de ADN recombinante. Para preparar peptidos correspondientes a los epftopos especfficos de esclerosis lateral amiotrofica por tecnicas de ADN recombinante, debe prepararse una secuencia de ADN que codifica el peptido correspondiente al epftopo especffico de esclerosis lateral amiotrofica. Por consiguiente, se describe el uso de acidos nucleicos purificados y aislados que comprenden una secuencia de nucleotidos que codifica epftopos especfficos de esclerosis lateral amiotrofica para tratar la esclerosis lateral amiotrofica o para provocar una respuesta inmunitaria.</span>Peptides corresponding to epftopes selectively presented or accessible in non-native forms of SOD1, including specific episodes of amyotrophic lateral sclerosis, specific for Alzheimer's disease or specific for Parkinson's disease are also produced by recombinant DNA technology. To prepare peptides corresponding to the specific episodes of amyotrophic lateral sclerosis by recombinant DNA techniques, a DNA sequence encoding the peptide corresponding to the specific epitope of amyotrophic lateral sclerosis should be prepared. Accordingly, the use of purified and isolated nucleic acids comprising a nucleotide sequence encoding specific episodes of amyotrophic lateral sclerosis to treat amyotrophic lateral sclerosis or to elicit an immune response is described.</span>
  </p>
  <p id="p00614" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, la secuencia de acido nucleico que codifica los peptidos correspondientes a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1, se incorpora en un vector de expresion adaptado para transfeccion o transformacion de una celula hospedadora. En otra descripcion, la secuencia de acido nucleico que codifica los peptidos correspondientes a epftopos especfficos de esclerosis lateral amiotrofica se incorpora en un vector de expresion adaptado para transfeccion o transformacion de una celula hospedadora. Las moleculas de acido nucleico pueden incorporarse de un modo conocido en un vector de expresion apropiado que asegura la expresion de la protefna. Los posibles vectores de expresion incluyen, aunque sin limitacion, cosmidos,</span>In a description, the nucleic acid sequence encoding the peptides corresponding to epftopos presented selectively or accessible in non-native forms of SOD1, is incorporated into an expression vector adapted for transfection or transformation of a host cell. In another description, the nucleic acid sequence encoding the peptides corresponding to specific episodes of amyotrophic lateral sclerosis is incorporated into an expression vector adapted for transfection or transformation of a host cell. Nucleic acid molecules can be incorporated in a known manner into an appropriate expression vector that ensures protein expression. Possible expression vectors include, but are not limited to, cosmetics,</span>
  </p>
  <p id="p00615" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00616" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00617" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00618" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00619" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00620" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00621" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00622" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00623" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00624" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00625" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00626" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00627" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00628" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">plasmidos o virus modificados (por ejemplo, retrovirus deficientes en replicacion, adenovirus y virus adenoasociados). El vector debe ser compatible con la celula hospedadora usada. Los vectores de expresion son "adecuados para transformacion de una celula hospedadora", lo que significa que los vectores de expresion contienen una molecula de acido nucleico que codifica los peptidos correspondientes a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer y epftopos especfficos de enfermedad de Parkinson, y secuencias reguladoras seleccionadas basandose en las celulas hospedadoras a usarse para la expresion, que estan unida de forma funcional a la molecula de acido nucleico. "Unido de forma funcional" pretende indicar que el acido nucleico esta unido a secuencias reguladoras de un modo que permite la expresion del acido nucleico.</span>modified plasmids or viruses (eg, replication-deficient retroviruses, adenoviruses and adeno-associated viruses). The vector must be compatible with the host cell used. Expression vectors are "suitable for transformation of a host cell", which means that the expression vectors contain a nucleic acid molecule that encodes peptides corresponding to epftopes selectively presented or accessible in non-native forms of SOD1, including specific epftopos of amyotrophic lateral sclerosis, specific epftopos of Alzheimer's disease and specific epftopos of Parkinson's disease, and selected regulatory sequences based on the host cells to be used for expression, which are functionally linked to the nucleic acid molecule. "Functionally linked" is intended to indicate that the nucleic acid is linked to regulatory sequences in a manner that allows the expression of the nucleic acid.</span>
  </p>
  <p id="p00629" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las secuencias reguladoras adecuadas pueden obtenerse de una diversidad de fuentes, incluyendo genes bacterianos, fungicos, vfricos, de mamffero o de insecto (por ejemplo, veanse las secuencias reguladoras descritas en Goeddel (20). La seleccion de secuencias reguladoras apropiadas depende de la celula hospedadora elegida como se analiza a continuacion, y puede conseguirse facilmente por los expertos en la materia. Ejemplos de dichas secuencias reguladoras incluyen: un promotor y potenciador de la transcripcion o secuencia de union a ARN polimerasa, una secuencia de union al ribosoma, incluyendo una senal de inicio de la traduccion. Adicionalmente, dependiendo de la celula hospedadora elegida y del vector empleado, pueden incorporarse otras secuencias, tales como un origen de replicacion, sitios de restriccion de ADN adicionales, potenciadores y secuencias que confieren capacidad de induccion de la transcripcion en el vector de expresion.</span>Suitable regulatory sequences can be obtained from a variety of sources, including bacterial, fungal, viral, mammalian or insect genes (for example, see the regulatory sequences described in Goeddel (20). The selection of appropriate regulatory sequences depends on the cell host chosen as discussed below, and can easily be achieved by those skilled in the art Examples of such regulatory sequences include: a promoter and enhancer of the transcription or RNA polymerase binding sequence, a ribosome binding sequence, including a Translation initiation signal Additionally, depending on the host cell chosen and the vector used, other sequences may be incorporated, such as an origin of replication, additional DNA restriction sites, enhancers and sequences that confer transcription induction capacity. in the expression vector.</span>
  </p>
  <p id="p00630" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los vectores de expresion recombinantes tambien pueden contener un gen marcador que facilita la seleccion de celulas hospedadoras transformadas o transfectadas con una molecula recombinante descrita en este documento. Ejemplos de genes marcadores de seleccion son genes que codifican una protefna tal como G418 e higromicina que confieren resistencia a ciertos farmacos, p-galactosidasa, cloranfenicol acetiltransferasa, luciferasa de luciernaga o una inmunoglobulina o parte de la misma tal como la parte Fc de una inmunoglobulina preferiblemente IgG. La transcripcion del gen marcador de seleccion se controla por cambios en la concentracion de la protefna marcadora de seleccion tal como p-galactosidasa, cloranfenicol acetiltransferasa o luciferasa de luciernaga. Si el gen marcador de seleccion codifica una protefna que confiere resistencia a antibioticos tal como resistencia a neomicina, las celulas transformantes pueden seleccionarse con G418. Las celulas que han incorporado el gen marcador de seleccion sobreviviran, mientras que las otras celulas moriran. Esto hace posible visualizar y ensayar la expresion de vectores de expresion recombinantes descritos en este documento y en particular para determinar el efecto de una mutacion sobre la expresion y fenotipo. Se apreciara que los marcadores de seleccion pueden introducirse en un vector diferente del acido nucleico de interes.</span>Recombinant expression vectors may also contain a marker gene that facilitates the selection of transformed or transfected host cells with a recombinant molecule described herein. Examples of selection marker genes are genes that encode a protein such as G418 and hygromycin that confer resistance to certain drugs, p-galactosidase, chloramphenicol acetyltransferase, firefly luciferase or an immunoglobulin or part thereof such as the Fc part of an immunoglobulin preferably IgG. The transcription of the selection marker gene is controlled by changes in the concentration of the selection marker protein such as p-galactosidase, chloramphenicol acetyltransferase or luciferase luciferase. If the selection marker gene encodes a protein that confers antibiotic resistance such as neomycin resistance, the transforming cells can be selected with G418. The cells that have incorporated the selection marker gene will survive, while the other cells will die. This makes it possible to visualize and test the expression of recombinant expression vectors described herein and in particular to determine the effect of a mutation on the expression and phenotype. It will be appreciated that the selection markers can be introduced into a different vector of the nucleic acid of interest.</span>
  </p>
  <p id="p00631" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los vectores de expresion recombinantes pueden introducirse en celulas hospedadoras para producir una celula hospedadora transformante. La expresion "celula hospedadora transformante" pretende incluir celulas procariotas y eucariotas que se han transformado o transfectado con un vector de expresion recombinante que codifica los epftopos especfficos de esclerosis lateral amiotrofica. Las expresiones "transformado con", "transfectado con", "transformacion" y "transfeccion" pretenden abarcar la introduccion de acido nucleico (por ejemplo, un vector) en una celula por una de muchas posibles tecnicas conocidas en la tecnica. Las celulas procariotas pueden transformase con acido nucleico por, por ejemplo, electroporacion o transformacion mediada por cloruro de calcio. El acido nucleico puede introducirse en celulas de mamffero mediante tecnicas convencionales tales como co-precipitacion con fosfato de calcio o con cloruro de calcio, transfeccion mediada por DEAE-dextrano, lipofectina, electroporacion o microinyeccion. Los metodos adecuados para transformar y transfectar celulas hospedadoras pueden encontrarse en Sambrook et al. (21), y otros libros de texto de laboratorio.</span>Recombinant expression vectors can be introduced into host cells to produce a transforming host cell. The term "transforming host cell" is intended to include prokaryotic and eukaryotic cells that have been transformed or transfected with a recombinant expression vector encoding the specific episodes of amyotrophic lateral sclerosis. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass the introduction of nucleic acid (eg, a vector) into a cell by one of many possible techniques known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium chloride mediated transformation. Nucleic acid can be introduced into mammalian cells by conventional techniques such as co-precipitation with calcium phosphate or with calcium chloride, transfection mediated by DEAE-dextran, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (21), and other laboratory textbooks.</span>
  </p>
  <p id="p00632" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las celulas hospedadoras adecuadas incluyen una amplia diversidad de celulas hospedadoras procariotas y eucariotas. Por ejemplo, las protefnas de la invencion pueden expresarse en celulas bacterianas tales como E. coli, celulas de insecto (usando baculovirus), celulas de levadura o celulas de mamffero. Otras celulas hospedadoras adecuadas pueden encontrarse en Goeddel (20).</span>Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus), yeast cells or mamffer cells. Other suitable host cells can be found in Goeddel (20).</span>
  </p>
  <p id="p00633" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mas particularmente, las celulas hospedadoras bacterianas adecuadas incluyen E. coli, B. subtilis, Salmonella typhimurium y diversas especies dentro del genero Pseudomonas, Streptomyces y Staphylococcus, asf como muchas otras especies bacterianas bien conocidas para los expertos en la materia. Los vectores de expresion bacterianos adecuados preferiblemente comprenden un promotor que funciona en la celula hospedadora, uno o mas marcadores fenotfpicos de seleccion y un origen bacteriano de replicacion. Los promotores representativos incluyen el sistema promotor de p-lactamasa (penicilinasa) y lactosa (vease Chang et al. (22)), el promotor trp (23) y promotor tac (24). Los marcadores de seleccion representativos incluyen diversos marcadores de resistencia a antibioticos tales como los genes de resistencia a canamicina o ampicilina. Los vectores de expresion adecuados incluyen, aunque sin limitacion, bacteriofagos tales como derivados de lambda o plasmidos tales como pBR322 (vease, Bolivar et al. (25)), los plasmidos pUC pUC18, pUC19, pUC118, pUC119 (vease, Messing (26) y Vieira y Messing (27)), y pNH8A, pNH16a, pNH18a, y Bluescript M13 (Stratagene, La Jolla, Calif.). Los vectores de expresion de fusion tfpicos que pueden usarse se han analizado anteriormente, por ejemplo, pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) y pRIT5 (Pharmacia, Piscataway, NJ). Ejemplos de vectores de expresion no de fusion inducibles incluyen pT rc (28) y pET 11 d (29).</span>More particularly, suitable bacterial host cells include E. coli, B. subtilis, Salmonella typhimurium and various species within the genus Pseudomonas, Streptomyces and Staphylococcus, as well as many other bacterial species well known to those skilled in the art. Suitable bacterial expression vectors preferably comprise a promoter that functions in the host cell, one or more phenotypic selection markers and a bacterial origin of replication. Representative promoters include the p-lactamase (penicillinase) and lactose promoter system (see Chang et al. (22)), the trp (23) and tac (24) promoter. Representative selection markers include various antibiotic resistance markers such as kanamycin or ampicillin resistance genes. Suitable expression vectors include, but are not limited to, bacteriophages such as lambda derivatives or plasmids such as pBR322 (see, Bolivar et al. (25)), pUC plasmids pUC18, pUC19, pUC118, pUC119 (see, Messing (26 ) and Vieira and Messing (27)), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, Calif.). Typical fusion expression vectors that can be used have been previously analyzed, for example, pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ). Examples of inducible non-fusion expression vectors include pT rc (28) and pET 11 d (29).</span>
  </p>
  <p id="p00634" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00635" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00636" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00637" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00638" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00639" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00640" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00641" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00642" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00643" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00644" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00645" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00646" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00647" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las celulas hospedadoras de levadura y fungicas adecuadas incluyen, aunque sin limitacion, Saccharomyces cerevisiae, Schizosaccharomyces pombe, los generos Pichia o Kluyveromyces y diversas especies del genero Aspergillus. Ejemplos de vectores para la expresion en la levadura S. cerevisiae incluyen pYepSecl (30), pMFa (31), pJRY88 (32), y pYES2 (Invitrogen Corporation, San Diego, CA). Los protocolos para transformacion de levaduras y hongos son bien conocidos para los expertos en la materia (vease, Hinnen et al. (33); Itoh et al. (34), y Cullen et al. (35)).</span>Suitable yeast and fungal host cells include, but are not limited to, Saccharomyces cerevisiae, Schizosaccharomyces pombe, the Pichia or Kluyveromyces genera and various species of the Aspergillus genus. Examples of vectors for expression in S. cerevisiae yeast include pYepSecl (30), pMFa (31), pJRY88 (32), and pYES2 (Invitrogen Corporation, San Diego, CA). The protocols for yeast and fungal transformation are well known to those skilled in the art (see, Hinnen et al. (33); Itoh et al. (34), and Cullen et al. (35)).</span>
  </p>
  <p id="p00648" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las celulas de mamffero adecuadas incluyen, entre otras: celulas COS (por ejemplo, ATCC N. CRL 1650 o 1651), BHK (por ejemplo, ATCC N. CRL 6281), CHO (ATCC N. CCL 61), HeLa (por ejemplo, ATCC N. CCL 2), 293 (ATCC N. 1573) y NS-1. Los vectores de expresion adecuados para dirigir la expresion en celulas de mamffero generalmente incluyen un promotor (por ejemplo, derivado de material vfrico tal como polioma, Adenovirus 2, citomegalovirus y virus 40 de simio), asf como otras secuencias del control de la transcripcion y la traduccion. Ejemplos de vectores de expresion en mamffero incluyen pCDM8 (36) y pMT2PC (37).</span>Suitable mamffer cells include, among others: COS cells (for example, ATCC No. CRL 1650 or 1651), BHK (for example, ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (for example, ATCC No. CCL 2), 293 (ATCC No. 1573) and NS-1. Expression vectors suitable for directing expression in mammalian cells generally include a promoter (eg, derived from viral material such as polyoma, Adenovirus 2, cytomegalovirus and simian virus 40), as well as other transcriptional control sequences and the translation. Examples of mammalian expression vectors include pCDM8 (36) and pMT2PC (37).</span>
  </p>
  <p id="p00649" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dados los contenidos proporcionados en este documento, los promotores, terminadores y metodos para introducir vectores de expresion de un tipo apropiado en celulas de plantas, aves e insectos tambien pueden conseguirse facilmente. Por ejemplo, las protefnas descritas en este documento pueden expresarse a partir de celulas vegetales (vease, Sinkar et al. (38), que revisa el uso de vectores de Agrobacterium rhizogenes; vease tambien Zambryski et al. (39), que describe el uso de vectores de expresion de celulas vegetales, incluyendo, entre otros, pAS2022, pAS2023, y pAS2034).</span>Given the contents provided in this document, promoters, terminators and methods for introducing expression vectors of an appropriate type into plant cells, birds and insects can also be easily achieved. For example, the proteins described herein can be expressed from plant cells (see, Sinkar et al. (38), which reviews the use of Agrobacterium rhizogenes vectors; see also Zambryski et al. (39), which describes the use of plant cell expression vectors, including, among others, pAS2022, pAS2023, and pAS2034).</span>
  </p>
  <p id="p00650" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las celulas de insecto adecuadas incluyen celulas y lfneas celulares de especies Bombyx o Spodotera. Los vectores baculovfricos disponibles para la expresion de protefnas en celulas cultivadas de insecto (celulas SF 9) incluyen la serie pAc (40) y la serie pVL (41). Algunos sistemas de expresion de baculovirus-celulas de insecto adecuados para la expresion de protefnas recombinantes se describen en el documento PCT/US/02442.</span>Suitable insect cells include cells and cell lines of Bombyx or Spodotera species. Baculovirus vectors available for protein expression in cultured insect cells (SF 9 cells) include the pAc series (40) and the pVL series (41). Some baculovirus-insect cell expression systems suitable for recombinant protein expression are described in PCT / US / 02442.</span>
  </p>
  <p id="p00651" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los vectores de expresion recombinantes que contienen las secuencias de nucleotidos que codifican el peptido correspondiente a epftopos presentados selectivamente o accesibles no nativas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer y epftopos especfficos de enfermedad de Parkinson tambien pueden contener genes que codifican un resto de fusion (es decir, una "protefna de fusion") que proporciona expresion aumentada del peptido recombinante; y ayuda a la purificacion del peptido recombinante diana actuando como ligando en purificacion por afinidad. Por ejemplo, puede anadirse un sitio de escision proteolftico a la protefna recombinante diana para permitir la separacion de la protefna recombinante del resto de fusion despues de la purificacion de la protefna de fusion. Los vectores de expresion de fusion tfpicos incluyen pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) y pRIT5 (Pharmacia, Piscataway, NJ) que fusionan la glutation S-transferasa (GST), la protefna de union a maltosa E, o protefna A, respectivamente, a la protefna recombinante.</span>Recombinant expression vectors containing the nucleotide sequences encoding the peptide corresponding to selectively presented or accessible non-native episodes of SOD1, including epitopes specific for amyotrophic lateral sclerosis, epftopos specific for Alzheimer's disease and epftopos specific for Parkinson's disease may also contain genes encoding a fusion moiety (ie, a "fusion protein") that provides increased expression of the recombinant peptide; and aids purification of the recombinant target peptide by acting as a ligand in affinity purification. For example, a proteolytic cleavage site can be added to the recombinant target protein to allow separation of the recombinant protein from the fusion moiety after purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) that fuse glutathione S-transferase (GST), the binding protein to maltose E, or protein A, respectively, to the recombinant protein.</span>
  </p>
  <p id="p00652" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones de acido nucleico para tratar enfermedades neurodegenerativas mediadas por SOD1</span>Nucleic acid compositions for treating neurodegenerative diseases mediated by SOD1</span>
  </p>
  <p id="p00653" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un acido nucleico que codifica un peptido correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado, donde el peptido corresponde a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 seleccionados del grupo que consiste en los peptidos de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A composition for eliciting an immune response in an animal is described, comprising an effective amount of a nucleic acid encoding a peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a suitable diluent or carrier, where The peptide corresponds to an epftope presented selectively or accessible in non-native forms of SOD1 selected from the group consisting of the peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00654" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen acidos nucleicos asilados que codifican los peptidos correspondientes a los epftopos presentados selectivamente o accesibles en formas no nativas de SOD1, incluyendo las siguientes moleculas de ARN, equivalentes de codones sinonimos de las mismas y sus equivalentes de ADN y complementos:</span>Asylum nucleic acids are described that encode peptides corresponding to epftopos presented selectively or accessible in non-native forms of SOD1, including the following RNA molecules, equivalents of synonymous codons thereof and their equivalents of DNA and complements:</span>
  </p>
  <p id="p00655" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para RLACGVIGI;</span>For RLACGVIGI;</span>
  </p>
  <p id="p00656" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AGGUUAGCUUGUGGUGUUAUAGGUAUA (SEQ ID NO: 19).</span>AGGUUAGCUUGUGGUGUUAUAGGUAUA (SEQ ID NO: 19).</span>
  </p>
  <p id="p00657" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para DLGKGGNEESTKTGNAGS;</span>For DLGKGGNEESTKTGNAGS;</span>
  </p>
  <p id="p00658" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GAUUUAGGUAAAGGUGGUAAUGAAGAAAGUACUAAAACUGGUAAUGCUGGUAGU (SEQ ID NO: 20).</span>GAUUUAGGUAAAGGUGGUAAUGAAGAAAGUACUAAAACUGGUAAUGCUGGUAGU (SEQ ID NO: 20).</span>
  </p>
  <p id="p00659" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para NPLSRKHGGPKDEE;</span>For NPLSRKHGGPKDEE;</span>
  </p>
  <p id="p00660" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AAUCCUUUAAGUCGUAAACACGGAGGACCGAAGGACGAGGAG (SEQ ID NO: 21).</span>AAUCCUUUAAGUCGUAAACACGGAGGACCGAAGGACGAGGAG (SEQ ID NO: 21).</span>
  </p>
  <p id="p00661" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para IKGLTEGLHGF;</span>For IKGLTEGLHGF;</span>
  </p>
  <p id="p00662" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AUAAAGGGGAAAACAGAAGGACUCCACGGCUUU (SEQ ID NO: 22).</span>AUAAAGGGGAAAACAGAAGGACUCCACGGCUUU (SEQ ID NO: 22).</span>
  </p>
  <p id="p00663" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00664" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00665" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00666" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00667" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00668" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00669" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00670" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00671" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00672" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00673" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00674" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00675" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00676" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para HCIIGRTLVVH;</span>For HCIIGRTLVVH;</span>
  </p>
  <p id="p00677" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CACUGUAUUAUUGGCAGGACCCUCGUUGUUCAC (SEQ ID NO: 23).</span>CACUGUAUUAUUGGCAGGACCCUCGUUGUUCAC (SEQ ID NO: 23).</span>
  </p>
  <p id="p00678" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otros acidos nucleicos utiles incluyen:</span>Other useful nucleic acids include:</span>
  </p>
  <p id="p00679" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para RLACGVIGI (DSE1: 143-151);</span>For RLACGVIGI (DSE1: 143-151);</span>
  </p>
  <p id="p00680" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGUUUGGCUUGUGGUGUAAUUGGGAUC (SEQ ID NO: 24).</span>CGUUUGGCUUGUGGUGUAAUUGGGAUC (SEQ ID NO: 24).</span>
  </p>
  <p id="p00681" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para ACGVIGI (DSE1: 145-151);</span>For ACGVIGI (DSE1: 145-151);</span>
  </p>
  <p id="p00682" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GCUUGUGGUGUAAUUGGGAUC (SEQ ID NO: 25).</span>GCUUGUGGUGUAAUUGGGAUC (SEQ ID NO: 25).</span>
  </p>
  <p id="p00683" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para DLGKGGNEESTKTGNAGS (DSE2: 125-142);</span>For DLGKGGNEESTKTGNAGS (DSE2: 125-142);</span>
  </p>
  <p id="p00684" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GACUUGGGCAAAGGUGGAAAUGAAGAAAGUACAAAGACAGGAAACGCUGGAAGU (SEQ ID NO: 26).</span>GACUUGGGCAAAGGUGGAAAUGAAGAAAGUACAAAGACAGGAAACGCUGGAAGU (SEQ ID NO: 26).</span>
  </p>
  <p id="p00685" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para NPLSRKHGGPKDEE (DSE3: 65-78);</span>For NPLSRKHGGPKDEE (DSE3: 65-78);</span>
  </p>
  <p id="p00686" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AAUCCUCUAUCCAGAAAACACGGUGGGCCAAAGGAUGAAGAG (SEQ ID NO: 27).</span>AAUCCUCUAUCCAGAAAACACGGUGGGCCAAAGGAUGAAGAG (SEQ ID NO: 27).</span>
  </p>
  <p id="p00687" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para KAVCVLK (DSE4: 3-9);</span>For KAVCVLK (DSE4: 3-9);</span>
  </p>
  <p id="p00688" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AAGGCCGUGUGCGUGCUGAAG (SEQ ID NO: 28).</span>AAGGCCGUGUGCGUGCUGAAG (SEQ ID NO: 28).</span>
  </p>
  <p id="p00689" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para IKGLTEGLHGF (DSE5: 35-45);</span>For IKGLTEGLHGF (DSE5: 35-45);</span>
  </p>
  <p id="p00690" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AUUAAAGGACUGACUGAAGGCCUGCAUGGAUUC (SEQ ID NO: 29).</span>AUUAAAGGACUGACUGAAGGCCUGCAUGGAUUC (SEQ ID NO: 29).</span>
  </p>
  <p id="p00691" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para HCIIGRTLVVH (DSE6: 110-120);</span>For HCIIGRTLVVH (DSE6: 110-120);</span>
  </p>
  <p id="p00692" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CAUUGCAUCAUUGGCCGCACACUGGUGGUCCAU (SEQ ID NO: 30).</span>CAUUGCAUCAUUGGCCGCACACUGGUGGUCCAU (SEQ ID NO: 30).</span>
  </p>
  <p id="p00693" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para GLHGFHVH (DSE7: 41-48);</span>For GLHGFHVH (DSE7: 41-48);</span>
  </p>
  <p id="p00694" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GGCCUGCAUGGAUUCCAUGUUCAU (SEQ ID NO: 31).</span>GGCCUGCAUGGAUUCCAUGUUCAU (SEQ ID NO: 31).</span>
  </p>
  <p id="p00695" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los acidos nucleicos se mencionan en este documento como "acidos nucleicos de la Tabla 2C".</span>Nucleic acids are referred to herein as "nucleic acids of Table 2C".</span>
  </p>
  <p id="p00696" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para tratar la esclerosis lateral amiotrofica en un sujeto, que comprende una cantidad eficaz de un acido nucleico aislado que codifica un epftopo especffico de esclerosis lateral amiotrofica aislado en mezcla con un diluyente o vehfculo adecuado, donde el epftopo especffico de esclerosis lateral amiotrofica comprende un peptido aislado seleccionado del grupo que consiste en los peptidos de la Tabla 2 o de la Tabla A, o un analogo de los mismos.</span>A composition for treating amyotrophic lateral sclerosis in a subject is described, which comprises an effective amount of an isolated nucleic acid encoding a specific epitope of isolated amyotrophic lateral sclerosis in admixture with a suitable diluent or vehicle, where the specific epiphypo of lateral sclerosis. Amyotrophic comprises an isolated peptide selected from the group consisting of the peptides of Table 2 or Table A, or an analogue thereof.</span>
  </p>
  <p id="p00697" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe una composicion para provocar una respuesta inmunitaria en un animal, que comprende una cantidad eficaz de un acido nucleico aislado que codifica un epftopo especffico de esclerosis lateral amiotrofica aislado en mezcla con un diluyente o vehfculo adecuado, donde el epftopo especffico de esclerosis lateral amiotrofica comprende un peptido aislado seleccionado del grupo que consiste en los peptidos de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A composition for eliciting an immune response in an animal is described, comprising an effective amount of an isolated nucleic acid encoding an isolated amyotrophic lateral sclerosis epftope in admixture with a suitable diluent or vehicle, where the amyotrophic lateral sclerosis specific epftope it comprises an isolated peptide selected from the group consisting of the peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00698" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen acidos nucleicos aislados que codifican los peptidos correspondientes a epftopos especfficos de esclerosis lateral amiotrofica, incluyendo las siguientes moleculas de ARN, equivalentes de codones sinonimos de las mismas y sus equivalentes de ADN enumerados en los acidos nucleicos de la Tabla 2C.</span>Isolated nucleic acids encoding peptides corresponding to specific episodes of amyotrophic lateral sclerosis are described, including the following RNA molecules, equivalents of synonymous codons thereof and their DNA equivalents listed in the nucleic acids of Table 2C.</span>
  </p>
  <p id="p00699" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que hay varios modos de administracion disponibles cuando se usa una composicion que contiene una molecula de acido nucleico aislada que codifica un peptido correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, incluyendo un epftopo especffico de esclerosis lateral amiotrofica aislado, un epftopo especffico de enfermedad de Alzheimer aislado y un epftopo especffico de enfermedad de Parkinson aislado. Las moleculas recombinantes descritas anteriormente pueden introducirse directamente en celulas o en tejidos in vivo usando vehfculos de suministro tales como vectores retrovfricos, vectores adenovfricos y vectores de virus ADN. Tambien pueden introducirse en celulas in vivo usando tecnicas ffsicas tales como microinyeccion y electroporacion o metodos qufmicos tales como co-precipitacion e incorporacion de ADN en liposomas. Las moleculas recombinantes tambien pueden suministrarse en forma de un aerosol o por lavado. Las moleculas de acido nucleico descritas en este documento tambien pueden aplicarse de</span>One skilled in the art will appreciate that there are several modes of administration available when using a composition containing an isolated nucleic acid molecule encoding a peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1, including a specific epftope of Isolated amyotrophic lateral sclerosis, an epftopo specific for Alzheimer's disease isolated and a specific epftopo for Parkinson's disease isolated. The recombinant molecules described above can be introduced directly into cells or tissues in vivo using delivery vehicles such as retrovirus vectors, adenophric vectors and DNA virus vectors. They can also be introduced into cells in vivo using physical techniques such as microinjection and electroporation or chemical methods such as co-precipitation and incorporation of DNA into liposomes. Recombinant molecules can also be supplied in the form of an aerosol or by washing. The nucleic acid molecules described herein can also be applied in</span>
  </p>
  <p id="p00700" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00701" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00702" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00703" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00704" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00705" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00706" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00707" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00708" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00709" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00710" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00711" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00712" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00713" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">forma extracelular, tal como por inyeccion directa en las celulas.</span>extracellular form, such as by direct injection into the cells.</span>
  </p>
  <p id="p00714" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodo de tratamiento medico de la enfermedad usando acidos nucleicos</span>Method of medical treatment of the disease using nucleic acids</span>
  </p>
  <p id="p00715" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los vectores que contienen las moleculas de acido nucleico descritas en este documento se administran opcionalmente al SNC de mamfferos, preferiblemente seres humanos, en terapia genica usando tecnicas descritas a continuacion. Los polipeptidos producidos a partir de las moleculas de acido nucleico se administran facilmente al SNC de mamfferos, preferiblemente seres humanos. La descripcion se refiere a un metodo de tratamiento medico de un mamffero, preferiblemente un ser humano, administrando al mamffero un vector de la invencion o una celula que contiene un vector descrito en este documento. Las enfermedades neurales tales como enfermedad de Parkinson, enfermedad de Alzheimer y esclerosis lateral amiotrofica se tratan como se describe en esta solicitud o usando metodos conocidos en la tecnica (patentes de Estados Unidos n. 7175840, 7157098, 7141044, 6.309.634; 6936594; solicitudes de Estados Unidos n. 2006073119; 2004265283; 2002107213; 2006122116). Las enfermedades, tales como enfermedades hematologicas o enfermedades neurales (neurodegenerativas), se tratan como se describe en esta solicitud y se conoce en la tecnica. Las enfermedades nerviosas de celulas madre a tratarse por trasplante de celulas madre neurales incluyen enfermedades que provocan dano o perdida de celulas neurales, por ejemplo, paralisis, enfermedad de Parkinson, enfermedad de Alzheimer, ALS, esclerosis multiple. El vector de la invencion es util como marcador de celulas madre y para expresar genes que causan que las celulas madre se diferencien (por ejemplo, factor de crecimiento).</span>The vectors containing the nucleic acid molecules described herein are optionally administered to the CNS of mammals, preferably humans, in genetic therapy using techniques described below. Polypeptides produced from nucleic acid molecules are easily administered to the CNS of mammals, preferably humans. The description refers to a method of medical treatment of a mammal, preferably a human being, by administering to the mammal a vector of the invention or a cell containing a vector described herein. Neural diseases such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis are treated as described in this application or using methods known in the art (US Pat. Nos. 7175840, 7157098, 7141044, 6,309,634; 6936594 ; U.S. applications No. 2006073119; 2004265283; 2002107213; 2006122116). Diseases, such as hematological diseases or neural (neurodegenerative) diseases, are treated as described in this application and known in the art. Nerve stem cell diseases to be treated by neural stem cell transplants include diseases that cause damage or loss of neural cells, for example, paralysis, Parkinson's disease, Alzheimer's disease, ALS, multiple sclerosis. The vector of the invention is useful as a marker for stem cells and to express genes that cause stem cells to differentiate (eg, growth factor).</span>
  </p>
  <p id="p00716" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodos de tratamiento usando peptidos aislados correspondientes a epftopos especfficos de enfermedad</span>Methods of treatment using isolated peptides corresponding to disease-specific epitopes</span>
  </p>
  <p id="p00717" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un aspecto de la invencion es las composiciones de la invencion para su uso en el tratamiento de la esclerosis lateral amiotrofica en un sujeto que lo necesite.</span>An aspect of the invention is the compositions of the invention for use in the treatment of amyotrophic lateral sclerosis in a subject in need.</span>
  </p>
  <p id="p00718" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo de tratamiento de la esclerosis lateral amiotrofica en un sujeto que lo necesite, que comprende administrar al sujeto una composicion que comprende un epftopo especffico de esclerosis lateral amiotrofica, en mezcla con un diluyente o vehfculo adecuado.</span>A method of treating amyotrophic lateral sclerosis is described in a subject in need thereof, comprising administering to the subject a composition comprising a specific epitope of amyotrophic lateral sclerosis, in admixture with a suitable diluent or vehicle.</span>
  </p>
  <p id="p00719" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el epftopo especffico de esclerosis lateral amiotrofica que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The specific epitopic of amyotrophic lateral sclerosis is described, comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00720" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodos de tratamiento usando acidos nucleicos aislados</span>Treatment methods using isolated nucleic acids</span>
  </p>
  <p id="p00721" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo de tratamiento de la esclerosis lateral amiotrofica en un sujeto que lo necesite, que comprende administrar al sujeto un acido nucleico aislado que codifica un peptido correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado. En ciertas descripciones, los acidos nucleicos comprenden acidos nucleicos seleccionados del grupo de acidos nucleicos de la Tabla 2C.</span>A method of treating amyotrophic lateral sclerosis is described in a subject in need, comprising administering to the subject an isolated nucleic acid encoding a peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a diluent. or suitable vehicle. In certain descriptions, nucleic acids comprise nucleic acids selected from the group of nucleic acids in Table 2C.</span>
  </p>
  <p id="p00722" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, el epftopo comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>In one description, the epftope comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00723" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo de tratamiento de la esclerosis lateral amiotrofica en un sujeto que lo necesite, que comprende administrar al sujeto una composicion que comprende un acido nucleico que codifica un peptido correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado. En una descripcion, el acido nucleico comprende un acido nucleico seleccionado del grupo de acidos nucleicos de la Tabla 2C.</span>A method of treating amyotrophic lateral sclerosis is described in a subject in need thereof, comprising administering to the subject a composition comprising a nucleic acid encoding a peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a diluent or vehicle. suitable. In one description, the nucleic acid comprises a nucleic acid selected from the group of nucleic acids of Table 2C.</span>
  </p>
  <p id="p00724" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion adicional, el epftopo especffico de esclerosis lateral amiotrofica comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>In a further description, the specific epitope of amyotrophic lateral sclerosis comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analog thereof.</span>
  </p>
  <p id="p00725" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para tratar a un sujeto que tiene una afeccion, enfermedad o trastorno medico mediado por una forma mal plegada de la superoxido dismutasa (SOD), comprendiendo el metodo la etapa de administrar al sujeto una composicion que comprende un vehfculo farmaceuticamente aceptable y un agente seleccionado de (1) un anticuerpo que se une selectivamente a la forma mal plegada de SOD y/o (2) un inmunogeno que provoca la produccion de dicho anticuerpo por dicho sujeto, y/o (3) una secuencia de acido nucleico que codifica (1) o (2).</span>A method for treating a subject having a medical condition, disease or disorder mediated by a misfolded form of superoxide dismutase (SOD) is described, the method comprising the step of administering to the subject a composition comprising a pharmaceutically acceptable carrier and an agent selected from (1) an antibody that selectively binds to the misfolded form of SOD and / or (2) an immunogen that causes the production of said antibody by said subject, and / or (3) a nucleic acid sequence encoding (1) or (2).</span>
  </p>
  <p id="p00726" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodos para provocar una respuesta inmunitaria usando un peptido aislado correspondiente a un epftopo especffico de enfermedad</span>Methods for eliciting an immune response using an isolated peptide corresponding to a disease specific epftope</span>
  </p>
  <p id="p00727" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones descritas pueden usarse para provocar una respuesta inmunitaria en un animal y pueden usarse en metodos para provocar una respuesta inmunitaria en un animal contra un epftopo presentado selectivamente o accesible en SOD1 no nativa, incluyendo el epftopo especffico de esclerosis lateral amiotrofica, el epftopo especffico de enfermedad de Alzheimer o el epftopo especffico de enfermedad de Parkinson.</span>The described compositions can be used to elicit an immune response in an animal and can be used in methods to elicit an immune response in an animal against an epftope selectively presented or accessible in non-native SOD1, including the specific epitope of amyotrophic lateral sclerosis, the specific epitope of Alzheimer's disease or the specific epitope of Parkinson's disease.</span>
  </p>
  <p id="p00728" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00729" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00730" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00731" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00732" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00733" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00734" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00735" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00736" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00737" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00738" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00739" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00740" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00741" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para provocar una respuesta inmunitaria en un animal usando una de las composiciones de la invencion.</span>A method for eliciting an immune response in an animal using one of the compositions of the invention is described.</span>
  </p>
  <p id="p00742" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para provocar una respuesta inmunitaria en un animal, usando una composicion que comprende un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado. Se describe el peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, que es un peptido seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A method for eliciting an immune response in an animal is described, using a composition comprising an isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a suitable diluent or carrier. The isolated peptide corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 is described, which is a peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00743" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para provocar una respuesta inmunitaria en un animal, usando una composicion que comprende un peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica en mezcla con un diluyente o vehfculo adecuado. Se describe el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica que es un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A method for eliciting an immune response in an animal is described, using a composition comprising an isolated peptide corresponding to a specific epitope of amyotrophic lateral sclerosis in admixture with a suitable diluent or carrier. The isolated peptide corresponding to a specific amyotrophic lateral sclerosis epftope is described which is an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00744" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodo para provocar una respuesta inmunitaria usando un acido nucleico aislado</span>Method to elicit an immune response using an isolated nucleic acid</span>
  </p>
  <p id="p00745" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para provocar una respuesta inmunitaria en un animal, usando una composicion que comprende un acido nucleico que codifica un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado para tratar la esclerosis lateral amiotrofica. Se describe el peptido aislado correspondiente a un epftopo que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A method for eliciting an immune response in an animal is described, using a composition comprising a nucleic acid encoding an isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a diluent or vehicle suitable for treating. Amyotrophic lateral sclerosis. The isolated peptide corresponding to an epftope comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00746" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo para provocar una respuesta inmunitaria en un animal, usando una composicion que comprende un acido nucleico que codifica un epftopo especffico de esclerosis lateral amiotrofica aislado en mezcla con un diluyente o vehfculo adecuado. Se describe el peptido aislado correspondiente a un epftopo especffico de esclerosis lateral amiotrofica que es un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A method for eliciting an immune response in an animal is described, using a composition comprising a nucleic acid encoding a specific epitope of isolated amyotrophic lateral sclerosis in admixture with a suitable diluent or carrier. The isolated peptide corresponding to a specific amyotrophic lateral sclerosis epftope is described which is an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00747" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso de un peptido aislado correspondiente a un epftopo especffico de enfermedad en la fabricacion de un medicamento</span>Use of an isolated peptide corresponding to a disease specific epftope in the manufacture of a medicament</span>
  </p>
  <p id="p00748" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en la fabricacion de un medicamento para tratar la esclerosis lateral amiotrofica. Se describe el peptido aislado correspondiente a un epftopo que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The use of an isolated peptide corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 in the manufacture of a medicament for treating amyotrophic lateral sclerosis is described. The isolated peptide corresponding to an epftope comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00749" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso de un acido nucleico aislado en la fabricacion de un medicamento</span>Use of an isolated nucleic acid in the manufacture of a medicine</span>
  </p>
  <p id="p00750" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un acido nucleico aislado que codifica un peptido que corresponde a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en la fabricacion de un medicamento para tratar la esclerosis lateral amiotrofica. Se describe el peptido aislado correspondiente a un epftopo que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The use of an isolated nucleic acid encoding a peptide corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 in the manufacture of a medicament for treating amyotrophic lateral sclerosis is described. The isolated peptide corresponding to an epftope comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00751" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se ha descrito anteriormente, la inmunogenicidad y, por tanto, la eficacia de una vacuna puede mejorarse significativamente si el agente de inmunizacion (por ejemplo, el peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1) y/o composiciones del mismo se co- inmunizan con un adyuvante. Por consiguiente, los metodos descritos y usos incluyen el uso de un adyuvante.</span>As described above, the immunogenicity and, therefore, the efficacy of a vaccine can be significantly improved if the immunization agent (for example, the isolated peptide corresponding to an epftope selectively presented or accessible in non-native forms of SOD1) and / or compositions thereof are co-immunized with an adjuvant. Accordingly, the methods described and uses include the use of an adjuvant.</span>
  </p>
  <p id="p00752" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso de acidos nucleicos aislados correspondientes a epftopos especfficos de enfermedad para tratar enfermedades neurodegenerativas mediadas por SOD1</span>Use of isolated nucleic acids corresponding to disease-specific epftopos to treat neurodegenerative diseases mediated by SOD1</span>
  </p>
  <p id="p00753" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un acido nucleico aislado que corresponde a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado para tratar la esclerosis lateral amiotrofica. Se describe el uso de un acido nucleico aislado que codifica un peptido que corresponde a un epftopo especffico de enfermedad. Se describe el acido nucleico que codifica un peptido que corresponde a un epftopo especffico de enfermedad que comprende un peptido seleccionado del grupo que consiste en los peptidos de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The use of an isolated nucleic acid corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 in admixture with a diluent or suitable vehicle for treating amyotrophic lateral sclerosis is described. The use of an isolated nucleic acid encoding a peptide corresponding to a disease specific epftope is described. The nucleic acid encoding a peptide that corresponds to a disease-specific epitope comprising a peptide selected from the group consisting of the peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00754" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un peptido aislado correspondiente a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado para tratar la esclerosis lateral amiotrofica. Se describe el peptido aislado correspondiente a un epftopo que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The use of an isolated peptide corresponding to an epftope presented selectively or accessible in non-native forms of SOD1 in admixture with a diluent or suitable vehicle for treating amyotrophic lateral sclerosis is described. The isolated peptide corresponding to an epftope comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00755" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00756" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00757" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00758" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00759" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00760" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00761" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00762" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00763" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00764" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00765" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00766" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00767" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00768" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones y usos de agentes de union especfficos para los epftopos especfficos de enfermedad que se unen a epftopos especfficos de enfermedad</span>Compositions and uses of specific binding agents for disease-specific epftopos that bind disease-specific epftopos</span>
  </p>
  <p id="p00769" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos presentados en SOD1 mal plegada pueden unirse y/o neutralizarse por varios agentes naturales o modificados por ingenierfa diferentes, tales como anticuerpos, otros polipeptidos, moleculas pequenas, aficuerpos (Wahlberg et al., Proc Natl Acad Sci USA, 100:3185-3190, 2003); anticalinas (Schlehuber y Skerra, Biophys Chem., 96:213-28, 2002); y aptameros de acido nucleico y proteicos (Cullen et al. Cell, 58: 423-466, 1989). En ciertas descripciones, el agente es un anticuerpo que se une selectivamente a un epftopo especffico de enfermedad o un analogo del mismo presentado o accesible en SOD1 no nativa.</span>Epftopes presented in poorly folded SOD1 can be bound and / or neutralized by several different natural or engineering-modified agents, such as antibodies, other polypeptides, small molecules, antibodies (Wahlberg et al., Proc Natl Acad Sci USA, 100: 3185- 3190, 2003); anticalinas (Schlehuber and Skerra, Biophys Chem., 96: 213-28, 2002); and nucleic acid and protein aptamers (Cullen et al. Cell, 58: 423-466, 1989). In certain descriptions, the agent is an antibody that selectively binds to a disease-specific epftope or an analog thereof presented or accessible in non-native SOD1.</span>
  </p>
  <p id="p00770" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos</span>Antibody generation</span>
  </p>
  <p id="p00771" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 pueden usarse para preparar anticuerpos. Se describen anticuerpos especfficos para moleculas de SOD1 mal plegada, preferiblemente moleculas de SOD1 mal plegada asociadas con enfermedad de Alzheimer, enfermedad de Parkinson y/o esclerosis lateral amiotrofica.</span>Epftopes presented selectively or accessible in non-native forms of SOD1 can be used to prepare antibodies. Antibodies specific for poorly folded SOD1 molecules, preferably poorly folded SOD1 molecules associated with Alzheimer's disease, Parkinson's disease and / or amyotrophic lateral sclerosis are described.</span>
  </p>
  <p id="p00772" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, los epftopos especfficos de esclerosis lateral amiotrofica pueden usarse para preparar anticuerpos especfficos para los epftopos especfficos de esclerosis lateral amiotrofica. En una descripcion, los anticuerpos son especfficos para las moleculas de SOD1 mal plegada. En otras descripciones, los anticuerpos son anticuerpos aislados.</span>In one description, specific episodes of amyotrophic sclerosis can be used to prepare antibodies specific for specific episodes of amyotrophic lateral sclerosis. In one description, the antibodies are specific for poorly folded SOD1 molecules. In other descriptions, the antibodies are isolated antibodies.</span>
  </p>
  <p id="p00773" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra descripcion, el anticuerpo aislado especffico para el epftopo especffico de esclerosis lateral amiotrofica se preparar administrando una de las composiciones descritas en este documento a un animal.</span>In another description, the specific isolated antibody for the specific epitope of amyotrophic lateral sclerosis is prepared by administering one of the compositions described herein to an animal.</span>
  </p>
  <p id="p00774" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otra descripcion incluye un anticuerpo aislado para un epftopo especffico de esclerosis lateral amiotrofica, donde el epftopo especffico de esclerosis lateral amiotrofica comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>Another description includes an isolated antibody for a specific amyotrophic lateral sclerosis epftope, where the specific amyotrophic lateral sclerosis epftope comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue of the same.</span>
  </p>
  <p id="p00775" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El termino "anticuerpo", como se usa en este documento, pretende incluir anticuerpos monoclonales incluyendo anticuerpos monoclonales quimericos y humanizados, anticuerpos policlonales, anticuerpos humanizados, anticuerpos humanos y anticuerpos quimericos. El anticuerpo puede ser de fuentes recombinantes y/o producirse en animales transgenicos. La expresion "fragmento de anticuerpo", como se usa en este documento, pretende incluir Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dfmeros, minicuerpos, diacuerpos y multfmeros de los mismos y fragmentos de anticuerpo biespecfficos. Los anticuerpos pueden fragmentarse usando tecnicas convencionales. Por ejemplo, los fragmentos F(ab')2 pueden generarse tratando el anticuerpo con pepsina. El fragmento F(ab')2 resultante puede tratarse para reducir los puentes disulfuro para producir fragmentos Fab'. La digestion con papafna puede conducir a la formacion de fragmentos Fab. Los fragmentos Fab, Fab' y F(ab')2, scFv, dsFv, ds-scFv, dfmeros, minicuerpos, diacuerpos, fragmentos de anticuerpo biespecfficos y otros fragmentos tambien pueden sintetizarse por tecnicas recombinantes. Los anticuerpos son opcionalmente de cualquier isotipo util, incluyendo IgM que, en una realizacion, se usa para aplicaciones de diagnostico e IgG, tal como IgG1, IgG2, IgG3 e IgG4 que es una realizacion que se usa para aplicaciones terapeuticas.</span>The term "antibody", as used herein, is intended to include monoclonal antibodies including chimeric and humanized monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies and chimeric antibodies. The antibody can be from recombinant sources and / or produced in transgenic animals. The term "antibody fragment", as used herein, is intended to include Fab, Fab ', F (ab') 2, scFv, dsFv, ds-scFv, dfimers, minibodies, diabodies and multfomers thereof and fragments of bispecific antibody. Antibodies can be fragmented using conventional techniques. For example, F (ab ') 2 fragments can be generated by treating the antibody with pepsin. The resulting F (ab ') 2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Digestion with papafna can lead to the formation of Fab fragments. The Fab, Fab 'and F (ab') 2 fragments, scFv, dsFv, ds-scFv, dfimers, minibodies, diabody, bispecific antibody fragments and other fragments can also be synthesized by recombinant techniques. The antibodies are optionally of any useful isotype, including IgM which, in one embodiment, is used for diagnostic applications and IgG, such as IgG1, IgG2, IgG3 and IgG4 which is an embodiment used for therapeutic applications.</span>
  </p>
  <p id="p00776" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anticuerpo aislado" se refiere al anticuerpo producido in vivo o in vitro que se ha retirado de la fuente que produjo el anticuerpo, por ejemplo, un animal, hibridoma u otra lfnea celular (tal como celulas recombinantes que producen anticuerpo). El anticuerpo aislado esta opcionalmente "purificado", que significa al menos: un 80 %, un 85 %, un 90 %, un 95 %, un 98 % o un 99 % de pureza y opcionalmente pureza de calidad farmaceutica.</span>"Isolated antibody" refers to the antibody produced in vivo or in vitro that has been removed from the source that produced the antibody, for example, an animal, hybridoma or other cell line (such as recombinant cells that produce antibody). The isolated antibody is optionally "purified", which means at least: 80%, 85%, 90%, 95%, 98% or 99% purity and optionally pharmaceutical quality purity.</span>
  </p>
  <p id="p00777" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anticuerpo endogeno" se refiere al anticuerpo producido por un sujeto, tal como un mamffero (por ejemplo, ser humano), como parte de una respuesta inmunitaria en el sujeto.</span>"Endogenous antibody" refers to the antibody produced by a subject, such as a mammal (for example, human), as part of an immune response in the subject.</span>
  </p>
  <p id="p00778" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anticuerpo exogeno" se refiere a un anticuerpo que es no propio o foraneo para un sujeto, tal como un mamffero (por ejemplo, un ser humano). La expresion "anticuerpo exogeno" abarca un anticuerpo aislado, asf como un anticuerpo aislado y purificado. Para producir anticuerpos monoclonales, pueden recogerse celulas productoras de anticuerpos (linfocitos) de un sujeto inmunizado con un inmunogeno que comprende un peptido aislado correspondiente a un epftopo especffico de SOD1 mal plegada, incluyendo un epftopo especffico de esclerosis lateral amiotrofica, un epftopo especffico de enfermedad de Alzheimer o un epftopo especffico de enfermedad de Parkinson, y puede fusionarse con celulas de mieloma por procedimientos convencionales de fusion de celulas somaticas inmortalizando de ese modo estas celulas y produciendo celulas de hibridoma. Dichas tecnicas son bien conocidas en la tecnica (por ejemplo, la tecnica de hibridoma desarrollada originalmente por Kohler y Milstein (42), asf como otras tecnicas tales como la tecnica de hibridoma de celulas B humanas (43), la tecnica de hibridoma EBV para producir anticuerpos monoclonales humanos (44), y la exploracion de bibliotecas combinatorias de anticuerpos (45)). Las celulas de hibridoma pueden explorarse de forma inmunoqufmica para la produccion de anticuerpos especfficamente reactivos con los epftopos especfficos de esclerosis lateral amiotrofica y los anticuerpos monoclonales pueden aislarse.</span>"Exogenous antibody" refers to an antibody that is non-self or foreign to a subject, such as a mammal (for example, a human being). The term "exogenous antibody" encompasses an isolated antibody, as well as an isolated and purified antibody. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be collected from a subject immunized with an immunogen comprising an isolated peptide corresponding to a poorly folded SOD1 specific epitope, including a specific amyotrophic lateral sclerosis epitope, a disease specific epitope of Alzheimer's or a specific epitope of Parkinson's disease, and can be fused with myeloma cells by conventional somatic cell fusion procedures thereby immortalizing these cells and producing hybridoma cells. Such techniques are well known in the art (for example, the hybridoma technique originally developed by Kohler and Milstein (42), as well as other techniques such as the human B cell hybridoma technique (43), the EBV hybridoma technique for produce human monoclonal antibodies (44), and scanning combinatorial antibody libraries (45)). Hybridoma cells can be screened immunochemically for the production of antibodies specifically reactive with the specific episodes of amyotrophic lateral sclerosis and monoclonal antibodies can be isolated.</span>
  </p>
  <p id="p00779" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00780" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00781" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00782" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00783" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00784" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00785" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00786" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00787" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00788" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00789" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00790" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00791" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00792" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos especfficos o fragmentos de anticuerpo, reactivos contra antfgenos o moleculas particulares, tales como epftopos presentados selectivamente o accesibles en formas mal plegadas de SOD1, incluyendo epftopos especfficos de esclerosis lateral amiotrofica, epftopos especfficos de enfermedad de Alzheimer o epftopos especfficos de enfermedad de Parkinson tambien pueden generarse explorando bibliotecas de expresion que codifican genes de inmunoglobulina o partes de los mismos, expresados en bacterias con componentes de superficie celular. Por ejemplo, los fragmentos Fab completos, las regiones VH y las regiones FV pueden expresarse en bacterias usando bibliotecas de expresion en fagos (vease, por ejemplo, Ward et al. (46); Huse et al. (45); y McCafferty et al. (47)).</span>Specific antibodies or antibody fragments, reactive against particular antigens or molecules, such as epftopos presented selectively or accessible in poorly folded forms of SOD1, including specific epitopes of amyotrophic lateral sclerosis, specific epftopos of Alzheimer's disease or specific epftopos of Parkinson's disease They can also be generated by exploring expression libraries that encode immunoglobulin genes or parts thereof, expressed in bacteria with cell surface components. For example, complete Fab fragments, VH regions and PV regions can be expressed in bacteria using phage expression libraries (see, for example, Ward et al. (46); Huse et al. (45); and McCafferty et al. (47)).</span>
  </p>
  <p id="p00793" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "anticuerpo humanizado", como se usa en este documento, significa que el anticuerpo o fragmento comprende regiones flanqueantes conservadas humanas (mencionadas alternativamente como regiones constantes) y las regiones hipervariables (mencionadas alternativamente como el dominio de union a antfgeno) que son de origen no humano. Por ejemplo, la region hipervariable puede ser de un raton, rata u otra especie. La inmunizacion de anticuerpo a partir de especies no humanas se ha descrito bien en la bibliograffa. Vease, por ejemplo, el documento EP-B1 0 239400 y Carter y Merchant 1997 (Curr Opin Biotechnol 8, 449-454, 1997). Los anticuerpos humanizados tambien se obtienen facilmente en el mercado (por ejemplo, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Gran Bretana.).</span>The term "humanized antibody", as used herein, means that the antibody or fragment comprises human conserved flanking regions (alternatively mentioned as constant regions) and hypervariable regions (alternatively mentioned as the antigen binding domain) that are of non-human origin For example, the hypervariable region may be of a mouse, rat or other species. Immunization of antibody from non-human species has been well described in the literature. See, for example, EP-B1 0 239400 and Carter and Merchant 1997 (Curr Opin Biotechnol 8, 449-454, 1997). Humanized antibodies are also readily available on the market (for example, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.).</span>
  </p>
  <p id="p00794" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las formas humanizadas de anticuerpos de roedor se generan facilmente por injerto de CDR (Riechmann et al. Nature, 332:323-327, 1988). En este enfoque, los seis bucles de CDR que comprenden el sitio de union a antfgeno del anticuerpo monoclonal de roedor se unen a las correspondientes regiones flanqueantes humanas. El injerto de CDR a menudo produce anticuerpos con afinidad reducida ya que los aminoacidos de las regiones flanqueantes pueden influir en el reconocimiento del antfgeno (Foote y Winter. J Mol Biol, 224: 487-499, 1992). Para mantener la afinidad del anticuerpo, a menudo es necesario remplazar ciertos restos flanqueantes por mutagenesis dirigida al sitio u otras tecnicas recombinantes y puede asistirse por modelado informatico del sitio de union a antfgeno (Co et al. J Immunol, 152: 2968-2976, 1994).</span>Humanized forms of rodent antibodies are easily generated by CDR grafting (Riechmann et al. Nature, 332: 323-327, 1988). In this approach, the six CDR loops comprising the antigen binding site of the rodent monoclonal antibody bind to the corresponding human flanking regions. CDR grafting often produces antibodies with reduced affinity since amino acids from flanking regions can influence antigen recognition (Foote and Winter. J Mol Biol, 224: 487-499, 1992). To maintain antibody affinity, it is often necessary to replace certain flanking moieties with site-directed mutagenesis or other recombinant techniques and can be assisted by computer modeling of the antigen binding site (Co et al. J Immunol, 152: 2968-2976, 1994).</span>
  </p>
  <p id="p00795" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las formas humanizadas de anticuerpos se obtienen opcionalmente por recubrimiento (Pedersen et al. J Mol Biol, 235: 959-973, 1994). En este enfoque, solamente se humanizan los restos superficiales de un anticuerpo de roedor.</span>Humanized forms of antibodies are optionally obtained by coating (Pedersen et al. J Mol Biol, 235: 959-973, 1994). In this approach, only the surface remains of a rodent antibody are humanized.</span>
  </p>
  <p id="p00796" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "anticuerpos humanos", como se usa en este documento, se refiere a anticuerpos que son, o corresponden a, anticuerpos que se producen de forma endogeno en un sujeto humano, sin embargo, los anticuerpos humanos tambien se producen opcionalmente de forma exogena a traves de tecnicas bioqufmicas. Los anticuerpos humanos especfficos para un antfgeno particular pueden identificarse por una estrategia de presentacion en fagos (Jespers et al. Bio/Technology, 12: 899-903, 1994). En un enfoque, la cadena pesada de un anticuerpo de roedor dirigido contra un antfgeno especffico se clona y aparea con un repertorio de cadenas ligeras humanas para presentarse como fragmentos Fab en fagos filamentosos. El fago se selecciona por union al antfgeno. La cadena ligera humana seleccionada posteriormente se aparea con un repertorio de cadenas pesadas humanas para su presentacion en fagos, y el fago se selecciona de nuevo por union al antfgeno. El resultado es un fragmento Fab de anticuerpo humano especffico para un antfgeno particular. En otro enfoque, se producen bibliotecas de fagos donde los miembros presentan diferentes fragmentos de anticuerpo humano (Fab o Fv) sobre sus superficies externas (Dower et al., documento WO 91/17271 y McCafferty et al., documento WO 92/01047). Los fagos que presentan anticuerpos con una especificidad deseada se seleccionan por enriquecimiento de afinidad para un antfgeno especffico. El fragmento Fab o Fv humano identificado a partir de cualquier enfoque puede volver a clonarse para su expresion como un anticuerpo humano en celulas de mamffero.</span>The term "human antibodies", as used herein, refers to antibodies that are, or correspond to, antibodies that are produced endogenously in a human subject, however, human antibodies are also optionally produced exogenously. through biochemical techniques. Human antibodies specific for a particular antigen can be identified by a phage display strategy (Jespers et al. Bio / Technology, 12: 899-903, 1994). In one approach, the heavy chain of a rodent antibody directed against a specific antigen is cloned and paired with a repertoire of human light chains to present as Fab fragments in filamentous phage. The phage is selected by binding to the antigen. The human light chain selected subsequently is paired with a repertoire of human heavy chains for phage display, and the phage is again selected by binding to the antigen. The result is a Fab fragment of human antibody specific for a particular antigen. In another approach, phage libraries are produced where members have different fragments of human antibody (Fab or Fv) on their external surfaces (Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047) . Phages that exhibit antibodies with a desired specificity are selected by affinity enrichment for a specific antigen. The human Fab or Fv fragment identified from any approach can be cloned again for expression as a human antibody in mammalian cells.</span>
  </p>
  <p id="p00797" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos humanos se obtienen opcionalmente de animales transgenicos (patentes de Estados Unidos n. 6.150.584; 6.114.598 y 5.770.429). En este enfoque, se deleciona el gen de la region de union de cadena pesada (Jh) en un raton mutante quimerico o de la lfnea germinal. La serie del gen de inmunoglobulina de lfnea germinal humana posteriormente se transfiere a dicho raton mutante. El raton transgenico resultante entonces es capaz de generar un repertorio completo de anticuerpos humanos tras exposicion al antfgeno.</span>Human antibodies are optionally obtained from transgenic animals (U.S. Patent Nos. 6,150,584; 6,114,598 and 5,770,429). In this approach, the heavy chain (Jh) binding region gene is deleted in a chimeric or germline mutant mouse. The human germline immunoglobulin gene series is subsequently transferred to said mutant mouse. The resulting transgenic mouse is then able to generate a complete repertoire of human antibodies after exposure to the antigen.</span>
  </p>
  <p id="p00798" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos humanizados o humanos se seleccionan de cualquier clase de inmunoglobulinas incluyendo: IgM, IgG, IgD, IgA o IgE; y cualquier isotipo, incluyendo: IgG1, IgG2, IgG3 e IgG4. El anticuerpo humanizado o humano puede incluir secuencias de uno o mas de un isotopo o clase. Ademas, estos anticuerpos se producen tfpicamente como fragmentos de union a antfgeno tales como Fab, Fab' F(ab')2, Fd, Fv y fragmentos de anticuerpo de un unico dominio, o como anticuerpos de cadena sencilla en que las cadenas pesada y ligera estan unidas por un espaciador. Ademas, los anticuerpos humanos o humanizados pueden existir en forma monomerica o polimerica. El anticuerpo humanizado opcionalmente comprende una cadena no humana y una cadena humanizada (es decir, una cadena pesada o ligera humanizada).</span>Humanized or human antibodies are selected from any class of immunoglobulins including: IgM, IgG, IgD, IgA or IgE; and any isotype, including: IgG1, IgG2, IgG3 and IgG4. The humanized or human antibody may include sequences of one or more of an isotope or class. In addition, these antibodies are typically produced as antigen binding fragments such as Fab, Fab 'F (ab') 2, Fd, Fv and antibody fragments of a single domain, or as single chain antibodies in which the heavy chains and Lightly joined by a spacer. In addition, human or humanized antibodies may exist in monomeric or polymeric form. The humanized antibody optionally comprises a non-human chain and a humanized chain (ie, a humanized heavy or light chain).</span>
  </p>
  <p id="p00799" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adicionalmente, los anticuerpos especfficos para los epftopos de la invencion se afslan facilmente explorando bibliotecas de presentacion en fagos de anticuerpos. Por ejemplo, opcionalmente se explora una biblioteca en fagos de anticuerpos usando un epftopo especffico de enfermedad de la presente invencion para identificar fragmentos de anticuerpos especfficos para el epftopo especffico de enfermedad. Los fragmentos de anticuerpo identificados opcionalmente se usan para producir una diversidad de anticuerpos recombinantes que son utiles con diferentes</span>Additionally, the antibodies specific for the epftopes of the invention are readily isolated by scanning antibody phage display libraries. For example, an antibody phage library is optionally screened using a disease specific epftope of the present invention to identify antibody fragments specific for the disease specific epftope. The optionally identified antibody fragments are used to produce a variety of recombinant antibodies that are useful with different</span>
  </p>
  <p id="p00800" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00801" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00802" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00803" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00804" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00805" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00806" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00807" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00808" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00809" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00810" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00811" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00812" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00813" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">realizaciones de la presente invencion. Las bibliotecas de presentacion en fagos de anticuerpos estan disponibles en el mercado, por ejemplo, a traves de Xoma (Berkeley, California). Los metodos para explorar bibliotecas en fagos de anticuerpos son bien conocidos en la tecnica.</span>embodiments of the present invention. Antibody phage display libraries are commercially available, for example, through Xoma (Berkeley, California). Methods for exploring antibody phage libraries are well known in the art.</span>
  </p>
  <p id="p00814" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambien se describen anticuerpos que compiten selectivamente con anticuerpos creados usando un inmunogeno que comprende un peptido aislado de la Tabla 2 y de la Tabla 2A y analogos de los mismos. Se realizan ensayos de competicion para proporcionar un metodo de determinacion de si un anticuerpo de ensayo desplaza a un anticuerpo descrito en este documento, que comprende poner en contacto un epftopo presentado en una forma no nativa de SOD1 con un anticuerpo de ensayo y un anticuerpo creado usando un inmunogeno que comprende un peptido aislado de la Tabla 2, Tabla 2A o analogos de los mismos y a continuacion determinando si el anticuerpo de ensayo desplaza selectivamente el anticuerpo descrito en este documento de la union del epftopo. El anticuerpo de ensayo se considera que desplaza selectivamente el anticuerpo descrito en este documento si el anticuerpo de ensayo tiene al menos 1,5 veces o al menos 2 veces mayor afinidad de union por el epftopo.</span>Antibodies that selectively compete with antibodies created using an immunogen comprising an isolated peptide from Table 2 and Table 2A and analogs thereof are also described. Competition tests are performed to provide a method of determining whether a test antibody displaces an antibody described herein, which comprises contacting an epftope presented in a non-native form of SOD1 with a test antibody and an antibody created. using an immunogen comprising an isolated peptide from Table 2, Table 2A or analogs thereof and then determining whether the test antibody selectively displaces the antibody described herein from the epitope binding. The test antibody is considered to selectively displace the antibody described herein if the test antibody has at least 1.5 times or at least 2 times greater binding affinity for the epitope.</span>
  </p>
  <p id="p00815" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos anticuerpos especfficos para epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 pueden usarse para tratar la esclerosis lateral amiotrofica. En una realizacion, los anticuerpos de la invencion pueden usarse para tratar la esclerosis lateral amiotrofica. Por ejemplo, la infusion pasiva de anticuerpos especfficos para un epftopo especffico de esclerosis lateral amiotrofica puede inhibir la formacion de agregados de SOD1 y/o puede bloquear el mal plegamiento dirigido por molde de SOD1.</span>These antibodies specific for epftopes selectively presented or accessible in non-native forms of SOD1 can be used to treat amyotrophic lateral sclerosis. In one embodiment, the antibodies of the invention can be used to treat amyotrophic lateral sclerosis. For example, passive infusion of antibodies specific for a specific amyotrophic lateral sclerosis epftope can inhibit the formation of aggregates of SOD1 and / or can block mold-directed misfolding of SOD1.</span>
  </p>
  <p id="p00816" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden anticuerpos</span>Compositions comprising antibodies</span>
  </p>
  <p id="p00817" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un aspecto adicional de la invencion es una composicion para tratar la esclerosis lateral amiotrofica, que comprende una cantidad eficaz de un anticuerpo especffico para un epftopo que consiste en DSE5 o en DSE7 o un analogo que consiste en DSE5 o en DSE7, comprendiendo el analogo la modificacion de un aminoacido por oxidacion o nitracion en mezcla con un diluyente o vehfculo adecuado. Se describe el epftopo que comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>A further aspect of the invention is a composition for treating amyotrophic lateral sclerosis, which comprises an effective amount of an epftope-specific antibody consisting of DSE5 or DSE7 or an analog consisting of DSE5 or DSE7, the analog comprising modification of an amino acid by oxidation or nitration in admixture with a suitable diluent or vehicle. The epftope comprising an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof is described.</span>
  </p>
  <p id="p00818" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un aspecto de la invencion es una composicion para tratar la esclerosis lateral amiotrofica, que comprende una cantidad eficaz de un anticuerpo especffico para un epftopo especffico de esclerosis lateral amiotrofica que consiste en DSE5 o en DSE7 o un analogo que consiste en DSE5 o en DSE7, comprendiendo el analogo la modificacion de un aminoacido por oxidacion o nitracion en mezcla con un diluyente o vehfculo adecuado.</span>An aspect of the invention is a composition for treating amyotrophic lateral sclerosis, which comprises an effective amount of a specific antibody for a specific epitope of amyotrophic lateral sclerosis consisting of DSE5 or DSE7 or an analog consisting of DSE5 or DSE7, the analog comprising the modification of an amino acid by oxidation or nitration in admixture with a suitable diluent or vehicle.</span>
  </p>
  <p id="p00819" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realizacion, los anticuerpos son anticuerpos humanizados. En otra realizacion, los anticuerpos se administran a la sangre o al fluido espinal de un sujeto con esclerosis lateral amiotrofica.</span>In one embodiment, the antibodies are humanized antibodies. In another embodiment, the antibodies are administered to the blood or spinal fluid of a subject with amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00820" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen metodos y usos de los anticuerpos para tratar la esclerosis lateral amiotrofica.</span>Methods and uses of antibodies to treat amyotrophic lateral sclerosis are described.</span>
  </p>
  <p id="p00821" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodo de tratamiento: inmunizacion pasiva</span>Treatment method: passive immunization</span>
  </p>
  <p id="p00822" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe un metodo de tratamiento de la esclerosis lateral amiotrofica en un sujeto que lo necesite, que comprende administrar al sujeto un anticuerpo que se une a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado.</span>A method of treating amyotrophic lateral sclerosis is described in a subject in need, comprising administering to the subject an antibody that binds to an epftope selectively presented or accessible in non-native forms of SOD1 in admixture with a suitable diluent or carrier.</span>
  </p>
  <p id="p00823" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ademas de anticuerpos, los epftopos presentados en SOD1 mal plegada pueden unirse y/o neutralizarse por varios agentes naturales o modificados por ingenierfa diferentes tales como otros polipeptidos, moleculas pequenas, aficuerpos (Wahlberg et al., Proc Natl Acad Sci USA, 100:3185-3190, 2003); anticalinas (Schlehuber y Skerra, Biophys Chem., 96:213-28, 2002); y aptameros de acido nucleico y proteicos (Cullen et al. Cell, 58: 423-466, 1989).</span>In addition to antibodies, epftopes presented in poorly folded SOD1 can be bound and / or neutralized by several different natural or engineering modified agents such as other polypeptides, small molecules, antibodies (Wahlberg et al., Proc Natl Acad Sci USA, 100: 3185 -3190, 2003); anticalinas (Schlehuber and Skerra, Biophys Chem., 96: 213-28, 2002); and nucleic acid and protein aptamers (Cullen et al. Cell, 58: 423-466, 1989).</span>
  </p>
  <p id="p00824" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los aficuerpos son protefnas de union modificadas por ingenierfa basadas en la estructura de triple helice del dominio Z derivado de la protefna A de estafilococos (Wahlberg et al., Proc Natl Acad Sci USA, 100:3185-3190, 2003). El dominio Z consiste en 58 restos que se unen a la parte Fc de IgG de diferentes especies (Nygren y Uhlen. Curr Opin Struct Biol., 7:463-469, 1997). Aleatorizando simultaneamente 13 posiciones de aminoacido localizadas en las dos helices que componen la superficie de union a Fc del dominio Z, se crea una biblioteca de protefnas de union (aficuerpos) y se usa para explorar la union a dianas deseadas por tecnologfa de presentacion en fagos (Nord, et al. Protein Eng., 8:601-608, 1995; Nord et al. Nat Biotechnol. 15:772-777, 1997). Los aficuerpos tienen una estructura secundaria similar al dominio Z nativo y tienen constantes de disociacion (KD) en el intervalo micromolar para sus dianas respectivas (Nord et al. Nat Biotechnol., 15:772-777, 1997).</span>The enzymes are engineering modified binding proteins based on the triple helix structure of the Z domain derived from Staphylococcus A protein (Wahlberg et al., Proc Natl Acad Sci USA, 100: 3185-3190, 2003). The Z domain consists of 58 residues that bind to the Fc part of IgG of different species (Nygren and Uhlen. Curr Opin Struct Biol., 7: 463-469, 1997). Simultaneously randomizing 13 amino acid positions located in the two helices that make up the Fc junction surface of the Z domain, a library of binding proteins (antibodies) is created and used to explore the binding to desired targets by phage display technology (Nord, et al. Protein Eng., 8: 601-608, 1995; Nord et al. Nat Biotechnol. 15: 772-777, 1997). The antibodies have a secondary structure similar to the native Z domain and have dissociation constants (KD) in the micromolar range for their respective targets (Nord et al. Nat Biotechnol., 15: 772-777, 1997).</span>
  </p>
  <p id="p00825" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las anticalinas son una clase de protefnas de union a ligando modificadas por ingenierfa derivadas de la estructura proteica de lipocalina (Schlehuber y Skerra, Biophys Chem., 96:213-28, 2002; Weiss y Lowman. Chem. Biol., 7:R177-R184, 2000; Skerra. J Biotechnol., 74:257-275, 2001). El proceso de preparacion de las anticalinas se describe en el documento EP1017814. El sitio de union a ligando de las anticalinas puede volver a modificarse por ingenierfa por sustituciones de aminoacido, u otros enfoques recombinantes, para alterar la especificidad de union de la protefna. Las anticalinas son similares a los anticuerpos porque poseen alta afinidad y especificidad por sus</span>Anticalins are a class of engineering-modified ligand binding proteins derived from the lipocalin protein structure (Schlehuber and Skerra, Biophys Chem., 96: 213-28, 2002; Weiss and Lowman. Chem. Biol., 7: R177 -R184, 2000; Skerra. J Biotechnol., 74: 257-275, 2001). The preparation process for anticalins is described in EP1017814. The ligand binding site of the anticalins can be engineered again by amino acid substitutions, or other recombinant approaches, to alter the specificity of protein binding. Anticalins are similar to antibodies because they have high affinity and specificity for their</span>
  </p>
  <p id="p00826" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00827" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00828" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00829" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00830" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00831" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00832" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00833" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00834" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00835" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00836" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00837" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00838" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00839" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ligandos prescritos. Sin embargo, las anticalinas tienen varias ventajas sobre los anticuerpos, incluyendo un tamano mas pequeno; una composicion peptfdica sencilla; y un sitio de union que se manipula facilmente.</span>prescribed ligands. However, anticalins have several advantages over antibodies, including a smaller size; a simple peptide composition; and a binding site that is easily manipulated.</span>
  </p>
  <p id="p00840" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los aptameros son cortos oligonucleotidos de ADN monocatenario, oligonucleotidos de ARN o polipeptidos con la capacidad de reconocer diversas moleculas diana con alta afinidad y especificidad (Cullen et al. Cell, 58: 423-466, 1989). Los aptameros se identifican opcionalmente por un proceso de evolucion y seleccion in vitro llamado SELEX (evolucion sistemica de ligandos por enriquecimiento exponencial), y los metodos para obtener aptameros especfficos para un polipeptido de interes son conocidos en la tecnica. Vease, por ejemplo, Brody E N, Gold L. J Biotechnol. Marzo de 2000; 74(1):5-13. Los metodos para la seleccion eficaz de aptameros que se unen a cualquier polipeptido de interes se describen en la publicacion de Estados Unidos n. 20050142582.</span>The aptamers are short single-stranded DNA oligonucleotides, RNA oligonucleotides or polypeptides with the ability to recognize various target molecules with high affinity and specificity (Cullen et al. Cell, 58: 423-466, 1989). Aptamers are optionally identified by an in vitro evolution and selection process called SELEX (systematic evolution of exponential enrichment ligands), and the methods for obtaining specific aptamers for a polypeptide of interest are known in the art. See, for example, Brody E N, Gold L. J Biotechnol. March 2000; 74 (1): 5-13. Methods for the effective selection of aptamers that bind to any polypeptide of interest are described in U.S. Publication No. 20050142582.</span>
  </p>
  <p id="p00841" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como los anticuerpos, los aptameros asumen una forma tridimensional especffica y estable in vivo, que proporciona union especffica a moleculas diana y provocan una respuesta biologica. Ademas, las afinidades de union de los aptameros son analogas a las de los anticuerpos (revisado en Nimjee et al. Annu Rev Med, 56: 555 - 83, 2005). Los aptameros tienen varias ventajas sobre los anticuerpos, incluyendo estabilidad a 80 C, semivida larga, baja inmunogenicidad (Retina, 22: 143-152, 2002), baja variabilidad entre lotes, amplia distribucion tisular debido a su pequeno tamano, se modifican facilmente para alterar su distribucion tisular y propiedades de eliminacion, por ejemplo, por pegilacion (Tucker et al. J Chromatogr B Biomed Sci Appl, 732: 203-212, 1999).</span>Like antibodies, aptamers assume a specific and stable three-dimensional form in vivo, which provides specific binding to target molecules and elicits a biological response. In addition, the binding affinities of aptamers are analogous to those of antibodies (reviewed in Nimjee et al. Annu Rev Med, 56: 555-83, 2005). Aptamers have several advantages over antibodies, including stability at 80  C, long half-life, low immunogenicity (Retina, 22: 143-152, 2002), low variability between batches, wide tissue distribution due to their small size, are easily modified to alter its tissue distribution and elimination properties, for example, by pegylation (Tucker et al. J Chromatogr B Biomed Sci Appl, 732: 203-212, 1999).</span>
  </p>
  <p id="p00842" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, el epftopo comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>In one description, the epftope comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00843" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso de anticuerpos para tratar la enfermedad</span>Use of antibodies to treat the disease</span>
  </p>
  <p id="p00844" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un anticuerpo que se une a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en mezcla con un diluyente o vehfculo adecuado para tratar la esclerosis lateral amiotrofica. En una descripcion, el epftopo comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2A, o un analogo de los mismos.</span>The use of an antibody that binds to an epftope presented selectively or accessible in non-native forms of SOD1 in admixture with a diluent or vehicle suitable for treating amyotrophic lateral sclerosis is described. In one description, the epftope comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2A, or an analogue thereof.</span>
  </p>
  <p id="p00845" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso del anticuerpo en la fabricacion de un medicamento</span>Use of the antibody in the manufacture of a medicine</span>
  </p>
  <p id="p00846" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describe el uso de un anticuerpo que se une a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 en la fabricacion de un medicamento para tratar la esclerosis lateral amiotrofica. En una descripcion, el epftopo comprende un peptido aislado seleccionado del grupo que consiste en los peptidos aislados de la Tabla 2 o de la Tabla 2a, o un analogo de los mismos.</span>The use of an antibody that binds to an epftope selectively presented or accessible in non-native forms of SOD1 in the manufacture of a medicament for treating amyotrophic lateral sclerosis is described. In one description, the epftope comprises an isolated peptide selected from the group consisting of the isolated peptides of Table 2 or Table 2a, or an analogue thereof.</span>
  </p>
  <p id="p00847" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los siguientes ejemplos se describen unicamente con fines de ilustracion y no pretenden limitar el alcance de la invencion.</span>The following examples are described only for purposes of illustration and are not intended to limit the scope of the invention.</span>
  </p>
  <p id="p00848" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodos de administracion de las composiciones</span>Methods of administration of the compositions</span>
  </p>
  <p id="p00849" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencion se administran facilmente, por ejemplo, por administracion parenteral, intravenosa, subcutanea, intramuscular, intracraneal, intraventricular, intratecal, intraorbital, oftalmica, intracapsular, intramedular, intracisternal, intraperitoneal, intranasal, en aerosol u oral.</span>The compositions of the invention are easily administered, for example, by parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraventricular, intrathecal, intraorbital, ophthalmic, intracapsular, intramedullary, intracisternal, intraperitoneal, intranasal, aerosol or oral administration.</span>
  </p>
  <p id="p00850" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicion farmaceutica se administra de forma sistemica.</span>In certain embodiments, the pharmaceutical composition is administered systematically.</span>
  </p>
  <p id="p00851" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones, la composicion farmaceutica se administra directamente al cerebro u otra parte del SNC. Por ejemplo, dichos metodos incluyen el uso de un cateter implantable y una bomba, que servirfa para descargar una dosis predeterminada a traves del cateter al sitio de infusion. Un experto en la materia reconocerfa adicionalmente que el cateter puede implantarse por tecnicas quirurgicas que permiten la visualizacion del cateter para posicionar el cateter adyacente al sitio deseado de administracion o infusion en el cerebro. Dichas tecnicas se describen en Elsberry et al., patente de Estados Unidos 5.814.014 "Techniques of Treating Neurodegenerative Disorders by Brain Infusion". Los inventores tambien han contemplado otros metodos tales como los descritos en la solicitud de patente de Estados Unidos 20060129126 (Kaplitt y During "Infusion device and method for infusing material into the brain of a patient"). Los dispositivos para suministrar farmacos al cerebro y otras partes del SNC estan disponibles en el mercado (por ejemplo, SynchroMed EL Infusion System; Medtronic, Minneapolis, Minnesota).</span>In other embodiments, the pharmaceutical composition is administered directly to the brain or another part of the CNS. For example, such methods include the use of an implantable catheter and a pump, which would serve to discharge a predetermined dose through the catheter to the infusion site. One skilled in the art would further recognize that the catheter can be implanted by surgical techniques that allow visualization of the catheter to position the catheter adjacent to the desired site of administration or infusion in the brain. Such techniques are described in Elsberry et al., US Patent 5,814,014 "Techniques of Treating Neurodegenerative Disorders by Brain Infusion". The inventors have also contemplated other methods such as those described in US patent application 20060129126 (Kaplitt and During "Infusion device and method for infusing material into the brain of a patient"). Devices for delivering drugs to the brain and other parts of the CNS are commercially available (for example, SynchroMed EL Infusion System; Medtronic, Minneapolis, Minnesota).</span>
  </p>
  <p id="p00852" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra realizacion, la composicion farmaceutica se administra al cerebro usando metodos tales como modificacion de los compuestos de la invencion para permitir el transporte mediado por receptor a traves de la barrera hematoencefalica.</span>In another embodiment, the pharmaceutical composition is administered to the brain using methods such as modification of the compounds of the invention to allow receptor-mediated transport through the blood-brain barrier.</span>
  </p>
  <p id="p00853" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras realizaciones contemplan la co-administracion de los compuestos de la invencion con moleculas biologicamente activas que se sabe que facilitan el transporte a traves de la barrera hematoencefalica.</span>Other embodiments contemplate the co-administration of the compounds of the invention with biologically active molecules that are known to facilitate transport across the blood-brain barrier.</span>
  </p>
  <p id="p00854" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra realizacion, los compuestos de la invencion se reformulan como protefnas de fusion o quimericas para</span>In another embodiment, the compounds of the invention are reformulated as fusion or chimeric proteins for</span>
  </p>
  <p id="p00855" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00856" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00857" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00858" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00859" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00860" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00861" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00862" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00863" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00864" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00865" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00866" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00867" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00868" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">posibilitar su transporte a traves de la barrera hematoencefalica. Dichas tecnologfas se describen en la patente de Estados Unidos 4902505, "Chimeric peptides for neuropeptide delivery through the blood-brain barrier".</span>enable its transport through the blood-brain barrier. Such technologies are described in US Patent 4902505, "Chimeric peptides for neuropeptide delivery through the blood-brain barrier".</span>
  </p>
  <p id="p00869" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencion tambien contempla metodos adicionales para administrar los compuestos a traves de la barrera hematoencefalica tales como los dirigidos a aumentar de forma transitoria la permeabilidad de la barrera hematoencefalica como se describe en la patente de Estados Unidos 7012061 "Method for increasing the permeability of the blood brain barrier".</span>The invention also contemplates additional methods for administering the compounds through the blood-brain barrier such as those directed to transiently increase the blood brain barrier permeability as described in US Patent 7012061 "Method for increasing the permeability of the blood brain barrier. "</span>
  </p>
  <p id="p00870" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia reconocera la diversidad de metodos adecuados para administrar los compuestos de la invencion directamente al cerebro o a traves de la barrera hematoencefalica y sera capaz de modificar estos metodos para administrar de forma segura los productos de la invencion.</span>One skilled in the art will recognize the diversity of suitable methods for administering the compounds of the invention directly to the brain or through the blood-brain barrier and will be able to modify these methods to safely administer the products of the invention.</span>
  </p>
  <p id="p00871" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dosis y formulaciones</span>Dosage and formulations</span>
  </p>
  <p id="p00872" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La forma de dosificacion es opcionalmente una forma lfquida de dosificacion. La expresion "forma lfquida de dosificacion" se refiere a formas no solidas de dosificacion adecuadas para, aunque sin limitacion, administracion parenteral, intravenosa, subcutanea, intramuscular, intracraneal, intraventricular, intratecal, intraorbital, oftalmica, intracapsular, intramedular, intracisternal, intraperitoneal, intranasal, en aerosol u oral. Pueden prepararse soluciones de un compuesto de la invencion en agua mezclada adecuadamente con un tensioactivo tal como hidroxipropilcelulosa. Tambien pueden prepararse dispersiones en glicerol, polietilenglicoles lfquidos, DMSO y mezclas de los mismos con o sin alcohol, y en aceites. En condiciones habituales de almacenamiento y uso, estas preparaciones contienen un conservante para evitar el crecimiento de microorganismos. Un experto en la materia conocerfa el modo de preparar formulaciones adecuadas. Los procedimientos convencionales e ingredientes para la seleccion y preparacion de formulaciones adecuadas se describen, por ejemplo, en Remington's Pharmaceutical Sciences (2003 - 20a edicion) y en la Farmacopea de Estados Unidos: The National Formulary (USP 24 NF19) publicada en 1999. Las formulaciones contienen opcionalmente excipientes incluyendo, aunque sin limitacion, agentes tamponantes, un antioxidante, un estabilizante, un vehfculo, un diluyente y un agente para el ajuste del pH.</span>The dosage form is optionally a liquid dosage form. The term "liquid dosage form" refers to non-solid dosage forms suitable for, but not limited to, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraventricular, intrathecal, intraorbital, ophthalmic, intracapsular, intramedullary, intracisternal, intraperitoneal administration, intranasal, aerosol or oral. Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under usual conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. One skilled in the art would know how to prepare suitable formulations. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003-20a edition) and in the United States Pharmacopoeia: The National Formulary (USP 24 NF19) published in 1999. Formulations optionally contain excipients including, but not limited to, buffering agents, an antioxidant, a stabilizer, a vehicle, a diluent and an agent for pH adjustment.</span>
  </p>
  <p id="p00873" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las formas farmaceuticas adecuadas para uso inyectable incluyen soluciones o dispersiones acuosas esteriles y polvos esteriles para la preparacion improvisada de soluciones o dispersiones inyectables esteriles. En todos los casos, la forma debe ser esteril y debe ser fluida en la medida que exista facilidad de inyeccion.</span>Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for improvised preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that there is ease of injection.</span>
  </p>
  <p id="p00874" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia reconocerfa que la forma de dosificacion y formulacion elegidas depende de las caracterfsticas de la composicion. Por ejemplo, un experto en la materia sabrfa que una composicion que comprende un anticuerpo puede requerir una formulacion diferente que una composicion que comprende un acido nucleico y elegirfa una formulacion y una forma de dosificacion adecuadas a la composicion.</span>One skilled in the art would recognize that the dosage form and formulation chosen depends on the characteristics of the composition. For example, one skilled in the art would know that a composition comprising an antibody may require a different formulation than a composition comprising a nucleic acid and would choose a formulation and dosage form suitable for the composition.</span>
  </p>
  <p id="p00875" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los factores adicionales que afectan a la dosis eficaz de una formulacion incluyen la via de administracion, el sitio diana, el estado fisiologico del sujeto, la especie del sujeto, si el tratamiento es profilactico o terapeutico, si se estan administrando otras medicaciones y si tambien se administra un adyuvante.</span>Additional factors that affect the effective dose of a formulation include the route of administration, the target site, the physiological state of the subject, the species of the subject, if the treatment is prophylactic or therapeutic, if other medications are being administered and if also an adjuvant is administered.</span>
  </p>
  <p id="p00876" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cronologfa de las inmunizaciones opcionalmente varfa de una vez al dfa, a una vez a la semana, a una vez al mes, a una vez al ano, a una vez cada diez anos. Un regimen tfpico incluye una inmunizacion seguida por inyecciones de refuerzo a intervalos de 6 semanas. Otro regimen consiste en inmunizacion seguida por inyecciones de refuerzo 1, 2 y 12 meses despues. Como alternativa, las inyecciones de refuerzo variaran dependiendo de la respuesta inmunitaria y el estado fisiologico del sujeto.</span>The chronology of immunizations optionally varies from once a day, once a week, once a month, once a year, once every ten years. A typical regimen includes an immunization followed by booster injections at 6-week intervals. Another regimen consists of immunization followed by booster injections 1, 2 and 12 months later. Alternatively, booster injections will vary depending on the immune response and the physiological state of the subject.</span>
  </p>
  <p id="p00877" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para inmunizacion pasiva usando un anticuerpo dirigido contra un epftopo derivado de una forma no nativa de SOD1, la dosis varfa opcionalmente de aproximadamente 0,0001 mg/kg a aproximadamente 100 mg/kg, de aproximadamente 0,01 mg/kg a aproximadamente 5 mg/kg, de aproximadamente 0,15 mg/kg a aproximadamente 3 mg/kg, de 0,5 mg/kg a aproximadamente 2 mg/kg y de aproximadamente 1 mg/kg a aproximadamente 2 mg/kg del peso corporal del sujeto. En otras realizaciones, la dosis varfa de aproximadamente 100 mg/kg a aproximadamente 5 g/kg, de aproximadamente 500 mg/kg a aproximadamente 2 mg/kg y de aproximadamente 750 mg/kg a aproximadamente 1.5 g/kg del peso corporal del sujeto.</span>For passive immunization using an antibody directed against an epftopo derived from a non-native form of SOD1, the dose optionally ranges from about 0.0001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 5 mg / kg, from about 0.15 mg / kg to about 3 mg / kg, from 0.5 mg / kg to about 2 mg / kg and from about 1 mg / kg to about 2 mg / kg of the subject's body weight. In other embodiments, the dose ranges from about 100 mg / kg to about 5 g / kg, from about 500 mg / kg to about 2 mg / kg and from about 750 mg / kg to about 1.5 g / kg of the subject's body weight .</span>
  </p>
  <p id="p00878" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para inmunizacion activa usando inmunogenos que comprende peptidos aislados o moleculas relacionadas correspondientes a epftopos especfficos de enfermedad de formas no nativas de SOD1, la dosis varfa opcionalmente de aproximadamente 0,0001 microgramos a 10 gramos, de aproximadamente 0,01 microgramos a aproximadamente 1 gramo, de aproximadamente 1 microgramos a aproximadamente 1 mg, y de aproximadamente 100 a 250 microgramos por tratamiento. En una realizacion, la cronologfa de administracion del tratamiento es en uno o mas de los siguientes: 0 meses, 2 meses, 6 meses, 9 meses, y/o 12 meses. En un regimen, la dosificacion es a 2, 6, 9, y 12 meses despues de la primera inmunizacion. En otro regimen, la dosificacion es a 2 y 4 semanas despues de la primera inmunizacion, y despues mensualmente despues de ello. En un regimen alternativo, la dosificacion varfa dependiendo del estado fisiologico del sujeto y/o la respuesta del sujeto a las inmunizaciones previas. La via de administracion opcionalmente incluye, aunque sin limitacion, inyecciones intramusculares e intraperitoneales. En una realizacion, la composicion se inyecta en el musculo deltoides.</span>For active immunization using immunogens comprising isolated peptides or related molecules corresponding to disease-specific epftopes of non-native forms of SOD1, the dose optionally ranges from about 0.0001 micrograms to 10 grams, from about 0.01 micrograms to about 1 gram, from about 1 micrograms to about 1 mg, and from about 100 to 250 micrograms per treatment. In one embodiment, the chronology of treatment administration is in one or more of the following: 0 months, 2 months, 6 months, 9 months, and / or 12 months. In a regimen, the dosage is 2, 6, 9, and 12 months after the first immunization. In another regimen, the dosage is 2 and 4 weeks after the first immunization, and then monthly after that. In an alternative regimen, the dosage varies depending on the physiological state of the subject and / or the subject's response to previous immunizations. The route of administration optionally includes, but is not limited to, intramuscular and intraperitoneal injections. In one embodiment, the composition is injected into the deltoid muscle.</span>
  </p>
  <p id="p00879" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00880" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00881" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00882" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00883" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00884" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00885" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00886" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00887" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00888" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00889" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00890" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00891" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00892" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando un peptido aislado correspondiente a un epftopo es demasiado pequeno para ser inmunogenico, o cuando la inmunogenicidad esta mejorada, el peptido se une opcionalmente o acopla a un vehfculo adecuado. Los vehfculos adecuados incluyen, aunque sin limitacion, hemocianina de lapa californiana, antfgeno MAP, albuminas sericas, moleculas de inmunoglobulina y toxoides de bacterias patogenicas. Los peptidos pueden unirse a vehfculos por reticulacion qufmica, por ejemplo, para formar dendrfmeros. En alternativa, los peptidos inmunogenicos pueden expresarse como protefnas de fusion con vehfculos.</span>When an isolated peptide corresponding to an epftope is too small to be immunogenic, or when the immunogenicity is enhanced, the peptide is optionally bound or coupled to a suitable vehicle. Suitable vehicles include, but are not limited to, California limpet hemocyanin, MAP antigen, serial albines, immunoglobulin molecules and pathogenic bacteria toxoids. Peptides can be linked to vehicles by chemical crosslinking, for example, to form dendrimers. Alternatively, immunogenic peptides can be expressed as fusion proteins with vehicles.</span>
  </p>
  <p id="p00893" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Pueden usarse anticuerpos monoclonales tales como mAb humanizados por infusion intravenosa. La concentracion terapeutica del anticuerpo humanizado contra SOD1 DES puede ser de 1-10 microgramos por ml de concentracion local en el SNC. En el entorno de una barrera hematoencefalica (BBB) no alterada, solamente 1-100 a 1-1000 de IgG penetra en el SNC. Por tanto, la concentracion del anticuerpo terapeutico en la circulacion periferica necesaria para alcanzar esta concentracion en el SNC serfa del orden de 100 microgramos/ml a como maximo 10 mg/ml, cerca del nivel de pre-tratamiento de IgG en plasma humano. Considerando que el volumen de sangre humana es de aproximadamente 5 litros, la dosificacion de 50 gramos serfa el lfmite superior, que es similar a la dosis de inmunoglobulina intravenosa policlonal combinada (IVIG) usada para tratar muchos trastornos inflamatorios y autoinmunitarios. Considerando que la degradacion de IgG humana requiere 3-4 semanas, la dosificacion una vez cada 3 semanas constituirfa un regimen eficaz. Sin embargo, la dosificacion de anticuerpos monoclonales humanizados anti-DSE podrfa ser muy inferior que el calculo anterior, basandose en los experimentos de tratamiento en ratones proporcionados en los siguientes ejemplos. Se ha descubierto que la dosificacion en ratones G93A por via intraperitoneal de 1 mg de anticuerpo contra-DSE2 era terapeuticamente eficaz. Considerando que el volumen de sangre en un raton es de 6-7 ml por 100 gramos de peso corporal, la concentracion en circulacion del mAb contra DSE2 era del orden de 1 mg/ml. Para dosificar a un ser humano con ALS, esto se traducirfa en 1/10 de la IgG normal en circulacion (habitualmente aproximadamente 10 mg/ml). El volumen de sangre humana es del orden de 5 litros, lo que sugerirfa una dosis terapeutica eficaz de anticuerpo humanizado contra DSE2 del orden de 5 gramos mediante infusion i.v. Ademas, se ha apreciado leve alteracion de la BBB en ALS, que presumiblemente es maxima en regiones de mayor neuroinflamacion, es decir, aquellas regiones en que la enfermedad es mas manifiesta, como las neuronas motoras del asta anterior, y las neuronas motoras corticales, asf como ciertos tramos de fibras que estan favorecidos por neuronas motoras corticales. Por tanto, es posible que la alteracion selectiva de BBB en regiones de enfermedad maxima permita la eficacia terapeutica para concentraciones en circulacion inferiores de anticuerpos contra SOD1 anti-DSE.</span>Monoclonal antibodies such as humanized mAbs can be used by intravenous infusion. The therapeutic concentration of the humanized antibody against SOD1 DES can be 1-10 micrograms per ml of local concentration in the CNS. In the environment of an unaltered blood-brain barrier (BBB), only 1-100 to 1-1000 of IgG penetrates the CNS. Therefore, the concentration of the therapeutic antibody in the peripheral circulation necessary to reach this concentration in the CNS would be of the order of 100 micrograms / ml at a maximum of 10 mg / ml, near the level of pre-treatment of IgG in human plasma. Considering that the volume of human blood is approximately 5 liters, the dosage of 50 grams would be the upper limit, which is similar to the dose of combined polyclonal intravenous immunoglobulin (IVIG) used to treat many inflammatory and autoimmune disorders. Considering that the degradation of human IgG requires 3-4 weeks, dosing once every 3 weeks would constitute an effective regimen. However, the dosage of humanized anti-DSE monoclonal antibodies could be much lower than the previous calculation, based on the mouse treatment experiments provided in the following examples. It has been found that the dosage in G93A mice intraperitoneally of 1 mg of anti-DSE2 antibody was therapeutically effective. Considering that the volume of blood in a mouse is 6-7 ml per 100 grams of body weight, the circulation concentration of the mAb against DSE2 was of the order of 1 mg / ml. To dose a human being with ALS, this would result in 1/10 of the normal circulating IgG (usually approximately 10 mg / ml). The volume of human blood is of the order of 5 liters, which would suggest an effective therapeutic dose of humanized antibody against DSE2 of the order of 5 grams by infusion i.v. In addition, slight alteration of the BBB in ALS has been observed, which is presumably maximal in regions of greater neuroinflammation, that is, those regions in which the disease is most manifest, such as motor neurons of the anterior horn, and cortical motor neurons, as well as certain sections of fibers that are favored by cortical motor neurons. Therefore, it is possible that selective alteration of BBB in regions of maximal disease allows therapeutic efficacy for lower circulating concentrations of antibodies against anti-DSE SOD1.</span>
  </p>
  <p id="p00894" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los mAb humanizados contra DSE pueden usarse para infusion directa en el SNC mediante la via intraventricular o por la via intratecal. Ejemplos de dispositivos medicos que se usan para este proposito se fabrican por MedTronic. Como el CSF recircula varias veces al dfa, se requiere infusion continua, en lugar de un regimen de dosificacion de 3-4 semanas. La concentracion final de 1-10 microgramos por ml se conseguira por infusion de como mucho 5 mg al dfa en los 500 ml por dfa de CSF.</span>Humanized mAbs against DSE can be used for direct infusion into the CNS by the intraventricular route or by the intrathecal route. Examples of medical devices used for this purpose are manufactured by MedTronic. As the CSF recirculates several times a day, continuous infusion is required, instead of a 3-4 week dosing regimen. The final concentration of 1-10 micrograms per ml will be achieved by infusion of at most 5 mg per day in the 500 ml per day of CSF.</span>
  </p>
  <p id="p00895" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapias de combinacion</span>Combination therapies</span>
  </p>
  <p id="p00896" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los metodos descritos, por tanto, proporcionan la aplicacion inmunoterapeutica de anticuerpos contra SOD1 en el tratamiento de afecciones, trastornos o enfermedades marcadas por la presencia de SOD1 mal plegada o monomerica.</span>The methods described, therefore, provide the immunotherapeutic application of antibodies against SOD1 in the treatment of conditions, disorders or diseases marked by the presence of poorly folded or monomeric SOD1.</span>
  </p>
  <p id="p00897" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento de un sujeto afectado puede realizarse por monoterapia, del modo justamente descrito, administrando un anticuerpo seleccionado o una vacuna basada en epftopos seleccionada. En realizaciones de la presente descripcion, el presente metodo puede realizarse administrando mas de una especie de anticuerpo o mas de una especie de epftopo. Por ejemplo, el metodo puede realizarse administrando un anticuerpo a la estructura de bucle electrostatico [dSe 2] y un anticuerpo contra un epftopo accesible solamente sobre la superficie de contacto del dfmero de SOD [DSE1a]. En una realizacion, el metodo de la presente descripcion se realiza usando anticuerpos que se unen selectivamente a al menos dos epftopos diferentes accesibles selectivamente sobre SOD1 mal plegada, tal como un epftopo de superficie sobre el dfmero de SOD, y un epftopo interfacial sobre el monomero de SOD. Asimismo, el metodo puede realizarse administrando dos epftopos diferentes, en forma de vacunas utiles para crear anticuerpos contra esos dos epftopos diferentes sobre SOD1 mal plegada o monomerica. En una descripcion, el metodo implica la administracion de dos o mas epftopos, por ejemplo, DSE1a y DSE2. En otra descripcion, el metodo implica la administracion de tres o mas epftopos, por ejemplo, DSE1a, DSE2 y DSE5. Ademas, el metodo puede realizarse usando una combinacion de inmunoterapia pasiva y tambien inmunoterapia activa, en que el sujeto se trata para recibir tanto un anticuerpo seleccionado como una vacuna basada en epftopos seleccionada.</span>The treatment of an affected subject can be carried out by monotherapy, in the manner just described, by administering a selected antibody or a vaccine based on selected epitopes. In embodiments of the present description, the present method can be performed by administering more than one species of antibody or more than one species of epftope. For example, the method can be performed by administering an antibody to the electrostatic loop structure [dSe 2] and an antibody against an epftope accessible only on the contact surface of the SOD dimer [DSE1a]. In one embodiment, the method of the present description is performed using antibodies that selectively bind to at least two different epftopes selectively accessible on poorly folded SOD1, such as a surface epftope on the SOD dimer, and an interfacial epftope on the monomer. of SOD. Likewise, the method can be performed by administering two different epftopos, in the form of useful vaccines to create antibodies against those two different epftopos on misfolded or monomeric SOD1. In one description, the method involves the administration of two or more epftopos, for example, DSE1a and DSE2. In another description, the method involves the administration of three or more epftopos, for example, DSE1a, DSE2 and DSE5. In addition, the method can be performed using a combination of passive immunotherapy and also active immunotherapy, in which the subject is treated to receive both a selected antibody and a selected epftopos-based vaccine.</span>
  </p>
  <p id="p00898" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El metodo tambien puede realizarse como una terapia de combinacion en que el anticuerpo contra SOD1 y/o epftopos seleccionados se administra en combinacion con otro agente util terapeuticamente en el tratamiento o control de la enfermedad particular.</span>The method can also be performed as a combination therapy in which the antibody against SOD1 and / or selected epftopes is administered in combination with another agent therapeutically used in the treatment or control of the particular disease.</span>
  </p>
  <p id="p00899" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En terapias de combinacion para el tratamiento de ALS, los presentes agentes terapeuticos pueden usarse en combinacion con riluzol y otros inhibidores de glutamato.</span>In combination therapies for the treatment of ALS, the present therapeutic agents can be used in combination with riluzole and other glutamate inhibitors.</span>
  </p>
  <p id="p00900" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores tambien han descubierto que se retiene cobre en SOD1 oxidada catalizada por metal, que es una</span>The inventors have also discovered that copper is retained in metal-catalyzed oxidized SOD1, which is a</span>
  </p>
  <p id="p00901" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00902" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00903" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00904" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00905" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00906" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00907" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00908" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00909" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00910" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00911" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00912" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00913" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00914" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">especie agregada inmunorreactiva de DSE2. Los inventores tambien han descubierto que SOD1 oxidada por tratamiento con peroxido de hidrogeno presenta inmunorreactividad de DSE2 (Figura 2). El anticuerpo contra DSE2, que reacciona contra el bucle electrostatico de SOD1 del sitio activo, puede estar bloqueando ffsicamente el acceso al cobre retenido de la especie mal plegada, y por tanto reduciendo la catalisis del oxfgeno reactivo y de la especie de nitrogeno a traves de la reaccion de Haber-Weiess, la reaccion de Fenton y otras. De forma notable, altas concentraciones de ascorbato en el SNC pueden estar facilitando el ciclo redox del cobre unido por SOD1 mal plegada, potenciando su capacidad de generar ROS y RNS. El estado agregado de SOD1, que se ha secretado p refe rente me nte de las neuronas (1), altera su eliminacion y degradacion, "atrapando" cobre en una forma neurotoxica catalfticamente activa en cercana proximidad a neuronas motoras en ALS, y en neuronas del hipocampo y en otras neuronas en AD. Se aprecia la posibilidad de que Abeta pueda contribuir a este ciclo redox toxico del cobre en AD (83).</span>DSE2 immunoreactive aggregate species. The inventors have also discovered that SOD1 oxidized by treatment with hydrogen peroxide presents immunoreactivity of DSE2 (Figure 2). The antibody against DSE2, which reacts against the SOD1 electrostatic loop of the active site, may be physically blocking access to the retained copper of the misfolded species, and thus reducing the catalysis of the reactive oxygen and the nitrogen species through the Haber-Weiess reaction, the Fenton reaction and others. Notably, high concentrations of ascorbate in the CNS may be facilitating the redox cycle of copper bonded by poorly folded SOD1, enhancing its ability to generate ROS and RNS. The aggregate state of SOD1, which has been secreted mainly from neurons (1), alters its elimination and degradation, "trapping" copper in a catalytically active neurotoxic form in close proximity to motor neurons in ALS, and in neurons of the hippocampus and in other neurons in AD. The possibility is appreciated that Abeta can contribute to this toxic redox cycle of copper in AD (83).</span>
  </p>
  <p id="p00915" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, en una terapia de combinacion particularmente util, los presentes agentes terapeuticos se usan en combinacion con un antioxidante, para el tratamiento de ALS, AD y PD, asf como para otros trastornos en que SOD1 disfuncional y/o la agregacion de SOD1 provoca la acumulacion toxica de especies reactivas de oxfgeno (ROS) o de especies reactivas de nitrogeno (RNS). Los antioxidantes son un grupo bien conocido de agentes facilmente disponibles, e incluyen las vitaminas acido ascorbico y alfa-tocoferol, y agentes farmacologicos tales como N- acetilcistefna. En realizaciones del presente metodo, el antioxidante es una SOD sintetica funcional, que imita la accion enzimatica de SOD endogena para reducir la acumulacion de radicales superoxido. Los farmacos utiles relacionados incluyen aquellos que estabilizan el dfmero de SOD, como se describe, por ejemplo, por Lansbury et al. en el documento US 2006/0194821. Otros farmacos que tienen el mismo efecto son utiles tambien. En realizaciones particulares, el antioxidante es un quelante de cobre, tal como penicilamina, clioquinol, 8-hidroxiquinolina y derivados tales como los descritos en el documento US2006/0089380, cuprizona, compuestos basados en acido picolfnico, compuestos de molibdeno, L-taurina y otros farmacos que tiene el efecto de inhibir el ciclo redox mediado por iones de cobre. Otros antioxidantes utiles mas incluyen eliminadores de superoxido, eliminadores de peroxido y eliminadores de RNS. En una realizacion particular de la invencion, los presentes agentes terapeuticos se usan en combinacion con resveritrol, un antioxidante presente en uvas rojas y vino tinto. En una realizacion especffica, el anticuerpo contra DSE2 o epftopo se usa en combinacion con resveritrol.</span>Therefore, in a particularly useful combination therapy, the present therapeutic agents are used in combination with an antioxidant, for the treatment of ALS, AD and PD, as well as for other disorders in which dysfunctional SOD1 and / or the aggregation of SOD1 causes Toxic accumulation of reactive oxygen species (ROS) or reactive nitrogen species (RNS). Antioxidants are a well known group of readily available agents, and include vitamins ascorbic acid and alpha-tocopherol, and pharmacological agents such as N-acetylcystephine. In embodiments of the present method, the antioxidant is a functional synthetic SOD, which mimics the enzymatic action of endogenous SOD to reduce the accumulation of superoxide radicals. Related useful drugs include those that stabilize the SOD dimer, as described, for example, by Lansbury et al. in US 2006/0194821. Other drugs that have the same effect are useful too. In particular embodiments, the antioxidant is a copper chelator, such as penicillamine, clioquinol, 8-hydroxyquinoline and derivatives such as those described in US2006 / 0089380, cuprizona, picolfnic acid based compounds, molybdenum compounds, L-taurine and other drugs that have the effect of inhibiting the redox cycle mediated by copper ions. Other useful antioxidants include superoxide scavengers, peroxide scavengers and RNS scavengers. In a particular embodiment of the invention, the present therapeutic agents are used in combination with resveritrol, an antioxidant present in red grapes and red wine. In a specific embodiment, the antibody against DSE2 or epftopo is used in combination with resveritrol.</span>
  </p>
  <p id="p00916" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando se usa en combinacion con los presentes agentes terapeuticos, el agente de combinacion se administra del modo prescrito para ese agente, de acuerdo con la practica convencional.</span>When used in combination with the present therapeutic agents, the combination agent is administered in the manner prescribed for that agent, in accordance with conventional practice.</span>
  </p>
  <p id="p00917" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diagnostico</span>Diagnosis</span>
  </p>
  <p id="p00918" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos especfficos para epftopos especfficos de enfermedad por SOD1 tales como epftopos especfficos de esclerosis lateral amiotrofica tambien pueden usarse para diagnosticar la esclerosis lateral amiotrofica. Por tanto, se describe un metodo de deteccion o de diagnostico de la esclerosis lateral amiotrofica en un sujeto, que comprende las etapas de:</span>Antibodies specific for specific episodes of SOD1 disease such as specific episodes of amyotrophic lateral sclerosis can also be used to diagnose amyotrophic lateral sclerosis. Therefore, a method of detecting or diagnosing amyotrophic lateral sclerosis in a subject is described, comprising the steps of:</span>
  </p>
  <p id="p00919" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(a) poner en contacto una muestra de ensayo de dicho sujeto con un anticuerpo de la invencion, donde el</span>(a) contacting a test sample of said subject with an antibody of the invention, wherein the</span>
  </p>
  <p id="p00920" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">anticuerpo se une a un epftopo especffico de esclerosis lateral amiotrofica para producir un complejo de</span>antibody binds to a specific epitope of amyotrophic lateral sclerosis to produce a complex of</span>
  </p>
  <p id="p00921" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">anticuerpo-antfgeno;</span>antibody-antigen;</span>
  </p>
  <p id="p00922" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) medir la cantidad del complejo de anticuerpo-antfgeno en la muestra de ensayo; y</span>(b) measure the amount of the antibody-antigen complex in the test sample; Y</span>
  </p>
  <p id="p00923" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(c) comparar la cantidad del complejo de anticuerpo-antfgeno en la muestra de ensayo con un control.</span>(c) compare the amount of the antibody-antigen complex in the test sample with a control.</span>
  </p>
  <p id="p00924" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Donde una diferencia en la cantidad del complejo de anticuerpo-antfgeno en la muestra de ensayo en comparacion con el control es indicativa de esclerosis lateral amiotrofica.</span>Where a difference in the amount of the antibody-antigen complex in the test sample compared to the control is indicative of amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00925" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Opcionalmente, en el caso donde el epftopo esta enmascarado dentro del agregado de SOD1, el metodo comprende la etapa adicional de tratar la muestra en condiciones de disgregacion, usando, por ejemplo, clorhidrato de guanidinio, para liberar la SOD1 mal plegada para su posterior deteccion.</span>Optionally, in the case where the epftope is masked within the aggregate of SOD1, the method comprises the additional step of treating the sample under disintegration conditions, using, for example, guanidinium hydrochloride, to release the misfolded SOD1 for subsequent detection. .</span>
  </p>
  <p id="p00926" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresion "detectar o controlar la esclerosis lateral amiotrofica" se refiere a un metodo o proceso de determinacion de si un sujeto tiene o no tiene esclerosis lateral amiotrofica o del grado de la esclerosis lateral amiotrofica. Ademas, los anticuerpos de la invencion pueden usarse para detectar o controlar la aparicion y progresion de agregacion de SOD1, y por tanto la progresion de la enfermedad. Los anticuerpos son adicionalmente utiles para controlar la progresion de la enfermedad durante el tratamiento con un metodo de la invencion.</span>The expression "detect or control amyotrophic lateral sclerosis" refers to a method or process of determining whether or not a subject has amyotrophic lateral sclerosis or the degree of amyotrophic lateral sclerosis. In addition, the antibodies of the invention can be used to detect or control the occurrence and progression of SOD1 aggregation, and therefore the progression of the disease. The antibodies are additionally useful for controlling the progression of the disease during treatment with a method of the invention.</span>
  </p>
  <p id="p00927" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El termino "control", como se usa en este documento, se refiere a una muestra de un sujeto o de un grupo de sujetos que sabe que tienen esclerosis lateral amiotrofica o que no tienen esclerosis lateral amiotrofica. Un experto en la materia apreciara que la diferencia en la cantidad del complejo de anticuerpo-antfgeno variara dependiendo del control. Por ejemplo, si se sabe que el control tiene esclerosis lateral amiotrofica, entonces menos complejo de anticuerpo-antfgeno medible en la muestra de ensayo en comparacion con el control indica que el sujeto no tiene esclerosis lateral amiotrofica o que tiene menor grado de esclerosis lateral amiotrofica. Si se sabe que el control tiene esclerosis lateral amiotrofica, entonces igual cantidad o mayor de complejo de anticuerpo-antfgeno medible en la muestra de ensayo en comparacion con el control indica que el sujeto tiene esclerosis lateral amiotrofica. Si se</span>The term "control," as used herein, refers to a sample of a subject or group of subjects who knows they have amyotrophic lateral sclerosis or who do not have amyotrophic lateral sclerosis. One skilled in the art will appreciate that the difference in the amount of the antibody-antigen complex will vary depending on the control. For example, if it is known that the control has amyotrophic lateral sclerosis, then less measurable antibody-antigen complex in the test sample compared to the control indicates that the subject does not have amyotrophic lateral sclerosis or has a lower degree of amyotrophic lateral sclerosis . If it is known that the control has amyotrophic lateral sclerosis, then an equal or greater amount of measurable antibody-antigen complex in the test sample compared to the control indicates that the subject has amyotrophic lateral sclerosis. Whether</span>
  </p>
  <p id="p00928" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00929" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00930" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00931" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00932" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00933" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00934" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00935" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00936" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00937" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00938" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00939" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00940" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">sabe que el control no tiene esclerosis lateral amiotrofica, entonces una cantidad menor o igual de complejo de anticuerpo-antfgeno medible en la muestra de ensayo en comparacion con el control indica que el sujeto no tiene esclerosis lateral amiotrofica. Si se sabe que el control no tiene esclerosis lateral amiotrofica, entonces mayor cantidad de complejo de anticuerpo-antfgeno medible en la muestra de ensayo en comparacion con el control indica que el sujeto tiene esclerosis lateral amiotrofica.</span>It is known that the control does not have amyotrophic lateral sclerosis, so a smaller or equal amount of measurable antibody-antigen complex in the test sample compared to the control indicates that the subject does not have amyotrophic lateral sclerosis. If it is known that the control does not have amyotrophic lateral sclerosis, then a greater amount of measurable antibody-antigen complex in the test sample compared to the control indicates that the subject has amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00941" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El termino "muestra", como se usa en este documento, se refiere a cualquier muestra de fluido, de celulas o de tejido de un sujeto que puede ensayarse para SOD1 mal plegada. En una realizacion, la muestra comprende, sin limitacion, fluido cefalorraqufdeo, plasma, suero sangufneo, sangre completa, tejido de medula espinal, celulas del cerebro, neuronas motoras, una parte del asta dorsal o celulas sangufneas perifericas, tales como eritrocitos, celulas mononucleares, linfocitos, monocitos y granulocitos.</span>The term "sample", as used herein, refers to any sample of fluid, cell or tissue of a subject that can be tested for misfolded SOD1. In one embodiment, the sample comprises, without limitation, cerebrospinal fluid, plasma, blood serum, whole blood, spinal cord tissue, brain cells, motor neurons, a part of the dorsal horn or peripheral blood cells, such as erythrocytes, mononuclear cells , lymphocytes, monocytes and granulocytes.</span>
  </p>
  <p id="p00942" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Opcionalmente, en el caso donde el epftopo esta enmascarado dentro del agregado de SOD1, el metodo comprende la etapa adicional de tratar la muestra en condiciones de disgregacion, usando, por ejemplo, clorhidrato de guanidinio, para liberar la SOD1 mal plegada para posterior deteccion.</span>Optionally, in the case where the epftope is masked within the aggregate of SOD1, the method comprises the additional step of treating the sample under disintegration conditions, using, for example, guanidinium hydrochloride, to release the misfolded SOD1 for later detection.</span>
  </p>
  <p id="p00943" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, los anticuerpos se usan para determinar si SOD1 mal plegada esta presente en la muestra. En otra realizacion, los anticuerpos se marcan con un marcador detectable.</span>In one description, the antibodies are used to determine if misfolded SOD1 is present in the sample. In another embodiment, the antibodies are labeled with a detectable label.</span>
  </p>
  <p id="p00944" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra realizacion, los epftopos se usan para controlar la aparicion y tftulo de los anticuerpos introducidos en o creados dentro de un destinatario. En esta descripcion, una muestra del paciente se muestra con el epftopo, y preferiblemente con un epftopo marcado, y se determina la presencia o cantidad de anticuerpo unido.</span>In another embodiment, epftopes are used to control the appearance and title of antibodies introduced into or created within a recipient. In this description, a sample of the patient is shown with the epftopo, and preferably with a labeled epftopo, and the presence or amount of bound antibody is determined.</span>
  </p>
  <p id="p00945" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El marcador es preferiblemente capaz de producir, directa o indirectamente, una senal detectable. Por ejemplo, el</span>The marker is preferably capable of producing, directly or indirectly, a detectable signal. For example, him</span>
  </p>
  <p id="p00946" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1 11 3 14 32 35 123 125 131 J '</span>1 11 3 14 32 35 123 125 131 J '</span>
  </p>
  <p id="p00947" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">marcador puede ser radiopaco o un radioisotopo, tal como H, C, P, S, I, I, I; un compuesto fluorescente (fluoroforo) o quimioluminiscente (cromoforo), tal como isotiocianato de fluorescefna, rodamina o luciferina; una enzima, tal como fosfatasa alcalina, beta-galactosidasa o peroxidasa de rabano rusticano; un agente de imagenes; o un ion metalico.</span>marker can be radiopaque or a radioisotope, such as H, C, P, S, I, I, I; a fluorescent (fluoroforo) or chemiluminescent (chromoforo) compound, such as fluorescephine isothiocyanate, rhodamine or luciferin; an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase; an image agent; or a metal ion.</span>
  </p>
  <p id="p00948" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra descripcion, la senal detectable es detectable indirectamente. Por ejemplo, puede usarse un anticuerpo secundario que es especffico para el anticuerpo de la invencion y contiene un marcador detectable, para detectar el anticuerpo de la invencion.</span>In another description, the detectable signal is indirectly detectable. For example, a secondary antibody that is specific for the antibody of the invention and contains a detectable label can be used to detect the antibody of the invention.</span>
  </p>
  <p id="p00949" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que pueden usarse varios metodos para determinar si SOD1 mal plegada esta presente en una mezcla usando los anticuerpos de la invencion, incluyendo inmunoensayos tales como citometrfa de flujo, transferencia de Western, ELISA e inmunoprecipitacion seguida por inmunocitoqufmica por SDS-PAGE.</span>One skilled in the art will appreciate that various methods can be used to determine if misfolded SOD1 is present in a mixture using the antibodies of the invention, including immunoassays such as flow cytometry, Western blotting, ELISA and immunoprecipitation followed by immunocytochemistry by SDS- PAGE</span>
  </p>
  <p id="p00950" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, se detecta o controla una enfermedad relacionada con SOD1 mal plegada, tal como enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad con cuerpos de Lewy y/o esclerosis lateral amiotrofica, en un sujeto usando citometrfa de flujo de una muestra del sujeto, incluyendo celulas sangufneas perifericas, tales como eritrocitos, celulas mononucleares, linfocitos, monocitos y/o granulocitos, o celulas mononucleares encontradas en fluido cefalorraqufdeo. En una realizacion adicional, las celulas ensayadas usando citometrfa de flujo pueden permeabilizarse usando reactivos conocidos para los expertos en la materia incluyendo, sin limitacion, detergentes, etanol, metanol y paraformaldehfdo.</span>In a description, a poorly folded SOD1-related disease, such as Alzheimer's disease, Parkinson's disease, Lewy body disease and / or amyotrophic lateral sclerosis, is detected or controlled in a subject using flow cytometry of a sample of the subject , including peripheral blood cells, such as erythrocytes, mononuclear cells, lymphocytes, monocytes and / or granulocytes, or mononuclear cells found in cerebrospinal fluid. In a further embodiment, the cells tested using flow cytometry can be permeabilized using reagents known to those skilled in the art including, without limitation, detergents, ethanol, methanol and paraformaldehyde.</span>
  </p>
  <p id="p00951" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una descripcion, puede detectarse o controlarse una enfermedad relacionada con SOD1 mal plegada, tal como enfermedad de Alzheimer, enfermedad de Parkinson y/o enfermedad con cuerpos de Lewy, en un sujeto usando citometrfa de flujo de una muestra del sujeto, incluyendo celulas sangufneas perifericas, tales como eritrocitos, celulas mononucleares, linfocitos, monocitos y/o granulocitos, o celulas mononucleares encontradas en fluido cefalorraqufdeo. En una realizacion adicional, las celulas ensayadas usando citometrfa de flujo pueden permeabilizarse usando reactivos conocidos para los expertos en la materia incluyendo, sin limitacion, detergentes, etanol, metanol y paraformaldehfdo.</span>In one description, a misfolded SOD1-related disease, such as Alzheimer's disease, Parkinson's disease and / or Lewy body disease, can be detected or controlled in a subject using flow cytometry of a sample of the subject, including blood cells peripherals, such as erythrocytes, mononuclear cells, lymphocytes, monocytes and / or granulocytes, or mononuclear cells found in cerebrospinal fluid. In a further embodiment, the cells tested using flow cytometry can be permeabilized using reagents known to those skilled in the art including, without limitation, detergents, ethanol, methanol and paraformaldehyde.</span>
  </p>
  <p id="p00952" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra descripcion, puede detectarse o controlarse una enfermedad relacionada con SOD1 mal plegada, tal como enfermedad de Alzheimer, enfermedad de Parkinson y/o enfermedad con cuerpos de Lewy, usando el ensayo de proteccion de epftopos descrito en el documento WO 2005/019828 titulado "Epitope Protection Assay and Method for Detecting Protein Conformations", que entro en fase nacional en los Estados Unidos el 17 de febrero de 2006. En otra descripcion, se detecta o controla la esclerosis lateral amiotrofica usando el ensayo de proteccion de epftopos descrito en el documento WO 2005/019828.</span>In another description, a misfolded SOD1-related disease, such as Alzheimer's disease, Parkinson's disease and / or Lewy body disease, can be detected or controlled, using the epftopos protection assay described in WO 2005/019828 entitled "Epitope Protection Assay and Method for Detecting Protein Conformations", which entered national phase in the United States on February 17, 2006. In another description, amyotrophic lateral sclerosis is detected or controlled using the epftopos protection test described in the WO 2005/019828.</span>
  </p>
  <p id="p00953" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquiera de los metodos descritos para diagnosticar, detectar o controlar la agregacion de SOD1 y el desarrollo de una enfermedad relacionada con SOD1 mal plegada puede usarse ademas de o en combinacion con tecnicas tradicionales de diagnostico para enfermedades relacionadas con SOD1 mal plegada.</span>Any of the methods described for diagnosing, detecting or controlling the aggregation of SOD1 and the development of a disease that is poorly folded with SOD1 can be used in addition to or in combination with traditional diagnostic techniques for diseases that are badly folded with SOD1.</span>
  </p>
  <p id="p00954" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00955" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00956" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00957" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00958" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00959" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00960" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00961" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00962" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00963" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00964" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00965" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00966" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p00967" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquiera de los metodos descritos para diagnosticar, detectar o controlar la agregacion de SOD1 y el desarrollo de esclerosis lateral amiotrofica puede usarse ademas de o en combinacion con tecnicas tradicionales de diagnostico para esclerosis lateral amiotrofica. Las tecnicas tradicionales de diagnostico para esclerosis lateral amiotrofica incluyen examenes ffsicos y neurologicos, y pueden incluir ensayos de electromiograffa, ensayos de velocidad de la condicion nerviosa e imagenes de resonancia magnetica.</span>Any of the methods described to diagnose, detect or control the aggregation of SOD1 and the development of amyotrophic lateral sclerosis can be used in addition to or in combination with traditional diagnostic techniques for amyotrophic lateral sclerosis. Traditional diagnostic techniques for amyotrophic lateral sclerosis include physical and neurological examinations, and may include electromyography tests, nerve condition velocity tests, and magnetic resonance imaging.</span>
  </p>
  <p id="p00968" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El diagnostico de una enfermedad neurodegenerativa, y el control de la progresion de estos trastornos, es insatisfactorio en estos momentos. El diagnostico definitivo puede hacerse solamente por examen tisular sobre evaluacion de necropsia despues de la muerte, o por biopsia (casi nunca utilizada en enfermedades neurodegenerativas). No es una exageracion indicar que el diagnostico presuntivo antemortem de ALS, de AD y de PD se hace sobre la base de caracterfsticas clfnicas, que a menudo estan compartidas con otras enfermedades, e intentando excluir otros trastornos que imitan la enfermedad en cuestion. Se realiza "diagnostico por exclusion" a traves de neuroimagenes (exploraciones MRI y CAT) y ensayos en sangre para descartar diagnosticos confusos (tales como ensayos de la funcion de la tiroides). El ensayo especializado para trastornos neurodegenerativos diferentes (tales como evaluacion neurosicologica para AD, exploracion PET para PD y electromiograffa para ALS), junto con el examen clfnico, son predictivos del diagnostico en autopsia del 70-90 % de los pacientes con AD y PD, y habitualmente mas del 90 % de pacientes con ALS.</span>The diagnosis of a neurodegenerative disease, and the control of the progression of these disorders, is unsatisfactory at the moment. The definitive diagnosis can be made only by tissue examination on necropsy evaluation after death, or by biopsy (almost never used in neurodegenerative diseases). It is no exaggeration to indicate that the presumptive diagnosis antemortem of ALS, AD and PD is made on the basis of clinical characteristics, which are often shared with other diseases, and trying to exclude other disorders that mimic the disease in question. "Exclusion diagnosis" is performed through neuroimaging (MRI and CAT scans) and blood tests to rule out confusing diagnoses (such as thyroid function tests). The specialized trial for different neurodegenerative disorders (such as neurosychological evaluation for AD, PET scanning for PD and electromyography for ALS), together with the clinical examination, are predictive of the autopsy diagnosis of 70-90% of patients with AD and PD, and usually more than 90% of patients with ALS.</span>
  </p>
  <p id="p00969" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos de la invencion se describen como utiles para diagnostico y se describen para su uso en la concentracion de bajas cantidades de protefnas mal plegadas presentes en fluidos y tejidos del paciente por metodos de concentracion tales como inmunoprecipitacion. En una descripcion, se usa un anticuerpo que reconoce un epftopo presentado selectivamente en formas no nativas de SOD1 para inmunoprecipitar SOD1 en sangre periferica. La presencia de SOD1 inmunoprecipitada puede detectarse opcionalmente por ELISA.</span>The antibodies of the invention are described as useful for diagnosis and are described for use in the concentration of low amounts of misfolded proteins present in fluids and tissues of the patient by concentration methods such as immunoprecipitation. In one description, an antibody that recognizes an epftope selectively presented in non-native forms of SOD1 is used to immunoprecipitate SOD1 in peripheral blood. The presence of immunoprecipitated SOD1 can optionally be detected by ELISA.</span>
  </p>
  <p id="p00970" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencion tambien incluye kits para diagnosticar la esclerosis lateral amiotrofica, que comprenden un anticuerpo de la invencion e instrucciones para el uso de los mismos. Un experto en la materia apreciara que el anticuerpo puede marcarse con un marcador detectable.</span>The invention also includes kits for diagnosing amyotrophic lateral sclerosis, which comprise an antibody of the invention and instructions for the use thereof. One skilled in the art will appreciate that the antibody can be labeled with a detectable label.</span>
  </p>
  <p id="p00971" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen kits para diagnosticar ALS, AD y/o PD, que comprenden uno o mas peptidos aislados correspondientes a epftopos especfficos de enfermedad. En una descripcion, el kit comprende un peptido aislado correspondiente a los epftopos especfficos de enfermedad seleccionados del grupo que comprende DSE1, DSE1 a, DSE2, DSE3, DSE4, DSE5, DSE6 y DSE7. Los peptidos aislados pueden incluirse ademas de un anticuerpo que se une a dicho epftopo. En una descripcion, el peptido aislado es un control positivo. En alternativa, el peptido aislado puede ser util per se para explorar una muestra para detectar cualquier anticuerpo contra DSE presente, por ejemplo, en un paciente que experimenta inmunoterapia activa o pasiva basada en dichos peptidos y anticuerpos.</span>Kits for diagnosing ALS, AD and / or PD are described, comprising one or more isolated peptides corresponding to disease-specific epitopes. In a description, the kit comprises an isolated peptide corresponding to the disease-specific epftopes selected from the group comprising DSE1, DSE1 a, DSE2, DSE3, DSE4, DSE5, DSE6 and DSE7. Isolated peptides may be included in addition to an antibody that binds to said epftope. In a description, the isolated peptide is a positive control. Alternatively, the isolated peptide may be useful per se to scan a sample to detect any antibody against DSE present, for example, in a patient undergoing active or passive immunotherapy based on said peptides and antibodies.</span>
  </p>
  <p id="p00972" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Seleccion de farmacos</span>Drug Selection</span>
  </p>
  <p id="p00973" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos de la invencion se describen como para usarse para identificar y seleccionar sustancias utiles para el tratamiento o prevencion de la esclerosis lateral amiotrofica o para la formacion de SOD1 mal plegada, que esta asociada con esclerosis lateral amiotrofica. Por ejemplo, el metodo de identificacion de sustancias para tratar, inhibir o prevenir la esclerosis lateral amiotrofica puede incluir:</span>The antibodies of the invention are described as being used to identify and select substances useful for the treatment or prevention of amyotrophic lateral sclerosis or for the formation of poorly folded SOD1, which is associated with amyotrophic lateral sclerosis. For example, the method of identifying substances to treat, inhibit or prevent amyotrophic lateral sclerosis may include:</span>
  </p>
  <p id="p00974" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(a) poner en contacto una muestra de un sujeto tratado con una sustancia con uno cualquiera de los anticuerpos de la invencion, donde la union es indicativa de la presencia de SOD1 mal plegada en la muestra,</span>(a) contacting a sample of a subject treated with a substance with any one of the antibodies of the invention, where the binding is indicative of the presence of poorly folded SOD1 in the sample,</span>
  </p>
  <p id="p00975" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) detectar el nivel de union en la muestra, y</span>(b) detect the level of union in the sample, and</span>
  </p>
  <p id="p00976" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(c) comparar el nivel de union en la muestra con el nivel de union en un control,</span>(c) compare the level of union in the sample with the level of union in a control,</span>
  </p>
  <p id="p00977" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">donde un nivel alterado de union en la muestra en comparacion con el control es indicativo de una sustancia para el tratamiento o prevencion de la esclerosis lateral amiotrofica.</span>where an altered level of union in the sample compared to the control is indicative of a substance for the treatment or prevention of amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00978" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que el control puede ser una muestra de un sujeto no tratado con una sustancia o tratado con una sustancia que se sabe que no trata o previene la esclerosis lateral amiotrofica. Por tanto, si el "nivel alterado de union" es un nivel reducido de union en la muestra en comparacion con el control, entonces esto es indicativo de una sustancia util para el tratamiento o prevencion de la esclerosis lateral amiotrofica. Ademas, el control puede ser una muestra del mismo sujeto, pero antes del tratamiento con la sustancia a ensayar o muestras del sujeto tomadas en diferentes puntos temporales durante el tratamiento con la sustancia a ensayar.</span>One skilled in the art will appreciate that the control may be a sample of a subject not treated with a substance or treated with a substance known to not treat or prevent amyotrophic lateral sclerosis. Therefore, if the "altered level of union" is a reduced level of union in the sample compared to the control, then this is indicative of a substance useful for the treatment or prevention of amyotrophic lateral sclerosis. In addition, the control may be a sample of the same subject, but before treatment with the substance to be tested or samples of the subject taken at different time points during treatment with the substance to be tested.</span>
  </p>
  <p id="p00979" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las sustancias para el tratamiento o prevencion de la esclerosis lateral amiotrofica tambien pueden identificarse usando celulas o lfneas celulares. Por ejemplo, las celulas o lfneas celulares pueden ponerse en contacto con una sustancia y despues puede detectarse la presencia de SOD1 mal plegada en las celulas usando las protefnas de union de la invencion y pueden compararse con un control.</span>Substances for the treatment or prevention of amyotrophic lateral sclerosis can also be identified using cells or cell lines. For example, cells or cell lines can be contacted with a substance and then the presence of poorly folded SOD1 can be detected in the cells using the binding proteins of the invention and can be compared with a control.</span>
  </p>
  <p id="p00980" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un experto en la materia apreciara que puede explorarse una biblioteca de moleculas controlando el efecto de los compuestos candidatos sobre la inhibicion de la conversion de SOD1 en una conformacion mal plegada o especffica de enfermedad.</span>One skilled in the art will appreciate that a library of molecules can be explored by controlling the effect of the candidate compounds on the inhibition of SOD1 conversion in a poorly folded or disease-specific conformation.</span>
  </p>
  <p id="p00981" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p00982" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p00983" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p00984" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p00985" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p00986" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p00987" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p00988" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p00989" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p00990" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p00991" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p00992" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p00993" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen sustancias identificadas usando los metodos de la invencion, que son utiles para el tratamiento de la esclerosis lateral amiotrofica o para la formacion de SOD1 mal plegada y/o agregada, que esta asociada con esclerosis lateral amiotrofica.</span>Substances identified using the methods of the invention are described, which are useful for the treatment of amyotrophic lateral sclerosis or for the formation of poorly folded and / or aggregated SOD1, which is associated with amyotrophic lateral sclerosis.</span>
  </p>
  <p id="p00994" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los siguientes ejemplos no limitantes son ilustrativos de las realizaciones de la presente invencion:</span>The following non-limiting examples are illustrative of the embodiments of the present invention:</span>
  </p>
  <p id="p00995" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplos</span>Examples</span>
  </p>
  <p id="p00996" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inmunogenos que comprenden peptidos aislados correspondientes a epftopos especfficos de enfermedad, por ejemplo, DSE1a, pueden referirse en los siguientes ejemplos a secuencias analogas de DSE (por ejemplo, el analogo DSE1 GGGRLAC*GVIGIGSG que comprende secuencias de G N-terminales adicionales) como el numero DSE (por ejemplo, DSE1) que esta relacionado con el analogo.</span>Immunogens comprising isolated peptides corresponding to disease-specific epitopes, for example, DSE1a, may refer in the following examples to analog sequences of DSE (for example, analogue DSE1 GGGRLAC * GVIGIGSG comprising additional N-terminal G sequences) as the DSE number (for example, DSE1) that is related to the analog.</span>
  </p>
  <p id="p00997" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 1</span>Example 1</span>
  </p>
  <p id="p00998" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales contra DSE2</span>Generation of monoclonal antibodies against DSE2</span>
  </p>
  <p id="p00999" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un peptido aislado correspondiente al epftopo especffico de esclerosis lateral amiotrofica (DLGKGGNEESTKTGNAGS) que alberga un resto Cys N-terminal se conjugo con KLH para inmunizacion de ratones BALB/c, y con BSA para exploracion ELISA. Se dieron multiples inyecciones a cada raton a intervalos de 21 dfas. El adyuvante para la primera inyeccion fue adyuvante completo de Freund (Sigma, n. Cat. F5881-6 x 10 ml). El adyuvante incompleto de Freund (Sigma, n. Cat. F5506-6 x 10 ml) fue el adyuvante usado para las inyecciones restantes. Se recogio sangre de los ratones 7-10 dfas despues de la 3a inyeccion. La fusion celular se hizo 3-4 dfas despues del refuerzo final sin ningun adyuvante.</span>An isolated peptide corresponding to the specific epitope of amyotrophic lateral sclerosis (DLGKGGNEESTKTGNAGS) that harbors an N-terminal Cys residue was conjugated to KLH for immunization of BALB / c mice, and with BSA for ELISA scanning. Multiple injections were given to each mouse at intervals of 21 days. The adjuvant for the first injection was Freund's complete adjuvant (Sigma, Cat. No. F5881-6 x 10 ml). Freund's incomplete adjuvant (Sigma, Cat. No. F5506-6 x 10 ml) was the adjuvant used for the remaining injections. Blood was collected from the mice 7-10 days after the 3rd injection. Cell fusion was done 3-4 days after final reinforcement without any adjuvant.</span>
  </p>
  <p id="p01000" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El companero de fusion usado fue Sp 2/0-Ag14 (ATCC n. CRL-1581). La fusion entre el companero de fusion SP2/0 y las celulas esplenicas se hizo a una relacion 1:5 (2,0 x 107:1,0 x 108) en 1 ml de PEG precalentado (MW1450: Sigma, n. Cat. P7181). Las celulas de fusion se resuspendieron en 50 ml de DMEM con FBS al 10 % y se sembraron en 5 placas de 96 pocillos a 100 pl/pocillo. Se anadieron 100 pl/pocillo de medio HAT DMEM 2 x a las celulas de fusion despues de 24 horas. Los medios se cambiaron en los dfas 5 y 7 con medio HAT 1 x fresco. En el dfa 10-12, se recogieron 50 pl de sobrenadante de cada pocillo para la primera exploracion ELISA. Los clones positivos se transfirieron a placas de 24 pocillos. Tras la confluencia, se exploraron los sobrenadantes de anticuerpo por ELISA con el antfgeno usado para inmunizar los ratones y un antfgeno no relacionado (transferrina humana). Los clones positivos se transfirieron a placas de 6 pocillos para la expansion o la subclonacion de hibridoma. La subclonacion se hizo por dilucion limitante a 50-70 celulas/placa de 90 pocillos.</span>The fusion partner used was Sp 2/0-Ag14 (ATCC No. CRL-1581). The fusion between the SP2 / 0 fusion partner and the splenic cells was done at a 1: 5 ratio (2.0 x 107: 1.0 x 108) in 1 ml of preheated PEG (MW1450: Sigma, Cat. P7181). The fusion cells were resuspended in 50 ml of DMEM with 10% FBS and seeded in 5 96-well plates at 100 pl / well. 100 pl / well of 2 x DMAT HAT medium was added to the fusion cells after 24 hours. The media were changed on days 5 and 7 with 1 x fresh HAT medium. On day 10-12, 50 l of supernatant was collected from each well for the first ELISA scan. Positive clones were transferred to 24-well plates. After confluence, antibody supernatants were screened by ELISA with the antigen used to immunize mice and an unrelated antigen (human transferrin). Positive clones were transferred to 6-well plates for expansion or subcloning of hybridoma. Subcloning was done by limiting dilution to 50-70 cells / 90-well plate.</span>
  </p>
  <p id="p01001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 2</span>Example 2</span>
  </p>
  <p id="p01002" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Produccion a gran escala de anticuerpos monoclonales</span>Large-scale production of monoclonal antibodies</span>
  </p>
  <p id="p01003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la produccion a gran escala de anticuerpos, se inyectaron 0,2-0,5 ml de Pristano (Sigma, n. Cat. T-7640) o IFA cada raton (BALB/c) por i.p. para la sensibilizacion. En el dfa 7-11, se inyectaron de 500.000 a 5.000.000 de celulas de hibridoma en 0,5 ml de PBS 1 x en fase logarftmica a cada raton por i.p. Se permitio que el fluido ascftico se acumulara durante 1-2 semanas. Pueden recogerse 2-5 ml de fluido ascftico de cada raton, con una concentracion de IgG de aproximadamente 1-9 mg/ml. Se uso protefna A para la purificacion de IgG2 y 3, y la protefna G para IgG1.</span>For large-scale antibody production, 0.2-0.5 ml of Pristane (Sigma, Cat. No. T-7640) or IFA each mouse (BALB / c) was injected by i.p. for awareness. On day 7-11, 500,000 to 5,000,000 hybridoma cells were injected in 0.5 ml of 1 x PBS in the log phase to each mouse for i.p. The ascites fluid was allowed to accumulate for 1-2 weeks. 2-5 ml of ascites fluid can be collected from each mouse, with an IgG concentration of approximately 1-9 mg / ml. Protein A was used for the purification of IgG2 and 3, and protein G for IgG1.</span>
  </p>
  <p id="p01004" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El clon IgG mAb se denomino 10E11C11. Este anticuerpo presenta propiedades coherentes con su reconocimiento de un epftopo especffico de enfermedad para SOD1 mal plegada. Este mAb se une a SOD1 desnaturalizada en membranas de inmunotransferencia, que reconoce SOD1 desnaturalizada monomerica (no estructurada). El mAb no reconoce la SOD1 dimerica en inmunotransferencia. En inmunoprecipitaciones mediadas por perlas magneticas conjugadas con 10E11C11, no hay union detectable de SOD1 nativa de cerebro humano normal o de cerebro de raton y medula espinal. El mAb no inmunoprecipita de forma eficaz SOD1 deliberadamente mal plegada por bajo pH, el caotropo guanidina, o ambos. De forma mas importante, 10E11C11 inmunoprecipita de forma eficaz SOD1 mal plegada en un modelo de raton de ALS causado por sobreexpresion transgenica de SOD1 mutante (G93A). De forma notable, SOD1 endogena de raton presente en el mismo tejido no se inmunoprecipita, lo que sugiere que la SOD1 mutante humana mal plegada no "co-recluta" SOD de raton normal en este modelo de enfermedad.</span>The clone IgG mAb was named 10E11C11. This antibody has properties consistent with its recognition of a disease-specific epftope for poorly folded SOD1. This mAb binds to denatured SOD1 in immunoblot membranes, which recognizes monomeric (unstructured) denatured SOD1. The mAb does not recognize the dimeric SOD1 in immunoblot. In immunoprecipitations mediated by magnetic beads conjugated with 10E11C11, there is no detectable union of SOD1 native to normal human brain or to mouse brain and spinal cord. The mAb does not effectively immunoprecipitate SOD1 deliberately misfolded by low pH, the guanidine chaotrope, or both. More importantly, 10E11C11 effectively immunoprecipitates SOD1 misfolded in a mouse model of ALS caused by transgenic overexpression of mutant SOD1 (G93A). Notably, endogenous mouse SOD1 present in the same tissue is not immunoprecipitated, suggesting that poorly folded human mutant SOD1 does not "co-recruit" normal mouse SOD in this disease model.</span>
  </p>
  <p id="p01005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambien se crearon anticuerpos de una manera similar al epftopo NPLSRKHGGPKDEE, que alberga un resto Cys N-terminal.</span>Antibodies were also created in a manner similar to the NPLSRKHGGPKDEE epftope, which houses an N-terminal Cys residue.</span>
  </p>
  <p id="p01006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dichos anticuerpos estan facilmente disponibles y pueden obtenerse de Neil Cashman at the Brain Research Centre, UBC Hospital, 2211 Wesbrook Mall, Vancouver, Columbia Britanica, V6T 2B5, Canada <br class="style-scope patent-text">(neil.cashman@utoronto.ca).</span>Such antibodies are readily available and can be obtained from Neil Cashman at the Brain Research Center, UBC Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, V6T 2B5, Canada <br class="style-scope patent-text"> (neil.cashman@utoronto.ca).</span>
  </p>
  <p id="p01008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 3</span>Example 3</span>
  </p>
  <p id="p01019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodo 2 de generacion de anticuerpos monoclonales contra DSE2</span>Method 2 of generating monoclonal antibodies against DSE2</span>
  </p>
  <p id="p01020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales de raton: 4 ratones BALB/c hembra se inmunizaron inicialmente por inyecciones intraperitoneales con 25 pg de KLH acoplada al peptido correspondiente a DSE2 (DLGKGGNEESTKTGNAGS, mas una cistefna N-terminal para el acoplamiento con KLH por formacion de puente disulfuro) por raton en adyuvante completo de Freund. Se administraron cuatro refuerzos posteriores como anteriormente, espaciados a intervalos de 3 semanas, con adyuvante incompleto de Freund. Cuando el tftulo del suero se habfa elevado mas de 10 veces desde una muestra de suero preinmune, determinado por ELISA, los 2 mayores respondedores de raton se reforzaron cada uno por via intravenosa con 10 pg de KLH acoplado al antfgeno proteico de peptido, en 100 pl de PBS esteril, pH 7,4. Tres dfas despues los ratones donantes se sacrificaron y se recogieron las celulas esplenicas y se combinaron. La fusion de los esplenocitos con celulas de mieloma parentales SP2/0 BALB/c se realizo como se ha descrito previamente (vease el Ejemplo 1 anterior) excepto que se realizo seleccion de una etapa y clonacion de los hibridomas en medio Clone Ez. Este medio semisolido permite la seleccion en HAT y la clonacion en una unica etapa y elimina el crecimiento excesivo de clones deseables de crecimiento mas lento por hibridomas de crecimiento mas rapido, quiza indeseables. Los clones se picaron 11 dfas despues de la fusion y se resuspendieron en pocillos de placas de cultivo tisular de 96 pocillos en: 200 pl de medio DMEM (Invitrogen) que contenfa suero bovino fetal al 20 %. Despues de 4 dfas, los sobrenadantes se exploraron por ELISA indirecto para la actividad del anticuerpo en placas recubiertas con 1 pl/pocillo de peptido acoplado a BSA.</span>Generation of mouse monoclonal antibodies: 4 female BALB / c mice were initially immunized by intraperitoneal injections with 25 pg of KLH coupled to the peptide corresponding to DSE2 (DLGKGGNEESTKTGNAGS, plus an N-terminal cysteine for coupling with KLH by disulfide bridge formation) by mouse in Freund's complete adjuvant. Four subsequent reinforcements were administered as above, spaced at intervals of 3 weeks, with incomplete Freund's adjuvant. When the serum titer had been raised more than 10 times from a preimmune serum sample, determined by ELISA, the 2 largest mouse responders were each reinforced intravenously with 10 pg of KLH coupled to the peptide protein antigen, in 100 pl of sterile PBS, pH 7.4. Three days later, donor mice were sacrificed and splenic cells were collected and combined. The fusion of the splenocytes with SP2 / 0 BALB / c parental myeloma cells was performed as previously described (see Example 1 above) except that one stage selection and cloning of the hybridomas in Clone Ez medium was performed. This semi-solid medium allows HAT selection and cloning in a single stage and eliminates the overgrowth of desirable clones of slower growth by faster growing hybridomas, perhaps undesirable. The clones were chopped 11 days after the fusion and resuspended in wells of 96-well tissue culture plates in: 200 pl of DMEM medium (Invitrogen) containing 20% fetal bovine serum. After 4 days, the supernatants were screened by indirect ELISA for antibody activity on plates coated with 1 pl / well of peptide coupled to BSA.</span>
  </p>
  <p id="p01021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Condiciones de ELISA:</span>ELISA conditions:</span>
  </p>
  <p id="p01022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la exploration y el ensayo: El antfgeno DSE-2-BSA se recubrio en la placa en dH2O a 1 pg/pocillo y se seco durante una noche a 37 C.</span>For exploration and testing: The DSE-2-BSA antigen was coated on the plate in dH2O at 1 pg / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01023" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el ensayo sobre antfgeno de control negativo: se recubrio 0,5 pg/pocillo de antfgeno HT (transferrina humana) sobre la placa en dH2O a 50 pl/pocillo y se seco durante una noche a 37 C. Bloqueo: Las placas se bloquearon con leche desnatada en polvo al 3 % en PBS (pH 7,4) a 100 pl/pocillo y se incubaron durante 1 hora a temperatura ambiente.</span>For the negative control antigen assay: 0.5 pg / well of HT antigen (human transferrin) was coated on the plate in dH2O at 50 pl / well and dried overnight at 37  C. Blocking: The plates were blocked with 3% skimmed milk powder in PBS (pH 7.4) at 100 pl / well and incubated for 1 hour at room temperature.</span>
  </p>
  <p id="p01024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1er anticuerpo: Se anadieron sobrenadante de cultivo tisular de hibridoma anti-DSE2 de raton y controles monoclonales de anticuerpo a 100 pl netos por pocillo para la exploracion y ensayo y se incubaron durante 1 hora a temperatura ambiente con agitacion.</span>1st antibody: Mouse culture supernatant of mouse anti-DSE2 hybridoma and monoclonal antibody controls were added at 100 pl net per well for exploration and assay and incubated for 1 hour at room temperature with shaking.</span>
  </p>
  <p id="p01025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 anticuerpo usado para exploration y ensayo: Se uso anticuerpo de cabra anti-Fc de IgG de raton conjugado con HRP 1/10000 diluido en PBS-Tween (pH 7,4), se anadio a 100 pl/pocillo y se incubo durante 1 hora a 37 C con agitacion.</span>2nd antibody used for exploration and assay: Goat anti-Fc mouse IgG antibody conjugated with HRP 1/10000 diluted in PBS-Tween (pH 7.4) was used, added at 100 pl / well and incubated for 1 hour at 37  C with stirring.</span>
  </p>
  <p id="p01026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sustrato: Se anadio tampon TMB (BioFx n. cat. TMBW-1000-01) a 50 pl/pocillo y se incubo en la oscuridad a temperatura ambiente. La reaccion se detuvo con 50 pl de HCl 1 M por pocillo despues de 15 minutos y se leyo a DO450 nm.</span>Substrate: TMB buffer (BioFx Cat. No. TMBW-1000-01) was added at 50 pl / well and incubated in the dark at room temperature. The reaction was stopped with 50 l of 1M HCl per well after 15 minutes and read at OD450 nm.</span>
  </p>
  <p id="p01027" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 3 muestra la exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra el epftopo especffico de enfermedad DLGKGGNEESTKTGNAGS (DSE2). Los anticuerpos generados por varios de los clones de hibridoma eran altamente especfficos para peptidos correspondientes al epftopo especffico de enfermedad, y no reconocfan de forma detectable el antfgeno de control HT (transferrina humana). Estos resultados muestran que pueden producirse anticuerpos monoclonales contra peptidos correspondientes a epftopos identificados como presentados selectivamente o accesibles en formas mal plegadas de SOD1.</span>Table 3 shows the ELISA scan of hybridoma clones for antibodies directed against the disease-specific epftope DLGKGGNEESTKTGNAGS (DSE2). Antibodies generated by several of the hybridoma clones were highly specific for peptides corresponding to the disease-specific epitope, and did not detect the control antigen HT (human transferrin) detectably. These results show that monoclonal antibodies against peptides corresponding to epftopes identified as selectively presented or accessible in poorly folded forms of SOD1 can be produced.</span>
  </p>
  <p id="p01028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 3: Exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra</span>Table 3: ELISA scan of hybridoma clones for antibodies directed against</span>
  </p>
  <p id="p01029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DLGKGGNEESTKTGNAGS</span>DLGKGGNEESTKTGNAGS</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Exp. n. 1 Antfgeno DSE-2-BSA  Exp. n. 2 Antfgeno DSE-2-BSA  Antfgeno HT  Isotipo </span>&nbsp;Exp. # 1 DSE-2-BSA Antigen Exp. # 2 DSE-2-BSA Antigen HT Antigen Isotype</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2A11 </span>&nbsp;2A11</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,624  2,000  0,086  IgG </span>&nbsp;2,624 2,000 0,086 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3H1 </span>&nbsp;3H1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,982  1,908  0,081  IgG </span>&nbsp;1,982 1,908 0,081 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5G5 </span>&nbsp;5G5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,712  2,014  0,068  IgG </span>&nbsp;2,712 2,014 0,068 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5G12 </span>&nbsp;5G12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,072  1,755  0,064  IgG </span>&nbsp;2,072 1,755 0.064 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6C3 </span>&nbsp;6C3</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,527  1,889  0,071  IgG </span>&nbsp;2,527 1,889 0.071 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6G12 </span>&nbsp;6G12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,093  1,982  0,069  IgG </span>&nbsp;2,093 1,982 0.069 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7E10 </span>&nbsp;7E10</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,586  2,047  0,068  IgG </span>&nbsp;2,586 2,047 0.068 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7F8 </span>&nbsp;7F8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,317  1,961  0,079  IgG </span>&nbsp;2,317 1,961 0.079 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8C9 </span>&nbsp;8C9</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,087  1,929  0,072  IgG </span>&nbsp;2,087 1,929 0.072 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8D1 </span>&nbsp;8D1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,238  1,931  0,067  IgG </span>&nbsp;2,238 1,931 0.067 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10C12 </span>&nbsp;10C12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3,032  1,909  0,061  IgG </span>&nbsp;3,032 1,909 0.061 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10F2 </span>&nbsp;10F2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,599  1,699  0,059  IgG_____ </span>&nbsp;2,599 1,699 0.059 IgG_____</span>
      </dd>
    </dl>
  
  <p id="p01095" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El clon de hibridoma 3H1 (numero de acceso 220207-02) se deposito en la International Depository Authority of</span>The hybridoma clone 3H1 (access number 220207-02) was deposited with the International Depository Authority of</span>
  </p>
  <p id="p01096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01097" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01098" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01099" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01101" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01103" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01105" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p01107" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p01108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Clon |Exp. n. 1 Antigeno DSE-2-BSA |Exp. n. 2 Antigeno DSE-2-BSA |Antigeno HT \lsotipo</span>Clone | Exp. # 1 Antigen DSE-2-BSA | Exp. # 2 DSE-2-BSA Antigen | HT Antigen</span>
  </p>
  <p id="p01109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Canada localizada en Winnipeg, Canada el 22 de febrero de 2007.____________________________________</span>Canada located in Winnipeg, Canada on February 22, 2007 .____________________________________</span>
  </p>
  <p id="p01110" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 4</span>Example 4</span>
  </p>
  <p id="p01111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos policlonales contra DSE1 Generation y purification de anticuerpos</span>Polyclonal antibodies against DSE1 Generation and purification of antibodies</span>
  </p>
  <p id="p01112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La sfntesis de peptidos se realizo usando qufmica basada en Fmoc convencional en un Perseptives Biosystems 9050 Plus Pepsynthesizer. Se sintetizo el peptido multiple antigenico en una resina [Fmoc-Lys(Fmoc)]4-Lys2-Lys- Cys(Acm)-p-Ala-Wang (Advanced ChemTech, SM5104, Louisville, Kentucky) usando aminoacidos protegidos con Fmoc (Advanced ChemTech; Novabiochem, San Diego, California; Applied Biosystems, Foster City, California). La secuencia era Acetil-GGRLACGVIGIGGKG-; la composicion y la secuencia se verificaron por analisis de aminoacidos y por analisis de absorbancia UV en lfnea del sintetizador de peptidos. Este peptido se escindio y purifico por dialisis frente a Tris 10 mM, acetato sodico 10 nM (Sigma); se realizo dialisis a pH 8,0 para permitir la formacion de enlaces disulfuro entre hebras adyacentes del dendrfmero peptfdico. El antigeno MAP tenia un peso molecular de ~11 kDa y se uso sin conjugacion con una protefna de vehfculo. El antigeno se envio a Sigma-Genosys (Oakville, Ontario, Canada) para la produccion de antisuero de conejo ("paquete parcial" del fabricante). La produccion de antisuero siguio el protocolo convencional (Sigma-Genosys) y estaba de acuerdo con el acta de bienestar de animales (EE. UU.).</span>Peptide synthesis was performed using conventional Fmoc-based chemistry in a Perseptives Biosystems 9050 Plus Pepsynthesizer. The antigenic multiple peptide was synthesized in a resin [Fmoc-Lys (Fmoc)] 4-Lys2-Lys-Cys (Acm) -p-Ala-Wang (Advanced ChemTech, SM5104, Louisville, Kentucky) using Fmoc protected amino acids (Advanced ChemTech; Novabiochem, San Diego, California; Applied Biosystems, Foster City, California). The sequence was Acetyl-GGRLACGVIGIGGKG-; the composition and sequence were verified by amino acid analysis and by online UV absorbance analysis of the peptide synthesizer. This peptide was cleaved and purified by dialysis against 10 mM Tris, 10 nM sodium acetate (Sigma); Dialysis was performed at pH 8.0 to allow the formation of disulfide bonds between adjacent strands of the peptide dendrimer. The MAP antigen had a molecular weight of ~ 11 kDa and was used without conjugation with a vehicle protein. The antigen was sent to Sigma-Genosys (Oakville, Ontario, Canada) for the production of rabbit antiserum ("partial package" from the manufacturer). The production of antiserum followed the conventional protocol (Sigma-Genosys) and was in accordance with the animal welfare act (USA).</span>
  </p>
  <p id="p01113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sintetizo un peptido lineal con secuencia identica al antigeno en una resina TentaGel-SH [no escindible] (Advanced ChemTech). Esta resina se desprotegio y compacto en columnas desechables (Evergreen Scientific, Los Angeles, CA) para la purificacion de antisuero. El antisuero se pre-aclaro por centrifugacion (16.000 x g) y se diluyo 1:10 en solucion salina tamponada con tris (TBS) antes de la purificacion. El antisuero diluido se volvio a hacer circular sobre la columna de purificacion por afinidad 3 x a un caudal de ~1 ml/min. a temperatura ambiente para la union. La columna unida al anticuerpo se lavo con un mfnimo de 100 ml de TBS (~1 ml/min.), hasta que el eluyente de lavado no tuvo protefna (A28q = 0). Las fracciones de anticuerpo se eluyeron con glicina 50 mM, pH 2,8 en 1/5 volumenes de Tris 1,5 M enfriado en hielo, NaCl 150 mM, pH 8,0, se mezclaron y se colocaron inmediatamente en hielo. Estas fracciones se centrifugaron 16.000 x g y se determino la concentracion del anticuerpo en el sobrenadante usando un 280 = 220.000 y un peso molecular de IgG de 150.00 Da. La columna de purificacion se regenero por lavado en exceso con glicina 50 mM, pH 2,8, seguido por tratamiento con guanidina-HCl saturado, Tris 50 mM, pH 8,0. La columna se equilibro con TBS antes de la aplicacion de antisuero. Se uso solamente el suero del tercer sangrado o posterior. En todos los casos, el anticuerpo se purifico inmediatamente antes de su uso y se almaceno con 2 mg/ml de BSA para estabilizar el anticuerpo.</span>A linear peptide with an antigen-identical sequence was synthesized in a TentaGel-SH [non-cleavable] resin (Advanced ChemTech). This resin was deprotected and compact in disposable columns (Evergreen Scientific, Los Angeles, CA) for purification of antiserum. The antiserum was pre-clarified by centrifugation (16,000 x g) and diluted 1:10 in tris buffered saline solution (TBS) before purification. The diluted antiserum was circulated again on the 3 x affinity purification column at a flow rate of ~ 1 ml / min. at room temperature for the union. The antibody bound column was washed with a minimum of 100 ml of TBS (~ 1 ml / min.), Until the wash eluent had no protein (A28q = 0). The antibody fractions were eluted with 50 mM glycine, pH 2.8 in 1/5 volumes of ice-cold 1.5 M Tris, 150 mM NaCl, pH 8.0, mixed and immediately placed on ice. These fractions were centrifuged 16,000 x g and the concentration of the antibody in the supernatant was determined using a  280 = 220,000 and an IgG molecular weight of 150.00 Da. The purification column is regenerated by excess washing with 50 mM glycine, pH 2.8, followed by treatment with saturated guanidine-HCl, 50 mM Tris, pH 8.0. The column was equilibrated with TBS before antiserum application. Only serum from the third or subsequent bleeding was used. In all cases, the antibody was purified immediately before use and stored with 2 mg / ml of BSA to stabilize the antibody.</span>
  </p>
  <p id="p01114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SDS-PAGE y transferencia de Western</span>SDS-PAGE and Western transfer</span>
  </p>
  <p id="p01115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se realizo SDS-PAGE usando el sistema de tampon Tris-glicina con geles de gradiente de poliacrilamida al 4-20 % pre-moldeados (Invitrogen, Carlsbad, CA). Para geles parcialmente desnaturalizantes, la SOD1 de eritrocitos humanos (Sigma) se hirvio durante 15 minutos con betamercaptoetanol (Aldrich) al 4 % en tampon de SDS-carga o se mantuvo en hielo durante 15 minutos en tampon de SDS-carga. Se procesaron 1-5 pg de SOD1 en cada carril con resultados equivalentes. Para transferencia de Western, los geles se transfirieron a membrana de PVDF, se bloquearon durante una noche en leche al 5 %-TBST (solucion salina tamponada con Tris, Tween-20 al 0,05 %). Se usaron 0,2 pg/ml (nota: hasta al menos 5 pg/ml produjeron resultados equivalentes) de anticuerpo SEDI contra SOD (policlonal anti-DSE1) diluido en leche al 5 %-TBSt como anticuerpo primario, y se uso dilucion 1:5000 de anticuerpo anti-IgG de conejo-HRP (Stressgen, Victoria, Canada) como anticuerpo secundario. Las transferencias de Western se revelaron usando ECL-Plus (Amersham, Buckinghamshire, R.U.) y se visualizaron en pelfcula Kodak. Para experimentos de competicion de peptidos, se pre-incubo el anticuerpo SEDI contra SOD diluido con un exceso 500 x (molar) del peptido lineal libre con la misma secuencia que el antigeno a 4 C durante una noche o durante 1 hora a temperatura ambiente antes de su uso.</span>SDS-PAGE was performed using the Tris-glycine buffer system with pre-molded 4-20% polyacrylamide gradient gels (Invitrogen, Carlsbad, CA). For partially denaturing gels, SOD1 from human erythrocytes (Sigma) was boiled for 15 minutes with 4% betamercaptoethanol (Aldrich) in SDS-loading buffer or kept on ice for 15 minutes in SDS-loading buffer. 1-5 pg of SOD1 was processed in each lane with equivalent results. For Western blotting, the gels were transferred to PVDF membrane, blocked overnight in 5% milk -TBST (Tris buffered saline, 0.05% Tween-20). 0.2 pg / ml (note: up to at least 5 pg / ml produced equivalent results) of SEDI antibody against SOD (polyclonal anti-DSE1) diluted in 5% milk -TBSt as primary antibody was used, and dilution 1 was used : 5000 rabbit anti-rabbit IgG-HRP antibody (Stressgen, Victoria, Canada) as secondary antibody. Western blots were revealed using ECL-Plus (Amersham, Buckinghamshire, R.U.) and displayed on Kodak movie. For peptide competition experiments, the SEDI antibody against SOD diluted with a 500 x (molar) excess of the free linear peptide was pre-incubated with the same sequence as the antigen at 4  C overnight or for 1 hour at room temperature Before its use.</span>
  </p>
  <p id="p01116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
  </p>
  <p id="p01117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diseno y validation de anticuerpos</span>Design and validation of antibodies</span>
  </p>
  <p id="p01118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La investigacion de la conformacion de protefnas in vivo es un problema desafiante. Una posible estrategia es disenar un anticuerpo que reconozca conformaciones mal plegadas especfficas, pero no la protefna nativa. Este enfoque dirigido por hipotesis se ha aplicado previamente a otros trastornos neurodegenerativos que implican la agregacion de protefnas, pero estos disenos han dependido de informacion bioffsica de baja resolucion sobre la estructura de la protefna mal plegada. El enfoque de los inventores emplea el uso de datos de estructura cristalina de rayos X detallada para disenar un anticuerpo contra SOD1 mal plegada SOD1 (6, 71). Se postulo la hipotesis de que un anticuerpo que reconoce un epftopo inaccesible en SOD1 dimerica nativa pero expuesto en agregados de SOD1 e intermedios de agregacion, serfa capaz de detectar selectivamente SOD1 mal plegada in vivo. El examen de la estructura de rayos X del dfmero de SOD1 nativa (codigo pdb: 1SPD) (72) muestra que los restos 145-151</span>In vivo protein conformation research is a challenging problem. One possible strategy is to design an antibody that recognizes specific misfolded conformations, but not the native protein. This hypothesis-driven approach has previously been applied to other neurodegenerative disorders that involve the aggregation of proteins, but these designs have relied on low-resolution bi-physical information about the poorly folded protein structure. The inventors' approach employs the use of detailed X-ray crystal structure data to design an anti-folded SOD1 antibody SOD1 (6, 71). The hypothesis was postulated that an antibody that recognizes an inaccessible epftope in native dimeric SOD1 but exposed in aggregates of SOD1 and aggregation intermediates, would be able to selectively detect SOD1 misfolded in vivo. Examination of the X-ray structure of the native SOD1 dimer (pdb code: 1SPD) (72) shows that residues 145-151</span>
  </p>
  <p id="p01119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p01130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p01131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p01132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ACGVIGI) estan secuestrados en la superficie de contacto del dfmero de SOD1 y estan inaccesibles en SOD1 nativa. Se postula la hipotesis de que un anticuerpo creado contra este epftopo reconoce formas mal plegadas de SOD1 donde la superficie de contacto del dfmero nativo esta alterada y expuesta, tal como en monomeros y oligomeros no nativos. Por consiguiente, los inventores han llamado a este el anticuerpo contra la superficie de contacto del dfmero de SOD1 (anticuerpo SEDI, tambien mencionado como anticuerpo policlonal anti-DSE1). Los inventores sintetizaron un peptido antigenico multiple donde cada brazo del dendrfmero tenia la secuencia ggRLACGVIGlggkg; la secuencia en letras mayusculas es parte de la secuencia de SOD1 (restos 143-151). Los restos de SOD1 143 y 144 se anadieron al peptido antigenico para aumentar su solubilidad; se anadieron enlazadores Gly/Lys N-terminales y C-terminales para contextualizar el epftopo en una secuencia interna, aumentar la solubilidad y aumentar el peso molecular para inmunogenicidad potenciada. El antisuero de conejo producido a partir de la inmunizacion con este antfgeno se purifico por afinidad usando un peptido lineal inmovilizado con secuencia identica al antfgeno. Se realizaron transferencias de Western para examinar si el anticuerpo podia discriminar entre SOD1 dimerica y SOD1 monomerica con el epftopo seleccionado expuesto. SOD1 nativa es suficientemente estable de modo que en condiciones no reductoras SOD1 se procesa principalmente como un dfmero en SDS-PAGE. Cuando se reducen condiciones desnaturalizantes, se procesan predominantemente como el monomero, pero con algun dfmero aun detectable. En estos geles, el anticuerpo SEDI reacciona solamente con SOD1 monomerica y no con SOD1 dimerica nativa. Este anticuerpo, por tanto, reaccionara con conformeros de SOD1 donde el epftopo seleccionado esta expuesto, pero no con SOD1 nativa. Esto contrasta con los anticuerpos disponibles en el mercado contra SOD1 que detectan SOD1 tanto nativa como mal plegada de forma indiscriminada. La competicion con el peptido antigenico confirmo la especificidad del anticuerpo. El anticuerpo SEDI, por tanto, satisface los criterios de diseno y proporciona un inol selectivamente presentado o accesible para ensayar la hipotesis in vivo.</span>(ACGVIGI) are sequestered on the contact surface of the SOD1 dimer and are inaccessible in native SOD1. It is hypothesized that an antibody created against this epftope recognizes poorly folded forms of SOD1 where the contact surface of the native dimer is altered and exposed, such as in non-native monomers and oligomers. Accordingly, the inventors have called this the antibody against the contact surface of the SOD1 dimer (SEDI antibody, also mentioned as a polyclonal anti-DSE1 antibody). The inventors synthesized a multiple antigenic peptide where each arm of the dendrimer had the sequence ggRLACGVIGlggkg; The sequence in capital letters is part of the sequence of SOD1 (residues 143-151). The remains of SOD1 143 and 144 were added to the antigenic peptide to increase its solubility; N-terminal and C-terminal Gly / Lys linkers were added to contextualize the epftope in an internal sequence, increase solubility and increase molecular weight for enhanced immunogenicity. The rabbit antiserum produced from immunization with this antigen was purified by affinity using a linear peptide immobilized with sequence identical to the antigen. Western blots were made to examine whether the antibody could discriminate between dimeric SOD1 and monomeric SOD1 with the selected selected epitope. Native SOD1 is sufficiently stable so that under non-reducing conditions SOD1 is mainly processed as a dimer in SDS-PAGE. When denaturing conditions are reduced, they are predominantly processed as the monomer, but with some size still detectable. In these gels, the SEDI antibody reacts only with monomeric SOD1 and not with native dimeric SOD1. This antibody, therefore, will react with SOD1 conformers where the selected epitope is exposed, but not with native SOD1. This contrasts with the commercially available antibodies against SOD1 that detect both native and misfolded SOD1 indiscriminately. The competition with the antigenic peptide confirmed the specificity of the antibody. The SEDI antibody, therefore, meets the design criteria and provides a selectively presented or accessible inol to test the hypothesis in vivo.</span>
  </p>
  <p id="p01133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 5</span>Example 5</span>
  </p>
  <p id="p01134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales contra DSE1</span>Generation of monoclonal antibodies against DSE1</span>
  </p>
  <p id="p01135" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales de raton: se inmunizaron inicialmente 4 ratones BALB/c hembra por inyecciones intraperitoneales con 25 pg de antfgeno proteico por raton en adyuvante completo de Freund. Se administraron 4 refuerzos posteriores como anteriormente, espaciados a intervalos de 3 semanas, con adyuvante incompleto de Freund. Cuando el tftulo del suero se habfa elevado mas de 10 veces desde una muestra de suero preinmune, determinado por ELISA, los 2 mayores respondedores se reforzaron cada uno por via intravenosa con 10 pg de antfgeno proteico, en 100 pl de PBS esteril, pH 7,4. Tres dfas despues los ratones donantes se sacrificaron y se recogieron y se combinaron las celulas esplenicas. La fusion de los esplenocitos con celulas de mieloma parentales SP2/0 BALB/c se realiza como se ha descrito previamente en el Ejemplo 1 anteriormente, excepto que se realiza seleccion de una etapa y clonacion de los hibridomas en medio Clone EZ. Este medio semisolido permite la seleccion en HAT y la clonacion en una unica etapa y elimina el crecimiento excesivo de clones deseables de crecimiento mas lento por hibridomas de crecimiento mas rapido, quiza indeseables. Los clones se picaron 11 dfas despues de la fusion y se resuspendieron en pocillos de placas de cultivo tisular de 96 pocillos en: 200 pl de medio DMEM (Invitrogen) que contenfa suero bovino fetal al 20 %. Despues de 4 dfas, los sobrenadantes se exploraron por ELISA indirecto para la actividad del anticuerpo en placas recubiertas con 1 pg/pocillo de antfgeno proteico.</span>Mouse monoclonal antibody generation: 4 female BALB / c mice were initially immunized by intraperitoneal injections with 25 pg of protein antigen per mouse in Freund's complete adjuvant. Four subsequent reinforcements were administered as above, spaced at intervals of 3 weeks, with incomplete Freund's adjuvant. When the serum titer had been raised more than 10 times from a preimmune serum sample, determined by ELISA, the 2 largest responders were each reinforced intravenously with 10 pg of protein antigen, in 100 pl of sterile PBS, pH 7 ,4. Three days later the donor mice were sacrificed and collected and the splenic cells were combined. The fusion of the splenocytes with SP2 / 0 BALB / c parental myeloma cells is performed as previously described in Example 1 above, except that one stage selection and cloning of the hybridomas in Clone EZ medium is performed. This semi-solid medium allows HAT selection and cloning in a single stage and eliminates the overgrowth of desirable clones of slower growth by faster growing hybridomas, perhaps undesirable. The clones were chopped 11 days after the fusion and resuspended in wells of 96-well tissue culture plates in: 200 pl of DMEM medium (Invitrogen) containing 20% fetal bovine serum. After 4 days, supernatants were screened by indirect ELISA for antibody activity on plates coated with 1 pg / well of protein antigen.</span>
  </p>
  <p id="p01136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Condiciones de ELISA:</span>ELISA conditions:</span>
  </p>
  <p id="p01137" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la exploracion y el ensayo: Se recubre el antfgeno DSE-1-BSA sobre la placa en dH2O a 1 pg/pocillo y se seca durante una noche a 37 C.</span>For exploration and testing: The DSE-1-BSA antigen is coated on the plate in dH2O at 1 pg / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el ensayo sobre antfgeno de control negativo: se recubren 0,5 pg/pocillo de antfgeno HT (transferrina humana) sobre la placa en dH2O a 50 pl/pocillo y se secan durante una noche a 37 C.</span>For the negative control antigen test: 0.5 pg / well of HT antigen (human transferrin) is coated on the plate in dH2O at 50 pl / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01139" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bloqueo: Las placas se bloquearon con leche desnatada en polvo al 3 % en PBS (pH 7,4) a 100 pl/pocillo y se incubaron durante 1 hora a temperatura ambiente.</span>Blocking: The plates were blocked with 3% skimmed milk powder in PBS (pH 7.4) at 100 pl / well and incubated for 1 hour at room temperature.</span>
  </p>
  <p id="p01140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1er anticuerpo: Se anadieron sobrenadante de cultivo tisular de hibridoma anti-DSE1 de raton y controles monoclonales de raton a 100 pl netos por pocillo para la exploracion y el ensayo. Se anadieron suero inmune anti-DSE1a de raton y suero preinmune de raton diluido 1/800 en el sobrenadante de cultivo tisular SP2/0 a 100 pl/pocillo y se incubaron durante 1 hora a temperatura ambiente con agitacion.</span>1st antibody: Tissue culture supernatant of mouse anti-DSE1 hybridoma and mouse monoclonal controls at 100 pl net per well were added for exploration and testing. Mouse anti-DSE1a immune serum and mouse preimmune serum diluted 1/800 in the tissue culture supernatant SP2 / 0 at 100 pl / well were added and incubated for 1 hour at room temperature with shaking.</span>
  </p>
  <p id="p01141" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 anticuerpo usado para exploracion y ensayo: Se uso anticuerpo de cabra anti-Fc de IgG de raton conjugado con HRP 1/10000. El anticuerpo secundario se diluyo en PBS-Tween (pH 7,4), se anadio a 100 pl/pocillo y se incubo durante 1 hora a 37 C con agitacion.</span>2nd antibody used for screening and testing: Goat anti-Fc mouse IgG antibody conjugated with HRP 1/10000 was used. The secondary antibody was diluted in PBS-Tween (pH 7.4), added at 100 pl / well and incubated for 1 hour at 37  C with stirring.</span>
  </p>
  <p id="p01142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sustrato: Se anadio tampon TMB (BioFx n. cat. TMBW-1000-01) a 50 pl/pocillo y se incubo en la oscuridad a temperatura ambiente. La reaccion se detuvo con 50 pl de HCl 1 M por pocillo despues de 15 minutos y se leyo a DO450 nm.</span>Substrate: TMB buffer (BioFx Cat. No. TMBW-1000-01) was added at 50 pl / well and incubated in the dark at room temperature. The reaction was stopped with 50 l of 1M HCl per well after 15 minutes and read at OD450 nm.</span>
  </p>
  <p id="p01143" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01145" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01147" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01150" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01152" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 6</span>Example 6</span>
  </p>
  <p id="p01154" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Produccion de anticuerpos contra DSE1a</span>Production of antibodies against DSE1a</span>
  </p>
  <p id="p01155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se conjugo el peptido aislado correspondiente al epftopo DSE1a (GGGRLAC*GVIGIGSG) con KLH para inmunizacion de ratones BALB/c, y con bSa para exploracion ELISA.</span>The isolated peptide corresponding to the DSE1a epitope (GGGRLAC * GVIGIGSG) was conjugated with KLH for immunization of BALB / c mice, and with bSa for ELISA scanning.</span>
  </p>
  <p id="p01156" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales de raton: se inmunizaron inicialmente 4 ratones BALB/c hembra por inyecciones intraperitoneales con 25 pg de antfgeno proteico por raton en adyuvante completo de Freund. Se administraron 4 refuerzos posteriores como anteriormente, espaciados a intervalos de 3 semanas, con adyuvante incompleto de Freund. Cuando el tftulo del suero se habfa elevado mas de 10 veces de una muestra de suero preinmune, determinado por ELISA, los 2 mayores respondedores se reforzaron cada uno por via intravenosa con 10 pg de antfgeno proteico, en 100 pl de PBS esteril, pH 7,4. Tres dfas despues, los ratones donantes se sacrificaron y se recogieron y se combinaron las celulas esplenicas. La fusion de los esplenocitos con celulas de mieloma parentales SP2/0 BALB/c se realizo como se ha descrito previamente en el Ejemplo 1 anterior, excepto que se realiza seleccion de una etapa y clonacion de los hibridomas en medio Clone EZ. Este medio semisolido permite la seleccion en HAT y la clonacion en una unica etapa y elimina el crecimiento excesivo de clones deseables de crecimiento mas lento por hibridomas de crecimiento mas rapido, quiza indeseables. Los clones se picaron 11 dfas despues de la fusion y se resuspendieron en pocillos de placas de cultivo tisular de 96 pocillos en: 200 pl de medio DMEM (Invitrogen) que contenfa suero bovino fetal al 20 %. Despues de 4 dfas, los sobrenadantes se exploraron por ELISA indirecto para la actividad del anticuerpo en placas recubiertas con 1 pg/pocillo de antfgeno proteico.</span>Mouse monoclonal antibody generation: 4 female BALB / c mice were initially immunized by intraperitoneal injections with 25 pg of protein antigen per mouse in Freund's complete adjuvant. Four subsequent reinforcements were administered as above, spaced at intervals of 3 weeks, with incomplete Freund's adjuvant. When the serum titer had been raised more than 10 times from a sample of preimmune serum, determined by ELISA, the 2 largest responders were each reinforced intravenously with 10 pg of protein antigen, in 100 pl of sterile PBS, pH 7 ,4. Three days later, the donor mice were sacrificed and collected and the splenic cells were combined. The fusion of the splenocytes with parental myeloma cells SP2 / 0 BALB / c was performed as previously described in Example 1 above, except that one stage selection and cloning of the hybridomas in Clone EZ medium is performed. This semi-solid medium allows HAT selection and cloning in a single stage and eliminates the overgrowth of desirable clones of slower growth by faster growing hybridomas, perhaps undesirable. The clones were chopped 11 days after the fusion and resuspended in wells of 96-well tissue culture plates in: 200 pl of DMEM medium (Invitrogen) containing 20% fetal bovine serum. After 4 days, supernatants were screened by indirect ELISA for antibody activity on plates coated with 1 pg / well of protein antigen.</span>
  </p>
  <p id="p01157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Condiciones de ELISA:</span>ELISA conditions:</span>
  </p>
  <p id="p01158" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la exploration y el ensayo: Se recubrio el antfgeno DSE-1-BSA sobre la placa en dH2O a 1 pg/pocillo y se seco durante una noche a 37 C.</span>For exploration and testing: The DSE-1-BSA antigen was coated on the plate in dH2O at 1 pg / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el ensayo sobre el antfgeno de control negativo: se recubrieron 0,5 pg/pocillo de antfgeno HT (transferrina humana) sobre la placa en dH2O a 50 pl/pocillo y se seco durante una noche a 37 C.</span>For the test on the negative control antigen: 0.5 pg / well of HT antigen (human transferrin) was coated on the plate in dH2O at 50 pl / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01160" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bloqueo: Las placas se bloquean con leche desnatada en polvo al 3 % en PBS (pH 7,4) a 100 pl/pocillo y se incuban durante 1 hora a temperatura ambiente.</span>Blocking: The plates are blocked with 3% skimmed milk powder in PBS (pH 7.4) at 100 pl / well and incubated for 1 hour at room temperature.</span>
  </p>
  <p id="p01161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1er anticuerpo: Se anade sobrenadante de cultivo tisular de hibridoma anti-DSE1 de raton y controles monoclonales de raton a 100 pl netos por pocillo para la exploracion y el ensayo. Se anaden suero inmune anti- DSE1a de raton y suero preinmune de raton diluido 1/800 en el sobrenadante de cultivo tisular SP2/0 a 100 pl/pocillo y se incuban durante 1 hora a temperatura ambiente con agitacion.</span>1st antibody: Add tissue culture supernatant of mouse anti-DSE1 hybridoma and mouse monoclonal controls at 100 pl net per well for exploration and testing. Mouse anti-DSE1a immune serum and mouse preimmune serum diluted 1/800 are added to the tissue culture supernatant SP2 / 0 at 100 pl / well and incubated for 1 hour at room temperature with shaking.</span>
  </p>
  <p id="p01162" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 anticuerpo usado para exploration y ensayo: Se usa anticuerpo de cabra anti-Fc de IgG de raton conjugado con HRP 1/10000. El anticuerpo secundario se diluye en PBS-Tween (pH 7,4), se anade a 100 pl/pocillo y se incuba durante 1 hora a 37 C con agitacion.</span>2nd antibody used for exploration and assay: Goat anti-Fc mouse IgG antibody conjugated with HRP 1/10000 is used. The secondary antibody is diluted in PBS-Tween (pH 7.4), added to 100 pl / well and incubated for 1 hour at 37  C with shaking.</span>
  </p>
  <p id="p01163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sustrato: Se anade tampon TMB (BioFx n. cat. TMBW-1000-01) a 50 pl/pocillo y se incuba en la oscuridad a temperatura ambiente. La reaccion se detiene con 50 pl de HCl 1 M por pocillo despues de 15 minutos y se lee a DO450 nm.</span>Substrate: TMB buffer (BioFx Cat. No. TMBW-1000-01) is added at 50 pl / well and incubated in the dark at room temperature. The reaction is stopped with 50 l of 1M HCl per well after 15 minutes and read at OD450 nm.</span>
  </p>
  <p id="p01164" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 4 muestra la exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra el peptido correspondiente al epftopo especffico de enfermedad GGGRLAC*GVIGIGSG (DSE1a). Los anticuerpos generados por los clones de hibridoma eran altamente especfficos para el epftopo especffico de enfermedad, y no reconocfan de forma detectable el antfgeno de control HT (transferrina humana). Estos resultados muestran que pueden producirse anticuerpos monoclonales contra peptidos correspondientes a epftopos identificados como presentados o accesibles en formas mal plegadas de SOD1.</span>Table 4 shows the ELISA scan of hybridoma clones for antibodies directed against the peptide corresponding to the disease-specific epitope GGGRLAC * GVIGIGSG (DSE1a). The antibodies generated by the hybridoma clones were highly specific for the disease-specific epitope, and did not detect the control antigen HT (human transferrin) detectably. These results show that monoclonal antibodies against peptides corresponding to epftopes identified as presented or accessible in misfolded forms of SOD1 can be produced.</span>
  </p>
  <p id="p01165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 4: Exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra el epftopo</span>Table 4: ELISA screening of hybridoma clones for antibodies directed against the epftopo</span>
  </p>
  <p id="p01166" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GGGRLAC*GVIGIGSG (DSE1a)</span>GGGRLAC * GVIGIGSG (DSE1a)</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Exp. n. 1 Antfgeno DSE-1 a-BSA  Exp. n. 2 Antfgeno DSE-1a-BSA  Antfgeno HT  Isotipo </span>&nbsp;Exp. # 1 DSE-1 a-BSA Antigen Exp. # 2 DSE-1a-BSA Antigen HT Antigen Isotype</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C1 </span>&nbsp;3C1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,484  0,265  0,105  IgG </span>&nbsp;0.484 0.265 0.105 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C11 </span>&nbsp;3C11</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,702  0,186  0,093  IgG </span>&nbsp;0.702 0.186 0.093 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3D2 </span>&nbsp;3D2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,542  1,035  0,058  IgG </span>&nbsp;1,542 1,035 0.058 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3F1 </span>&nbsp;3F1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3,072  2,143  0,080  IgG </span>&nbsp;3,072 2,143 0.080 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4B5 </span>&nbsp;4B5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,506  0,238  0,065  IgG </span>&nbsp;0.506 0.238 0.065 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4H6 </span>&nbsp;4H6</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,244  0,957  0,085  IgG </span>&nbsp;1,244 0.957 0.085 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5F6 </span>&nbsp;5F6</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,862  0,663  0,089  IgG </span>&nbsp;0.862 0.663 0.089 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6D8 </span>&nbsp;6D8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,690  2,186  0,089  IgG </span>&nbsp;2,690 2,186 0.089 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 9A4 </span>&nbsp;9A4</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,538  2,313  0,071  IgG </span>&nbsp;2,538 2,313 0.071 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 9A8 </span>&nbsp;9A8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,489  0,884  0,100  IgG </span>&nbsp;1,489 0.884 0.100 IgG</span>
      </dd>
    </dl>
  
  <p id="p01222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01225" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Exp. n. 1 Antfgeno DSE-1 a-BSA  Exp. n. 2 Antfgeno DSE-1a-BSA  Antfgeno HT  Isotipo </span>&nbsp;Exp. # 1 DSE-1 a-BSA Antigen Exp. # 2 DSE-1a-BSA Antigen HT Antigen Isotype</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10C3 </span>&nbsp;10C3</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,446  2,200  0,067  IgG </span>&nbsp;2,446 2,200 0,067 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10C12 </span>&nbsp;10C12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,867  2,016  0,089  IgG </span>&nbsp;2,867 2,016 0.089 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> El clon de hibridoma 6D8 (numero de acceso 220207-01) se deposito en Canada localizada en Winnipeg, Canada el 22 de febrero de 2007. </span>&nbsp;The hybridoma clone 6D8 (access number 220207-01) was deposited in Canada located in Winnipeg, Canada on February 22, 2007.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> la International Depository Authority of </span>&nbsp;the International Depository Authority of</span>
      </dd>
    </dl>
  
  <p id="p01245" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se generaron anticuerpos contra DSE4, 6 y 7 usando tecnicas similares.</span>Antibodies against DSE4, 6 and 7 were generated using similar techniques.</span>
  </p>
  <p id="p01246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 7</span>Example 7</span>
  </p>
  <p id="p01247" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos dirigidos contra DSE1a no reconocen el peptido DSE1</span>Antibodies directed against DSE1a do not recognize the DSE1 peptide</span>
  </p>
  <p id="p01248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se comparo la capacidad del anticuerpo anti-DSEIa de reconocer su secuencia peptfdica affn (DSE1a) con la capacidad del anticuerpo anti-DSEIa de reconocer el peptido no oxidado (DSE1).</span>The ability of the anti-DSEIa antibody to recognize its affn peptide sequence (DSE1a) was compared with the ability of the anti-DSEIa antibody to recognize the non-oxidized peptide (DSE1).</span>
  </p>
  <p id="p01249" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se recubrieron pocillos de placa de microtitulacion con el peptido DSE1 o con el peptido DSE1a acoplado a BSA. Despues se bloquearon los sitios libres de union en cada uno con BSA, se anadieron sobrenadantes de cultivo tisular que contenfan anticuerpos de los clones de hibridoma DSE1a, y se permitio que el anticuerpo se uniera a los peptidos acoplados a BSA. El anticuerpo unido entonces se detecto con un anticuerpo secundario acoplado a peroxidasa. La Figura 1 y la Tabla 5 muestran que todos los anticuerpos ensayados reconocen preferentemente DSE1a sobre DSE1.</span>Microtiter plate wells were coated with the DSE1 peptide or with the DSE1a peptide coupled to BSA. After binding sites were blocked in each with BSA, tissue culture supernatants containing antibodies from the DSE1a hybridoma clones were added, and the antibody was allowed to bind to the BSA-coupled peptides. The bound antibody was then detected with a secondary antibody coupled to peroxidase. Figure 1 and Table 5 show that all antibodies tested preferentially recognize DSE1a over DSE1.</span>
  </p>
  <p id="p01250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando los ratones se inmunizaron con peptido DSE1, principalmente se formaron anticuerpos de isotipo IgM. Un anticuerpo IgM probablemente tiene una afinidad inferior por el epftopo que los anticuerpos contra DSE1a creados como se ha indicado anteriormente, que son del isotipo IgG. La modificacion de DSE1 para que comprenda una cistefna oxidada provoco la produccion de anticuerpos con avidez operativamente mayor.</span>When mice were immunized with DSE1 peptide, mainly IgM isotype antibodies were formed. An IgM antibody probably has a lower affinity for the epftope than antibodies against DSE1a created as indicated above, which are of the IgG isotype. The modification of DSE1 to comprise an oxidized cysteine caused the production of antibodies with avidity greater operation.</span>
  </p>
  <p id="p01251" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 5. ELISA que muestra que los clones de anticuerpo anti-DSEIa reconocen preferentemente el peptido</span>Table 5. ELISA showing that anti-DSEIa antibody clones preferentially recognize the peptide</span>
  </p>
  <p id="p01252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE1a oxidado</span>Rusty DSE1a</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Peptido  Peptido   Clon   Peptido  Peptido </span>&nbsp;Peptide Peptide Clone Peptide Peptide</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C1 </span>&nbsp;3C1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,141  0,243  4H6  0,674  0,233 </span>&nbsp;1,141 0.243 4H6 0.674 0.233</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,405  0,234      0,685  0,29 </span>&nbsp;1,405 0,234 0.685 0.29</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,273  0,2385   Des. Rel.   0,6795  0,2615 </span>&nbsp;1,273 0,2385 Des. Rel. 0.6795 0.2615</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 14,66 %  2,67 %   Promedio   1,14%  15,41% </span>&nbsp;14.66% 2.67% Average 1.14% 15.41%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C11 </span>&nbsp;3C11</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,165  0,197  6D8  2,303  0,366 </span>&nbsp;1,165 0,197 6D8 2,303 0,366</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,732  0,216      2,168  0,242 </span>&nbsp;0.732 0.216 2,168 0.242</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,9485  0,2065   Des. Rel.   2,2355  0,304 </span>&nbsp;0.9485 0.2065 Des. Rel. 2,2355 0.304</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 32,28 %  6,51 %   Promedio   4,27 %  28,84 % </span>&nbsp;32.28% 6.51% Average 4.27% 28.84%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3D2 </span>&nbsp;3D2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,073  0,219  9A4  1,006  0,203 </span>&nbsp;1,073 0.219 9A4 1,006 0.203</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,93  0,209      0,687  0,343 </span>&nbsp;0.93 0.209 0.687 0.343</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,0015  0,214   Des. Rel.   0,8465  0,273 </span>&nbsp;1,0015 0,214 Des. Rel. 0.8465 0.273</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10,10 %  3,30 %   Promedio   26,65 %  36,26 % </span>&nbsp;10.10% 3.30% Average 26.65% 36.26%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3D9 </span>&nbsp;3D9</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,195  0,223  9A8  2,101  0,21 </span>&nbsp;0.195 0.223 9A8 2.101 0.21</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,164  0,195      2,194  0,276 </span>&nbsp;0.164 0.195 2,194 0.276</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,1795  0,209   Des. Rel.   2,1475  0,243 </span>&nbsp;0.1795 0.209 Des. Rel. 2,1475 0,243</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 12,21 %  9,47 %   Promedio   3,06 %  19,21 % </span>&nbsp;12.21% 9.47% Average 3.06% 19.21%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3F1 </span>&nbsp;3F1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,948  0,247  10C3  2,227  0,233 </span>&nbsp;2,948 0,247 10C3 2,227 0,233</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3,005  0,269      2,087  0,22 </span>&nbsp;3,005 0,269 2,087 0.22</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,9765  0,258   Des. Rel.   2,157  0,2265 </span>&nbsp;2.9765 0.258 Des. Rel. 2,157 0,2265</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,35 %  6,03 %   Promedio   4,59 %  4,06 % </span>&nbsp;1.35% 6.03% Average 4.59% 4.06%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE1a  DSE1      DSE1a  DSE1 </span>&nbsp;DSE1a DSE1 DSE1a DSE1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4B5 </span>&nbsp;4B5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,671  0,185  PBST  0,199  0,192 </span>&nbsp;0.671 0.185 PBST 0.199 0.192</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,481  0,169      0,194  0,166 </span>&nbsp;0.481 0.169 0.194 0.166</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Rel. </span>&nbsp;Des. Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,576  0,177   Des. Rel.   0,1965  0,179 </span>&nbsp;0.576 0.177 Des. Rel. 0.1965 0.179</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 23,32 %  6,39 %   Promedio   1,80 %  10,27 % </span>&nbsp;23.32% 6.39% Average 1.80% 10.27%</span>
      </dd>
    </dl>
  
  <p id="p01439" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 8</span>Example 8</span>
  </p>
  <p id="p01440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Produccion de anticuerpos contra DSE5</span>Production of antibodies against DSE5</span>
  </p>
  <p id="p01441" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales de raton: se inmunizaron inicialmente 4 ratones BALB/c hembra por</span>Mouse monoclonal antibody generation: 4 female BALB / c mice were initially immunized by</span>
  </p>
  <p id="p01442" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01444" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01446" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01448" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01450" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01451" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p01453" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p01454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">inyecciones intraperitoneales con 25 pg de inmunogeno que comprende el peptido (IKGLTEGLHGF) correspondiente a DSE5 acoplado a KLH por formacion de disulfuro con una cistefna que se anadio a la N por raton en adyuvante completo de Freund. Se administraron 4 refuerzos posteriores como anteriormente, espaciados a intervalos de 3 semanas, con adyuvante incomplete de Freund. Cuando el tftulo de anticuerpo se habfa elevado mas de 10 veces desde una muestra de suero preinmune, determinado por ELISA, los 2 mayores respondedores se reforzaron cada uno por via intravenosa con 10 pg de antfgeno proteico, en 100 pl de PBS esteril, pH 7,4. Tres dfas despues los ratones donantes se sacrificaron y se recogieron y se combinaron las celulas esplenicas. La fusion de los esplenocitos con celulas de mieloma parentales SP2/0 BALB/c se realiza como se ha descrito previamente en el Ejemplo 1 anteriormente, excepto que se realiza seleccion de una etapa y clonacion de los hibridomas en medio Clone EZ. Este medio semisolido permite la seleccion en HAT y la clonacion en una unica etapa y elimina el crecimiento excesivo de clones deseables de crecimiento mas lento por hibridomas de crecimiento mas rapido, quiza indeseables. Los clones se picaron 11 dfas despues de la fusion y se resuspendieron en pocillos de placas de cultivo tisular de 96 pocillos en: 200 pl de medio DMEM (Invitrogen) que contenfa suero bovino fetal al 20 %. Despues de 4 dfas, los sobrenadantes se exploraron por ELISA indirecto para la actividad del anticuerpo en placas recubiertas con 1 pg/pocillo de antfgeno proteico.</span>intraperitoneal injections with 25 pg of immunogen comprising the peptide (IKGLTEGLHGF) corresponding to DSE5 coupled to KLH by disulfide formation with a cysteine that was added to the N by mouse in Freund's complete adjuvant. Four subsequent reinforcements were administered as above, spaced at intervals of 3 weeks, with Freund's incomplete adjuvant. When the antibody titer had been raised more than 10 times from a preimmune serum sample, determined by ELISA, the 2 largest responders were each reinforced intravenously with 10 pg of protein antigen, in 100 pl of sterile PBS, pH 7 ,4. Three days later the donor mice were sacrificed and collected and the splenic cells were combined. The fusion of the splenocytes with SP2 / 0 BALB / c parental myeloma cells is performed as previously described in Example 1 above, except that one stage selection and cloning of the hybridomas in Clone EZ medium is performed. This semi-solid medium allows HAT selection and cloning in a single stage and eliminates the overgrowth of desirable clones of slower growth by faster growing hybridomas, perhaps undesirable. The clones were chopped 11 days after the fusion and resuspended in wells of 96-well tissue culture plates in: 200 pl of DMEM medium (Invitrogen) containing 20% fetal bovine serum. After 4 days, supernatants were screened by indirect ELISA for antibody activity on plates coated with 1 pg / well of protein antigen.</span>
  </p>
  <p id="p01455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Condiciones de ELISA:</span>ELISA conditions:</span>
  </p>
  <p id="p01456" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la exploration y el ensayo: Se recubrio el antfgeno DSE5-BSA sobre la placa en dH2O a 1 pg/pocillo y se seco durante una noche a 37 C.</span>For exploration and testing: The DSE5-BSA antigen was coated on the plate in dH2O at 1 pg / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el ensayo sobre antfgeno de control negativo: se recubrieron 0,5 pg/pocillo de antfgeno HT (transferrina humana) sobre la placa en dH2O a 50 pl/pocillo y se secaron durante una noche a 37 C.</span>For the negative control antigen assay: 0.5 pg / well of HT antigen (human transferrin) was coated on the plate in dH2O at 50 pl / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01458" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bloqueo: Las placas se bloquearon con leche desnatada en polvo al 3 % en PBS (pH 7,4) a 100 pl/pocillo y se incubaron durante 1 hora a temperatura ambiente.</span>Blocking: The plates were blocked with 3% skimmed milk powder in PBS (pH 7.4) at 100 pl / well and incubated for 1 hour at room temperature.</span>
  </p>
  <p id="p01459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1er anticuerpo: Se anadieron sobrenadante de cultivo tisular de hibridoma anti-DSE5 de raton y controles monoclonales de raton a 100 pl netos por pocillo para la exploracion y el ensayo. Se anadieron suero inmune anti-DSE1a de raton y suero preinmune de raton diluido 1/800 en el sobrenadante de cultivo tisular SP2/0 a 100 pl/pocillo y se incubaron durante 1 hora a temperatura ambiente con agitacion.</span>1st antibody: Tissue culture supernatant of mouse anti-DSE5 hybridoma and mouse monoclonal controls were added at 100 pl net per well for exploration and testing. Mouse anti-DSE1a immune serum and mouse preimmune serum diluted 1/800 in the tissue culture supernatant SP2 / 0 at 100 pl / well were added and incubated for 1 hour at room temperature with shaking.</span>
  </p>
  <p id="p01460" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 anticuerpo usado para exploration y ensayo: Se uso anticuerpo de cabra anti-Fc de IgG de raton conjugado con HRP 1/10000. El anticuerpo secundario se diluyo en PBS-Tween (pH 7,4), se anadio a 100 pl/pocillo y se incubo durante 1 hora a 37 C con agitacion.</span>2nd antibody used for exploration and assay: Goat anti-Fc mouse IgG antibody conjugated with HRP 1/10000 was used. The secondary antibody was diluted in PBS-Tween (pH 7.4), added at 100 pl / well and incubated for 1 hour at 37  C with stirring.</span>
  </p>
  <p id="p01461" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sustrato: Se anadio tampon TMB (BioFx n. cat. TMBW-1000-01) a 50 pl/pocillo y se incubo en la oscuridad a temperatura ambiente. La reaccion se detuvo con 50 pl de HCl 1 M por pocillo despues de 15 minutos y se leyo a DO450 nm.</span>Substrate: TMB buffer (BioFx Cat. No. TMBW-1000-01) was added at 50 pl / well and incubated in the dark at room temperature. The reaction was stopped with 50 l of 1M HCl per well after 15 minutes and read at OD450 nm.</span>
  </p>
  <p id="p01462" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 6 muestra la exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra el epftopo especffico de enfermedad (IKGLTEGLHGF). Los anticuerpos generados por varios clones de hibridoma eran altamente especfficos para el peptido correspondiente al epftopo, y no reconocfan de forma detectable el antfgeno de control hT (transferrina humana). Estos resultados muestran que pueden producirse anticuerpos monoclonales contra peptidos correspondientes a epftopos identificados como selectivamente presentados o accesibles en formas mal plegadas de SOD1.</span>Table 6 shows the ELISA scan of hybridoma clones for antibodies directed against the disease specific epftope (IKGLTEGLHGF). Antibodies generated by several hybridoma clones were highly specific for the peptide corresponding to the epitope, and did not detect the hT control antigen (human transferrin) detectably. These results show that monoclonal antibodies against peptides corresponding to epftopes identified as selectively presented or accessible in poorly folded forms of SOD1 can be produced.</span>
  </p>
  <p id="p01463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 6: Exploracion por ELISA de clones de hibridoma para anticuerpos dirigidos contra el epftopo _________________________________IKGLTEGLHGF (DSE5)_________________________________</span>Table 6: ELISA scan of hybridoma clones for antibodies directed against the epftope _________________________________IKGLTEGLHGF (DSE5) _________________________________</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Exp. n. 1 antfgeno DSE-5-BSA  Exp. n. 2 antfgeno DSE-5-BSA  Antfgeno HT  Isotipo </span>&nbsp;Exp. # 1 DSE-5-BSA antigen Exp. # 2 DSE-5-BSA antigen HT antigen Isotype</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5C6 </span>&nbsp;5C6</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2,779  1,787  0,079  IgG </span>&nbsp;2,779 1,787 0.079 IgG</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> El clon de hibridoma 5C6 (numero de acceso 280207-01) se deposito en la International Depository Authority of </span>&nbsp;The hybridoma clone 5C6 (accession number 280207-01) was deposited with the International Depository Authority of</span>
      </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Canada localizada en Winnipeg, Canada el 28 de febrero de 2007. </span>&nbsp;Canada located in Winnipeg, Canada on February 28, 2007.</span>
      </dt>
      <dd class="style-scope patent-text">    </dd>
    </dl>
  
  <p id="p01478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 9</span>Example 9</span>
  </p>
  <p id="p01479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Produccion de anticuerpos contra epftopos especfficos de enfermedad (DSE) y/o determinantes antigenicos DSE</span>Production of antibodies against disease-specific epftopos (DSE) and / or DSE antigenic determinants</span>
  </p>
  <p id="p01480" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 se conjuga con KLH para inmunizacion de ratones BALB/c para generar celulas B reactivas contra el epftopo. El epftopo para la inmunizacion se selecciona del grupo de peptidos que consiste en: GGGRLACGVIGIGsG (DSE1); gGgRLAC*GVIGIGSG (DSE1a); CDLGKGGNEESTKTGNAGS (DSE2); CNPLSRKHGGPKDEE (DSE3); CIKGLTEGLHGF (DSE5); GSGKAVCVLK (DSE4); y CGLHGFHVH (DSE7). Como alternativa, se conjuga una parte de cualquiera de los peptidos mencionados anteriormente que comprende uno o mas determinantes antigenicos con KLH, que comprenden de forma minima 3 o 5 aminoacidos contiguos de cualquiera de las secuencias peptfdicas que son inmunogenicas en solitario o cuando se acoplan a KLH.</span>An epftopo presented selectively or accessible in non-native forms of SOD1 is conjugated to KLH for immunization of BALB / c mice to generate B cells reactive against the epftopo. The epftope for immunization is selected from the group of peptides consisting of: GGGRLACGVIGIGsG (DSE1); gGgRLAC * GVIGIGSG (DSE1a); CDLGKGGNEESTKTGNAGS (DSE2); CNPLSRKHGGPKDEE (DSE3); CIKGLTEGLHGF (DSE5); GSGKAVCVLK (DSE4); and CGLHGFHVH (DSE7). Alternatively, a part of any of the aforementioned peptides comprising one or more antigenic determinants with KLH is conjugated, which minimally comprise 3 or 5 contiguous amino acids of any of the peptide sequences that are immunogenic alone or when coupled to KLH</span>
  </p>
  <p id="p01481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01483" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01485" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01486" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p01487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p01488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p01489" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p01490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p01491" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p01492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p01493" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generacion de anticuerpos monoclonales de raton: se inmunizan inicialmente 4 ratones BALB/c hembra por inyecciones intraperitoneales con 25 pg de antfgeno proteico por raton en adyuvante completo de Freund. Se administran 4 refuerzos posteriores como anteriormente, espaciados a intervalos de 3 semanas, con adyuvante incompleto de Freund. Cuando el tftulo de anticuerpo se habfa elevado mas de 10 veces a partir una muestra de suero preinmune, determinado por ELISA, los 2 mayores respondedores se refuerzan cada uno por via intravenosa con 10 pg de antfgeno proteico, en 100 pl de PBS esteril, pH 7,4. Tres dfas despues los ratones donantes se sacrifican y se recogen y se combinan las celulas esplenicas. La fusion de los esplenocitos con celulas de mieloma parentales SP2/0 BALB/c se realiza como se ha descrito previamente en el Ejemplo 1 anteriormente, excepto que se realiza seleccion de una etapa y clonacion de los hibridomas en medio Clone EZ. Este medio semisolido permite la seleccion en HAT y la clonacion en una unica etapa y elimina el crecimiento excesivo de clones deseables de crecimiento mas lento por hibridomas de crecimiento mas rapido, quiza indeseables. Los clones se pican 11 dfas despues de la fusion y se resuspenden en pocillos de placas de cultivo tisular de 96 pocillos en: 200 pl de medio DMEM (Invitrogen) que contiene suero bovino fetal al 20 %. Despues de 4 dfas, los sobrenadantes se exploran por ELISA indirecto para la actividad de los anticuerpos en placas recubiertas con 1 pg/pocillo de antfgeno proteico.</span>Mouse monoclonal antibody generation: 4 female BALB / c mice are initially immunized by intraperitoneal injections with 25 pg of protein antigen per mouse in Freund's complete adjuvant. 4 subsequent reinforcements are administered as above, spaced at intervals of 3 weeks, with incomplete Freund's adjuvant. When the antibody titer had been raised more than 10 times from a preimmune serum sample, determined by ELISA, the 2 largest responders are each reinforced intravenously with 10 pg of protein antigen, in 100 pl of sterile PBS, pH 7.4. Three days later, the donor mice are sacrificed and the splenic cells are collected and combined. The fusion of the splenocytes with SP2 / 0 BALB / c parental myeloma cells is performed as previously described in Example 1 above, except that one stage selection and cloning of the hybridomas in Clone EZ medium is performed. This semi-solid medium allows HAT selection and cloning in a single stage and eliminates the overgrowth of desirable clones of slower growth by faster growing hybridomas, perhaps undesirable. The clones are chopped 11 days after the fusion and resuspended in wells of 96-well tissue culture plates in: 200 pl of DMEM medium (Invitrogen) containing 20% fetal bovine serum. After 4 days, the supernatants are screened by indirect ELISA for antibody activity on plates coated with 1 pg / well of protein antigen.</span>
  </p>
  <p id="p01494" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Condiciones de ELISA:</span>ELISA conditions:</span>
  </p>
  <p id="p01495" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la exploration y el ensayo: Se recubre el antfgeno DSE-BSA en la placa en dH2O a 1 pg/pocillo y se seca durante una noche a 37 C.</span>For exploration and testing: The DSE-BSA antigen is coated on the plate in dH2O at 1 pg / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01496" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el ensayo sobre antfgeno de control negativo: se recubren 0,5 pg/pocillo de antfgeno HT (transferrina humana) en la placa en dH2O a 50 pl/pocillo y se secan durante una noche a 37 C.</span>For the negative control antigen assay: 0.5 pg / well of HT antigen (human transferrin) is coated on the plate in dH2O at 50 pl / well and dried overnight at 37  C.</span>
  </p>
  <p id="p01497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bloqueo: Las placas se bloquean con leche desnatada en polvo al 3 % en PBS (pH 7,4) a 100 pl/pocillo y se incuban durante 1 hora a temperatura ambiente.</span>Blocking: The plates are blocked with 3% skimmed milk powder in PBS (pH 7.4) at 100 pl / well and incubated for 1 hour at room temperature.</span>
  </p>
  <p id="p01498" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1er anticuerpo: Se anaden sobrenadante de cultivo tisular de hibridoma anti-DSE de raton y controles monoclonales de raton a 100 pl netos por pocillo para la exploracion y el ensayo. Se anaden suero inmune anti- DSE1a de raton y suero preinmune de raton diluido 1/800 en el sobrenadante de cultivo tisular SP2/0 a 100 pl/pocillo y se incuban durante 1 hora a temperatura ambiente con agitacion.</span>1st antibody: Tissue culture supernatant of mouse anti-DSE hybridoma and mouse monoclonal controls at 100 pl net per well are added for exploration and testing. Mouse anti-DSE1a immune serum and mouse preimmune serum diluted 1/800 are added to the tissue culture supernatant SP2 / 0 at 100 pl / well and incubated for 1 hour at room temperature with shaking.</span>
  </p>
  <p id="p01499" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2 anticuerpo usado para exploration y ensayo: Se usa anticuerpo de cabra anti-Fc de IgG de raton conjugado con HRP 1/10000. El anticuerpo secundario se diluye en PBS-Tween (pH 7,4), se anade a 100 pl/pocillo y se incuba durante 1 hora a 37 C con agitacion.</span>2nd antibody used for exploration and assay: Goat anti-Fc mouse IgG antibody conjugated with HRP 1/10000 is used. The secondary antibody is diluted in PBS-Tween (pH 7.4), added to 100 pl / well and incubated for 1 hour at 37  C with shaking.</span>
  </p>
  <p id="p01500" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sustrato: Se anade tampon TMB (BioFx n. cat. TMBW-1000-01) a 50 pl/pocillo y se incuba en la oscuridad a temperatura ambiente. La reaccion se detiene con 50 pl de HCl 1 M por pocillo despues de 15 minutos y se lee a DO450 nm.</span>Substrate: TMB buffer (BioFx Cat. No. TMBW-1000-01) is added at 50 pl / well and incubated in the dark at room temperature. The reaction is stopped with 50 l of 1M HCl per well after 15 minutes and read at OD450 nm.</span>
  </p>
  <p id="p01501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 10</span>Example 10</span>
  </p>
  <p id="p01502" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo de ELISA de anticuerpos dirigidos contra DSE1a por afinidad a SOD1 desnaturalizada</span>ELISA assay of antibodies directed against DSE1a by affinity to denatured SOD1</span>
  </p>
  <p id="p01503" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se exploraron los clones de hibridoma que producen anticuerpos dirigidos contra DSE1a (GGGRLAC*GVIGIGSG) por ELISA para la reactividad especffica a SOD1 plegada de forma nativa (SOD1 en PBS) desnaturalizada o SOD1 mal plegada (SOD1 en tampon de desnaturalizacion con GdnHCl 6 M), o control de BSA plegado de forma nativa y mal plegado.</span>Hybridoma clones that produce antibodies directed against DSE1a (GGGRLAC * GVIGIGSG) were screened by ELISA for specific reactivity to natively folded SOD1 (SOD1 in PBS) or denatured SOD1 (SOD1 in 6 M GdnHCl denaturation buffer) , or control of BSA folded natively and misfolded.</span>
  </p>
  <p id="p01504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 7 muestra la afinidad de clones de hibridoma por SOD1 plegada de forma nativa y mal plegada. Se detecto la absorbancia de cada muestra a 450 nm (columnas 2 - 5). Cada muestra se ensayo por duplicado. Los valores de las columnas 6 - 7 proporcionan los valores promedio de la afinidad de cada clon y el porcentaje de diferencia entre las dos muestras. La columna 10 representa la afinidad especffica del anticuerpo por la SOD1 plegada de forma nativa (es decir, la afinidad del anticuerpo por SOD1 menos la union no especffica a la protefna bSa irrelevante). La columna 11 representa la afinidad especffica del anticuerpo por la SOD1 no plegada (es decir, la afinidad del anticuerpo por SOD1 menos la union no especffica para BSA). La columna 12 proporciona el aumento factorial de la afinidad especffica por SOD1 mal plegada sobre SOD1 plegada de forma nativa. Estos resultados demuestran la afinidad especffica de anticuerpos monoclonales dirigidos contra el epftopo DSE1a por SOD1 y que los anticuerpos preferiblemente estan dirigidos a formas mal plegadas de SOD1 con una afinidad 2 - 4 veces mayor que por la forma plegada de forma nativa.</span>Table 7 shows the affinity of hybridoma clones for SOD1 folded natively and misfolded. The absorbance of each sample was detected at 450 nm (columns 2-5). Each sample was tested in duplicate. The values in columns 6-7 provide the average affinity values of each clone and the percentage difference between the two samples. Column 10 represents the specific affinity of the antibody for the SOD1 folded natively (ie, the affinity of the antibody for SOD1 minus non-specific binding to the irrelevant bSa protein). Column 11 represents the specific affinity of the antibody for the unfolded SOD1 (ie, the affinity of the antibody for SOD1 minus the non-specific binding for BSA). Column 12 provides the factorial increase in specific affinity for SOD1 misfolded over natively folded SOD1. These results demonstrate the specific affinity of monoclonal antibodies directed against the DSE1a epitope by SOD1 and that the antibodies are preferably directed to misfolded forms of SOD1 with an affinity 2-4 times greater than by the natively folded form.</span>
  </p>
  <p id="p01505" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se seleccionaron los clones 4H6, 6D8, 10C3 para produccion a gran escala.</span>Clones 4H6, 6D8, 10C3 were selected for large scale production.</span>
  </p>
  <p id="p01506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p01507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p01508" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p01509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p01510" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p01511" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 7: Ensayo de ELISA de clones de hibridoma DSE1a para SOD1 desnaturalizada</span>Table 7: ELISA assay of DSE1a hybridoma clones for denatured SOD1</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1 </span>&nbsp;one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2  3  4  5    6  7  8  9  10  11  12 </span>&nbsp;2 3 4 5 6 7 8 9 10 11 12</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD1      BSA          SOD1      BSA </span>&nbsp;SOD1 BSA SOD1 BSA</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Gdn      Gdn      Gdn      Gdn  S-N  S-N </span>&nbsp;Gdn Gdn Gdn Gdn S-N S-N</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBS  HCl  PBS  HCl  PBS  HCl  PBS  HCl  (F)  (U)  U/F </span>&nbsp;PBS HCl PBS HCl PBS HCl PBS HCl (F) (U) U / F</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clon </span>&nbsp;Clone</span>
      </dt>
      <dd class="style-scope patent-text">                        </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C1 </span>&nbsp;3C1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,423  0,712  0,144  0,  170  0,417  0,662  0,145  0,178  0,256  0,501  1,961 </span>&nbsp;0.423 0.712 0.144 0. 170 0.417 0.662 0.145 0.178 0.256 0.501 1,961</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,410  0,612  0,145  0,  185  2 %  11 %  0 %  6 % </span>&nbsp;0.410 0.612 0.145 0.185 2% 11% 0% 6%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3C11 </span>&nbsp;3C11</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,352  0,693  0,153  0,  155  0,355  0,668  0,154  0,150  0,203  0,516  2,544 </span>&nbsp;0.352 0.693 0.153 0.155 0.355 0.668 0.154 0.155 0.203 0.516 2.544</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,357  0,642  0,155  0,  144  1 %  5 %  1 %  5 % </span>&nbsp;0.357 0.642 0.155 0.144 1% 5% 1% 5%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3D2 </span>&nbsp;3D2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,364  0,727  0,134  0,  130  0,357  0,690  0,127  0,125  0,231  0,564  2,442 </span>&nbsp;0.364 0.727 0.134 0, 130 0.357 0.690 0.127 0.125 0.231 0.564 2.442</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,349  0,652  0,119  0,  119  3 %  8 %  8 %  6 % </span>&nbsp;0.349 0.652 0.119 0, 119 3% 8% 8% 6%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3D9 </span>&nbsp;3D9</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,304  0,661  0,121  0,  124  0,314  0,674  0,137  0,115  0,188  0,548  2,920 </span>&nbsp;0.304 0.661 0.121 0.124 0.314 0.674 0.137 0.115 0.188 0.548 2.920</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,323  0,687  0,152  0,  106  4 %  3 %  16 %  11 % </span>&nbsp;0.323 0.687 0.152 0, 106 4% 3% 16% 11%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3F1 </span>&nbsp;3F1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,354  0,585  0,140  0,  146  0,327  0,577  0,133  0,131  0,195  0,445  2,284 </span>&nbsp;0.354 0.585 0.134 0, 146 0.327 0.577 0.133 0.131 0.195 0.445 2.284</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text"> </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,299  0,568  0,125  0,  116  12 %  2 %  8 %  16 % </span>&nbsp;0.299 0.568 0.125 0, 116 12% 2% 8% 16%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4B5 </span>&nbsp;4B5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,352  0,643  0,145  0,  140  0,338  0,637  0,137  0,137  0,201  0,500  2,491 </span>&nbsp;0.352 0.643 0.145 0, 140 0.338 0.637 0.137 0.137 0.201 0.500 2.491</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,323  0,630  0,129  0,  134  6 %  1 %  8 %  3 % </span>&nbsp;0.323 0.630 0.129 0, 134 6% 1% 8% 3%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4H6 </span>&nbsp;4H6</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,334  0,615  0,156  0,  122  0,332  0,626  0,135  0,122  0,203  0,498  2,451 </span>&nbsp;0.334 0.615 0.156 0.122 0.332 0.626 0.135 0.122 0.203 0.489 2.451</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,329  0,637  0,114  0,  122  1 %  2 %  22 %  0 % </span>&nbsp;0.329 0.637 0.114 0, 122 1% 2% 22% 0%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6D8 </span>&nbsp;6D8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,380  0,788  0,148  0,  139  0,385  0,732  0,145  0,134  0,246  0,593  2,413 </span>&nbsp;0,380 0,788 0,148 0, 139 0,385 0,732 0,145 0,134 0,246 0,593 2,413</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,390  0,676  0,142  0,  129  2 %  11 %  3 %  5 % </span>&nbsp;0.390 0.676 0.142 0. 129 2% 11% 3% 5%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 9A4 </span>&nbsp;9A4</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,305  0,634  0,144  0,  127  0,302  0,604  0,133  0,125  0,173  0,475  2,740 </span>&nbsp;0.305 0.634 0.144 0.127 0.302 0.604 0.133 0.125 0.173 0.475 2.740</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,299  0,573  0,122  0,  122  1 %  7 %  12 %  3 % </span>&nbsp;0.299 0.573 0.122 0, 122 1% 7% 12% 3%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 9A8 </span>&nbsp;9A8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,253  0,601  0,150  0,  115  0,259  0,593  0,139  0,119  0,130  0,464  3,578 </span>&nbsp;0.253 0.601 0.115 0.115 0.259 0.593 0.139 0.119 0.134 0.464 3.578</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,264  0,585  0,127  0,  123  3 %  2 %  12 %  5 % </span>&nbsp;0.264 0.585 0.127 0. 123 3% 2% 12% 5%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10C3 </span>&nbsp;10C3</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,284  0,609  0,153  0,  117  0,282  0,628  0,229  0,112  0,112  0,458  4,085 </span>&nbsp;0.284 0.609 0.153 0.117 0.282 0.628 0.229 0.121 0.1212 0.458 4.085</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,280  0,646  0,304  0,  106  1 %  4 %  47 %  7 % </span>&nbsp;0.280 0.646 0.304 0, 106 1% 4% 47% 7%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10C12 </span>&nbsp;10C12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,326  0,562  0,121  0,  115  0,313  0,551  0,121  0,122  0,191  0,429  2,244 </span>&nbsp;0,326 0,562 0,121 0, 115 0,313 0,551 0,121 0,122 0,191 0,429 2,244</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,299  0,539  0,121  0,  128  6 %  3 %  0 %  8 % </span>&nbsp;0.299 0.539 0.121 0, 128 6% 3% 0% 8%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Bkg </span>&nbsp;Bkg</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,112  0,142  0,117  0,  151  0,122  0,143  0,118  0,147       </span>&nbsp;0,112 0,142 0,117 0, 151 0,122 0,143 0,118 0,147</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,132  0,144  0,118  0,  143  12 %  1 %  1 %  4 % </span>&nbsp;0.132 0.144 0.118 0, 143 12% 1% 1% 4%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p id="p01913" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">S = senal, N = ruido, F= plegada de forma nativa, U = no plegada/mal plegada</span>S = signal, N = noise, F = natively folded, U = not folded / misfolded</span>
  </p>
  <p id="p01914" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 11</span>Example 11</span>
  </p>
  <p id="p01915" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo de ELISA de anticuerpos dirigidos contra DSE2 para la afinidad por SOD1 desnaturalizada</span>ELISA assay of antibodies directed against DSE2 for affinity for denatured SOD1</span>
  </p>
  <p id="p01916" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se exploraron clones de hibridoma que producen anticuerpos dirigidos contra DSE2 (DLGKGGNEESTKTGNAGS) por ELlSA para la reactividad especffica contra SOD1 plegada de forma nativa (SOD1 en PBS) desnaturalizada o SOD1 mal plegada (SOD1 en tampon de desnaturalizacion con GdnHCl 6 M), o control de BSA plegada de forma nativa y mal plegada.</span>Hybridoma clones that produce antibodies directed against DSE2 (DLGKGGNEESTKTGNAGS) were screened by ELlSA for specific reactivity against natively folded SOD1 (SOD1 in PBS) or denatured SOD1 (SOD1 in denaturation buffer with 6M GdnHCl) BSA folded natively and misfolded.</span>
  </p>
  <p id="p01917" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 8 muestra la afinidad de clones de hibridoma por SOD1 plegada de forma nativa y no plegada. Se detecto la absorbancia de cada muestra a 450 nm (columnas 2 - 5). Cada muestra se ensayo por duplicado. Los valores de las columnas 6 - 9 proporcionan los valores promedio de la afinidad de cada clon y el porcentaje de diferencia entre las dos muestras. La columna 10 representa la afinidad especffica del anticuerpo por la SOD1 plegada de forma nativa (es decir, la afinidad del anticuerpo por SOD1 menos la union no especffica a BSA). La columna 11 representa la afinidad especffica del anticuerpo por la SOD1 mal plegada (es decir, la afinidad del anticuerpo de SOD1 menos la union no especffica para BSA). La columna 12 proporciona el aumento factorial de la afinidad especffica por SOD1 mal plegada sobre SOD1 plegada de forma nativa. Estos resultados demuestran la afinidad especffica de anticuerpos monoclonales dirigidos contra el epftopo DSE2 por SOD1 y que los anticuerpos preferiblemente estan dirigidos a formas mal plegadas de SOD1.</span>Table 8 shows the affinity of hybridoma clones for SOD1 folded natively and not folded. The absorbance of each sample was detected at 450 nm (columns 2-5). Each sample was tested in duplicate. The values in columns 6-9 provide the average affinity values of each clone and the percentage difference between the two samples. Column 10 represents the specific affinity of the antibody for SOD1 folded natively (ie, the affinity of the antibody for SOD1 minus non-specific binding to BSA). Column 11 represents the specific affinity of the antibody for the misfolded SOD1 (ie, the affinity of the SOD1 antibody minus the non-specific binding for BSA). Column 12 provides the factorial increase in specific affinity for SOD1 misfolded over natively folded SOD1. These results demonstrate the specific affinity of monoclonal antibodies directed against the DSE2 epitope by SOD1 and that the antibodies are preferably directed to misfolded forms of SOD1.</span>
  </p>
  <p id="p01918" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se seleccionaron los clones 3H1, 5G5 y 8D1 para produccion a gran escala.</span>Clones 3H1, 5G5 and 8D1 were selected for large scale production.</span>
  </p>
  <p id="p01919" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 8: Ensayo de ELISA de clones de hibridoma DSE2 para SOD1 desnaturalizada</span>Table 8: ELISA assay of DSE2 hybridoma clones for denatured SOD1</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1 </span>&nbsp;one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2  3  4  5  6  7  8  9  10 11  12 </span>&nbsp;2 3 4 5 6 7 8 9 10 11 12</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD1      BSA  GdnH  SOD1  GdnH  BSA  GdnH  S-N S-N </span>&nbsp;SOD1 BSA GdnH SOD1 GdnH BSA GdnH S-N S-N</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBS  GdnHCl  PBS  Cl  PBS  Cl  PBS  Cl  (F) (U)  U/F </span>&nbsp;PBS GdnHCl PBS Cl PBS Cl PBS Cl (F) (U) U / F</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2A9 </span>&nbsp;2A9</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,321  0,593  0,125  0,137  0,316  0,589  0,116  0,141  0,187 0,460  2,460 </span>&nbsp;0.321 0.593 0.125 0.137 0.316 0.589 0.161 0.141 0.187 0.460 2.460</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,31  0,584  0,107  0,145  2 %  1 %  11 %  4 % </span>&nbsp;0.31 0.584 0.107 0.145 2% 1% 11% 4%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2A11 </span>&nbsp;2A11</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,345  0,71  0,119  0,124  0,347  0,719  0,114  0,140  0,220 0,592  2,693 </span>&nbsp;0.345 0.71 0.119 0.124 0.347 0.719 0.114 0.142 0.220 0.592 2.693</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,348  0,727  0,108  0,156  1 %  2 %  7 %  16 % </span>&nbsp;0.348 0.727 0.108 0.156 1% 2% 7% 16%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3H1 </span>&nbsp;3H1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,257  2,189  0,161  0,165  0,410  2,145  0,156  0,164  0,251 1,986  7,926 </span>&nbsp;0.257 2,189 0.161 0.165 0.410 2.145 0.156 0.164 0.251 1,986 7,926</span>
      </dd>
    </dl>
  
  <p id="p02008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1 </span>&nbsp;one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2  3  4  5  6  7  8  9  10  11  12 </span>&nbsp;2 3 4 5 6 7 8 9 10 11 12</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD1      BSA  GdnH  SOD1  GdnH  BSA  GdnH  S-N  S-N </span>&nbsp;SOD1 BSA GdnH SOD1 GdnH BSA GdnH S-N S-N</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBS  GdnHCl  PBS  Cl  PBS  Cl  PBS  Cl  (F)  (U)  U/F </span>&nbsp;PBS GdnHCl PBS Cl PBS Cl PBS Cl (F) (U) U / F</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,563  2,101  0,15  0,162  53 %  3 %  5 %  1 % </span>&nbsp;0.563 2.101 0.15 0.162 53% 3% 5% 1%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5G5 </span>&nbsp;5G5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,308  1,032  0,22  0,145  0,307  0,879  0,171  0,149  0,147  0,719  4,881 </span>&nbsp;0.308 1.032 0.22 0.145 0.307 0.879 0.171 0.149 0.147 0.719 4.881</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,306  0,725  0,122  0,152  0 %  25 %  41 %  3 % </span>&nbsp;0.306 0.725 0.122 0.152 0% 25% 41% 3%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5G12 </span>&nbsp;5G12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,346  0,604  0,124  0,131  0,309  0,583  0,135  0,122  0,181  0,455  2,516 </span>&nbsp;0.346 0.604 0.124 0.131 0.309 0.583 0.135 0.122 0.181 0.455 2.516</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,272  0,562  0,145  0,113  17 %  5 %  11 %  10 % </span>&nbsp;0.272 0.562 0.145 0.113 17% 5% 11% 10%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6C3 </span>&nbsp;6C3</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,325  0,67  0,129  0,126  0,317  0,673  0,126  0,136  0,187  0,543  2,909 </span>&nbsp;0.325 0.67 0.129 0.126 0.317 0.673 0.126 0.136 0.177 0.543 2.909</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,309  0,676  0,122  0,145  4 %  1 %  4 %  10 % </span>&nbsp;0.309 0.676 0.122 0.145 4% 1% 4% 10%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6G12 </span>&nbsp;6G12</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,29  0,414  0,125  0,114  0,293  0,558  0,112  0,111  0,181  0,446  2,462 </span>&nbsp;0.29 0.414 0.125 0.114 0.293 0.558 0.121 0.111 0.181 0.446 2.462</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,295  0,701  0,099  0,107  1 %  36 %  16 %  4 % </span>&nbsp;0.295 0.701 0.099 0.107 1% 36% 16% 4%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7E10 </span>&nbsp;7E10</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,34  0,787  0,199  0,179  0,331  0,761  0,171  0,158  0,166  0,597  3,589 </span>&nbsp;0.34 0,787 0,199 0,179 0,331 0,761 0,171 0,158 0,166 0,597 3,589</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,321  0,735  0,142  0,137  4 %  5 %  24 %  19 % </span>&nbsp;0.321 0.735 0.142 0.137 4% 5% 24% 19%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7F8 </span>&nbsp;7F8</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,366  0,605  0,131  0,121  0,327  0,612  0,135  0,121  0,199  0,484  2,430 </span>&nbsp;0.366 0.605 0.131 0.121 0.327 0.612 0.135 0.121 0.199 0.484 2.430</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,288  0,619  0,138  0,121  17 %  2 %  4 %  0 % </span>&nbsp;0.288 0.619 0.138 0.121 17% 2% 4% 0%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8C9 </span>&nbsp;8C9</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,354  0,701  0,131  0,132  0,347  0,713  0,122  0,135  0,218  0,584  2,679 </span>&nbsp;0.354 0.701 0.131 0.132 0.347 0.713 0.122 0.135 0.218 0.584 2.699</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,339  0,724  0,113  0,138  3 %  2 %  10 %  3 % </span>&nbsp;0.339 0.724 0.133 0.138 3% 2% 10% 3%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8D1 </span>&nbsp;8D1</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,516  1,626  0,185  0,167  0,465  1,768  0,173  0,180  0,288  1,591  5,520 </span>&nbsp;0.516 1,626 0.185 0.167 0.465 1,768 0.173 0.178 0.288 1.591 5.520</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,413  1,909  0,161  0,192  16 %  11 %  10 %  10 % </span>&nbsp;0.413 1,909 0.161 0.192 16% 11% 10% 10%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10F2 </span>&nbsp;10F2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,263  0,632  0,119  0,172  0,413  0,661  0,118  0,174  0,268  0,515  1,925 </span>&nbsp;0.263 0.632 0.119 0.172 0.413 0.661 0.118 0.174 0.268 0.515 1.925</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,563  0,689  0,116  0,175  51 %  6 %  2 %  1 % </span>&nbsp;0.563 0.689 0.116 0.175 51% 6% 2% 1%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Bkg </span>&nbsp;Bkg</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,112  0,142  0,117  0,151  0,122  0,143  0,118  0,147       </span>&nbsp;0,112 0,142 0,117 0,151 0,122 0,143 0,118 0,147</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,132  0,144  0,118  0,143  12 %  1 %  1 %  4 % </span>&nbsp;0.132 0.144 0.118 0.143 12% 1% 1% 4%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p id="p02302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">S = senal, N = ruido, F= plegada de forma nativa, U = no plegada/mal plegada</span>S = signal, N = noise, F = natively folded, U = not folded / misfolded</span>
  </p>
  <p id="p02303" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 9</span>Example 9</span>
  </p>
  <p id="p02304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo de ELISA de anticuerpos dirigidos contra DSE5 para la afinidad por SOD1 desnaturalizada</span>ELISA assay of antibodies directed against DSE5 for affinity for denatured SOD1</span>
  </p>
  <p id="p02305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se exploraron clones de hibridoma que producen anticuerpos dirigidos contra DSE5 (IKGLTEGLHGF) por ELISA para la reactividad especffica contra SODl plegada de forma nativa (SOD1 en PBS) desnaturalizada o SOD1 mal plegada (SOD1 en tampon de desnaturalizacion con GdnHCl 6 M), o control de BSA plegada de forma nativa y mal plegada.</span>Hybridoma clones producing antibodies directed against DSE5 (IKGLTEGLHGF) were screened by ELISA for specific reactivity against natively folded SOD1 (SOD1 in PBS) denatured or SOD1 misfolded (SOD1 in denaturation buffer with 6 M GdnHCl), or control BSA folded natively and misfolded.</span>
  </p>
  <p id="p02306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 9 muestra la afinidad de clones de hibridoma por SOD1 plegada de forma nativa y mal plegada. Se detecto la absorbancia de cada muestra a 450 nm (columnas 2 - 5). Cada muestra se ensayo por duplicado. Los valores de las columnas 6 - 9 proporcionan los valores promedio de la afinidad de cada clon y el porcentaje de diferencia entre las dos muestras. La columna 10 representa la afinidad especffica del anticuerpo por la SOD1 plegada de forma nativa (es decir, la afinidad del anticuerpo por SOD1 menos la afinidad no especffica por BSA). La columna 11 representa la afinidad especffica del anticuerpo por la SOD1 mal plegada (es decir, la afinidad del anticuerpo por SOD1 menos la afinidad no especffica para BSA). La columna 12 proporciona el aumento factorial de la afinidad especffica de SOD1 mal plegada sobre SOD1 plegada de forma nativa. Estos resultados demuestran la afinidad especffica de anticuerpos monoclonales dirigidos contra el epftopo DSE5 por SOD1 y que los anticuerpos preferiblemente estan dirigidos a formas mal plegadas de SOD1.</span>Table 9 shows the affinity of hybridoma clones for SOD1 folded natively and misfolded. The absorbance of each sample was detected at 450 nm (columns 2-5). Each sample was tested in duplicate. The values in columns 6-9 provide the average affinity values of each clone and the percentage difference between the two samples. Column 10 represents the specific affinity of the antibody for the SOD1 folded natively (ie, the affinity of the antibody for SOD1 minus non-specific affinity for BSA). Column 11 represents the specific affinity of the antibody for the misfolded SOD1 (ie, the affinity of the antibody for SOD1 minus the non-specific affinity for BSA). Column 12 provides the factorial increase in the specific affinity of misfolded SOD1 over natively folded SOD1. These results demonstrate the specific affinity of monoclonal antibodies directed against the DSE5 epftope by SOD1 and that the antibodies are preferably directed to misfolded forms of SOD1.</span>
  </p>
  <p id="p02307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 9: Ensayo de ELISA de clones de hibridoma para SOD1 desnaturalizada</span>Table 9: ELISA assay of hybridoma clones for denatured SOD1</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1 </span>&nbsp;one</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2  3  4  5  6  7  8  9  10  11  12 </span>&nbsp;2 3 4 5 6 7 8 9 10 11 12</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD1  Gdn  BSA  Gdn  SOD1  Gdn  BSA  Gdn  S-N  S-N </span>&nbsp;SOD1 Gdn BSA Gdn SOD1 Gdn BSA Gdn S-N S-N</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBS  HCl  PBS  HCl  PBS  HCl  PBS  HCl  (F)  (U)  U/F </span>&nbsp;PBS HCl PBS HCl PBS HCl PBS HCl (F) (U) U / F</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DSE </span>&nbsp;DSE</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">                 0.14     </span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.14</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5 </span>&nbsp;5</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,272  0,622  0,122  0,188  0,279  0,626  0,113  0,163  1  0,488  3,457 </span>&nbsp;0.272 0.622 0.122 0.188 0.299 0.626 0.133 0.161 1 0.488 3.457</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,286  0,629  0,104  0,138  4 %  1 %  11 %  22 % </span>&nbsp;0.286 0.629 0.104 0.138 4% 1% 11% 22%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Bkg </span>&nbsp;Bkg</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,112  0,142  0,117  0,132  0,151  0,122  0,143  0,118  0,147     </span>&nbsp;0,112 0,142 0,117 0,132 0,151 0,122 0,143 0,118 0,147</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,132  0,144  0,118  0,143  12 %  1 %  1 %  4 % </span>&nbsp;0.132 0.144 0.118 0.143 12% 1% 1% 4%</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p id="p02404" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">S = senal, N = ruido, F= plegada de forma nativa, U = no plegada/mal plegada</span>S = signal, N = noise, F = natively folded, U = not folded / misfolded</span>
  </p>
  <p id="p02405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 13</span>Example 13</span>
  </p>
  <p id="p02406" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reconocimiento de SOD1 oxidada por anticuerpos dirigidos contra DSE2</span>Recognition of SOD1 oxidized by antibodies directed against DSE2</span>
  </p>
  <p id="p02407" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sucede dano oxidativo de las enzimas en enfermedades neurodegenerativas, y el dano oxidativo a SOD1 provoca mal plegamiento y formacion de SOD1 agregada. Los inventores demostraron que anticuerpos dirigidos contra el epftopo DSE2 (clones de hibridoma 10E11C11 y 3H1) reconocen dicha SOD1 modificada de forma oxidativa</span>Oxidative damage of enzymes occurs in neurodegenerative diseases, and oxidative damage to SOD1 causes poor folding and formation of added SOD1. The inventors demonstrated that antibodies directed against the DSE2 epitope (hybridoma clones 10E11C11 and 3H1) recognize said oxidatively modified SOD1</span>
  </p>
  <p id="p02408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">incubando SOD1 purificada con 100 uM a 10 mM de H2O2 o con una mezcla de ascorbato y cloruro de cobre. Se sabe que estos dos tratamientos oxidan los aminoacidos en SOD1. Posteriormente, se permitio que esta SOD1 oxidada se uniera a pocillos de placa de microtitulacion y se anadio uno de dos anticuerpos anti-DSE2 diferentes. Para comparacion, los pocillos de microtitulacion se recubrieron con SOD1 no tratada y plegada normalmente en 5 tampon, o con SOD1 que se desnaturalizo con una solucion de un agente caotropico (cloruro de guanidinio, GdnHCl). Como se muestra en la Figura 2, los anticuerpos anti-DSE2 se unen preferentemente a SOD1 mal plegada en GdnHCl pero mucho menos bien que a SOD1 plegada de forma nativa en tampon. Sin embargo, despues de la oxidacion, SOD1 se reconoce de forma eficaz por los anticuerpos anti-DSE2. Esto demuestra que los anticuerpos anti-DSE2 (tanto 10E11C11 como 3H1) reconocen el tipo de SOD1 modificada de forma oxidativa que sucede en 10 pacientes con enfermedades neurodegenerativas. Estos resultados se presentan en la Tabla 10 a continuacion.</span>incubating purified SOD1 with 100 uM at 10 mM H2O2 or with a mixture of ascorbate and copper chloride. It is known that these two treatments oxidize the amino acids in SOD1. Subsequently, this oxidized SOD1 was allowed to bind to microtiter plate wells and one of two different anti-DSE2 antibodies was added. For comparison, the microtiter wells were coated with untreated SOD1 and normally folded in 5 buffer, or with SOD1 which was denatured with a solution of a chaotropic agent (guanidinium chloride, GdnHCl). As shown in Figure 2, anti-DSE2 antibodies preferentially bind to SOD1 misfolded in GdnHCl but much less well than SOD1 natively folded in buffer. However, after oxidation, SOD1 is effectively recognized by anti-DSE2 antibodies. This demonstrates that anti-DSE2 antibodies (both 10E11C11 and 3H1) recognize the type of oxidatively modified SOD1 that occurs in 10 patients with neurodegenerative diseases. These results are presented in Table 10 below.</span>
  </p>
  <p id="p02409" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 10. Reconocimiento de SOD1 oxidada por anticuerpos dirigidos contra DSE2 Tratamiento Clones Tratamiento Clones</span>Table 10. Recognition of SOD1 oxidized by antibodies directed against DSE2 Clones Treatment Clones Treatment</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C1  1  3H1 </span>&nbsp;PBST 10E11C1 1 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD-Gnd </span>&nbsp;SOD-Gnd</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,118  1,243  2,29 </span>&nbsp;0,118 1,243 2.29</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,092 </span>&nbsp;0.092</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,254  2,295 </span>&nbsp;1,254 2,295</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,086 </span>&nbsp;0.086</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,225   </span>&nbsp;1,225</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,098  66666  7  1,240666  667  2,2925 </span>&nbsp;0.098 66666 7 1,240666 667 2.2925</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 17,24  %  1,18 %  0,15 % </span>&nbsp;17.24% 1.18% 0.15%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C11  3H1 </span>&nbsp;PBST 10E11C11 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> SOD-PBS </span>&nbsp;SOD-PBS</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,088  0,357  0,34 </span>&nbsp;0.088 0.357 0.34</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,094 </span>&nbsp;0.094</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,362  0,335 </span>&nbsp;0.362 0.335</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,082 </span>&nbsp;0.082</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,389   </span>&nbsp;0.399</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,088  0,3693333  33  0,337  5 </span>&nbsp;0.088 0.3693333 33 0.337 5</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6,82 %  4,66 %  1,05  % </span>&nbsp;6.82% 4.66% 1.05%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C1  1  3H1 </span>&nbsp;PBST 10E11C1 1 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> CuCl 3 h </span>&nbsp;3 h CuCl</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,087  1,061  1,717 </span>&nbsp;0.087 1,061 1,717</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,101 </span>&nbsp;0.101</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,06  1,621 </span>&nbsp;1.06 1,621</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,088 </span>&nbsp;0.088</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,076   </span>&nbsp;1,076</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,092  1,065666  667  1,669 </span>&nbsp;0.092 1,065666 667 1,669</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8,49 %  0,84 %  4,07 % </span>&nbsp;8.49% 0.84% 4.07%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C11  3H1 </span>&nbsp;PBST 10E11C11 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> CuCI 6 h </span>&nbsp;CuCI 6 h</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,082  1,044  1,379 </span>&nbsp;0.082 1,044 1,379</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,093 </span>&nbsp;0.093</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,987  1,489 </span>&nbsp;0.987 1,489</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,089 </span>&nbsp;0.089</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,042   </span>&nbsp;1,042</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,088  1,0243333 33  1,434 </span>&nbsp;0.088 1,0243333 33 1,434</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6,33 %  3,16 %  5,42  % </span>&nbsp;6.33% 3.16% 5.42%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C1  1  3H1 </span>&nbsp;PBST 10E11C1 1 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> CuCl 0 h </span>&nbsp;CuCl 0 h</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,073  0,67  0,527 </span>&nbsp;0.073 0.67 0.527</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,087 </span>&nbsp;0.087</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,669  0,59 </span>&nbsp;0.699 0.59</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,071 </span>&nbsp;0.071</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,664   </span>&nbsp;0.664</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,077  0,667666  667  0,5585 </span>&nbsp;0.077 0.667666 667 0.5585</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 11,32  %  0,48 %  7,98 % </span>&nbsp;11.32% 0.48% 7.98%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C11  3H1 </span>&nbsp;PBST 10E11C11 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> CuCI 1 h </span>&nbsp;CuCI 1 h</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,075  1,023  1,592 </span>&nbsp;0.075 1,023 1,592</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,083 </span>&nbsp;0.083</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,035  1,435 </span>&nbsp;1,035 1,435</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,072 </span>&nbsp;0.072</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1,026   </span>&nbsp;1,026</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,076  66666  7  1,028  1,513  5 </span>&nbsp;0.076 66666 7 1,028 1,513 5</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7,42 %  0,61 %  7,34  % </span>&nbsp;7.42% 0.61% 7.34%</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C11  3H1          PBST  10E11C1  1  3H1 </span>&nbsp;PBST 10E11C11 3H1 PBST 10E11C1 1 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> BSA-PBS </span>&nbsp;BSA-PBS</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,073  0,12  0,078  H2O2 100 uM  0,071  0,489  0,436 </span>&nbsp;0.073 0.12 0.078 H2O2 100 uM 0.071 0.489 0.436</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,083 </span>&nbsp;0.083</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,098  0,076    0,086  0,476  0,425 </span>&nbsp;0.098 0.076 0.086 0.476 0.425</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,073 </span>&nbsp;0.073</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,091      0,107  0,453   </span>&nbsp;0.091 0.107 0.453</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,076 </span>&nbsp;0.076</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 33333                      0,472666 </span>&nbsp;33333 0.472666</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3  0,103  0,077     Promedio   0,088  667  0,4305 </span>&nbsp;3 0.103 0.077 Average 0.088 667 0.4305</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> PBST  10E11C11  3H1          PBST  10E11C1  1  3H1 </span>&nbsp;PBST 10E11C11 3H1 PBST 10E11C1 1 3H1</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> H2O2 1 mM </span>&nbsp;1 mM H2O2</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,074  0,776  0,744    H2O2 100 mM  0,078  0,836  0,763 </span>&nbsp;0.074 0.776 0.744 H2O2 100 mM 0.078 0.836 0.763</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,081  0,752  0,717          0,092  0,84  0,726 </span>&nbsp;0.081 0.752 0.717 0.092 0.84 0.726</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,074  0,781              0,083  0,878 </span>&nbsp;0.074 0.781 0.083 0.878</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 0,076                  0,084 </span>&nbsp;0.076 0.084</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 33333  0,7696666  0,730          33333  0,851333 </span>&nbsp;33333 0.7696666 0.730 33333 0.851333</span>
      </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Promedio </span>&nbsp;Average</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3  67  5     Promedio   3  333  0,7445 </span>&nbsp;3 67 5 Average 3 333 0.7445</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Des. Tip. Rel. </span>&nbsp;Des. Tip Rel.</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5,29 %  2,01 %  2,61     Des. Tip. Rel.   8,41 %  2,72 %  3,51 % </span>&nbsp;5.29% 2.01% 2.61 Des. Tip Rel. 8.41% 2.72% 3.51%</span>
      </dd>
    </dl>
  
  <p id="p02692" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02693" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02694" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02695" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02696" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02697" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02698" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02699" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02700" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02701" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02702" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02703" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02704" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02705" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14</span>Example 14</span>
  </p>
  <p id="p02706" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prediccion, sfntesis y refinamiento de epftopos especfficos de ALS</span>Prediction, synthesis and refinement of specific episodes of ALS</span>
  </p>
  <p id="p02707" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos presentados por SOD1 mal plegada y no presentados por SOD1 nativa pueden determinarse analizando la estructura de SOD1 nativa para regiones de secuencia que estan ocultas por la conformacion nativa plegada normalmente de SOD1. Por ejemplo, los bucles DSE2 y DSE3 estan inaccesibles para la union al anticuerpo en la estructura nativa de SOD1, pero se demostro que se estrufan del sitio activo de SOD1 en fibrillas amiloides y estructuras de nanotubos (84). Por tanto, la exposicion de estos bucles puede ser un marcador del mal plegamiento de SOD1, pero tambien constituyen "dominios de reclutamiento" de SOD1 que estan implicados en el mal plegamiento dirigido por molde de SOD1. Los inventores identificaron DSE1, DSE4 y DSE7 como secuencias putativamente ocultas que podrfan quedar accesibles tras el mal plegamiento de SOD1.</span>The epftopos presented by poorly folded SOD1 and not presented by native SOD1 can be determined by analyzing the structure of native SOD1 for sequence regions that are hidden by the normally folded native conformation of SOD1. For example, the DSE2 and DSE3 loops are inaccessible for antibody binding in the native structure of SOD1, but it was shown that they were structured from the active site of SOD1 in amyloid fibrils and nanotube structures (84). Therefore, the exposure of these loops may be a marker of the poor folding of SOD1, but they also constitute "recruitment domains" of SOD1 that are involved in the mold-directed misfolding of SOD1. The inventors identified DSE1, DSE4 and DSE7 as putatively hidden sequences that could be accessible after the bad folding of SOD1.</span>
  </p>
  <p id="p02708" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos presentados por SOD1 mal plegada y no presentados por SOD1 nativa pueden predecirse analizando regiones de secuencia que tienen estructura restringida. Las estructuras restringidas son menos capaces de acomodar cualquier cambio en el plegamiento resultante en cambios conformacionales en la region de secuencia y en la presentacion de epftopos accesibles no presentes en la estructura restringida. Los epftopos DSE2, 3, 5 y 6 se predijeron sobre esta base.</span>Epftopes presented by SOD1 misfolded and not presented by native SOD1 can be predicted by analyzing sequence regions that have restricted structure. Restricted structures are less able to accommodate any change in folding resulting in conformational changes in the sequence region and in the presentation of accessible epftopes not present in the restricted structure. DSE2, 3, 5 and 6 epftopos were predicted on this basis.</span>
  </p>
  <p id="p02709" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las dianas peptfdicas para SOD1 agregada mal plegada proporcionan inmunogenos para el desarrollo de anticuerpos monoclonales de raton para caracterizacion bioqufmica de exposicion de epftopos que se sintetizaron y caracterizaron. Estas dianas incluyen la secuencia:</span>Peptide targets for poorly folded SOD1 aggregate provide immunogens for the development of mouse monoclonal antibodies for biochemical characterization of epftopos exposure that were synthesized and characterized. These targets include the sequence:</span>
  </p>
  <p id="p02710" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RLACGVIGI (DSE1);</span>RLACGVIGI (DSE1);</span>
  </p>
  <p id="p02711" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DLGKGGNEESTKTGNAGS (DSE2);</span>DLGKGGNEESTKTGNAGS (DSE2);</span>
  </p>
  <p id="p02712" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NPLSRKHGGPKDEE (DSE 3);</span>NPLSRKHGGPKDEE (DSE 3);</span>
  </p>
  <p id="p02713" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">IKGLTEGLHGF (DSE5);</span>IKGLTEGLHGF (DSE5);</span>
  </p>
  <p id="p02714" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HCIIGRTLVVH (DSE6);</span>HCIIGRTLVVH (DSE6);</span>
  </p>
  <p id="p02715" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GSGKAVCVLK (DSE4); y CGLHGFHVH (DSE7).</span>GSGKAVCVLK (DSE4); and CGLHGFHVH (DSE7).</span>
  </p>
  <p id="p02716" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los peptidos DSE se sintetizaron y conjugaron con KLH (hemocianina de lapa californiana). Los peptidos DSE que tienen una cistefna endogena (DSE1, DSE1a, DSE4 y DSE6) se conjugaron con KLH usando el metodo DMS (reactivo y metodo de Pierce) para conjugacion amino. Los peptidos DSE que no tienen un resto de cistefna endogeno (DSE2, DSE3, DSE5 y DSE7) se conjugaron con KLH usando el metodo de sulfo-MBS (reactivo y metodo de Pierce) para conjugacion de grupos tiol.</span>DSE peptides were synthesized and conjugated with KLH (California limpet hemocyanin). DSE peptides having an endogenous cystephine (DSE1, DSE1a, DSE4 and DSE6) were conjugated with KLH using the DMS method (reagent and Pierce method) for amino conjugation. DSE peptides that do not have an endogenous cysteine residue (DSE2, DSE3, DSE5 and DSE7) were conjugated with KLH using the sulfo-MBS method (reagent and Pierce method) for conjugation of thiol groups.</span>
  </p>
  <p id="p02717" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sintetiza opcionalmente y se caracteriza un epftopo "de control" expuesto sobre la superficie molecular de SOD1 normal nativa. Un epftopo de control es opcionalmente un epftopo que se presenta tanto en SOD1 plegada de forma nativa como mal plegada.</span>It is optionally synthesized and a "control" epftope exposed on the native normal SOD1 molecular surface is characterized. A control epftopo is optionally an epftopo that occurs in both natively folded and misfolded SOD1.</span>
  </p>
  <p id="p02718" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los epftopos identificados pueden tener multiples determinantes antigenicos. Los epftopos se analizan adicionalmente para determinar sub-partes de los peptidos (por ejemplo, epftopos concretos) que son inmunogenicos. El analisis de inmunogenicidad de SOD1, incluyendo el diagrama de antigenicidad, se usa para identificar epftopos concretos, peptidos aislados correspondientes a estos epftopos concretos, que se sintetizan y un inmunogeno que comprende el peptido aislado correspondiente a uno o mas de estos epftopos concretos se usa para generar anticuerpos. Se generan y ensayan anticuerpos como se describe en otros Ejemplos.</span>The epftopos identified can have multiple antigenic determinants. The epftopos are further analyzed to determine sub-parts of the peptides (eg, specific epftopos) that are immunogenic. The immunogenicity analysis of SOD1, including the antigenicity diagram, is used to identify specific epftopes, isolated peptides corresponding to these specific epftopes, which are synthesized and an immunogen comprising the isolated peptide corresponding to one or more of these specific epftopos. to generate antibodies. Antibodies are generated and tested as described in other Examples.</span>
  </p>
  <p id="p02719" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un ejemplo de un diagrama de antigenicidad se proporciona en la Figura 3. La secuencia de aminoacidos de SOD1 se sometio al metodo informatizado de Hopps y Woods disponible al publico para predecir las localizaciones de determinantes antigenicos proteicos (Figura 3A). Ademas, la secuencia de SOD1 se sometio al metodo de Kolaskar y Tongaonkar (85) de prediccion de determinantes antigenicos (Figura 3B). Este ultimo metodo identifico los aminoacidos 4-11 (AVCVLKGD), los aminoacidos 27-33 (GPVKvWg), los aminoacidos 42-48 (LHGFHVH), los aminoacidos 93-121 GVADVSIEDSVISLSGDHCIIGRTLVVHE y los aminoacidos 142-149 (SRLACGVI) de SOD1 (SEQ ID NO: 15) como antigenicos.</span>An example of an antigenicity diagram is provided in Figure 3. The amino acid sequence of SOD1 was subjected to the Hopps and Woods computerized method available to the public to predict the locations of protein antigenic determinants (Figure 3A). In addition, the SOD1 sequence was subjected to the method of Kolaskar and Tongaonkar (85) for predicting antigenic determinants (Figure 3B). This last method identified amino acids 4-11 (AVCVLKGD), amino acids 27-33 (GPVKvWg), amino acids 42-48 (LHGFHVH), amino acids 93-121 GVADVSIEDSVISLSGDHCIIGRTLVVHE and amino acids 142-149 (SRLACG1 (SODACVI1) ID NO: 15) as antigenics.</span>
  </p>
  <p id="p02720" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se hacen modificaciones adicionales a las secuencias peptfdicas aisladas correspondientes a los epftopos descritos o a los epftopos concretos identificados para potenciar la inmunogenicidad. Por ejemplo, puede oxidarse un resto de cistefna dentro del peptido aislado en acido cisteico. Un ejemplo es DSE1a donde la cistefna presente en DSE1 se remplaza con cistefna oxidada en forma de acido cisteico y se usa para crear anticuerpos.</span>Additional modifications are made to the isolated peptide sequences corresponding to the epftopos described or to the specific epftopos identified to enhance immunogenicity. For example, a cysteine residue can be oxidized within the isolated peptide in cysteic acid. An example is DSE1a where the cysteine present in DSE1 is replaced with oxidized cysteine in the form of cysteic acid and is used to create antibodies.</span>
  </p>
  <p id="p02721" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 15</span>Example 15</span>
  </p>
  <p id="p02722" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Epftopos analogos</span>Analog epftopos</span>
  </p>
  <p id="p02723" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sintetizan peptidos de epftopos analogos incorporando uno o mas aminoacidos oxidados o nitrados de acuerdo</span>Peptides of analog epftopos are synthesized incorporating one or more oxidized or nitrated amino acids according</span>
  </p>
  <p id="p02724" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02725" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02726" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02727" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02728" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02729" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02730" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02731" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02732" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02733" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02734" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02735" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02736" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02737" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">con la siguiente lista. El resto de cistefna (C) en DSE1 se oxida en acido sulffnico de cistefna o acido cisteico (es decir, DSE1a). El resto de lisina (K) en DSE2 se oxida en un grupo carbonilo. Uno o mas de los restos de arginina (R), lisina (K) e histidina (H) en DSE3 se oxidan para formar un grupo carbonilo. En DSE4, la lisina (K) se oxida en un grupo carbonilo y/o la cistefna (C) se oxida en acido sulffnico de cistefna o acido cisteico. En DSE5 uno o mas de K y H se oxidan en un grupo carbonilo y/o la fenilalanina se nitra en nitrotriptofano. En DSE6, uno o mas de H o R se oxida en un grupo carbonilo y/o C se oxida en acido sulffnico de cistefna o acido cisteico. En DSE7, H se oxida en un grupo carbonilo y/o F se nitra a nitrotriptofano.</span>With the following list. The remainder of cysteine (C) in DSE1 is oxidized in sulphonic acid of cysteine or cysteic acid (ie, DSE1a). The lysine (K) moiety in DSE2 is oxidized in a carbonyl group. One or more of the arginine (R), lysine (K) and histidine (H) residues in DSE3 are oxidized to form a carbonyl group. In DSE4, lysine (K) is oxidized in a carbonyl group and / or cysteine (C) is oxidized in cysteine sulphonic acid or cysteic acid. In DSE5 one or more of K and H are oxidized in a carbonyl group and / or phenylalanine is nitrated in nitrotriptan. In DSE6, one or more of H or R is oxidized in a carbonyl group and / or C is oxidized in cysteine sulphonic acid or cysteic acid. In DSE7, H is oxidized in a carbonyl group and / or F is nitrated to nitrotriptan.</span>
  </p>
  <p id="p02738" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE1: 145-151, RLACGVIGI: C</span>DSE1: 145-151, RLACGVIGI: C</span>
  </p>
  <p id="p02739" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE2: 125-142, DLGKGGNEESTKTGNAGS: K</span>DSE2: 125-142, DLGKGGNEESTKTGNAGS: K</span>
  </p>
  <p id="p02740" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE3: 65-78, NPLSRKHGGPKDEE: R, K, H</span>DSE3: 65-78, NPLSRKHGGPKDEE: R, K, H</span>
  </p>
  <p id="p02741" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE4: 3-9, KAVCVLK: K, C</span>DSE4: 3-9, KAVCVLK: K, C</span>
  </p>
  <p id="p02742" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE5: 35-45, IKGLTEGLHGF: K, H, F</span>DSE5: 35-45, IKGLTEGLHGF: K, H, F</span>
  </p>
  <p id="p02743" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE6: 110-120, HCIIGRTLVVH: H, C, R</span>DSE6: 110-120, HCIIGRTLVVH: H, C, R</span>
  </p>
  <p id="p02744" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DSE7: 41-48, GLHGFHVH: H, F</span>DSE7: 41-48, GLHGFHVH: H, F</span>
  </p>
  <p id="p02745" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">C: cistefna, se oxida en acido sulffnico de cistefna, y adicionalmente se oxida en acido cisteico.</span>C: cysteine, it is oxidized in cysteine sulphonic acid, and additionally it is oxidized in cysteic acid.</span>
  </p>
  <p id="p02746" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">H, R, K: formacion de carbonilo M: oxidacion, sulfoxido de metiona F: nitracion, nitrotriptofano</span>H, R, K: carbonyl formation M: oxidation, methion sulfoxide F: nitration, nitrotriptan</span>
  </p>
  <p id="p02747" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se usan analogos peptfdicos sintetizados como inmunogenos para crear anticuerpos, tales como anticuerpos monoclonales y para tratar a individuos que tienen una enfermedad mediada por SOD1 mal plegada tal como ALS, AD y/o PD. Los anticuerpos se exploran frente al analogo peptfdico humanizante para la especificidad. Los clones positivos se ensayan adicionalmente para su capacidad de reconocer SOD1 mal plegada. Los anticuerpos que reconocen especfficamente SOD1 se humanizan y usan para tratar a individuos que tienen una enfermedad mediada por SOD1 mal plegada tal como ALS, AD y/o PD.</span>Peptide analogs synthesized as immunogens are used to create antibodies, such as monoclonal antibodies and to treat individuals who have a poorly folded SOD1 mediated disease such as ALS, AD and / or PD. Antibodies are screened against the humanizing peptide analog for specificity. Positive clones are further tested for their ability to recognize misfolded SOD1. Antibodies that specifically recognize SOD1 are humanized and used to treat individuals who have a badly folded SOD1 mediated disease such as ALS, AD and / or PD.</span>
  </p>
  <p id="p02748" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 16</span>Example 16</span>
  </p>
  <p id="p02749" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunoprecipitacion de tejido cerebral</span>Immunoprecipitation of brain tissue</span>
  </p>
  <p id="p02750" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se obtiene tejido cerebral de pacientes diagnosticados con enfermedad de Alzheimer, enfermedad de Parkinson o ALS, y controles coincidentes. Las muestras se congelan inmediatamente en hielo seco y se pesan. El tejido congelado se corta en trozos mas pequenos y se homogeneiza (10 % p/v) en tampon de lisis (NaCl 100 mM, eDtA 10 mM, Tris 10 mM, desoxicolato al 0,5 %, NP-40 al 0,5 %, pH 7,4) y solucion de inhibidor completo de proteasa libre de EDTA Roche 1 x (Roche) con un homogeneizador con mano de mortero de sedimentacion. Este homogeneizado se centrifuga a 2000 x g; el sobrenadante se menciona como la "fraccion soluble" y la fraccion sedimentada se menciona como la "fraccion insoluble". Los homogeneizados tisulares se dividen en alfcuotas inmediatamente y se congelan a -80 C antes de su uso. Para experimentos con la fraccion insoluble, el sedimento se resuspende en tampon de lisis. La concentracion de protefnas se determina usando el ensayo de protefna BCA (Pierce). Se inmunoprecipitan 100 pg de protefna, diluida a 1 ml con PBS que contenfa inhibidores de proteasa 1 x, con 5-10 pg de un anticuerpo monoclonal que se une a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 acoplada a perlas magneticas activadas con tosilo Dynabeads M-280 (Dynal Biotech, Oslo, Noruega) de acuerdo con las instrucciones del fabricante.</span>Brain tissue is obtained from patients diagnosed with Alzheimer's disease, Parkinson's disease or ALS, and matching controls. The samples are immediately frozen in dry ice and weighed. The frozen tissue is cut into smaller pieces and homogenized (10% w / v) in lysis buffer (100 mM NaCl, 10 mM eDtA, 10 mM Tris, 0.5% deoxycholate, 0.5 NP-40 %, pH 7.4) and complete 1 x EDTA free protease inhibitor solution Roche (Roche) with a settling mortar homogenizer. This homogenate is centrifuged at 2000 x g; the supernatant is mentioned as the "soluble fraction" and the sedimented fraction is mentioned as the "insoluble fraction". Tissue homogenates are divided into alfcuotas immediately and frozen at -80  C before use. For experiments with the insoluble fraction, the sediment is resuspended in lysis buffer. Protein concentration is determined using the BCA protein assay (Pierce). 100 pg of protein is immunoprecipitated, diluted to 1 ml with PBS containing 1 x protease inhibitors, with 5-10 pg of a monoclonal antibody that binds to epftopes selectively presented or accessible in non-native forms of SOD1 coupled to activated magnetic beads. with Dynabeads M-280 tosyl (Dynal Biotech, Oslo, Norway) according to the manufacturer's instructions.</span>
  </p>
  <p id="p02751" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos que se unen a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 incluyen SEDI SOD (anti-DSE1) descrito en la solicitud de patente de Estados Unidos n. 60/741.462. Este anticuerpo es especffico para el epftopo que comprende la secuencia RLACGVIGI.</span>Antibodies that bind selectively or accessible epftopes presented in non-native forms of SOD1 include SEDI SOD (anti-DSE1) described in U.S. Patent Application No. 60 / 741,462. This antibody is specific for the epitope comprising the sequence RLACGVIGI.</span>
  </p>
  <p id="p02752" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En resumen, se dializan 100 pg de IgG SEDI SOD frente a 3 cambios de PBS. Esto se incuba con 300 pl de perlas magneticas de reserva pre-lavadas en PBS a 4 C durante un mfnimo de 96 h. Esto va seguido por bloqueo con BSA al 0,1 % en Tris 0,2 M, pH 8,5 durante 24 h a 4 C. En un protocolo alternativo, se usan perlas de protefna G sepharose (Sigma) para precipitar IgG SEDI SOD.</span>In summary, 100 pg of SEDI SOD IgG is dialyzed against 3 changes of PBS. This is incubated with 300 l of reserve magnetic beads pre-washed in PBS at 4  C for a minimum of 96 h. This is followed by blocking with 0.1% BSA in 0.2 M Tris, pH 8.5 for 24 h at 4  C. In an alternative protocol, G sepharose (Sigma) protein beads are used to precipitate IgG SEDI SOD.</span>
  </p>
  <p id="p02753" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un protocolo alternativo, se usan otros anticuerpos que se unen a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 en los experimentos de inmunoprecipitacion, incluyendo los epftopos descritos en el documento WO 2005/019828 (DLGKGGNEESTKTGNAGS y NPLSRKHGGPKDEE), y anticuerpos contra los mismos, creados, por ejemplo, como se describe en la solicitud de patente de Estados Unidos n. 60/778.379, presentada el 3 de marzo de 2006, y los epftopos descritos en Khare et al. (8) (IKGLTEGLHGF y HCIIGRTLVVH).</span>In an alternative protocol, other antibodies that bind selectively or accessible epftopos presented in non-native forms of SOD1 are used in immunoprecipitation experiments, including epftopos described in WO 2005/019828 (DLGKGGNEESTKTGNAGS and NPLSRKHGGPKDEE), and antibodies against they were created, for example, as described in U.S. Patent Application No. 60 / 778,379, filed on March 3, 2006, and the epftopos described in Khare et al. (8) (IKGLTEGLHGF and HCIIGRTLVVH).</span>
  </p>
  <p id="p02754" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 17</span>Example 17</span>
  </p>
  <p id="p02755" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunoprecipitacion y deteccion de SOD1 mal plegada a partir de tejido cerebral</span>Immunoprecipitation and detection of SOD1 misfolded from brain tissue</span>
  </p>
  <p id="p02756" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se obtienen tejidos cerebrales de un paciente humano normal, de un raton de tipo silvestre, de un raton transgenico</span>Brain tissues are obtained from a normal human patient, from a wild-type mouse, from a transgenic mouse</span>
  </p>
  <p id="p02757" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02758" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02759" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02760" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02761" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02762" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02763" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02764" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02765" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02766" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02767" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02768" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02769" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02770" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">que sobreexpresa SOD1 humana de tipo silvestre y de un raton modelo G93A para ALS, que expresa una forma mal plegada de SOD1. Las muestras se congelaron inmediatamente en hielo seco y se pesaron. El tejido congelado se corto en trozos mas pequenos y se homogeneizo (10 % p/v) en tampon de lisis (NaCl 100 mM, EDTA 10 mM, Tris 10 mM, desoxicolato al 0,5 %, NP-40 al 0,5 %, pH 7,4) y solucion de inhibidor completo de proteasa libre de EDRA Roche 1 x (Roche) con un homogeneizador con mano de mortero de sedimentacion. Este homogeneizado se centrifugo a 2000 x g; el sobrenadante se menciono como la "fraccion soluble" y la fraccion sedimentada se menciona como la "fraccion insoluble". Los homogeneizados tisulares se dividieron en alfcuotas inmediatamente y se congelaron a -80 C antes de su uso. Para experimentos con la fraccion insoluble, el sedimento se resuspendio en tampon de lisis. Se determino la concentracion de protefnas usando el ensayo de protefna BCA (Pierce). Se inmunoprecipitaron 100 pg de protefna, diluida a 1 ml con PBS que contenfa inhibidores de proteasa 1 x, con 5-10 pg de un anticuerpo monoclonal que se unfa a DLGKGGNEESTKTGNAGS, un epftopo presentado selectivamente o accesible en formas no nativas de SOD1, acoplado a perlas magneticas activadas con tosilo Dynabeads M-280 (Dynal Biotech, Oslo, Noruega) de acuerdo con las instrucciones del fabricante.</span>which overexpresses wild-type human SOD1 and a mouse model G93A for ALS, which expresses a misfolded form of SOD1. The samples were immediately frozen in dry ice and weighed. The frozen tissue was cut into smaller pieces and homogenized (10% w / v) in lysis buffer (100 mM NaCl, 10 mM EDTA, 10 mM Tris, 0.5% deoxycholate, 0.5 NP-40 %, pH 7.4) and complete 1 x EDRA free protease inhibitor solution Roche (Roche) with a settling mortar homogenizer. This homogenate was centrifuged at 2000 x g; the supernatant was mentioned as the "soluble fraction" and the sedimented fraction is referred to as the "insoluble fraction". Tissue homogenates were divided into alfcuotas immediately and frozen at -80  C before use. For experiments with the insoluble fraction, the sediment was resuspended in lysis buffer. Protein concentration was determined using the BCA protein assay (Pierce). 100 pg of protein, immunized to 1 ml with PBS containing 1 x protease inhibitors, was immunoprecipitated with 5-10 pg of a monoclonal antibody that binds to DLGKGGNEESTKTGNAGS, an epftope selectively presented or accessible in non-native forms of SOD1, coupled Dynabeads M-280 tosyl activated magnetic beads (Dynal Biotech, Oslo, Norway) according to the manufacturer's instructions.</span>
  </p>
  <p id="p02771" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la inmunotransferencia, se uso un anticuerpo dirigido contra DLGKGGNEESTKTGNAGS para detectar SOD1 a partir de protefnas celulares de muestras de tejido cerebral que se habfan resuelto por electroforesis en gel.</span>For immunoblotting, an antibody directed against DLGKGGNEESTKTGNAGS was used to detect SOD1 from cellular proteins of brain tissue samples that had been resolved by gel electrophoresis.</span>
  </p>
  <p id="p02772" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se demuestra en la Figura 4, un anticuerpo dirigido contra DLGKGGNEESTKTGNAGS (DSE2) inmunoprecipitaba con una forma mal plegada de SOD1 en tejidos cerebrales de ratones mutantes G93A, y a un grado mucho menor SOD1 humana de tipo silvestre sobreexpresada. Este anticuerpo no inmunoprecipitaba formas nativas de SOD1 de raton o humana. Sin embargo, el anticuerpo dirigido contra DSE2 reconocfa SOD1 humana y de raton desnaturalizada por inmunotransferencia directa.</span>As shown in Figure 4, an antibody directed against DLGKGGNEESTKTGNAGS (DSE2) immunoprecipitated with a poorly folded form of SOD1 in brain tissues of G93A mutant mice, and to a much lesser degree overexpressed wild-type human SOD1. This antibody did not immunoprecipitate native forms of mouse or human SOD1. However, the antibody directed against DSE2 recognized human and mouse SOD1 denatured by direct immunoblot.</span>
  </p>
  <p id="p02773" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un protocolo alternativo, se usan otros anticuerpos que se unen a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 en los experimentos de inmunoprecipitacion, incluyendo los epftopos descritos en el documento WO 2005/019828 (NPLSRKHGGPKDEE), y anticuerpos contra los mismos, creados, por ejemplo, como se describe en la solicitud de patente de Estados Unidos n. 60/778.379, presentada el 3 de marzo de 2006, y los epftopos descritos en Khare et al. (8) (IKGLTEGLHGF y HCIIGRTLVVH).</span>In an alternative protocol, other antibodies that bind selectively or accessible epftopos presented in non-native forms of SOD1 are used in immunoprecipitation experiments, including epftopos described in WO 2005/019828 (NPLSRKHGGPKDEE), and antibodies against them. , created, for example, as described in U.S. Patent Application No. 60 / 778,379, filed March 3, 2006, and the epftopos described in Khare et al. (8) (IKGLTEGLHGF and HCIIGRTLVVH).</span>
  </p>
  <p id="p02774" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 18</span>Example 18</span>
  </p>
  <p id="p02775" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunohistoqufmica de tejido cerebral</span>Immunohistochemistry of brain tissue</span>
  </p>
  <p id="p02776" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se obtiene tejido cerebral de pacientes diagnosticados con enfermedad de Alzheimer, enfermedad de Parkinson o ALS, y controles coincidentes. Las muestras se incuban con formalina tamponada con fosfato libre de metanol al 10 % (Fisher Scientific). Las muestras tisulares se diseccionan, incrustan en parafina y se cortan secciones de 6 pm de forma longitudinal o transversal usando un microtomo rotatorio. Todas las secciones para inmunohistoqufmica se tratan con H2O2 al 3 % (v/v) y tampon citrato sodico 10 mM, pH 6,0 antes del marcaje. Se usan anticuerpos que se unen a epftopos presentados selectivamente o accesibles a formas no nativas de SOD1. En todos los casos, los anticuerpos primarios se dejan reaccionar durante una noche a 4 C. Las secciones se revelan usando el sistema DakoCytomation Envison de acuerdo con las instrucciones del fabricante usando 3,3'-diaminobencidina (DAB) como cromogeno. Para marcaje doble, se usa el kit de tincion doble DakoCytomation Envison DoubleStain con nitro-azul de tetrazolio (NBT) como cromogeno. Las secciones tenidas se visualizan usando un microscopio Leica DM 6000 y se obtienen imagenes digitales con una camara digital a color Micropublisher 3.3 RTV (Qimaging).</span>Brain tissue is obtained from patients diagnosed with Alzheimer's disease, Parkinson's disease or ALS, and matching controls. Samples are incubated with 10% methanol-free phosphate buffered formalin (Fisher Scientific). Tissue samples are dissected, embedded in paraffin and 6 pm sections are cut lengthwise or transversely using a rotary microtome. All sections for immunohistochemistry are treated with 3% H2O2 (v / v) and 10 mM sodium citrate buffer, pH 6.0 before labeling. Antibodies that bind selectively presented or accessible epftopes to non-native forms of SOD1 are used. In all cases, the primary antibodies are allowed to react overnight at 4  C. Sections are developed using the DakoCytomation Envison  system according to the manufacturer's instructions using 3,3'-diaminobenzidine (DAB) as chromogen. For double labeling, the DakoCytomation Envison  DoubleStain double staining kit with tetrazolium nitro blue (NBT) is used as chromogen. The sections taken are visualized using a Leica DM 6000 microscope and digital images are obtained with a Micropublisher 3.3 RTV (Qimaging) color digital camera.</span>
  </p>
  <p id="p02777" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 19</span>Example 19</span>
  </p>
  <p id="p02778" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunohistoqufmica de tejido cerebral de enfermedad de Alzheimer</span>Immunohistochemistry of Alzheimer's disease brain tissue</span>
  </p>
  <p id="p02779" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los tejidos se prepararon por fijacion en formalina y se incrustaron en parafina. Los tejidos se seccionaron (4 micrometres), se montaron en portaobjetos de microscopio cargados y se calentaron en un horno de secado de tejidos durante 45 minutos a 60 C. Los portaobjetos se desparafinizaron lavando los portaobjetos en xileno (3 x 5 min.) y se rehidrataron lavando los portaobjetos en concentraciones decrecientes de alcohol (3 x 3 min. usando alcohol al 100 %; 2 x 3 min. usando alcohol al 95 %; 1 x 3 min. usando alcohol al 80 %) y agua destilada. Los portaobjetos se vaporizaron en tampon citrato sodico 0,01 M, pH 6,0 a 99-100 C durante 20 minutos y se incubaron a TA durante 20 minutos. Los portaobjetos se aclararon en TBS 1 x con Tween (TBST) durante 1 minuto a TA.</span>The tissues were prepared by formalin fixation and embedded in paraffin. The tissues were sectioned (4 micrometres), mounted on loaded microscope slides and heated in a tissue drying oven for 45 minutes at 60  C. The slides were dewaxed by washing the slides in xylene (3 x 5 min.) And rehydrated by washing the slides at decreasing concentrations of alcohol (3 x 3 min. Using 100% alcohol; 2 x 3 min. Using 95% alcohol; 1 x 3 min. Using 80% alcohol) and distilled water. The slides were vaporized in 0.01 M sodium citrate buffer, pH 6.0 at 99-100  C for 20 minutes and incubated at RT for 20 minutes. The slides were rinsed in 1 x TBS with Tween (TBST) for 1 minute at RT.</span>
  </p>
  <p id="p02780" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los portaobjetos se incubaron con un bloqueo de protefnas durante 20 minutos, se sondearon con anticuerpo primario durante 45 minutos y se aclararon con TBST. Los portaobjetos se incubaron con un anticuerpo secundario biotinilado durante 30 minutos y despues se aclararon con TBST. Los portaobjetos a continuacion se incubaron en estreptavidina con fosfatasa alcalina durante 30 minutos, se aclararon en TBST y se incubaron con sustrato durante 30 minutos. Despues de aclarar en agua destilada, los portaobjetos se examinaron por microscopia.</span>The slides were incubated with a protein block for 20 minutes, probed with primary antibody for 45 minutes and rinsed with TBST. The slides were incubated with a biotinylated secondary antibody for 30 minutes and then rinsed with TBST. The slides were then incubated in streptavidin with alkaline phosphatase for 30 minutes, rinsed in TBST and incubated with substrate for 30 minutes. After rinsing in distilled water, the slides were examined by microscopy.</span>
  </p>
  <p id="p02781" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se obtuvo tejido cerebral del hipocampo de la autopsia de una mujer de 78 anos de edad diagnosticada con enfermedad de Alzheimer y tejido normal de hipocampo de control de una mujer de 52 anos de edad. Las muestras se incubaron con formalina tamponada con fosfato libre de metanol al 10 % (Fisher Scientific). Las muestras</span>Autopsy hippocampal brain tissue was obtained from a 78-year-old woman diagnosed with Alzheimer's disease and normal control hippocampus tissue from a 52-year-old woman. Samples were incubated with 10% methanol-free phosphate buffered formalin (Fisher Scientific). The samples</span>
  </p>
  <p id="p02782" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02783" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02784" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02785" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02786" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02787" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02788" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02789" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02790" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02791" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02792" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02793" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02794" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02795" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">tisulares se diseccionaron, incrustaron en parafina y se cortaron en secciones de 6 pm de forma longitudinal o transversal usando un microtomo rotatorio. Todas las secciones para inmunohistoqufmica se trataron con H2O2 al 3 % (v/v) y tampon citrato sodico 10 mM, pH 6,0 antes del marcaje. Se uso un anticuerpo especffico para el epftopo especffico de enfermedad de Alzheimer DLGKGGNEESTKTGNAGS (DSE2) como anticuerpo primario para tenir las secciones tisulares a una concentracion de 5 pg/ml (Figura 5). Los anticuerpos se dejaron reaccionar durante una noche a 4 C. Las secciones se revelaron usando el sistema DakoCytomation Envison de acuerdo con las instrucciones del fabricante usando 3,3'-diaminobencidina (DAB) como cromogeno. Para marcaje doble, se usa el kit de tincion doble DakoCytomation Envison DoubleStain con nitro-azul de tetrazolio (NBT) como cromogeno. Las secciones tenidas se visualizaron usando un microscopio Leica DM 6000 y se obtuvieron imagenes digitales con una camara digital a color Micropublisher 3.3 RTV (Qimaging). La seccion del hipocampo obtenida de la mujer de 78 anos de edad con enfermedad de Alzheimer en fase tardfa mostro fuerte tincion de placas seniles en el cerebro con enfermedad de Alzheimer con el anticuerpo dirigido contra DSE2 (Figura 5B, panel de la izquierda), asf como tincion aumentada con subconjuntos de neuronas en la seccion del hipocampo con enfermedad de Alzheimer (Figura 5B, panel de la derecha) en comparacion con el hipocampo normal (Figura 5A).</span>Tissues were dissected, embedded in paraffin and cut into 6 pm sections longitudinally or transversely using a rotary microtome. All sections for immunohistochemistry were treated with 3% H2O2 (v / v) and 10 mM sodium citrate buffer, pH 6.0 before labeling. A specific antibody was used for the specific Alzheimer's disease epftopo DLGKGGNEESTKTGNAGS (DSE2) as the primary antibody to have the tissue sections at a concentration of 5 pg / ml (Figure 5). The antibodies were allowed to react overnight at 4  C. Sections were developed using the DakoCytomation Envison  system according to the manufacturer's instructions using 3,3'-diaminobenzidine (DAB) as chromogen. For double labeling, the DakoCytomation Envison  DoubleStain double staining kit with tetrazolium nitro blue (NBT) is used as chromogen. The sections taken were visualized using a Leica DM 6000 microscope and digital images were obtained with a Micropublisher 3.3 RTV (Qimaging) color digital camera. The hippocampus section obtained from the 78-year-old woman with late-stage Alzheimer's disease showed strong staining of senile plaques in the brain with Alzheimer's disease with the antibody directed against DSE2 (Figure 5B, left panel), asf as an increased staining with subsets of neurons in the section of the hippocampus with Alzheimer's disease (Figure 5B, right panel) compared to the normal hippocampus (Figure 5A).</span>
  </p>
  <p id="p02796" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos datos demuestran que SOD1 mal plegada esta presente de forma intracelular y extracelular en cerebros de pacientes con enfermedad de Alzheimer y que el anticuerpo dirigido contra el epftopo DSE2 CDLGKGGNEESTKTGNAGS reconoce protefnas S0D1 mal plegadas encontradas en los cerebros de pacientes con enfermedad de Alzheimer.</span>These data demonstrate that poorly folded SOD1 is present intracellularly and extracellularly in brains of patients with Alzheimer's disease and that the antibody directed against the DSE2 CDLGKGGNEESTKTGNAGS epftope recognizes poorly folded S0D1 proteins found in the brains of patients with Alzheimer's disease.</span>
  </p>
  <p id="p02797" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 20</span>Example 20</span>
  </p>
  <p id="p02798" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunohistoqufmica de tejido cerebral de enfermedad de Parkinson</span>Immunohistochemistry of brain tissue of Parkinson's disease</span>
  </p>
  <p id="p02799" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los tejidos se prepararon por fijacion en formalina y se incrustaron en parafina. Los tejidos se seccionaron (4 micrometres), se montaron en portaobjetos de microscopio cargados y se calentaron en un horno de secado de tejidos durante 45 minutos a 60 C. Los portaobjetos se desparafinizaron lavando los portaobjetos en xileno (3 x 5 min.) y se rehidrataron lavando los portaobjetos en concentraciones decrecientes de alcohol (3 x 3 min. usando alcohol al 100 %; 2 x 3 min. usando alcohol al 95 %; 1 x 3 min. usando alcohol al 80 %) y agua destilada. Los portaobjetos se vaporizaron en tampon citrato sodico 0,01 M, pH 6,0 a 99-100 C durante 20 minutos y se incubaron a TA durante 20 minutos. Los portaobjetos se aclararon en TBS 1 x con Tween (TBST) durante 1 minuto a TA.</span>The tissues were prepared by formalin fixation and embedded in paraffin. The tissues were sectioned (4 micrometres), mounted on loaded microscope slides and heated in a tissue drying oven for 45 minutes at 60  C. The slides were dewaxed by washing the slides in xylene (3 x 5 min.) And rehydrated by washing the slides at decreasing concentrations of alcohol (3 x 3 min. Using 100% alcohol; 2 x 3 min. Using 95% alcohol; 1 x 3 min. Using 80% alcohol) and distilled water. The slides were vaporized in 0.01 M sodium citrate buffer, pH 6.0 at 99-100  C for 20 minutes and incubated at RT for 20 minutes. The slides were rinsed in 1 x TBS with Tween (TBST) for 1 minute at RT.</span>
  </p>
  <p id="p02800" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los portaobjetos se incubaron con un bloqueo de protefnas durante 20 minutos, se sondearon con anticuerpo primario durante 45 minutos y se aclararon con TBST. Los portaobjetos se incubaron con un anticuerpo secundario biotinilado durante 30 minutos y despues se aclararon con TBST. Los portaobjetos a continuacion se incubaron en estreptavidina con fosfatasa alcalina durante 30 minutos, se aclararon en TBST y se incubaron con sustrato durante 30 minutos. Despues de aclarar en agua destilada, los portaobjetos se examinaron por microscopia.</span>The slides were incubated with a protein block for 20 minutes, probed with primary antibody for 45 minutes and rinsed with TBST. The slides were incubated with a biotinylated secondary antibody for 30 minutes and then rinsed with TBST. The slides were then incubated in streptavidin with alkaline phosphatase for 30 minutes, rinsed in TBST and incubated with substrate for 30 minutes. After rinsing in distilled water, the slides were examined by microscopy.</span>
  </p>
  <p id="p02801" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se obtuvo una muestra de cerebro de una mujer de 79 anos de edad con demencia. La seccion tenida con H y E (Figura 6, panel A) mostro sustancia negra con neuronas dopaminergicas que mostraban cuerpos de Lewy ocasionales coherentes con enfermedad de Parkinson. El anticuerpo anti-DSE2 mostro tincion debil principalmente negativa a inusual en neuronas pigmentadas y no pigmentadas dentro de la sustancia negra (Figura 6, panel B, C, D y E). Los cuerpos de Lewy fueron negativos (Figura 6, panel B). El neuropilo adyacente fue escasamente positivo, y los astrocitos eran de escasamente a ocasionalmente moderadamente positivos. Los cuerpos amilaceos fueron fuertemente positivos. Esta muestra demostro placas seniles inusuales en la materia gris adyacente que era fuertemente positiva (Figura 6, panel F). Se evaluaron secciones en serie adyacentes en ausencia de anticuerpo primario como control y todas fueron negativas.</span>A brain sample was obtained from a 79-year-old woman with dementia. The section taken with H and E (Figure 6, panel A) showed black substance with dopaminergic neurons that showed occasional Lewy bodies consistent with Parkinson's disease. The anti-DSE2 antibody showed weak staining mainly negative to unusual in pigmented and non-pigmented neurons within the black substance (Figure 6, panel B, C, D and E). Lewy bodies were negative (Figure 6, panel B). The adjacent neuropil was poorly positive, and the astrocytes were sparsely to occasionally moderately positive. Amylaceous bodies were strongly positive. This sample showed unusual senile plaques in adjacent gray matter that was strongly positive (Figure 6, panel F). Adjacent serial sections were evaluated in the absence of primary antibody as a control and all were negative.</span>
  </p>
  <p id="p02802" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos datos demuestran que S0D1 mal plegada esta presente en cerebros de pacientes con enfermedad de Parkinson y que el anticuerpo dirigido contra el epftopo DSE2 DLGKGGNEESTKTGNAGS reconoce protefnas S0D1 mal plegadas encontradas en los cerebros de pacientes con enfermedad de Parkinson.</span>These data demonstrate that misfolded S0D1 is present in the brains of patients with Parkinson's disease and that the antibody directed against the DSE2 DLGKGGNEESTKTGNAGS epitope recognizes poorly folded S0D1 proteins found in the brains of patients with Parkinson's disease.</span>
  </p>
  <p id="p02803" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 21</span>Example 21</span>
  </p>
  <p id="p02804" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunorreactividad de DSE2 de SOD1 en enfermedad</span>DSE2 immunoreactivity of SOD1 in disease</span>
  </p>
  <p id="p02805" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han detectado inmunorreactividad de DSE2 en todos los tipos de ALS (formas esporadicas, asf como ALS familiar de S0D1 y ALS familiar sin mutaciones de S0D1). La inmunorreactividad es detectable como depositos densos concretos dentro de algunas neuronas motoras de la medula espinal, incluyendo axones motores en la rafz ventral, asf como depositos marcados extracelulares dentro de las astas anteriores de la medula espinal, y dentro de los axones del tracto motor. Ademas, la inmunorreactividad de DSE2 es detectable de forma intracelular en neuronas del hipocampo en AD, pero no en individuos normales de edad coincidente. Ademas, la inmunorreactividad de DSE2 tambien se aprecia en forma regionalmente difusa en placas seniles y depositos marcados de forma extracelular en el hipocampo. S0D1 mal plegada extracelular en enfermedades neurodegenerativas es claramente una diana para inmunoterapia, que puede "neutralizar" la actividad toxica de las especies mal plegadas acelerando la degradacion por la microglia, y/o por bloqueo de la actividad enzimatica</span>The inventors have detected DSE2 immunoreactivity in all types of ALS (sporadic forms, as well as family ALS of S0D1 and family ALS without mutations of S0D1). Immunoreactivity is detectable as specific dense deposits within some motor neurons of the spinal cord, including motor axons in the ventral root, as well as marked extracellular deposits within the anterior horns of the spinal cord, and within the axons of the motor tract. In addition, the immunoreactivity of DSE2 is detectable intracellularly in hippocampal neurons in AD, but not in normal individuals of matching age. In addition, the immunoreactivity of DSE2 is also regionally diffuse in senile plaques and extracellularly marked deposits in the hippocampus. S0D1 misfolded extracellular in neurodegenerative diseases is clearly a target for immunotherapy, which can "neutralize" the toxic activity of misfolded species accelerating the degradation by microglia, and / or by blocking the enzymatic activity</span>
  </p>
  <p id="p02806" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02807" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02808" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02809" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02810" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02811" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02812" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02813" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02814" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02815" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02816" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02817" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02818" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02819" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">anormal de esta protefna mal plegada.</span>Abnormal of this misfolded protein.</span>
  </p>
  <p id="p02820" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 22</span>Example 22</span>
  </p>
  <p id="p02821" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion con epftopo especffico de ALS de ratones de modelo de ALS</span>Immunization with ALS specific epftopo of mice of ALS model</span>
  </p>
  <p id="p02822" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Este estudio muestra que la vacunacion con secuencias peptfdicas especfficas de la enzima superoxido dismutasa uno (SOD1) previene la enfermedad neurodegenerativa esclerosis lateral amiotrofica (ALS).</span>This study shows that vaccination with specific peptide sequences of the enzyme superoxide dismutase one (SOD1) prevents neurodegenerative disease amyotrophic lateral sclerosis (ALS).</span>
  </p>
  <p id="p02823" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se inmunizan IP ratones transgenicos que expresan SOD1 mutante humana G93A y G37R con epftopo especffico de esclerosis lateral amiotrofica acoplado a KLH y peptidos de control cada mes antes de la aparicion de la enfermedad de neurona motoras (4 meses y 6 meses, respectivamente). El retardo o la anulacion de la agregacion de SOD y la aparicion de la enfermedad sucede para epftopos terapeuticamente activos, y se controlan las manifestaciones autoinmunitarias potenciales para los epftopos especfficos de esclerosis lateral amiotrofica y para los epftopos de control.</span>Transgenic mice that express human mutant SOD1 G93A and G37R are immunized with KLH-coupled amyotrophic lateral sclerosis epftope and control peptides every month before the onset of motor neuron disease (4 months and 6 months, respectively). The delay or cancellation of the aggregation of SOD and the occurrence of the disease occurs for therapeutically active epftopos, and the potential autoimmune manifestations for the specific episodes of amyotrophic lateral sclerosis and for the control epftopos are controlled.</span>
  </p>
  <p id="p02824" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos metodos se usan con los ratones de modelo G93A y G37R. Los ratones de modelo G93A y G37R expresan ciertas formas mutantes de la protefna SOD1 humana y desarrollan una enfermedad tipo ALS de forma clfnica y neuropatologica. Se usan setenta y dos de cada raton modelo para este estudio. Se ensayan siete diferentes epftopos peptfdicos especfficos de ALS para formas no nativas de SOD1 y se comparan con dos grupos de control (uno no tratado y uno tratado con adyuvante en solitario). Cada grupo consistfa en 8 animales.</span>These methods are used with the G93A and G37R model mice. Model G93A and G37R mice express certain mutant forms of the human SOD1 protein and develop an ALS-like disease clinically and neuropathologically. Seventy-two of each mouse model are used for this study. Seven different peptide epftopos specific for ALS are tested for non-native forms of SOD1 and compared with two control groups (one untreated and one treated with adjuvant alone). Each group consisted of 8 animals.</span>
  </p>
  <p id="p02825" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se asignaron aleatoriamente ratones transgenicos hemicigoticos de cuatro semanas de edad (transgen y numero de copias confirmados por PCR y transferencia de Southern) en uno de nueve grupos para inmunizacion: sin inmunizacion (NI); hemocianina de lapa californiana (KLH) en solitario mas adyuvante; o una de siete secuencias peptfdicas DSE de SOD1. Todos los peptidos se sintetizan, purifican y acoplan a KLH usando SMCC-Sulfolink. Todos los ratones se inmunizan inicialmente a traves de inyeccion intraperitoneal (IP) con 100 pg de peptido acoplado a KLH o KLH en solitario, emulsionado 1:1 en adyuvante completo de Freund (FCA), en un volumen total inyectado de 100 pl. Tres semanas despues, se da a los ratones una inyeccion subcutanea de peptido acoplado a KLh emulsionado en adyuvante incompleto de Freund (IFA). Despues de ello, se da a los ratones inyecciones subcutaneas mensuales de peptido acoplado a KLH emulsionado en IFA. Despues de cuatro inmunizaciones, se recogen 100 pl de sangre de la vena safena, y se determinan los tftulos de anticuerpo en plasma.</span>Four week old hemicigotic transgenic mice (transgene and number of copies confirmed by PCR and Southern blot) were randomly assigned to one of nine groups for immunization: no immunization (NI); Californian Barnacle Hemocyanin (KLH) alone more adjuvant; or one of seven DSE peptide sequences of SOD1. All peptides are synthesized, purified and coupled to KLH using SMCC-Sulfolink. All mice are initially immunized through intraperitoneal (IP) injection with 100 pg of peptide coupled to KLH or KLH alone, emulsified 1: 1 in Freund's complete adjuvant (FCA), in a total injected volume of 100 pl. Three weeks later, mice are given a subcutaneous injection of KLh-coupled peptide emulsified in incomplete Freund's adjuvant (IFA). After that, mice are given monthly subcutaneous injections of KLH-coupled peptide emulsified in IFA. After four immunizations, 100 l of blood is collected from the saphenous vein, and the plasma antibody titres are determined.</span>
  </p>
  <p id="p02826" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se pesan 2-3 veces por semana. Se evalua el reflejo de extension de la pata cuando los animales se levantan por la base de la cola y se retiran de su jaula para pesarlos. La reduccion en la extension de la pata es un deficit prematuro observado en ratones transgenicos de SOD1 mutante. El comportamiento de los ratones se controla semanalmente usando el ensayo de campo abierto (EthoVision, Noldus Information Technology, Leesburg, VA, EE. UU.) y se hace el analisis de la forma de caminar semanalmente usando DigiGait. Las evaluaciones del comportamiento inicial y la forma de caminar se completan justo antes de la primera inmunizacion y sirven como datos basales.</span>Animals are weighed 2-3 times per week. The paw extension reflex is evaluated when the animals are lifted by the base of the tail and removed from their cage to weigh them. The reduction in leg extension is a premature deficit observed in transgenic mice of mutant SOD1. The behavior of the mice is monitored weekly using the open field assay (EthoVision, Noldus Information Technology, Leesburg, VA, USA) and the analysis of the way of walking weekly is done using DigiGait. Evaluations of initial behavior and walking are completed just before the first immunization and serve as baseline data.</span>
  </p>
  <p id="p02827" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizan los sistemas de cerebro, medula espinal y otros organos no del SNC postmortem para los indices morfologicos y bioqufmicos de neurodegeneracion.</span>The brain, spinal cord and other non-CNS postmortem CNS systems for morphological and biochemical indices of neurodegeneration are analyzed.</span>
  </p>
  <p id="p02828" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se pesan y controlan regularmente para los efectos adversos tales como signos de dolor y sufrimiento que podrfan ser un resultado de las inmunizaciones. Tambien se controla la autoinmunidad.</span>Animals are weighed and monitored regularly for adverse effects such as signs of pain and suffering that could be a result of immunizations. Autoimmunity is also controlled.</span>
  </p>
  <p id="p02829" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La vacunacion con epftopos peptfdicos especfficos de ALS previene la enfermedad neurodegenerativa esclerosis lateral amiotrofica (ALS). El retardo o anulacion de la agregacion de SOD y la aparicion de la enfermedad suceden para epftopos terapeuticamente activos, y no para los controles.</span>Vaccination with specific peptide epitopes of ALS prevents neurodegenerative disease amyotrophic lateral sclerosis (ALS). The delay or cancellation of the aggregation of SOD and the occurrence of the disease occur for therapeutically active epftopos, and not for the controls.</span>
  </p>
  <p id="p02830" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 23</span>Example 23</span>
  </p>
  <p id="p02831" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion con epftopo especffico de ALS para ratones de modelo de ALS</span>Immunization with specific epitope of ALS for mice of ALS model</span>
  </p>
  <p id="p02832" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se asignaron aleatoriamente ratones de modelo G93A o G37R de cuatro semanas de edad en uno de siete grupos para inmunizacion: solucion salina; hemocianina de lapa californiana (KLH); DSE1; DSE1a; DSE2; DSE5; y DSE1a + DSE2 + DSE5. Todos los peptidos se conjugan con KLH. Todas las inmunizaciones se administran junto con un excipiente farmaceuticamente aceptable.</span>Four week old G93A or G37R model mice were randomly assigned in one of seven groups for immunization: saline solution; California limpet hemocyanin (KLH); DSE1; DSE1a; DSE2; DSE5; and DSE1a + DSE2 + DSE5. All peptides are conjugated with KLH. All immunizations are administered together with a pharmaceutically acceptable excipient.</span>
  </p>
  <p id="p02833" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se evaluan para cambios en el reflejo de extension de la pata, el comportamiento y la forma de caminar. Se analizan los sistemas de cerebro, medula espinal y otros organos no del SNC postmortem para indices morfologicos y bioqufmicos de neurodegeneracion.</span>Animals are evaluated for changes in the paw extension reflex, behavior and the way of walking. The brain, spinal cord and other non-CNS postmortem CNS systems for morphological and biochemical indices of neurodegeneration are analyzed.</span>
  </p>
  <p id="p02834" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La vacunacion con un acido nucleico que codifica un epftopo especffico de ALS previene la enfermedad neurodegenerativa esclerosis lateral amiotrofica (ALS). El retardo o anulacion de la agregacion de SOD y la</span>Vaccination with a nucleic acid that encodes a specific epitope of ALS prevents neurodegenerative disease amyotrophic lateral sclerosis (ALS). The delay or cancellation of the SOD aggregation and the</span>
  </p>
  <p id="p02835" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02836" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02837" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02838" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02839" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02840" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02841" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02842" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02843" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02844" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02845" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02846" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02847" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02848" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aparicion de la enfermedad suceden para epftopos terapeuticamente activos, y no para los controles.</span>Disease occurrence occur for therapeutically active epftopos, and not for controls.</span>
  </p>
  <p id="p02849" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 24</span>Example 24</span>
  </p>
  <p id="p02850" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion de ratones del modelo de ALS con acido nucleico</span>Immunization of mice of the ALS model with nucleic acid</span>
  </p>
  <p id="p02851" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se asignan aleatoriamente ratones de modelo G93A o G37R de cuatro semanas de edad para inmunizacion con un acido nucleico que codifica un epftopo especffico de ALS y un acido nucleico de control no relacionado. Todos los acidos nucleicos se administran con un excipiente farmaceuticamente aceptable.</span>Four-week-old G93A or G37R model mice are randomly assigned for immunization with a nucleic acid encoding a specific ALS epftope and an unrelated control nucleic acid. All nucleic acids are administered with a pharmaceutically acceptable excipient.</span>
  </p>
  <p id="p02852" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se evaluan para cambios en el reflejo de extension de la pata, el comportamiento y la forma de caminar. Se evaluan los sistemas de cerebro, medula espinal y otros organos no del SNC postmortem para los indices morfologicos y bioquimicos de neurodegeneracion.</span>Animals are evaluated for changes in the paw extension reflex, behavior and the way of walking. The systems of the brain, spinal cord and other organs of the postmortem CNS for the morphological and biochemical indices of neurodegeneration are evaluated.</span>
  </p>
  <p id="p02853" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La vacunacion con un acido nucleico que codifica un epftopo especffico de ALS previene la enfermedad neurodegenerativa esclerosis lateral amiotrofica (ALS). El retardo o anulacion de la agregacion de SOD y la aparicion de la enfermedad suceden para epftopos terapeuticamente activos, y no para los controles.</span>Vaccination with a nucleic acid that encodes a specific epitope of ALS prevents neurodegenerative disease amyotrophic lateral sclerosis (ALS). The delay or cancellation of the aggregation of SOD and the occurrence of the disease occur for therapeutically active epftopos, and not for the controls.</span>
  </p>
  <p id="p02854" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 25</span>Example 25</span>
  </p>
  <p id="p02855" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Infusion de anticuerpo contra epftopo especffico de ALS de ratones de modelo de ALS</span>Infusion of antibody against specific ALS epftopo of mice of ALS model</span>
  </p>
  <p id="p02856" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A ratones G93A y G37R se les infundio por via intravenosa (IV) anticuerpos monoclonales dirigidos contra los epftopos especfficos de esclerosis lateral amiotrofica tras la aparicion de la enfermedad, para un modelo mas cercano de inmunoterapia de ALS. La ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos, sin efecto por los anticuerpos de control de isotipo. Se controla la autoinmunidad para el epftopo especffico de esclerosis lateral amiotrofica y para anticuerpos de control, incluyendo epftopo expuesto nativo.</span>G93A and G37R mice were infused intravenously (IV) with monoclonal antibodies directed against specific episodes of amyotrophic lateral sclerosis after the onset of the disease, for a closer model of ALS immunotherapy. The slowing or stopping of the aggregation of SOD and the progression of the disease occurs for therapeutically active antibodies, without effect by the isotype control antibodies. Autoimmunity is controlled for the specific amyotrophic lateral sclerosis epftopo and for control antibodies, including native exposed epftopo.</span>
  </p>
  <p id="p02857" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones de modelo G93A y G37R expresan ciertas formas mutantes de la protefna SOD1 humana y desarrollan una enfermedad tipo ALS de forma clfnica y neuropatologica. Se usan treinta y dos ratones de cada cepa para este estudio, con 8 ratones asignados aleatoriamente a cada uno de dos grupos de tratamiento con anticuerpos dirigidos contra un epftopo presentado selectivamente o accesibles en formas no nativas de SOD1 y dos grupos de control. Se asignan aleatoriamente ratones de 8 semanas de edad en uno de 4 grupos: 1. Un anticuerpo dirigido contra un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 inyectado por via intraperitoneal (IP); 2. Un anticuerpo dirigido contra un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 infundido por via intracerebroventricular (ICV); 3. PBS inyectada IP (control); y 4. Solucion salina tamponada con fosfato (PBS) infundida ICV (control).</span>Model G93A and G37R mice express certain mutant forms of the human SOD1 protein and develop an ALS-like disease clinically and neuropathologically. Thirty-two mice of each strain are used for this study, with 8 mice randomly assigned to each of two treatment groups with antibodies directed against an epftope selectively presented or accessible in non-native forms of SOD1 and two control groups. 8-week-old mice are randomly assigned in one of 4 groups: 1. An antibody directed against an epftope presented selectively or accessible in non-native forms of SOD1 injected intraperitoneally (IP); 2. An antibody directed against an epftopo presented selectively or accessible in non-native forms of SOD1 infused intracerebroventricularly (ICV); 3. PBS injected IP (control); and 4. Phosphate buffered saline solution (PBS) infused with ICV (control).</span>
  </p>
  <p id="p02858" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones reciben inyecciones IP semanalmente de 1 ml de anticuerpo purificado en PBS (250 pl/ml) o PBS en solitario. Para infusion ICV, los ratones se anestesian con gas isoflurano suministrado por una mascarilla, y se les implanta bombas mini-osmoticas (Alzet modelo n. 2004; longitud: 3 cm, volumen total: 200 ul, caudal: 0,25 ul/h). Esta bomba proporciona infusion constante de 0,125 ug/h (un total de 25 ug por semana) durante al menos 4 semanas. Las bombas que contienen anticuerpo contra DSE2 purificado o PBS se instalan en un kit de infusion cerebral (kit 3 de infusion cerebral Alzet), usando una canula colocada en el tercer ventrfculo. Las bombas se remplazan despues de 4 semanas de uso.</span>Mice receive weekly IP injections of 1 ml of purified antibody in PBS (250 pl / ml) or PBS alone. For ICV infusion, mice are anesthetized with isoflurane gas supplied by a mask, and mini-osmotic pumps are implanted (Alzet model No. 2004; length: 3 cm, total volume: 200 ul, flow rate: 0.25 ul / h). This pump provides constant infusion of 0.125 ug / h (a total of 25 ug per week) for at least 4 weeks. Pumps containing antibody against purified DSE2 or PBS are installed in a cerebral infusion kit (Alzet cerebral infusion kit 3), using a cannula placed in the third ventricle. The pumps are replaced after 4 weeks of use.</span>
  </p>
  <p id="p02859" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones se pesan y evaluan para la funcion motora y el comportamiento antes de las inyecciones IP o del implante de las bombas para que sirvan como datos basales. Despues de ello, se realizan estos ensayos una vez por semana. Los ensayos incluyen:</span>Mice are weighed and evaluated for motor function and behavior before IP injections or pump implants to serve as baseline data. After that, these tests are performed once a week. The essays include:</span>
  </p>
  <p id="p02860" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a. ) Reflejo de extension de la extremidad posterior: Reduccion en la extension de la extremidad posterior cuando los animales se levantan por la cola como un deficit prematuro observado en ratones transgenicos de SOD1 mutante. Los animales se levantan por la base de la cola y se valoran los reflejos de extension y postural de la extremidad posterior. El valor 3 indica extension completa y reflejo postural normal. El valor 2 indica extension moderada y reflejo postural normal. El valor 1 indica mala extension y reflejo postural. El valor 0 indica ausencia de movimiento de la extremidad posterior.</span>to. ) Reflection of extension of the posterior limb: Reduction in the extension of the posterior limb when the animals are raised by the tail as a premature deficit observed in transgenic mice of mutant SOD1. The animals are lifted by the base of the tail and the extension and postural reflexes of the posterior limb are assessed. The value 3 indicates full extension and normal postural reflex. The value 2 indicates moderate extension and normal postural reflex. The value 1 indicates bad extension and postural reflex. The value 0 indicates absence of movement of the posterior limb.</span>
  </p>
  <p id="p02861" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b. ) Ensayo de campo abierto: El ensayo de campo abierto se hace semanalmente usando EthoVision Pro Version 3.1 (Noldus Information Technology, Leesburg, VA, EE. UU.). Los animales se colocan en un area circular cerrada (50 cm de diametro) con una parte superior abierta y se registran durante aproximadamente 5 minutos con una videocamara digital suspendida. Se cuantifican fuera de lfnea varios parametros de comportamiento. Se controlan cuatro animales simultaneamente en areas separadas.</span>b. ) Open field test: The open field test is done weekly using EthoVision Pro Version 3.1 (Noldus Information Technology, Leesburg, VA, USA). The animals are placed in a closed circular area (50 cm in diameter) with an open top and recorded for approximately 5 minutes with a suspended digital video camera. Several behavioral parameters are quantified out of line. Four animals are controlled simultaneously in separate areas.</span>
  </p>
  <p id="p02862" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">c. ) Analisis de la forma de caminar: el analisis de la forma de caminar se hace semanalmente usando DigiGait (Mouse Specifics, Boston, MA, EE. UU.). Se presentan cambios en la colocacion de la pata y en la longitud de zancada como los cambios funcionales mas prematuros observados en ratones transgenicos B6.Cg-Tg SOD1 G93A, evaluados usando DigiGait.</span>C. ) Analysis of the way of walking: the analysis of the way of walking is done weekly using DigiGait (Mouse Specifics, Boston, MA, USA). Changes in leg placement and stride length are presented as the most premature functional changes observed in B6.Cg-Tg SOD1 G93A transgenic mice, evaluated using DigiGait.</span>
  </p>
  <p id="p02863" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02864" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02865" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02866" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02867" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02868" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02869" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02870" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02871" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02872" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02873" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02874" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02875" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A las 12 semanas de edad, se recogen 100 pi de sangre de los ratones a traves de la vena safena y se determinan los tftulos de anticuerpo en plasma. Para ratones tratados ICV, la sangre se recoge con anestesia cuando se remplazan las bombas. Los ratones tratados IP tambien se anestesian con isoflurano para facilitar la recogida de sangre.</span>At 12 weeks of age, 100 pi of blood is collected from the mice through the saphenous vein and plasma antibody titres are determined. For mice treated with ICV, blood is collected with anesthesia when the pumps are replaced. IP treated mice are also anesthetized with isoflurane to facilitate blood collection.</span>
  </p>
  <p id="p02876" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se pesan y controlan regularmente para los efectos adversos tales como signos de dolor y sufrimiento mientras dura el estudio. A los animales que parecen tener dolor se les administra Buprenorfina.</span>Animals are weighed and monitored regularly for adverse effects such as signs of pain and suffering during the study. Animals that appear to have pain are given Buprenorphine.</span>
  </p>
  <p id="p02877" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizan los sistemas de cerebro, medula espinal y otros organos no del SNC postmortem para los indices morfologicos y bioquimicos de neurodegeneracion.</span>The systems of the brain, spinal cord and other organs of the postmortem CNS for the morphological and biochemical indices of neurodegeneration are analyzed.</span>
  </p>
  <p id="p02878" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La inyeccion o infusion de anticuerpos dirigidos contra un epitopo presentado selectivamente o accesible en formas no nativas de SOD1 es eficaz en el tratamiento de la enfermedad neurodegenerativa esclerosis lateral amiotrofica (ALS). El tratamiento de ratones de modelo G93A y G37R a traves de inyeccion o infusion de anticuerpos dirigidos contra un epitopo presentado selectivamente o accesible en formas no nativas de SOD1: ha neutralizado y eliminado SOD1 mutante; a prevenido la formacion de agregados de SOD1; ha retardado la aparicion de la enfermedad; y/o ha ralentizado la progresion de la enfermedad.</span>The injection or infusion of antibodies directed against an epitope presented selectively or accessible in non-native forms of SOD1 is effective in the treatment of neurodegenerative disease amyotrophic lateral sclerosis (ALS). The treatment of G93A and G37R model mice through injection or infusion of antibodies directed against an epitope selectively presented or accessible in non-native forms of SOD1: has neutralized and eliminated mutant SOD1; has prevented the formation of aggregates of SOD1; has delayed the onset of the disease; and / or has slowed the progression of the disease.</span>
  </p>
  <p id="p02879" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 26</span>Example 26</span>
  </p>
  <p id="p02880" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de ratones G93A con anticuerpo contra DSE2</span>Treatment of G93A mice with antibody against DSE2</span>
  </p>
  <p id="p02881" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A ratones de modelo G93A se les infundio anticuerpos monoclonales dirigidos contra la secuencia peptfdica DSE2. Los ratones de modelo G93A expresan formas mutantes de la protefna SOD1 humana y desarrollan una enfermedad tipo ALS de forma clfnica y neuropatologica. El anticuerpo se administro por infusion intracerebroventricular (ICV), usando un cateter cerebral (cateteres Alzet) y una bomba implantada por via subcutanea (bombas osmoticas Alzet) o por inyeccion intraperitoneal de anticuerpo anti-DSE2.</span>G93A mice were infused with monoclonal antibodies directed against the DSE2 peptide sequence. G93A model mice express mutant forms of the human SOD1 protein and develop an ALS-like disease clinically and neuropathologically. The antibody was administered by intracerebroventricular infusion (ICV), using a cerebral catheter (Alzet catheters) and a pump implanted subcutaneously (Alzet osmotic pumps) or by intraperitoneal injection of anti-DSE2 antibody.</span>
  </p>
  <p id="p02882" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para infusion ICV, se asignaron aleatoriamente 8 ratones a cualquier grupo de tratamiento (4 animales) o al grupo de control (4 animales). Para el tratamiento, se llenaron las bombas Alzet con 200 ul de solucion de anticuerpo (de 0,5 a 0,6 mg/ml) en solucion salina, o en solucion salina en solitario para el control. El anticuerpo se suministro a un caudal de 0,125 ug/h durante 4 semanas. A 2 ratones adicionales se les infundio por inyeccion intraperitoneal (IP) 1 mg de anticuerpo anti-DSE2, seguido por 3 inyecciones adicionales de 1 mg de anticuerpo anti-DSE2 en solucion salina a intervalos semanales. A 2 ratones se les inyecto el control con solucion salina sin anticuerpo.</span>For ICV infusion, 8 mice were randomly assigned to any treatment group (4 animals) or to the control group (4 animals). For treatment, Alzet pumps were filled with 200 ul of antibody solution (0.5 to 0.6 mg / ml) in saline solution, or in saline solution alone for control. The antibody was supplied at a flow rate of 0.125 ug / h for 4 weeks. An additional 2 mice were infused with intraperitoneal (IP) injection of 1 mg of anti-DSE2 antibody, followed by 3 additional injections of 1 mg of anti-DSE2 antibody in saline solution at weekly intervals. Two mice were injected with saline solution without antibody.</span>
  </p>
  <p id="p02883" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se controlo la progresion de la enfermedad en ratones tratados y no tratados usando el analisis de la forma de caminar (DigiGait, Mouse Specifics Inc, Boston, MA). El analisis Digigait permite una medicion muy precisa de los cambios en los parametros de la forma de caminar en este modelo de raton que permite una evaluacion muy precisa y objetiva de la progresion de la enfermedad (Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, Seburn KL.; Gait analysis detects early changes in transgenic SOD1 (G93A) mice. Muscle Nerve. Julio de 2005;32(1):43-50). Segun progresa la enfermedad, aumenta el tiempo de zancada. Los inventores han descubierto que el tiempo de zancada es un parametro sensible para medir la progresion de la enfermedad.</span>Disease progression was monitored in treated and untreated mice using the analysis of the way of walking (DigiGait, Mouse Specifics Inc, Boston, MA). The Digigait analysis allows a very precise measurement of the changes in the parameters of the way of walking in this mouse model that allows a very precise and objective evaluation of the progression of the disease (Wooley CM, Sher RB, Kale A, Frankel WN , Cox GA, Seburn KL .; Gait analysis detects early changes in transgenic SOD1 (G93A) mice, Muscle Nerve, July 2005; 32 (1): 43-50). As the disease progresses, stride time increases. The inventors have discovered that stride time is a sensitive parameter to measure disease progression.</span>
  </p>
  <p id="p02884" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Tabla 11 muestra los resultados de las mediciones del tiempo de zancada usando analisis Digigait de animales tratados despues de 25 dfas de tratamiento (inyeccion IP) y de 28 a 35 dfas de tratamiento (infusion ICV). El tiempo de zancada se mide en segundos y se promedia sobre la longitud del estudio y las cuatro patas. El tiempo de zancada promedio 0,3238 segundos en el control infundido ICV. La progresion de la enfermedad, medida por el tiempo de zancada, se retarda significativamente despues de 35 dfas de tratamiento. El tiempo de zancada es menor en animales tratados y se reduce hasta 0,2988 segundos. El tiempo de zancada tambien se mejora en ratones inyectados IP. El tiempo de zancada promedio 0,3366 segundos para animales de control y mejoro hasta 0,3206 segundos despues de 28 dfas de tratamiento.</span>Table 11 shows the results of stride time measurements using Digigait analysis of treated animals after 25 days of treatment (IP injection) and 28 to 35 days of treatment (ICV infusion). Stride time is measured in seconds and averaged over the length of the study and the four legs. The average stride time 0.3238 seconds in the control infused ICV. The progression of the disease, measured by the stride time, is significantly delayed after 35 days of treatment. Stride time is shorter in treated animals and is reduced to 0.2988 seconds. Stride time is also improved in mice injected IP. The average stride time 0.3366 seconds for control animals and improved to 0.3206 seconds after 28 days of treatment.</span>
  </p>
  <p id="p02885" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para la comparacion y para demostrar el efecto de la progresion de la enfermedad, se determino el tiempo de zancada para ratones no tratados en un promedio de 66 y 122 dfas de edad (edad del animal en el mismo intervalo que los grupos de tratamiento). A los 66 dfas, los ratones no tratados tienen un tiempo de zancada promedio de 0,3254 segundos (DES.TIP. 0,0313). A los 122 dfas, el tiempo de zancada ha aumentado hasta 0,3492 segundos (DES.TIP. 0,0288). Claramente, en ausencia de tratamiento, este parametro aumenta con alta significancia estadfstica. Los inventores descubrieron que ambos metodos de tratamiento revierten el alargamiento del tiempo de zancada que se observas en los animales no tratados con el tiempo. Esto demuestra la eficacia de este tratamiento de anticuerpo para revertir la enfermedad asociada al fenotipo del modelo de raton de ALS.</span>For comparison and to demonstrate the effect of disease progression, the stride time for untreated mice was determined at an average of 66 and 122 days of age (age of the animal in the same range as the treatment groups). At 66 days, untreated mice have an average stride time of 0.3254 seconds (DES.TIP. 0.0313). At 122 days, the stride time has increased to 0.3492 seconds (DES.TIP. 0.0288). Clearly, in the absence of treatment, this parameter increases with high statistical significance. The inventors discovered that both treatment methods reverse the lengthening of stride time observed in animals not treated over time. This demonstrates the efficacy of this antibody treatment to reverse the disease associated with the ALS mouse model phenotype.</span>
  </p>
  <p id="p02886" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02887" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02888" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02889" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02890" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02891" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02892" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02893" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02894" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02895" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02896" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 11. Retardo en la progresion de la enfermedad: Tiempo de zancada de animales tratados con ____________________anticuerpos contra SOD1 especifica de enfermedad____________________</span>Table 11. Delay in disease progression: Stride time of animals treated with ____________________ antibodies against disease-specific SOD1 ____________________</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Estudio </span>&nbsp;study</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Grupo    Tiempo de zancada </span>&nbsp;Stride Time Group</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Infusion ICV </span>&nbsp;ICV Infusion</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Tratamiento  Promedio  0,2988 s </span>&nbsp;Average Treatment 0.2988 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0044 </span>&nbsp;DES.TIP. 0.0044</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Control  Promedio  0,3238 s </span>&nbsp;Average Control 0.3238 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0449 </span>&nbsp;DES.TIP. 0.0449</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Valor P  4,30E-02 </span>&nbsp;P value 4.30E-02</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Inyeccion IP </span>&nbsp;IP Injection</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Tratamiento  Promedio  0,3206 s </span>&nbsp;Treatment Average 0.3206 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0044 </span>&nbsp;DES.TIP. 0.0044</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Control  Promedio  0,3366 s </span>&nbsp;Average Control 0.3366 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0148 </span>&nbsp;DES.TIP. 0.0148</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Valor P  1,82E-02 </span>&nbsp;P value 1.82E-02</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Progresion de la enfermedad </span>&nbsp;Disease progression</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 66 dfas  Promedio  0,3254 s </span>&nbsp;66 days Average 0.3254 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0313 </span>&nbsp;DES.TIP. 0.0313</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 122 dfas  Promedio  0,3492 s </span>&nbsp;122 days Average 0,3492 s</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> DES.TIP.  0,0288 </span>&nbsp;DES.TIP. 0.0288</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text"> </dd>
      <dt class="style-scope patent-text">  </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Valor P  1,04E-05 </span>&nbsp;P Value 1.04E-05</span>
      </dd>
    </dl>
  
  <p id="p02961" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 27</span>Example 27</span>
  </p>
  <p id="p02962" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion de ratones transgenicos TgCRND8</span>Immunization of TgCRND8 transgenic mice</span>
  </p>
  <p id="p02963" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El raton TgCRND8 es un modelo murino de enfermedad de Alzheimer. Estos ratones expresan un transgen pAPP695 humano mutante (K670N/M671L y V717F) bajo la regulacion del promotor del prion de hamster sirio en el fondo de la cepa C3H/B6. Estos ratones tienen defectos de aprendizaje espacial a los 3 meses de edad que estan acompanados por niveles crecientes de Ap soluble en SDS y tambien de cantidades crecientes de placas amiloides que contienen Ap en el cerebro. Vease Janus C et al. (65).</span>The TgCRND8 mouse is a murine model of Alzheimer's disease. These mice express a mutant human pAPP695 transgene (K670N / M671L and V717F) under the regulation of the Syrian hamster prion promoter at the bottom of strain C3H / B6. These mice have spatial learning defects at 3 months of age that are accompanied by increasing levels of soluble SDS Ap and also increasing amounts of amyloid plaques containing Ap in the brain. See Janus C et al. (65).</span>
  </p>
  <p id="p02964" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones TgCRND8 se inmunizan IP con KLH acoplada a un epftopo presentado selectivamente o accesibles en formas no nativas de SOD1 o a un peptido de control a las 6, 8, 12, 16 y 20 semanas.</span>TgCRND8 mice are immunized IP with KLH coupled to an epftope selectively presented or accessible in non-native forms of SOD1 or to a control peptide at 6, 8, 12, 16 and 20 weeks.</span>
  </p>
  <p id="p02965" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones se ensayan en una version de memoria de referencia del ensayo de laberinto de agua de Morris a las 11, 15, 19 y 23 semanas (vease, Janus C et al. (65); Janus C (66); Gass P et al. (67); y Wehner JM (6B)).</span>Mice are tested in a reference memory version of the Morris water maze test at 11, 15, 19 and 23 weeks (see, Janus C et al. (65); Janus C (66); Gass P et al. (67); and Wehner JM (6B)).</span>
  </p>
  <p id="p02966" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El retardo o la anulacion de la agregacion de SOD1 y la aparicion de la enfermedad sucede para el epftopo terapeuticamente activo, y se controlan las manifestaciones autoinmunitarias. Ademas de la agregacion de SOD1, se evalua la deposicion de Ap fibrilar cerebral (vease, Janus C et al. (65)).</span>The delay or cancellation of the aggregation of SOD1 and the occurrence of the disease occurs for the therapeutically active epitope, and autoimmune manifestations are controlled. In addition to the addition of SOD1, the deposition of cerebral fibrillary Ap is evaluated (see, Janus C et al. (65)).</span>
  </p>
  <p id="p02967" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 28</span>Example 28</span>
  </p>
  <p id="p02968" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Infusion de anticuerpos de ratones transgenicos TgCRND8</span>Infusion of antibodies from TgCRND8 transgenic mice</span>
  </p>
  <p id="p02969" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A ratones TgCRND8 se les infunden anticuerpos que se unen a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 o a anticuerpos de control de isotipo. Como se ha descrito anteriormente, los ratones se ensayan en una version de memoria de referencia del ensayo de laberinto de agua de Morris.</span>TgCRND8 mice are infused with antibodies that bind selectively or accessible epftopos presented in non-native forms of SOD1 or isotype control antibodies. As described above, mice are tested in a reference memory version of the Morris water maze test.</span>
  </p>
  <p id="p02970" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La ralentizacion o detencion de la agregacion de SOD1 y la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos, sin efecto de los anticuerpos de control de isotipo. Se controla la autoinmunidad.</span>The slowing or stopping of the aggregation of SOD1 and the progression of the disease occurs for therapeutically active antibodies, without the effect of isotype control antibodies. Autoimmunity is controlled.</span>
  </p>
  <p id="p02971" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ademas de la agregacion de SOD1, se evalua la deposicion de Ap fibrilar cerebral (vease, Janus C et al. (65)).</span>In addition to the addition of SOD1, the deposition of cerebral fibrillary Ap is evaluated (see, Janus C et al. (65)).</span>
  </p>
  <p id="p02972" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 29</span>Example 29</span>
  </p>
  <p id="p02973" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion de ratones transgenicos TgCRND8 con acido nucleico</span>Immunization of TgCRND8 transgenic mice with nucleic acid</span>
  </p>
  <p id="p02974" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El raton TgCRND8 es un modelo murino de enfermedad de Alzheimer. Estos ratones expresan un transgen pAPP695 humano mutante (K670N/M671L y V717F) bajo la regulacion del promotor del prion de hamster sirio en el fondo de la cepa C3H/B6. Estos ratones tienen defectos de aprendizaje espacial a los 3 meses de edad que estan acompanados por niveles crecientes de Ap soluble en SDS y tambien de cantidades crecientes de placas amiloides que contienen Ap en el cerebro. Vease Janus C et al. (65).</span>The TgCRND8 mouse is a murine model of Alzheimer's disease. These mice express a mutant human pAPP695 transgene (K670N / M671L and V717F) under the regulation of the Syrian hamster prion promoter at the bottom of strain C3H / B6. These mice have spatial learning defects at 3 months of age that are accompanied by increasing levels of soluble SDS Ap and also increasing amounts of amyloid plaques containing Ap in the brain. See Janus C et al. (65).</span>
  </p>
  <p id="p02975" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones TgCRND8 se inmunizan IP con KLH acoplada a un acido nucleico que codifica un epftopo presentado selectivamente o accesibles en formas no nativas de SOD1 o a un acido nucleico de control a las 6, 8, 12, 16 y 20 semanas.</span>TgCRND8 mice are immunized IP with KLH coupled to a nucleic acid encoding an epftope selectively presented or accessible in non-native forms of SOD1 or to a control nucleic acid at 6, 8, 12, 16 and 20 weeks.</span>
  </p>
  <p id="p02976" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p02977" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p02978" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p02979" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p02980" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p02981" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p02982" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p02983" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p02984" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p02985" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p02986" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p02987" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p02988" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p02989" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones se ensayan en una version de memoria de referenda del ensayo de laberinto de agua de Morris a las 11, 15, 19 y 23 semanas (vease, Janus C et al. (65); Janus C (66); Gass P et al. (67); y Wehner JM (6B)). Ademas de la agregacion de SOD1 se puede evaluar la deposicion de Ap fibrilar cerebral (vease, Janus C et al. (65)).</span>Mice are tested in a reference memory version of the Morris water maze test at 11, 15, 19 and 23 weeks (see, Janus C et al. (65); Janus C (66); Gass P et al. (67); and Wehner JM (6B)). In addition to the addition of SOD1, the deposition of cerebral fibrillary Ap (see, Janus C et al. (65)) can be evaluated.</span>
  </p>
  <p id="p02990" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La vacunacion con un acido nucleico que codifica un epftopo presentado selectivamente o accesibles en formas no nativas de SOD1 previene la enfermedad de Alzheimer. El retardo o anulacion de la agregacion de SOD y la aparicion de la enfermedad sucede para el acido nucleico terapeuticamente activo, y no para los controles.</span>Vaccination with a nucleic acid encoding an epftope presented selectively or accessible in non-native forms of SOD1 prevents Alzheimer's disease. The delay or cancellation of the aggregation of SOD and the occurrence of the disease occurs for therapeutically active nucleic acid, and not for the controls.</span>
  </p>
  <p id="p02991" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 30</span>Example 30</span>
  </p>
  <p id="p02992" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion de ratones Ha-Syn Tg</span>Immunization of Ha-Syn Tg mice</span>
  </p>
  <p id="p02993" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se usan ratones transgenicos heterocigoticos que expresan ha-syn bajo el control regulador del promotor del factor p de crecimiento derivado de plaquetas (Masliah E et al. (69)). Estos animales se usan porque son un modelo para la enfermedad de Parkinson y para la enfermedad con cuerpos de Lewy (Masliah E et al. 70)).</span>Heterozygous transgenic mice expressing ha-syn are used under the regulatory control of the platelet-derived growth factor p promoter (Masliah E et al. (69)). These animals are used because they are a model for Parkinson's disease and for Lewy body disease (Masliah E et al. 70)).</span>
  </p>
  <p id="p02994" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones transgenicos ha-syn tg se inmunizan IP con KLH acoplada a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 o a un peptido de control a las 2, 6, 8, 12, 16 y 20 semanas.</span>Ha-syn tg transgenic mice are immunized IP with KLH coupled to an epftope selectively presented or accessible in non-native forms of SOD1 or to a control peptide at 2, 6, 8, 12, 16 and 20 weeks.</span>
  </p>
  <p id="p02995" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El retardo o anulacion de la agregacion de SOD y la aparicion de la enfermedad sucede para el epftopo terapeuticamente activo, y se controlan las manifestaciones autoinmunitarias.</span>The delay or cancellation of the aggregation of SOD and the occurrence of the disease occurs for the therapeutically active epftope, and autoimmune manifestations are controlled.</span>
  </p>
  <p id="p02996" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La progresion de la enfermedad se evalua controlando la acumulacion de ha-syn en el cerebro de los ratones y las caracterfsticas clfnicas de implicacion neurologica (vease, Masliah E et al. (70)).</span>The progression of the disease is evaluated by controlling the accumulation of ha-syn in the brains of mice and the clinical characteristics of neurological involvement (see, Masliah E et al. (70)).</span>
  </p>
  <p id="p02997" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 31</span>Example 31</span>
  </p>
  <p id="p02998" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunizacion de ratones Ha-Syn Tg son acido nucleico</span>Immunization of Ha-Syn Tg mice are nucleic acid</span>
  </p>
  <p id="p02999" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se usan ratones transgenicos heterocigoticos que expresan ha-syn bajo el control regulador del promotor del factor p de crecimiento derivado de plaquetas (Masliah E et al. (69)). Estos animales se usan porque son un modelo para la enfermedad de Parkinson y para la enfermedad con cuerpos de Lewy (Masliah E et al. 70)).</span>Heterozygous transgenic mice expressing ha-syn are used under the regulatory control of the platelet-derived growth factor p promoter (Masliah E et al. (69)). These animals are used because they are a model for Parkinson's disease and for Lewy body disease (Masliah E et al. 70)).</span>
  </p>
  <p id="p03000" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones transgenicos ha-syn tg se inmunizan IP con un acido nucleico que codifica a un epftopo presentado selectivamente o accesible en formas no nativas de SOD1 o a un acido nucleico de control a las 2, 6, 8, 12, 16 y 20 semanas.</span>Ha-syn tg transgenic mice are immunized IP with a nucleic acid encoding an epftope selectively presented or accessible in non-native forms of SOD1 or a control nucleic acid at 2, 6, 8, 12, 16 and 20 weeks.</span>
  </p>
  <p id="p03001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La progresion de la enfermedad se evalua controlando la acumulacion de ha-syn en el cerebro de los ratones y las caracterfsticas clfnicas de implicacion neurologica (vease, Masliah E et al. (70)).</span>The progression of the disease is evaluated by controlling the accumulation of ha-syn in the brains of mice and the clinical characteristics of neurological involvement (see, Masliah E et al. (70)).</span>
  </p>
  <p id="p03002" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La vacunacion con un acido nucleico que codifica un epftopo presentado selectivamente o accesibles en formas no nativas de SOD1 previene la enfermedad de Parkinson. El retardo o anulacion de la agregacion de SOD y la aparicion de la enfermedad sucede para el acido nucleico terapeuticamente activo, y no para los controles.</span>Vaccination with a nucleic acid encoding an epftope presented selectively or accessible in non-native forms of SOD1 prevents Parkinson's disease. The delay or cancellation of the aggregation of SOD and the occurrence of the disease occurs for therapeutically active nucleic acid, and not for the controls.</span>
  </p>
  <p id="p03003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 32</span>Example 32</span>
  </p>
  <p id="p03004" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Infusion de anticuerpos de ratones Ha-Syn Tg</span>Infusion of antibodies from Ha-Syn Tg mice</span>
  </p>
  <p id="p03005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones ha-syn tg se infunden con anticuerpos que se unen a epftopos presentados selectivamente o accesibles en formas no nativas de SOD1 o a anticuerpos de control de isotipo.</span>Ha-syn tg mice are infused with antibodies that bind selectively presented or accessible epftopes in non-native forms of SOD1 or isotype control antibodies.</span>
  </p>
  <p id="p03006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La ralentizacion o detencion de la agregacion de SOD1 y la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos, sin efecto de los anticuerpos de control de isotipo. Se controla la autoinmunidad.</span>The slowing or stopping of the aggregation of SOD1 and the progression of the disease occurs for therapeutically active antibodies, without the effect of isotype control antibodies. Autoimmunity is controlled.</span>
  </p>
  <p id="p03007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La progresion de la enfermedad se evalua controlando la acumulacion de ha-syn en el cerebro de los ratones y las caracterfsticas clfnicas de implicacion neurologica (vease, Masliah E et al. (70)).</span>The progression of the disease is evaluated by controlling the accumulation of ha-syn in the brains of mice and the clinical characteristics of neurological involvement (see, Masliah E et al. (70)).</span>
  </p>
  <p id="p03008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 33</span>Example 33</span>
  </p>
  <p id="p03009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion de peptidos aislados a pacientes con ALS</span>Administration of isolated peptides to patients with ALS</span>
  </p>
  <p id="p03010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran las composiciones que comprenden epftopos especfficos de ALS tales como GGGRLAC*GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) y IKGLTEGLHGF (DSE5) a pacientes humanos con ALS. Las composiciones se administran a pacientes con aLs.</span>Compositions comprising specific episodes of ALS such as GGGRLAC * GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) and IKGLTEGLHGF (DSE5) are administered to human patients with ALS. The compositions are administered to patients with aLs.</span>
  </p>
  <p id="p03011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y progresion de</span>Patients are monitored for indications of slowing or stopping the aggregation of SOD and progression of</span>
  </p>
  <p id="p03012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03023" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">la enfermedad.</span>the illness.</span>
  </p>
  <p id="p03026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podrfan ser un resultado de las inmunizaciones. Se controlan las manifestaciones autoinmunitarias.</span>Subjects are monitored on a regular basis for adverse effects such as signs of pain and suffering that could be a result of immunizations. Autoimmune manifestations are controlled.</span>
  </p>
  <p id="p03027" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La administracion de los epftopos especfficos de ALS GGGRLAC*GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) y IKGLTEGLHGF (DSE5) ralentiza la progresion de ALS. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para epftopos terapeuticamente activos.</span>The administration of specific episodes of ALS GGGRLAC * GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) and IKGLTEGLHGF (DSE5) slows the progression of ALS. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active epftopos.</span>
  </p>
  <p id="p03028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 34</span>Example 34</span>
  </p>
  <p id="p03029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion a pacientes con ALS: anticuerpos</span>Administration to patients with ALS: antibodies</span>
  </p>
  <p id="p03030" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran anticuerpos dirigidos contra los epftopos especfficos de ALS que comprenden GGGRLAC*GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) y IKGLTEGLHGF (DSE5) a pacientes humanos con ALS. Los anticuerpos se administran a los sujetos a las 2, 6, 8, 12, 16 y 20 semanas.</span>Antibodies directed against the specific episodes of ALS comprising GGGRLAC * GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) and IKGLTEGLHGF (DSE5) are administered to human patients with ALS. Antibodies are administered to subjects at 2, 6, 8, 12, 16 and 20 weeks.</span>
  </p>
  <p id="p03031" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y progresion de la enfermedad. Tambien se controlas las manifestaciones autoinmunitarias.</span>Patients are monitored for indications of slowing or stopping the aggregation of SOD and disease progression. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03032" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podrfan ser un resultado de las inmunizaciones. Se controlan las manifestaciones autoinmunitarias.</span>Subjects are monitored on a regular basis for adverse effects such as signs of pain and suffering that could be a result of immunizations. Autoimmune manifestations are controlled.</span>
  </p>
  <p id="p03033" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La administracion de anticuerpos dirigidos contra los epftopos especfficos de ALS GGGRLAC*GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) y IKGLTEGLHGF (DSE5) ralentiza la progresion de ALS. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para epftopos terapeuticamente activos.</span>The administration of antibodies directed against the specific epftopos of ALS GGGRLAC * GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) and IKGLTEGLHGF (DSE5) slows the progression of ALS. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active epftopos.</span>
  </p>
  <p id="p03034" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 35</span>Example 35</span>
  </p>
  <p id="p03035" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion de anticuerpos humanizados a pacientes con ALS</span>Administration of humanized antibodies to patients with ALS</span>
  </p>
  <p id="p03036" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran directamente anticuerpos humanizados dirigidos contra epftopos especfficos de esclerosis lateral amiotrofica a pacientes humanos con ALS. Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. La administracion de un anticuerpo humanizado dirigido contra un epftopo especffico de la enfermedad ALS ralentiza la progresion de la enfermedad ALS en los pacientes. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Humanized antibodies directed against specific episodes of amyotrophic lateral sclerosis are directly administered to human patients with ALS. Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. The administration of a humanized antibody directed against a specific epitope of ALS disease slows the progression of ALS disease in patients. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03037" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran anticuerpos humanizados dirigidos contra los epftopos especfficos de ALS que comprenden los peptidos GGGRLAC*GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) y IKGLTEGLHGF (DSE5) a pacientes humanos con ALS. Se administra una composicion farmaceutica que comprende 1-140 gramos (hasta 2 gramos/kilogramo) de los anticuerpos humanizados por infusion intravenosa para producir una concentracion local que varfa de 1 a 10 microgramos por ml en el SNC. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de ALS. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de ALS. El regimen de dosificacion variara con el estado fisiologico de los pacientes y con la respuesta del paciente al tratamiento. En un regimen de dosificacion, la dosificacion es una vez cada 3 o 4 semanas. En otros regfmenes, la dosificacion es una vez por semana, dos veces por semana, tres veces por semana o una vez cada 2 semanas.</span>Humanized antibodies directed against the specific episodes of ALS comprising peptides GGGRLAC * GVIGIGSG (DSE1a), DLGKGGNEESTKTGNAGS (DSE2) and IKGLTEGLHGF (DSE5) are administered to human patients with ALS. A pharmaceutical composition comprising 1-140 grams (up to 2 grams / kilogram) of the humanized antibodies is administered by intravenous infusion to produce a local concentration ranging from 1 to 10 micrograms per ml in the CNS. In a regimen, the formulation comprises an antibody directed against a specific ALS epitope. In another regime, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of ALS. The dosage regimen will vary with the physiological state of the patients and with the patient's response to the treatment. In a dosage regimen, the dosage is once every 3 or 4 weeks. In other regimes, the dosage is once a week, twice a week, three times a week or once every 2 weeks.</span>
  </p>
  <p id="p03038" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 36</span>Example 36</span>
  </p>
  <p id="p03039" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion intraventricular o intratecal de anticuerpos humanizados a pacientes con ALS</span>Intraventricular or intrathecal administration of humanized antibodies to patients with ALS</span>
  </p>
  <p id="p03040" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran directamente anticuerpos humanizados contra epftopos especfficos de ALS al SNC de pacientes con ALS por infusion intraventricular o intratecal usando una bomba de infusion tal como las bombas de infusion producidas por MedTronics (Minneapolis, MN, EE. UU.). A los pacientes con ALS se les infunden de 0,5 a 5 mg por dfa de anticuerpo humanizado para obtener una concentracion final de 1 - 10 microgramos por ml en el SNC infundidos a una tasa maxima de 1 ml/h. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de ALS. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de ALS.</span>Humanized antibodies against specific episodes of ALS are directly administered to the CNS of patients with ALS by intraventricular or intrathecal infusion using an infusion pump such as the infusion pumps produced by MedTronics (Minneapolis, MN, USA). Patients with ALS are infused 0.5 to 5 mg per day of humanized antibody to obtain a final concentration of 1-10 micrograms per ml in the CNS infused at a maximum rate of 1 ml / h. In a regimen, the formulation comprises an antibody directed against a specific ALS epitope. In another regime, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of ALS.</span>
  </p>
  <p id="p03041" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando los anticuerpos humanizados se administran a pacientes con ALS por inyeccion intratecal, se extrae un volumen igual de fluido cefalorraqufdeo a traves de la misma aguja usada para la inyeccion para evitar un aumento en la presion debido al volumen de inyeccion. Se da a los sujetos una dosis que varfa del 1 % al 10 % de la dosis sistemica correspondiente. Los sujetos reciben una unica dosis de la formulacion de anticuerpo humanizado. Como</span>When humanized antibodies are administered to patients with ALS by intrathecal injection, an equal volume of cerebrospinal fluid is extracted through the same needle used for injection to avoid an increase in pressure due to the volume of injection. The subjects are given a dose that varies from 1% to 10% of the corresponding systematic dose. Subjects receive a single dose of the humanized antibody formulation. How</span>
  </p>
  <p id="p03042" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03043" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03044" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03045" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03046" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03047" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03048" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03049" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03050" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03051" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03052" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03053" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03054" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03055" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">alternativa, los sujetos reciben multiples dosis de la formulacion de anticuerpo humanizado. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo espedfico de ALS. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente espedfico de ALS. En regfmenes alternativos, la dosificacion es una vez por semana, dos veces por semana, tres veces por semana o una vez cada 2 semanas, una vez cada 3 semanas o una vez al mes. En otro regimen, la dosificacion vana dependiendo del estado fisiologico del sujeto y de la respuesta del sujeto al tratamiento.</span>Alternatively, subjects receive multiple doses of the humanized antibody formulation. In one regimen, the formulation comprises an antibody directed against a specific ALS epitope. In another regime, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of ALS. In alternative regimens, the dosage is once a week, twice a week, three times a week or once every 2 weeks, once every 3 weeks or once a month. In another regimen, the dosage varies depending on the physiological state of the subject and the response of the subject to the treatment.</span>
  </p>
  <p id="p03056" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y progresion de la enfermedad. La administracion del anticuerpo humanizado dirigido contra un epftopo espedfico de la enfermedad ALS ralentiza la progresion de la enfermedad ALS en los pacientes. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Patients are monitored for indications of slowing or stopping the aggregation of SOD and disease progression. Administration of the humanized antibody directed against a specific epitope of ALS disease slows the progression of ALS disease in patients. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03057" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 37</span>Example 37</span>
  </p>
  <p id="p03058" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion a pacientes con enfermedad de Alzheimer: epftopos</span>Administration to patients with Alzheimer's disease: epftopos</span>
  </p>
  <p id="p03059" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El epftopo espedfico de enfermedad de Alzheimer DLGKGGNEESTKTGNAGS (DSE2) se administra a seres humanos con enfermedad de Alzheimer. Los epftopos se administran.</span>The specific Alzheimer's disease epftopo DLGKGGNEESTKTGNAGS (DSE2) is administered to humans with Alzheimer's disease. The epftopos are administered.</span>
  </p>
  <p id="p03060" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. En particular, se ensaya la memoria de los sujetos y se controla su comportamiento. Tambien se controlan las manifestaciones autoinmunitarias.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. In particular, the subjects' memory is tested and their behavior is controlled. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03061" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podnan ser un resultado de las inmunizaciones. Tambien se controlan las manifestaciones autoinmunitarias.</span>Subjects are monitored regularly for adverse effects such as signs of pain and suffering that could be a result of immunizations. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03062" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La administracion del epftopo espedfico de enfermedad de Alzheimer DLGKGGNEESTKTGNAGS (DSE2) ralentiza la progresion de la enfermedad de Alzheimer. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para epftopos terapeuticamente activos.</span>The administration of the specific Alzheimer's disease epftope DLGKGGNEESTKTGNAGS (DSE2) slows the progression of Alzheimer's disease. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active epftopos.</span>
  </p>
  <p id="p03063" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 38</span>Example 38</span>
  </p>
  <p id="p03064" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion a pacientes con enfermedad de Alzheimer: anticuerpos</span>Administration to patients with Alzheimer's disease: antibodies</span>
  </p>
  <p id="p03065" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administra un anticuerpo dirigido contra el epftopo espedfico de enfermedad de Alzheimer DLGKGGNEESTKTGNAGS (DSE2) a pacientes humanos con enfermedad de Alzheimer.</span>An antibody directed against the specific DLFKGGNEESTKTGNAGS (DSE2) Alzheimer's disease epftope is administered to human patients with Alzheimer's disease.</span>
  </p>
  <p id="p03066" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. En particular, se ensaya la memoria de los sujetos y se controla su comportamiento. Tambien se controlan las manifestaciones autoinmunitarias.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. In particular, the subjects' memory is tested and their behavior is controlled. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03067" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podnan ser un resultado de las inmunizaciones. Tambien se controlan las manifestaciones autoinmunitarias.</span>Subjects are monitored regularly for adverse effects such as signs of pain and suffering that could be a result of immunizations. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03068" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La administracion de un anticuerpo dirigido contra el epftopo espedfico de enfermedad de Alzheimer DLGKGGNEESTKTGNAGS (DSE2) ralentiza la progresion de la enfermedad de Alzheimer. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Administration of an antibody directed against the specific epftopo of Alzheimer's disease DLGKGGNEESTKTGNAGS (DSE2) slows the progression of Alzheimer's disease. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03069" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 39</span>Example 39</span>
  </p>
  <p id="p03070" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion de anticuerpos humanizados a pacientes con enfermedad de Alzheimer</span>Administration of humanized antibodies to patients with Alzheimer's disease</span>
  </p>
  <p id="p03071" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran directamente anticuerpos humanizados dirigidos contra epftopos espedficos de enfermedad de Alzheimer a pacientes humanos con enfermedad de Alzheimer. Los anticuerpos humanizados se administran por infusion intravenosa a una concentracion que vana de 1 a 10 microgramos por ml de concentracion local en el sNc. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo espedfico de enfermedad de Alzheimer. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente espedfico de enfermedad de Alzheimer. En un regimen de dosificacion, la dosificacion es una vez cada 3 semanas. En otros regfmenes, la dosificacion es una vez por semana, dos veces por semana, tres veces a la semana o una vez cada 2 semanas. Como alternativa, la dosificacion vana dependiendo del estado fisiologico de los pacientes y de la respuesta del paciente al tratamiento.</span>Humanized antibodies directed against specific episodes of Alzheimer's disease are directly administered to human patients with Alzheimer's disease. Humanized antibodies are administered by intravenous infusion at a concentration ranging from 1 to 10 micrograms per ml of local concentration in the sNc. In a regimen, the formulation comprises an antibody directed against a specific epftope of Alzheimer's disease. In another regimen, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of Alzheimer's disease. In a dosage regimen, the dosage is once every 3 weeks. In other regimes, the dosage is once a week, twice a week, three times a week or once every 2 weeks. As an alternative, the dosage varies depending on the physiological state of the patients and the patient's response to the treatment.</span>
  </p>
  <p id="p03072" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como alternativa, se administran directamente anticuerpos humanizados contra el epftopo espedfico de enfermedad de Alzheimer en el SNC de pacientes con enfermedad de Alzheimer por infusion intraventricular o intratecal. MedTronics (Minneapolis, MN, EE. UU.) proporciona dispositivos medicos para su uso en este ejemplo. La</span>Alternatively, humanized antibodies are directly administered against the specific epftopo of Alzheimer's disease in the CNS of patients with Alzheimer's disease due to intraventricular or intrathecal infusion. MedTronics (Minneapolis, MN, USA) provides medical devices for use in this example. The</span>
  </p>
  <p id="p03073" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03074" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03075" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03076" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03077" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03078" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03079" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03080" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03081" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03082" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03083" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03084" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03085" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03086" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">concentracion final de 1-10 microgramos por ml se consigue por infusion de como mucho 5 mg del anticuerpo humanizado por dfa a una tasa maxima de 1 ml/h. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de enfermedad de Alzheimer. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de enfermedad de Alzheimer. Los anticuerpos humanizados se administran a pacientes con enfermedad de Alzheimer por inyeccion intratecal. Para evitar un aumento en la presion debido al volumen de inyeccion, se extrae un volumen igual de fluido cefalorraqufdeo a traves de la misma aguja usada para la inyeccion. Se da a los sujetos una dosis que varfa del 1 % al 10 % de la dosis sistemica correspondiente. Los sujetos reciben una unica dosis de la formulacion de anticuerpo humanizado. Como alternativa, los sujetos reciben multiples dosis de la formulacion de anticuerpo humanizado. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de enfermedad de Alzheimer. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de enfermedad de Alzheimer. En regfmenes alternativos, la dosificacion es una vez por semana, dos veces por semana, tres veces a la semana, una vez cada dos semanas, una vez cada tres semanas o una vez al mes. En otro regimen, la dosificacion varfa dependiendo del estado fisiologico del sujeto y de la respuesta del sujeto al tratamiento.</span>Final concentration of 1-10 micrograms per ml is achieved by infusion of at most 5 mg of the humanized antibody per day at a maximum rate of 1 ml / h. In a regimen, the formulation comprises an antibody directed against an Alzheimer's disease specific epitope. In another regimen, the formulation comprises two or more humanized antibodies, each directed against a different epftopo specific to Alzheimer's disease. Humanized antibodies are administered to patients with Alzheimer's disease by intrathecal injection. To avoid an increase in pressure due to the volume of injection, an equal volume of cerebrospinal fluid is drawn through the same needle used for injection. The subjects are given a dose that varies from 1% to 10% of the corresponding systematic dose. Subjects receive a single dose of the humanized antibody formulation. Alternatively, subjects receive multiple doses of the humanized antibody formulation. In a regimen, the formulation comprises an antibody directed against an Alzheimer's disease specific epitope. In another regimen, the formulation comprises two or more humanized antibodies, each directed against a different epftopo specific to Alzheimer's disease. In alternative regimens, the dosage is once a week, twice a week, three times a week, once every two weeks, once every three weeks or once a month. In another regimen, the dosage varies depending on the physiological state of the subject and the response of the subject to the treatment.</span>
  </p>
  <p id="p03087" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. La administracion de un anticuerpo humanizado dirigido contra un epftopo especffico de enfermedad de Alzheimer ralentiza la progresion de la enfermedad de Alzheimer en los pacientes. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. The administration of a humanized antibody directed against a specific Alzheimer's disease epftope slows the progression of Alzheimer's disease in patients. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03088" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 40</span>Example 40</span>
  </p>
  <p id="p03089" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion a pacientes con enfermedad de Parkinson: epftopos</span>Administration to patients with Parkinson's disease: epftopos</span>
  </p>
  <p id="p03090" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administra un epftopo especffico de enfermedad de Parkinson a pacientes humanos con enfermedad de Parkinson.</span>A specific epitope of Parkinson's disease is administered to human patients with Parkinson's disease.</span>
  </p>
  <p id="p03091" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. En particular, se controla la forma de caminar, reflejo y comportamiento de los sujetos. Tambien se controlan las manifestaciones autoinmunitarias.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. In particular, the way of walking, reflex and behavior of the subjects is controlled. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03092" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podrfan ser un resultado de las inmunizaciones.</span>Subjects are monitored on a regular basis for adverse effects such as signs of pain and suffering that could be a result of immunizations.</span>
  </p>
  <p id="p03093" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La administracion de un epftopo especffico de enfermedad de Parkinson ralentiza la progresion de la enfermedad de Parkinson. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para epftopos terapeuticamente activos.</span>The administration of a specific epitope of Parkinson's disease slows the progression of Parkinson's disease. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active epftopos.</span>
  </p>
  <p id="p03094" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 41</span>Example 41</span>
  </p>
  <p id="p03095" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion a pacientes con enfermedad de Parkinson: anticuerpos</span>Administration to patients with Parkinson's disease: antibodies</span>
  </p>
  <p id="p03096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administra un anticuerpo dirigido contra el epftopo especffico de enfermedad de Parkinson a pacientes humanos con enfermedad de Parkinson.</span>An antibody directed against the specific epitope of Parkinson's disease is administered to human patients with Parkinson's disease.</span>
  </p>
  <p id="p03097" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. En particular, se controla la forma de caminar, reflejo y comportamiento de los sujetos. Tambien se controlan las manifestaciones autoinmunitarias.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. In particular, the way of walking, reflex and behavior of the subjects is controlled. Autoimmune manifestations are also controlled.</span>
  </p>
  <p id="p03098" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sujetos se controlan de forma regular para los efectos adversos tales como signos de dolor y sufrimiento que podrfan ser un resultado de las inmunizaciones. La administracion de un compuesto dirigido contra un epftopo especffico de enfermedad de Parkinson ralentiza la progresion de la enfermedad de Parkinson en los pacientes. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Subjects are monitored on a regular basis for adverse effects such as signs of pain and suffering that could be a result of immunizations. The administration of a compound directed against a specific epitope of Parkinson's disease slows the progression of Parkinson's disease in patients. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03099" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 42</span>Example 42</span>
  </p>
  <p id="p03100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Administracion de anticuerpos humanizados a pacientes con enfermedad de Parkinson.</span>Administration of humanized antibodies to patients with Parkinson's disease.</span>
  </p>
  <p id="p03101" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se administran directamente anticuerpos humanizados dirigidos contra epftopos especfficos de enfermedad de Parkinson a pacientes humanos con enfermedad de Parkinson. Los anticuerpos humanizados se administran por infusion intravenosa a una concentracion que varfa de 1 a 10 microgramos por ml de concentracion local en el SNC. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de enfermedad de Parkinson. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido</span>Humanized antibodies directed against specific episodes of Parkinson's disease are directly administered to human patients with Parkinson's disease. Humanized antibodies are administered by intravenous infusion at a concentration ranging from 1 to 10 micrograms per ml of local concentration in the CNS. In a regimen, the formulation comprises an antibody directed against a specific epitope of Parkinson's disease. In another regime, the formulation comprises two or more humanized antibodies, each directed</span>
  </p>
  <p id="p03102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03103" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03105" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03107" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03110" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">contra un epftopo diferente especffico de enfermedad de Parkinson. En un regimen de dosificacion, la dosificacion es una vez cada 3 semanas. En otros regfmenes, la dosificacion es una vez por semana, dos veces por semana, tres veces a la semana o una vez cada 2 semanas. Como alternativa, la dosificacion varfa dependiendo del estado fisiologico de los pacientes y de la respuesta del paciente al tratamiento.</span>against a different specific epitope of Parkinson's disease. In a dosage regimen, the dosage is once every 3 weeks. In other regimes, the dosage is once a week, twice a week, three times a week or once every 2 weeks. Alternatively, the dosage varies depending on the physiological state of the patients and the patient's response to the treatment.</span>
  </p>
  <p id="p03116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como alternativa, se administran directamente anticuerpos humanizados contra epftopos especfficos de enfermedad de Parkinson al SNC de pacientes con enfermedad de Parkinson por infusion intraventricular o intratecal. MedTronics (Minneapolis, MN, EE. UU.) proporciona dispositivos medicos para su uso en este ejemplo. La concentracion final de 1-10 microgramos por ml se consigue por infusion de como mucho 5 mg del anticuerpo humanizado por dfa a una tasa maxima de 1 ml/h. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de enfermedad de Parkinson. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de enfermedad de Parkinson.</span>Alternatively, humanized antibodies against specific epitopes of Parkinson's disease are directly administered to the CNS of patients with Parkinson's disease by intraventricular or intrathecal infusion. MedTronics (Minneapolis, MN, USA) provides medical devices for use in this example. The final concentration of 1-10 micrograms per ml is achieved by infusion of at most 5 mg of the humanized antibody per day at a maximum rate of 1 ml / h. In a regimen, the formulation comprises an antibody directed against a specific epitope of Parkinson's disease. In another regimen, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of Parkinson's disease.</span>
  </p>
  <p id="p03117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los anticuerpos humanizados contra epftopos especfficos de enfermedad de Parkinson se administran a pacientes con enfermedad de Parkinson por inyeccion intratecal. Para evitar un aumento en la presion debido al volumen de inyeccion, se extrae un volumen igual de fluido cefalorraqufdeo a traves de la misma aguja usada para la inyeccion. Se da a los sujetos una dosis que varfa del 1 % al 10 % de la dosis sistemica correspondiente. Los sujetos reciben una unica dosis de la formulacion de anticuerpo humanizado. Como alternativa, los sujetos reciben multiples dosis de la formulacion de anticuerpo humanizado. En un regimen, la formulacion comprende un anticuerpo dirigido contra un epftopo especffico de enfermedad de Parkinson. En otro regimen, la formulacion comprende dos o mas anticuerpos humanizados, cada uno dirigido contra un epftopo diferente especffico de enfermedad de Parkinson. En regfmenes alternativos, la dosificacion es una vez por semana, dos veces por semana, tres veces a la semana, una vez cada dos semanas, una vez cada tres semanas o una vez al mes. En otro regimen, la dosificacion varfa dependiendo del estado fisiologico del sujeto y de la respuesta del sujeto al tratamiento.</span>Humanized antibodies against specific episodes of Parkinson's disease are administered to patients with Parkinson's disease by intrathecal injection. To avoid an increase in pressure due to the volume of injection, an equal volume of cerebrospinal fluid is drawn through the same needle used for injection. The subjects are given a dose that varies from 1% to 10% of the corresponding systematic dose. Subjects receive a single dose of the humanized antibody formulation. Alternatively, subjects receive multiple doses of the humanized antibody formulation. In a regimen, the formulation comprises an antibody directed against a specific epitope of Parkinson's disease. In another regimen, the formulation comprises two or more humanized antibodies, each directed against a different specific epitope of Parkinson's disease. In alternative regimens, the dosage is once a week, twice a week, three times a week, once every two weeks, once every three weeks or once a month. In another regimen, the dosage varies depending on the physiological state of the subject and the response of the subject to the treatment.</span>
  </p>
  <p id="p03118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los pacientes se controlan para indicaciones de ralentizacion o detencion de la agregacion de SOD y la progresion de la enfermedad. La administracion de un anticuerpo humanizado dirigido contra un epftopo especffico de enfermedad de Parkinson ralentiza la progresion de la enfermedad de Parkinson en los pacientes. La ralentizacion o detencion de la agregacion de SOD1 o la anulacion de la progresion de la enfermedad sucede para anticuerpos terapeuticamente activos.</span>Patients are monitored for indications of slowing down or stopping the aggregation of SOD and disease progression. The administration of a humanized antibody directed against a specific epitope of Parkinson's disease slows the progression of Parkinson's disease in patients. The slowing or stopping of the aggregation of SOD1 or the cancellation of disease progression occurs for therapeutically active antibodies.</span>
  </p>
  <p id="p03119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 43</span>Example 43</span>
  </p>
  <p id="p03120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reproduccion de los modelos de raton de ALS G93A y G37R</span>Reproduction of the mouse models of ALS G93A and G37R</span>
  </p>
  <p id="p03121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cruzaron animales G93A y G37R macho hemicigoticos fundadores con ratones hembra de tipo silvestre de la misma cepa de fondo (C57BL/6). Las hembras no se cruzaron mas de 6 veces. Los machos G93A heterocigoticos se retiraron como reproductores a los 3 meses de edad, los ratones G37R heterocigoticos se retiraron como reproductores a los 6 meses de edad.</span>Founding animals G93A and G37R male hemicigotic founders with wild-type female mice of the same background strain (C57BL / 6). The females did not cross more than 6 times. Heterozygous G93A males were removed as breeders at 3 months of age, heterozygous G37R mice were removed as breeders at 6 months of age.</span>
  </p>
  <p id="p03122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Quince ratones macho G93A (o G37R) hemicigoticos y 30 ratones hembra C57BL/6 formaron 15 trios de reproduccion. Dos ratones hembra se alojaron inicialmente juntas, y se les indujo el celo exponiendo las hembras al lecho sucio de su companero (efecto Whitten). Al siguiente dfa, las hembras se introdujeron en las jaulas de los machos (2 hembras por macho). Las hembras se comprobaron cada manana para los tapones.</span>Fifteen hemicigotic G93A (or G37R) male mice and 30 C57BL / 6 female mice formed 15 trios of reproduction. Two female mice were initially housed together, and the heat was induced by exposing the females to the dirty bed of their partner (Whitten effect). The next day, females were introduced into male cages (2 females per male). The females were checked every morning for the plugs.</span>
  </p>
  <p id="p03123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La descendencia se identifico con perforacion en la oreja a las 3 semanas de edad, y el tejido perforado se uso para genotipado y para determinar el numero de copias del transgen. Si las perforaciones en la oreja no proporcionaban suficiente material para el genotipado y ensayo para el numero de copias del transgen, se realizaba entonces un recorte de la cola.</span>The offspring were identified with perforation in the ear at 3 weeks of age, and the perforated tissue was used for genotyping and to determine the number of copies of the transgene. If the perforations in the ear did not provide enough material for genotyping and testing for the number of copies of the transgene, then a tail trimming was performed.</span>
  </p>
  <p id="p03124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El destete tuvo lugar cuando la descendencia era de 3 semanas de edad, y los ratones hemicigoticos se asignaron aleatoriamente a grupos de tratamiento experimentales.</span>Weaning took place when the offspring were 3 weeks old, and hemicigotic mice were randomly assigned to experimental treatment groups.</span>
  </p>
  <p id="p03125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Despues del destete, los animales se mantuvieron 4 por jaula.</span>After weaning, the animals were kept 4 per cage.</span>
  </p>
  <p id="p03126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se uso un programa de reproduccion similar para ambas cepas, con ajustes apropiados para la supervivencia de los animales hemicigoticos que desarrollaban fenotipos de enfermedad (supervivencia de g93A - 145 dfas, supervivencia de G37R - 335 dfas).</span>A similar breeding program was used for both strains, with appropriate adjustments for the survival of hemicigotic animals that developed disease phenotypes (survival of g93A - 145 days, survival of G37R - 335 days).</span>
  </p>
  <p id="p03127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones heterocigoticos G93A desarrollaban debilidad predominantes en las extremidades posteriores en aproximadamente 100 dfas de edad. La debilidad progresaba hasta un punto de paralisis de las extremidades posteriores, y los animales no eran capaces de alimentarse o de beber (es decir, incapaces de alcanzar su alimento y el agua). Este punto se observo en aproximadamente 145 dfas. En este punto, los animales se sacrificaron por eutanasia. Los animales se sacrificaron por eutanasia de forma prematura si el peso corporal disminufa en un 20 % o si presentaban otros signos de morbilidad grave.</span>Heterozygous G93A mice developed predominant weakness in the hind limbs at approximately 100 days of age. The weakness progressed to a point of paralysis of the hind limbs, and the animals were not able to feed or drink (that is, unable to reach their food and water). This point was observed in approximately 145 days. At this point, the animals were sacrificed for euthanasia. The animals were euthanized early if the body weight decreased by 20% or if they had other signs of severe morbidity.</span>
  </p>
  <p id="p03128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03135" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03137" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03139" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03141" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El transgen G37R causaba signos clfnicos similares que al transgen G93A, sin embargo, la edad de aparicion de la debilidad en los heterocigotos era de aproximadamente 300 dfas, punto desde el cual la debilidad progresaba hasta paralisis de las extremidades posteriores. Los puntos finales fueron los mismos que para los ratones G93A, sin embargo, los puntos finales habitualmente se cumplieron en aproximadamente 335 dfas en el transgenico G37R (lfnea 29).</span>The G37R transgene caused similar clinical signs that the G93A transgene, however, the age of occurrence of the weakness in the heterozygotes was approximately 300 days, from which the weakness progressed to paralysis of the hind limbs. The endpoints were the same as for G93A mice, however, the endpoints were usually met in approximately 335 days in the G37R transgene (line 29).</span>
  </p>
  <p id="p03142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones reproductores se pesaron semanalmente y se sacrificaron por eutanasia si perdfan el 15 % o mas de su peso corporal. Sin embargo, una perdida de peso menor del 15 % combinada con otros signos de morbilidad grave, es decir, arrugamiento de la piel, aspecto encorvado, deshidratacion obvia, etc., se consideraron un punto final humanitario para estos animales.</span>Reproductive mice were weighed weekly and euthanized if they lost 15% or more of their body weight. However, a weight loss of less than 15% combined with other signs of severe morbidity, that is, wrinkling of the skin, hunched appearance, obvious dehydration, etc., were considered a humanitarian endpoint for these animals.</span>
  </p>
  <p id="p03143" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 44</span>Example 44</span>
  </p>
  <p id="p03144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Desarrollo de modelos de propagacion de ALS</span>Development of ALS propagation models</span>
  </p>
  <p id="p03145" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ALS, como en enfermedad por priones, la muerte neuronal se "propaga" por todo el neuroeje, implicando un mecanismo patologico para la propagacion del proceso patologico de una celula a otra. Se desarrolla un modelo de propagacion del mal plegamiento de SOD1 en sistemas sin celulas, en ensayos celulares in vitro y en animales basados en sistemas modelo similares en enfermedad de priones. Estos modelos proporcionan sistemas mas "relevantes para la enfermedad" para ensayar inmunoterapias, y evitaran los potenciales resultados falsos negativos y falsos positivos de los modelos actuales.</span>In ALS, as in prion disease, neuronal death "spreads" throughout the neuroaxis, involving a pathological mechanism for the propagation of the pathological process from one cell to another. A propagation model of the bad folding of SOD1 is developed in systems without cells, in in vitro cell tests and in animals based on similar model systems in prion disease. These models provide more "disease-relevant" systems for testing immunotherapies, and will avoid the potential false negative and false positive results of the current models.</span>
  </p>
  <p id="p03146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los depositos biologicos de las lfneas celulares de hibridomas se hicieron de acuerdo con el Tratado de Budapest y estan disponibles en la International Depository Authority of Canada 1015 Arlington Street, Winnipeg, Canada R3E 3R2.</span>Biological deposits of hybridoma cell lines were made in accordance with the Budapest Treaty and are available from the International Depository Authority of Canada 1015 Arlington Street, Winnipeg, Canada R3E 3R2.</span>
  </p>
  <p id="p03147" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Citas completas para referencias mencionadas en la memoria descriptiva</span>Full citations for references mentioned in the specification</span>
  </p>
  <p id="p03148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. Enero de 2006;9(1):108-18.</span>1. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci January 2006; 9 (1): 108-18.</span>
  </p>
  <p id="p03149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Turner BJ, Atkin JD, Farg MA, Zang da W, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis J Neurosci. 5 de enero de 2005;25(1):108-17).</span>2. Turner BJ, Atkin JD, Farg MA, Zang da W, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis J Neurosci. January 5, 2005; 25 (1): 108-17).</span>
  </p>
  <p id="p03150" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Cashman NR, Griffin JK, Zou W-Q, Allele-selective recruitment and disease progression in familial amyotrophic lateral sclerosis. Neurology, 2002.</span>3. Cashman NR, Griffin JK, Zou W-Q, Allele-selective recruitment and disease progression in familial amyotrophic lateral sclerosis. Neurology, 2002.</span>
  </p>
  <p id="p03151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Cashman NR y Caughey B. Prion diseases--close to effective therapy? Nature Reviews in Drug Discovery. Octubre de 2004;3(10):874-84.</span>4. Cashman NR and Caughey B. Prion diseases - close to effective therapy? Nature Reviews in Drug Discovery. October 2004; 3 (10): 874-84.</span>
  </p>
  <p id="p03152" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, Griffin J, Cleveland DW, Cashman NR, Chakrabartty A. An immunological epitopeselective for pathological monomer/misfolded SOD1 in ALS. Nature Medicine, 2007 (en impresion)</span>5. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, Griffin J, Cleveland DW, Cashman NR, Chakrabartty A. An immunological epitopeselective for pathological monomer / misfolded SOD1 in ALS. Nature Medicine, 2007 (in print)</span>
  </p>
  <p id="p03153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou W-Q, Estey LA., Kondejewski LH, Francoeur GP, Papadopoulos M, Haghighat A, Spatz SJ, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR. A prion protein epitope selective for the pathologically misfolded conformation. Nature Medicine 9:893-9, 2003.</span>6. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou WQ, Estey LA., Kondejewski LH, Francoeur GP, Papadopoulos M, Haghighat A, Spatz SJ, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR . A prion protein epitope selective for the pathologically misfolded conformation. Nature Medicine 9: 893-9, 2003.</span>
  </p>
  <p id="p03154" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. Lehto, M. T., Ashman, D. A. y Cashman, N. R. Treatment of ScN2a cells with prion-specific YYR antibodies. Proc. First Intl Conf. Network Excellence: Neuroprion (Paris, 2004).</span>7. Lehto, M. T., Ashman, D. A. and Cashman, N. R. Treatment of ScN2a cells with prion-specific YYR antibodies. Proc. First Intl Conf. Network Excellence: Neuroprion (Paris, 2004).</span>
  </p>
  <p id="p03155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Khare et al., PROTEINS: Structure, Function and Bioinformatics, 61:617-632 (2005).</span>8. Khare et al., PROTEINS: Structure, Function and Bioinformatics, 61: 617-632 (2005).</span>
  </p>
  <p id="p03156" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Thompson, JD, Higgins DG, Gibson TJ, 1994, Nucleic Acids Res. 22(22): 4673-4680.</span>9. Thompson, JD, Higgins DG, Gibson TJ, 1994, Nucleic Acids Res. 22 (22): 4673-4680.</span>
  </p>
  <p id="p03157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. Henikoff S. y Henikoff J.G., 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919.</span>10. Henikoff S. and Henikoff J.G., 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919.</span>
  </p>
  <p id="p03158" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. Needleman y Wunsch. J. Mol. Biol., 1970, 48:443.</span>11. Needleman and Wunsch. J. Mol. Biol., 1970, 48: 443.</span>
  </p>
  <p id="p03159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Smith y Waterman. Adv. Appl. Math. 1981,2:482.</span>12. Smith and Waterman. Adv. Appl. Math 1981.2: 482.</span>
  </p>
  <p id="p03160" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Carillo y Lipton SIAM J. Applied Math. 1988, 48:1073.</span>13. Carillo and Lipton SIAM J. Applied Math. 1988, 48: 1073.</span>
  </p>
  <p id="p03161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Computational Molecular Biology, Lesk, e.d. Oxford University Press, Nueva York, 1988, Biocomputing: Informatics and Genomics Projects.</span>14. Computational Molecular Biology, Lesk, e.d. Oxford University Press, New York, 1988, Biocomputing: Informatics and Genomics Projects.</span>
  </p>
  <p id="p03162" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03164" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03166" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03167" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03168" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03169" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03170" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03171" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03172" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03173" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03174" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03175" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Devereux et al., Nucleic Acids Res., 1984, 12:387.</span>15. Devereux et al., Nucleic Acids Res., 1984, 12: 387.</span>
  </p>
  <p id="p03176" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. Altschul et al., J. Molec. Biol., 1990: 215:403.</span>16. Altschul et al., J. Molec. Biol., 1990: 215: 403.</span>
  </p>
  <p id="p03177" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. Remington's Pharmaceutical Sciences, 20a ed., Mack Publishing Company, Easton, Pa., EE. UU., 2000.</span>17. Remington's Pharmaceutical Sciences, 20th ed., Mack Publishing Company, Easton, Pa., USA. UU., 2000.</span>
  </p>
  <p id="p03178" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. Merrifield, J. Am. Chem. Assoc. 85:2149-2154 (1964).</span>18. Merrifield, J. Am. Chem. Assoc. 85: 2149-2154 (1964).</span>
  </p>
  <p id="p03179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15, pts. I y II, Thieme, Stuttgart (1987).</span>19. Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15, pts. I and II, Thieme, Stuttgart (1987).</span>
  </p>
  <p id="p03180" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA 1990.</span>20. Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA 1990.</span>
  </p>
  <p id="p03181" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. Sambrook et al. Molecular Cloning: A Laboratory Manual, 2a Edicion, Cold Spring Harbor Laboratory press (1989).</span>21. Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989).</span>
  </p>
  <p id="p03182" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">22. Chang et al., Nature 275:615 (1978).</span>22. Chang et al., Nature 275: 615 (1978).</span>
  </p>
  <p id="p03183" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">23. Nichols y Yanofsky, Meth. in Enzymology 101:155, 1983.</span>23. Nichols and Yanofsky, Meth. in Enzymology 101: 155, 1983.</span>
  </p>
  <p id="p03184" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">24. Russell et al., Gene 20: 231, 1982.</span>24. Russell et al., Gene 20: 231, 1982.</span>
  </p>
  <p id="p03185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25. Bolivar et al., Gene 2:9S, 1977.</span>25. Bolivar et al., Gene 2: 9S, 1977.</span>
  </p>
  <p id="p03186" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">26. Messing, Meth in Enzymology 101:20-77, 1983.</span>26. Messing, Meth in Enzymology 101: 20-77, 1983.</span>
  </p>
  <p id="p03187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27. Vieira y Messing, Gene 19:259-268 (1982).</span>27. Vieira and Messing, Gene 19: 259-268 (1982).</span>
  </p>
  <p id="p03188" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">28. Amann et al., Gene 69:301-315 (1988).</span>28. Amann et al., Gene 69: 301-315 (1988).</span>
  </p>
  <p id="p03189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">29. Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California, 60-89 (1990).</span>29. Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California, 60-89 (1990).</span>
  </p>
  <p id="p03190" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30. Baldari et al., Embo J. 6:229-234 (1987).</span>30. Baldari et al., Embo J. 6: 229-234 (1987).</span>
  </p>
  <p id="p03191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">31. Kurjan y Herskowitz, Cell 30:933-943 (1982).</span>31. Kurjan and Herskowitz, Cell 30: 933-943 (1982).</span>
  </p>
  <p id="p03192" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">32. Schultz et al., Gene 54:113-123 (1987).</span>32. Schultz et al., Gene 54: 113-123 (1987).</span>
  </p>
  <p id="p03193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">33. Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929 (1978).</span>33. Hinnen et al., Proc. Natl. Acad. Sci. USA 75: 1929 (1978).</span>
  </p>
  <p id="p03194" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">34. Itoh et al., J. Bacteriology 153:163 (1983).</span>34. Itoh et al., J. Bacteriology 153: 163 (1983).</span>
  </p>
  <p id="p03195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35. Cullen et al. Bio/Technology 5:369 (1987).</span>35. Cullen et al. Bio / Technology 5: 369 (1987).</span>
  </p>
  <p id="p03196" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">36. Seed, B., Nature 329:840 (1987).</span>36. Seed, B., Nature 329: 840 (1987).</span>
  </p>
  <p id="p03197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">37. Kaufman et al., EMBO J. 6:187-195 (1987).</span>37. Kaufman et al., EMBO J. 6: 187-195 (1987).</span>
  </p>
  <p id="p03198" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">38. Sinkar et al., J. Biosci (Bangalore) 11:47-58 (1987).</span>38. Sinkar et al., J. Biosci (Bangalore) 11: 47-58 (1987).</span>
  </p>
  <p id="p03199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">39. Zambryski et al., Genetic Engineering, Principles and Methods, Hollaender and Setlow (eds.), Vol. VI, pag. 253-278, Plenum Press, Nueva York (1984).</span>39. Zambryski et al., Genetic Engineering, Principles and Methods, Hollaender and Setlow (eds.), Vol. VI, p. 253-278, Plenum Press, New York (1984).</span>
  </p>
  <p id="p03200" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40. Smith et al., Mol. Cell Biol. 3:2156-2165 (1983).</span>40. Smith et al., Mol. Cell Biol. 3: 2156-2165 (1983).</span>
  </p>
  <p id="p03201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">41. Lucklow, V.A., y Summers, M.D., Virology 170:31-39 (1989).</span>41. Lucklow, V.A., and Summers, M.D., Virology 170: 31-39 (1989).</span>
  </p>
  <p id="p03202" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">42. Kohler y Milstein Nature 256:495-497 (1975).</span>42. Kohler and Milstein Nature 256: 495-497 (1975).</span>
  </p>
  <p id="p03203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">43. Kozbor et al., Immunol. Today 4:72 (1983).</span>43. Kozbor et al., Immunol. Today 4:72 (1983).</span>
  </p>
  <p id="p03204" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">44. Cole et al., Methods Enzymol, 121:140-67 (1986).</span>44. Cole et al., Methods Enzymol, 121: 140-67 (1986).</span>
  </p>
  <p id="p03205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45. Huse et al., Science 246:1275 (1989).</span>45. Huse et al., Science 246: 1275 (1989).</span>
  </p>
  <p id="p03206" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">46. Ward et al., Nature 341:544-546 (1989).</span>46. Ward et al., Nature 341: 544-546 (1989).</span>
  </p>
  <p id="p03207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03208" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03210" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03212" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03214" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03215" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03216" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03218" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03220" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">47. McCafferty et al., Nature 348:552-554 (1990).</span>47. McCafferty et al., Nature 348: 552-554 (1990).</span>
  </p>
  <p id="p03221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">48. Dobson CM. (2004) Experimental investigation of protein folding and misfolding. Methods. 34(1):4-14. Revision.</span>48. Dobson CM. (2004) Experimental investigation of protein folding and misfolding. Methods 34 (1): 4-14. Revision.</span>
  </p>
  <p id="p03222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">49. Prusiner SB. (2001) Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med. 344:1516-26.</span>49. Prusiner SB. (2001) Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med. 344: 1516-26.</span>
  </p>
  <p id="p03223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50. Selkoe DJ, Schenk D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 43:545-84.</span>50. Selkoe DJ, Schenk D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 43: 545-84.</span>
  </p>
  <p id="p03224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">51. St George-Hyslop PH, Petit A. (2005) Molecular biology and genetics of Alzheimer's disease. C R Biol. 328(2):119-30.</span>51. St George-Hyslop PH, Petit A. (2005) Molecular biology and genetics of Alzheimer's disease. C R Biol. 328 (2): 119-30.</span>
  </p>
  <p id="p03225" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">52. Puglielli L, Tanzi RE, Kovacs DM. (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci. 6:345-51.</span>52. Puglielli L, Tanzi RE, Kovacs DM. (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6: 345-51.</span>
  </p>
  <p id="p03226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">53. Mehta PD, Pirttila T, Mehta SP. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57:100-5.</span>53. Mehta PD, Pirttila T, Mehta SP. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100-5.</span>
  </p>
  <p id="p03227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">54. Clark CM, Xie S, Chittams J et al. (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 60:1696-702.</span>54. Clark CM, Xie S, Chittams J et al. (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60: 1696-702.</span>
  </p>
  <p id="p03228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55. Green AJ. (2002) Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol. 28:427-40.</span>55. Green AJ. (2002) Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol. 28: 427-40.</span>
  </p>
  <p id="p03229" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">56. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. (1999) Immunization with amyloid-beta attenuates Alzheimer- disease-like pathology in the PDAPP mouse. Nature. 400(6740): 173-7.</span>56. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (6740): 173-7.</span>
  </p>
  <p id="p03230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">57. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. (2005) Clinical effects of Abeta immunization (AN 1792) in patients with AD in an interrupted trial. Neurology. 64(9):1553-62.</span>57. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792 (QS-21) -201 Study Team. (2005) Clinical effects of Abeta immunization (AN 1792) in patients with AD in an interrupted trial. Neurology 64 (9): 1553-62.</span>
  </p>
  <p id="p03231" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">58. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study Team. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 64(9):1563-72.</span>58. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792 (QS-21) -201 Study Team. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (9): 1563-72.</span>
  </p>
  <p id="p03232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">59. Olanow CW. (2004) The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 55:41-60.</span>59. Olanow CW. (2004) The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 55: 41-60.</span>
  </p>
  <p id="p03233" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60. Iwatsubo T. (2003) Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol 250 Supl 3:11111-4.</span>60. Iwatsubo T. (2003) Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol 250 Suppl 3: 11111-4.</span>
  </p>
  <p id="p03234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">61. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. (2003) Caught in the ac: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40:453-6.</span>61. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. (2003) Caught in the ac: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40: 453-6.</span>
  </p>
  <p id="p03235" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">62. McKeith I, Mintzer J, Aarsland D et al. (2004) Dementia with Lewy bodies. Lancet Neurol 3:19-28.</span>62. McKeith I, Mintzer J, Aarsland D et al. (2004) Dementia with Lewy bodies. Lancet Neurol 3: 19-28.</span>
  </p>
  <p id="p03236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">63. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 46(6):857-68.</span>63. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46 (6): 857-68.</span>
  </p>
  <p id="p03237" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">64. Choi J, Rees HD, Weintraub ST, et al. (2005) Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Bio. Chem.; 280(12): 11648-11655.</span>64. Choi J, Rees HD, Weintraub ST, et al. (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Bio. Chem .; 280 (12): 11648-11655.</span>
  </p>
  <p id="p03238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65. Janus, C. et al. (2000) Nature 408:979-982.</span>65. Janus, C. et al. (2000) Nature 408: 979-982.</span>
  </p>
  <p id="p03239" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">66. Janus, C. (2000) Neurobiology of Aging 21: 541-549.</span>66. Janus, C. (2000) Neurobiology of Aging 21: 541-549.</span>
  </p>
  <p id="p03240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">67. Gass, P. et al. (1998) Learn Mem. 5:274-288.</span>67. Gass, P. et al. (1998) Learn Mem. 5: 274-288.</span>
  </p>
  <p id="p03241" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">68. Wehner, J. M. (1990) Brain Research 523: 181-187).</span>68. Wehner, J. M. (1990) Brain Research 523: 181-187).</span>
  </p>
  <p id="p03242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">69. Masliah, E. et al. (2000) Science 287:1265-1269.</span>69. Masliah, E. et al. (2000) Science 287: 1265-1269.</span>
  </p>
  <p id="p03243" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03245" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03247" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03249" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03251" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03254" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03256" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">70. Masliah, E. et al. (2005) Neuron 46:857-868.</span>70. Masliah, E. et al. (2005) Neuron 46: 857-868.</span>
  </p>
  <p id="p03257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">71. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-9 (2003).</span>71. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-9 (2003).</span>
  </p>
  <p id="p03258" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">72. Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047-51 (1993).</span>72. Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261, 1047-51 (1993).</span>
  </p>
  <p id="p03259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">73. Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Schler Other Motor Neuron Disord. Supl1:S37-41 (2001).</span>73. Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Schler Other Motor Neuron Disord. Suppl1: S37-41 (2001).</span>
  </p>
  <p id="p03260" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">74. Trojanowski et al 2000 Ann NY Acad Sci 924:62-7.</span>74. Trojanowski et al 2000 Ann NY Acad Sci 924: 62-7.</span>
  </p>
  <p id="p03261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">75. Calne et al 1989; Can J Neurol Sci 16:547-50.</span>75. Calne et al 1989; Can J Neurol Sci 16: 547-50.</span>
  </p>
  <p id="p03262" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">76. Shaw et al., 2002. Cell Mol Bioll 48:127-36.</span>76. Shaw et al., 2002. Cell Mol Bioll 48: 127-36.</span>
  </p>
  <p id="p03263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">77. Olivieri et al 2001. J Neurochem 76:224-33.</span>77. Olivieri et al 2001. J Neurochem 76: 224-33.</span>
  </p>
  <p id="p03264" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">78. Shimohama et al 1999. Rinsho Shinkeigaku 39:4-6.</span>78. Shimohama et al 1999. Rinsho Shinkeigaku 39: 4-6.</span>
  </p>
  <p id="p03265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">79. Keller et al 1998. Rev Neurosci 9:105-16.</span>79. Keller et al 1998. Rev Neurosci 9: 105-16.</span>
  </p>
  <p id="p03266" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">80. Simonian et al 1996. Annu Rev Pharmacol Toxicol 36:83-106.</span>80. Simonian et al 1996. Annu Rev Pharmacol Toxicol 36: 83-106.</span>
  </p>
  <p id="p03267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">81. Imam et al 2001. Ann NY Acad Sci 939:366-80).</span>81. Imam et al 2001. Ann NY Acad Sci 939: 366-80).</span>
  </p>
  <p id="p03268" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">82. Lazoura, E y Apostolopoulos, V. Rational Peptide-based vaccine design for cancer immunotherapeutic applications Curr Med Chem. (2005) 12:629-39.</span>82. Lazoura, E and Apostolopoulos, V. Rational Peptide-based vaccine design for cancer immunotherapeutic applications Curr Med Chem. (2005) 12: 629-39.</span>
  </p>
  <p id="p03269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">83. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for b- amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 91: 3270-3274 (1994).</span>83. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for b-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 91: 3270-3274 (1994).</span>
  </p>
  <p id="p03270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">84. Elam JS, Taylor AB, Strange R, Antonyuk S, Doucette PA, Rodriguez JA, Hasnain SS, Hayward LJ, Valentine JS, Yeates TO, Hart PJ Nat Struct Biol (2003) 10:461-7.</span>84. Elam JS, Taylor AB, Strange R, Antonyuk S, Doucette PA, Rodriguez JA, Hasnain SS, Hayward LJ, Valentine JS, Yeates TO, Hart PJ Nat Struct Biol (2003) 10: 461-7.</span>
  </p>
  <p id="p03271" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">85. Kolaskar, AS y Tongaonkar PC, FEBS Lett. (1990) 276:172-4 LISTADO DE SECUENCIAS</span>85. Kolaskar, AS and Tongaonkar PC, FEBS Lett. (1990) 276: 172-4 LIST OF SEQUENCES</span>
  </p>
  <p id="p03272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;110&gt; Amorfix Life Sciences Ltd University Health Network</span>&lt;110&gt; Amorfix Life Sciences Ltd University Health Network</span>
  </p>
  <p id="p03273" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;120&gt; Metodos y Composiciones para Tratar y Detectar Enfermedades Mediadas por SOD1 Mal Plegada</span>&lt;120&gt; Methods and Compositions for Treating and Detecting SOD1-mediated Diseases Misfolded</span>
  </p>
  <p id="p03274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;130&gt; 1.10.98336/04</span>&lt;130&gt; 1.10.98336 / 04</span>
  </p>
  <p id="p03275" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;150&gt; US 60/798.727 &lt;151&gt; </span>&lt;150&gt; US 60 / 798,727 &lt;151&gt;</span>
  </p>
  <p id="p03276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;150&gt; US 60/798.728 &lt;151&gt; </span>&lt;150&gt; US 60 / 798,728 &lt;151&gt;</span>
  </p>
  <p id="p03277" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;150&gt; US 60/778.379 &lt;151&gt; </span>&lt;150&gt; US 60 / 778,379 &lt;151&gt;</span>
  </p>
  <p id="p03278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;150&gt; US 11/367.609 &lt;151&gt; </span>&lt;150&gt; US 11 / 367,609 &lt;151&gt;</span>
  </p>
  <p id="p03279" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;150&gt; US 11/565.967 &lt;151&gt; </span>&lt;150&gt; US 11 / 565,967 &lt;151&gt;</span>
  </p>
  <p id="p03280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;160&gt; 31</span>&lt;160&gt; 31</span>
  </p>
  <p id="p03281" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;170&gt; PatentIn version 3.3</span>&lt;170&gt; PatentIn version 3.3</span>
  </p>
  <p id="p03282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03283" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03285" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 1 &lt;211&gt;9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 1 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 1</span>&lt;400&gt; 1</span>
  </p>
  <p id="p03287" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Arg Leu Ala Cys Gly val lie Gly lie 1 5</span>Arg Leu Ala Cys Gly val lie Gly lie 1 5</span>
  </p>
  <p id="p03288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;2 &lt;211 &gt; 18 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 2 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03289" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt;2</span>&lt;400&gt; 2</span>
  </p>
  <p id="p03290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala 15 10 15</span>Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala 15 10 15</span>
  </p>
  <p id="p03291" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gly Ser</span>Gly Ser</span>
  </p>
  <p id="p03292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;3</span>&lt;210&gt; 3</span>
  </p>
  <p id="p03293" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20 &lt;211&gt; 14</span>20 &lt;211&gt; 14</span>
  </p>
  <p id="p03294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03295" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt;3 25</span>&lt;400&gt; 3 25</span>
  </p>
  <p id="p03296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Asn Pro Leu ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu 15 10</span>Asn Pro Leu ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu 15 10</span>
  </p>
  <p id="p03297" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;4 &lt;211&gt;7</span>&lt;210&gt; 4 &lt;211&gt; 7</span>
  </p>
  <p id="p03298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30 &lt;212&gt; PRT</span>30 &lt;212&gt; PRT</span>
  </p>
  <p id="p03299" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;213&gt; Homo sapiens</span>&lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 4</span>&lt;400&gt; 4</span>
  </p>
  <p id="p03301" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;5 &lt;211&gt; 11 &lt;212&gt; PRT</span>&lt;210&gt; 5 &lt;211&gt; 11 &lt;212&gt; PRT</span>
  </p>
  <p id="p03303" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40 &lt;213&gt; Homo sapiens</span>40 &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 5</span>&lt;400&gt; 5</span>
  </p>
  <p id="p03305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lys Ala Val Cys Val Leu Lys 1 5</span>Lys Wing Val Cys Val Leu Lys 1 5</span>
  </p>
  <p id="p03306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe 15 10</span>Lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe 15 10</span>
  </p>
  <p id="p03307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;6 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt; Homo sapiens 50</span>&lt;210&gt; 6 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt; Homo sapiens 50</span>
  </p>
  <p id="p03309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt;6</span>&lt;400&gt; 6</span>
  </p>
  <p id="p03310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03313" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03315" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03317" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03319" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03321" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">His Cys lie lie Gly Arg Thr Leu Val Val His 15 10</span>His Cys lie lie Gly Arg Thr Leu Val Val His 15 10</span>
  </p>
  <p id="p03322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;7 &lt;211&gt;8 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 7 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03323" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 7</span>&lt;400&gt; 7</span>
  </p>
  <p id="p03324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gly Leu His Gly Phe His Val His 1 5</span>Gly Leu His Gly Phe His Val His 1 5</span>
  </p>
  <p id="p03325" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;8 &lt;211&gt;9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 8 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;220&gt;</span>&lt;220&gt;</span>
  </p>
  <p id="p03327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;221&gt; MISC_FEATURE &lt;222&gt; (4)..(4)</span>&lt;221&gt; MISC_FEATURE &lt;222&gt; (4) .. (4)</span>
  </p>
  <p id="p03328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;223&gt; Cistefna oxidada a acido cisteico &lt;400&gt;8</span>&lt;223&gt; Cysteic acid oxidized cysteine &lt;400&gt; 8</span>
  </p>
  <p id="p03329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Arg Leu Ala Cys Gly Val lie Gly lie 1 5</span>Arg Leu Ala Cys Gly Val lie Gly lie 1 5</span>
  </p>
  <p id="p03330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt;9 &lt;211&gt;7 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 9 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt;9</span>&lt;400&gt; 9</span>
  </p>
  <p id="p03332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ala Cys Gly Val lie Gly lie 1 5</span>Wing Cys Gly Val lie Gly lie 1 5</span>
  </p>
  <p id="p03333" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 10 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 10 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;220&gt;</span>&lt;220&gt;</span>
  </p>
  <p id="p03335" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;221&gt; MOD_RES &lt;222&gt; (1)..(1)</span>&lt;221&gt; MOD_RES &lt;222&gt; (1) .. (1)</span>
  </p>
  <p id="p03336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;223&gt; ACETILACION</span>&lt;223&gt; ACETILATION</span>
  </p>
  <p id="p03337" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 10</span>&lt;400&gt; 10</span>
  </p>
  <p id="p03338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gly Gly Arg Leu Ala Cys Gly Val lie Gly Gly Gly Lys Gly 15 10</span>Gly Gly Arg Leu Wing Cys Gly Val lie Gly Gly Gly Gly Lys Gly 15 10</span>
  </p>
  <p id="p03339" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 11 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 11 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 11</span>&lt;400&gt; 11</span>
  </p>
  <p id="p03341" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03342" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03343" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03344" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03345" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03347" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cys Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn 15 10 15</span>Cys Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn 15 10 15</span>
  </p>
  <p id="p03352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ala Gly Ser</span>Gly Ser wing</span>
  </p>
  <p id="p03353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 12 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 12 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 12</span>&lt;400&gt; 12</span>
  </p>
  <p id="p03355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cys Asn Pro Leu Ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu 15 10 15</span>Cys Asn Pro Leu Ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu 15 10 15</span>
  </p>
  <p id="p03356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 13 &lt;211&gt;7 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 13 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;220&gt;</span>&lt;220&gt;</span>
  </p>
  <p id="p03358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;221&gt; MISC_FEATURE &lt;222&gt; (2)..(2)</span>&lt;221&gt; MISC_FEATURE &lt;222&gt; (2) .. (2)</span>
  </p>
  <p id="p03359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;223&gt; Cistefna oxidada a acido cisteico &lt;400&gt; 13</span>&lt;223&gt; Cysteic acid oxidized cysteine &lt;400&gt; 13</span>
  </p>
  <p id="p03360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ala Cys Gly val lie Gly lie 1 5</span>Wing Cys Gly val lie Gly lie 1 5</span>
  </p>
  <p id="p03361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 14 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 14 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03362" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 14</span>&lt;400&gt; 14</span>
  </p>
  <p id="p03363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cys lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe 1 5 10</span>Cys lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe 1 5 10</span>
  </p>
  <p id="p03364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 15 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 15 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;220&gt;</span>&lt;220&gt;</span>
  </p>
  <p id="p03366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;221&gt; MISC_FEATURE &lt;222&gt; (8)..(8)</span>&lt;221&gt; MISC_FEATURE &lt;222&gt; (8) .. (8)</span>
  </p>
  <p id="p03367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;223&gt; Cistefna oxidada a acido cisteico &lt;400&gt; 15</span>&lt;223&gt; Cysteic acid oxidized cysteine &lt;400&gt; 15</span>
  </p>
  <p id="p03368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cys Gly Gly Gly Arg Leu Ala Cys Gly Val lie Gly lie Gly Ser Gly 15 10 15</span>Cys Gly Gly Gly Arg Leu Ala Cys Gly Val lie Gly lie Gly Ser Gly 15 10 15</span>
  </p>
  <p id="p03369" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 16 &lt;211&gt;9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 16 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gly Ser Gly Lys Ala Val Cys Leu Lys 1 5</span>Gly Ser Gly Lys Ala Val Cys Leu Lys 1 5</span>
  </p>
  <p id="p03374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 17 &lt;211 &gt; 154 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>&lt;210&gt; 17 &lt;211&gt; 154 &lt;212&gt; PRT &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 17</span>&lt;400&gt; 17</span>
  </p>
  <p id="p03376" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Met Ala Thr Lys Ala Val Cys Val Leu Lys Gly Asp Gly Pro Val Gin 15 10 15</span>Met Wing Thr Lys Wing Val Cys Val Leu Lys Gly Asp Gly Pro Val Gin 15 10 15</span>
  </p>
  <p id="p03377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gly lie lie Asn Phe Glu Gin Lys Glu Ser Asrt Gly Pro Val Lys Val 20 25 30</span>Gly lie lie Asn Phe Glu Gin Lys Glu Ser Asrt Gly Pro Val Lys Val 20 25 30</span>
  </p>
  <p id="p03378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Trp Gly Ser lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe His Val 35 40 45</span>Trp Gly Ser lie Lys Gly Leu Thr Glu Gly Leu His Gly Phe His Val 35 40 45</span>
  </p>
  <p id="p03379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">His Glu Phe Gly Asp Asn Thr Ala Gly Cys Thr Ser Ala Gly Pro His 50 55 60</span>His Glu Phe Gly Asp Asn Thr Ala Gly Cys Thr Ser Ala Gly Pro His 50 55 60</span>
  </p>
  <p id="p03380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Phe Asn Pro Leu ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu Arg 65 70 75 80</span>Phe Asn Pro Leu ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu Arg 65 70 75 80</span>
  </p>
  <p id="p03381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">His Val Gly Asp Leu Gly Asn Val Thr Ala Asp Lys Asp Gly Val Ala 85 90 95</span>His Val Gly Asp Leu Gly Asn Val Thr Ala Asp Lys Asp Gly Val Ala 85 90 95</span>
  </p>
  <p id="p03382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Asp Val Ser lie Glu Asp Ser Val lie Ser Leu Ser Gly Asp His Cys 100 105 110</span>Asp Val Ser lie Glu Asp Ser Val lie Ser Leu Ser Gly Asp His Cys 100 105 110</span>
  </p>
  <p id="p03383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">lie lie Gly Arg Thr Leu val val His Glu Lys Ala Asp Asp Leu Gly 115 120 125</span>lie lie Gly Arg Thr Leu val val His Glu Lys Wing Asp Asp Leu Gly 115 120 125</span>
  </p>
  <p id="p03384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala Gly Ser Arg 130 135 140</span>Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Wing Gly Ser Arg 130 135 140</span>
  </p>
  <p id="p03385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Leu Ala cys Gly val lie Gly lie Ala Gin 145 150</span>Leu Ala cys Gly val lie Gly lie Ala Gin 145 150</span>
  </p>
  <p id="p03386" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 18 &lt;211&gt; 981 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 18 &lt;211&gt; 981 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03387" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 18</span>&lt;400&gt; 18</span>
  </p>
  <p id="p03388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03389" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03391" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03393" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gtttggggcc </span>&nbsp;gtttggggcc</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> agagtgggcg  aggcgcggag  gtctggccta  taaagtagtc  gcggagacgg  60 </span>&nbsp;agagtgggcg aggcgcggag gtctggccta taaagtagtc gcggagacgg 60</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ggtgctggtt </span>&nbsp;ggtgctggtt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> tgcgtcgtag  tctcctgcag  cgtctggggt  ttccgttgca  gtceteggaa  120 </span>&nbsp;tgcgtcgtag tctcctgcag cgtctggggt ttccgttgca gtceteggaa 120</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ccaggacctc </span>&nbsp;ccaggacctc</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ggcgtggcct  agcgagttat  ggcgacgaag  gccgtgtgcg  tgctgaaggg  180 </span>&nbsp;ggcgtggcct agcgagttat ggcgacgaag gccgtgtgcg tgctgaaggg 180</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> cgacggccca </span>&nbsp;cgacggccca</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gtgcagggca  tcatcaattt  cgagcagaag  gaaagtaatg  gaccagtgaa  240 </span>&nbsp;gtgcagggca tcatcaattt cgagcagaag gaaagtaatg gaccagtgaa 240</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ggtgtgggga </span>&nbsp;ggtgtgggga</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> agcattaaag  gactgactga  aggcctgcat  ggattccatg  ttcatgagtt  300 </span>&nbsp;agcattaaag gactgactga aggcctgcat ggattccatg ttcatgagtt 300</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> tggagataat </span>&nbsp;tggagataat</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> acagcaggct  gtaccagtgc  aggtcctcac  tttaatcctc  tatccagaaa  360 </span>&nbsp;acagcaggct gtaccagtgc aggtcctcac tttaatcctc tatccagaaa 360</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> acacggtggg </span>&nbsp;acacggtggg</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ccaaaggatg  aagagaggca  tgttggagac  ttgggcaatg  tgactgctga  420 </span>&nbsp;ccaaaggatg aagagaggca tgttggagac ttgggcaatg tgactgctga 420</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> caaagatggt </span>&nbsp;caaagatggt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gtggccgatg  tgtctattga  agattctgtg  atctcactct  caggagacca  480 </span>&nbsp;gtggccgatg tgtctattga agattctgtg atctcactct caggagacca 480</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ttgcatcatt </span>&nbsp;ttgcatcatt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ggccgcacac  tggtggtcca  tgaaaaagca  gatgacttgg  gcaaaggtgg  540 </span>&nbsp;ggccgcacac tggtggtcca tgaaaaagca gatgacttgg gcaaaggtgg 540</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> aaatgaagaa </span>&nbsp;aaatgaagaa</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> agtacaaaga  caggaaacgc  tggaagtcgT  ttggcttgtg  gtgtaattgg  600 </span>&nbsp;agtacaaaga caggaaacgc tggaagtcgT ttggcttgtg gtgtaattgg 600</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gatcgcccaa </span>&nbsp;gatcgcccaa</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> taaacattcc  cttggatgta  gtctgaggcc  ccttaactca  tctgttatcc  660 </span>&nbsp;taaacattcc cttggatgta gtctgaggcc ccttaactca tctgttatcc 660</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> tgcragctgt </span>&nbsp;tgcragctgt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> agaaatgtat  cctgataaac  attaaacact  gtaatcttaa  aagtgtaatt  720 </span>&nbsp;agaaatgtat cctgataaac attaaacact gtaatcttaa aagtgtaatt 720</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gtgtgacttt </span>&nbsp;gtgtgacttt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ttcagagttg  ctttaaagta  cctgtagtga  gaaactgatt  tatgatcact  780 </span>&nbsp;ttcagagttg ctttaaagta cctgtagtga gaaactgatt tatgatcact 780</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> tggaagattt </span>&nbsp;tggaagattt</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> gtatagtttt  ataaaactca  gttaaaatgt  ctgtttcaat  gacctgtatt  840 </span>&nbsp;gtatagtttt ataaaactca gttaaaatgt ctgtttcaat gacctgtatt 840</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ttgccagact </span>&nbsp;ttgccagact</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> taaatcacag  atgggtatta  aacttgtcag  aatttctttg  tcattcaagc  900 </span>&nbsp;taaatcacag atgggtatta aacttgtcag aatttctttg tcattcaagc 900</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> ctgtgaataa </span>&nbsp;ctgtgaataa</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> aaaccctgta  tggcacttat  tatgaggcta  ttaaaagaat  ccaaattcaa  960 </span>&nbsp;aaaccctgta tggcacttat tatgaggcta ttaaaagaat ccaaattcaa 960</span>
      </dd>
    </dl>
  
  <p class="style-scope patent-text">
    </p> <dl class="style-scope patent-text">
      <dt class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> actaaaaaaa </span>&nbsp;actaaaaaaa</span>
      </dt>
      <dd class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> aaaaaaaaaa  a        981 </span>&nbsp;aaaaaaaaaa a 981</span>
      </dd>
    </dl>
  
  <p id="p03514" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 19 &lt;211&gt; 27 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 19 &lt;211&gt; 27 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03515" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 19</span>&lt;400&gt; 19</span>
  </p>
  <p id="p03516" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">agguuagcuu gugguguuau agguaua 27</span>agguuagcuu gugguguuau agguaua 27</span>
  </p>
  <p id="p03517" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 20 &lt;211&gt; 54 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 20 &lt;211&gt; 54 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03518" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 20</span>&lt;400&gt; 20</span>
  </p>
  <p id="p03519" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gauuuaggua aaggugguaa ugaagaaagu acuaaaacug guaaugcugg uagu 54</span>gauuuaggua aaggugguaa ugaagaaagu acuaaaacug guaaugcugg uagu 54</span>
  </p>
  <p id="p03520" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 21 &lt;211&gt; 42 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 21 &lt;211&gt; 42 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03521" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 21</span>&lt;400&gt; 21</span>
  </p>
  <p id="p03522" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aauccuuuaa gucguaaaca cggaggaccg aaggacgagg ag 42</span>aauccuuuaa gucguaaaca cggaggaccg aaggacgagg ag 42</span>
  </p>
  <p id="p03523" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 22 &lt;211&gt; 33 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 22 &lt;211&gt; 33 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03524" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 22</span>&lt;400&gt; 22</span>
  </p>
  <p id="p03525" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">auaaagggga aaacagaagg acuccacggc uuu 33</span>auaaagggga aaacagaagg acuccacggc uuu 33</span>
  </p>
  <p id="p03526" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 23 &lt;211&gt; 33 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 23 &lt;211&gt; 33 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03527" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
  </p>
  <p id="p03528" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
  </p>
  <p id="p03529" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
  </p>
  <p id="p03530" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
  </p>
  <p id="p03531" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
  </p>
  <p id="p03532" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
  </p>
  <p id="p03533" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
  </p>
  <p id="p03534" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
  </p>
  <p id="p03535" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
  </p>
  <p id="p03536" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
  </p>
  <p id="p03537" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
  </p>
  <p id="p03538" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
  </p>
  <p id="p03539" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
  </p>
  <p id="p03540" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 23</span>&lt;400&gt; 23</span>
  </p>
  <p id="p03541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cacuguauua uuggcaggac ccucguuguu cac 33</span>cacuguauua uuggcaggac ccucguuguu cac 33</span>
  </p>
  <p id="p03542" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 24 &lt;211&gt; 27 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 24 &lt;211&gt; 27 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03543" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 24</span>&lt;400&gt; 24</span>
  </p>
  <p id="p03544" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cguuuggcuu gugguguaau ugggauc</span>cguuuggcuu gugguguaau ugggauc</span>
  </p>
  <p id="p03545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 25 &lt;211&gt; 21 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 25 &lt;211&gt; 21 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03546" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27</span>27</span>
  </p>
  <p id="p03547" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 25</span>&lt;400&gt; 25</span>
  </p>
  <p id="p03548" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gcuuguggug uaauugggau c 21</span>gcuuguggug uaauugggau c 21</span>
  </p>
  <p id="p03549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 26 &lt;211&gt; 54 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 26 &lt;211&gt; 54 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03550" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 26</span>&lt;400&gt; 26</span>
  </p>
  <p id="p03551" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gacuugggca aagguggaaa ugaagaaagu acaaagacag gaaacgcugg aagu</span>gacuugggca aagguggaaa ugaagaaagu acaaagacag gaaacgcugg aagu</span>
  </p>
  <p id="p03552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 27 &lt;211&gt; 42 &lt;212&gt;ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 27 &lt;211&gt; 42 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03553" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 27</span>&lt;400&gt; 27</span>
  </p>
  <p id="p03554" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aauccucuau ccagaaaaca cggugggcca aaggaugaag ag</span>aauccucuau ccagaaaaca cggugggcca aaggaugaag ag</span>
  </p>
  <p id="p03555" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 28 &lt;211&gt; 21 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 28 &lt;211&gt; 21 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">42</span>42</span>
  </p>
  <p id="p03557" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 28</span>&lt;400&gt; 28</span>
  </p>
  <p id="p03558" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aaggccgugu gcgugcugaa g 21</span>aaggccgugu gcgugcugaa g 21</span>
  </p>
  <p id="p03559" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 29 &lt;211&gt; 33 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 29 &lt;211&gt; 33 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03560" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 29</span>&lt;400&gt; 29</span>
  </p>
  <p id="p03561" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">auuaaaggac ugacugaagg ccugcaugga uuc 33</span>auuaaaggac ugacugaagg ccugcaugga uuc 33</span>
  </p>
  <p id="p03562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 30 &lt;211&gt; 33 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 30 &lt;211&gt; 33 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03563" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 30</span>&lt;400&gt; 30</span>
  </p>
  <p id="p03564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cauugcauca uuggccgcac acuggugguc cau 33</span>cauugcauca uuggccgcac acuggugguc cau 33</span>
  </p>
  <p id="p03565" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;210&gt; 31 &lt;211&gt; 24 &lt;212&gt; ADN &lt;213&gt; Homo sapiens</span>&lt;210&gt; 31 &lt;211&gt; 24 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</span>
  </p>
  <p id="p03566" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&lt;400&gt; 31</span>&lt;400&gt; 31</span>
  </p>
  <p id="p03567" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ggccugcaug gauuccaugu ucau</span>ggccugcaug gauuccaugu ucau</span>
  </p>
  <p id="p03568" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">54</span>54</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(15)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM108423579" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5</span>5</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10</span>10</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15</span>fifteen</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20</span>twenty</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25</span>25</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30</span>30</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35</span>35</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40</span>40</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">45</span>Four. Five</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50</span>fifty</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">55</span>55</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">60</span>60</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">65</span>65</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composicion adecuada para tratar la esclerosis lateral amiotrofica (ALS), comprendiendo dicha composicion un vehfculo farmaceuticamente aceptable y un agente seleccionado de:</span>1. A composition suitable for treating amyotrophic lateral sclerosis (ALS), said composition comprising a pharmaceutically acceptable carrier and an agent selected from:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) un anticuerpo exogeno o un fragmento del mismo que se une selectivamente a un epftopo que consiste en:</span>(1) an exogenous antibody or a fragment thereof that selectively binds to an epftope consisting of:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(a) IKGLTEGLHGF [DSE5];</span>(a) IKGLTEGLHGF [DSE5];</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) GLHGFHVH [DSE7]; o</span>(b) GLHGFHVH [DSE7]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(c) un analogo que consiste en IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7], comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion; y</span>(c) an analogue consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration; Y</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) un inmunogeno que comprende un peptido de menos de 20 restos de SOD1 que comprende:</span>(2) an immunogen comprising a peptide of less than 20 residues of SOD1 comprising:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) IKGLTEGLHGF [DSE5]; o</span>a) IKGLTEGLHGF [DSE5]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) GLHGFHVH [DSE7]; o</span>b) GLHGFHVH [DSE7]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">c) un analogo de a) o b), comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion.</span>c) an analog of a) or b), the analog comprising a modification of an amino acid by oxidation or nitration.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. La composicion de acuerdo con la reivindicacion 1, en la que el agente es un anticuerpo monoclonal, policlonal, quimerico o humanizado.</span>2. The composition according to claim 1, wherein the agent is a monoclonal, polyclonal, chimeric or humanized antibody.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. La composicion de acuerdo con la reivindicacion 1, en la que el agente es dicho inmunogeno.</span>3. The composition according to claim 1, wherein the agent is said immunogen.</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Un anticuerpo aislado que se une selectivamente a un epftopo que consiste en:</span>4. An isolated antibody that selectively binds to an epftope consisting of:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7]; o</span>a) IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) un analogo que consiste en IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7], comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion.</span>b) an analogue consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. El anticuerpo de acuerdo con la reivindicacion 4, en el que el anticuerpo se produce por el hibridoma denominado 5C6 depositado con el numero de acceso 280207-01 en la International Depository Authority of Canada.</span>5. The antibody according to claim 4, wherein the antibody is produced by the hybridoma called 5C6 deposited with accession number 280207-01 in the International Depository Authority of Canada.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. Un inmunogeno que comprende un peptido de menos de 20 restos de SOD1 que comprende:</span>6. An immunogen comprising a peptide of less than 20 residues of SOD1 comprising:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7]; o</span>a) IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) un analogo que consiste en IKGLTEGLHGF [DSE5] o GLHGFHVH [DSE7], comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion.</span>b) an analogue consisting of IKGLTEGLHGF [DSE5] or GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. El inmunogeno de la reivindicacion 6, o la composicion de la reivindicacion 1 o de la reivindicacion 3, en el que dicho inmunogeno comprende adicionalmente una molecula que potencia la inmunogenicidad preferiblemente en el que la molecula es hemocianina de lapa californiana.</span>7. The immunogen of claim 6, or the composition of claim 1 or claim 3, wherein said immunogen further comprises a molecule that potentiates the immunogenicity preferably wherein the molecule is hemocyanin of California limpet.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composicion, el anticuerpo aislado o el inmunogeno de acuerdo con una cualquiera de las reivindicaciones 1 a 7, en la que el epftopo o peptido consiste en:</span>8. The composition, the isolated antibody or the immunogen according to any one of claims 1 to 7, wherein the epftope or peptide consists of:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) IKGLTEGLHGF [DSE5]; o</span>a) IKGLTEGLHGF [DSE5]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) un analogo que consiste en IKGLTEGLHGF [DSE5], comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion.</span>b) an analogue consisting of IKGLTEGLHGF [DSE5], the analog comprising a modification of an amino acid by oxidation or nitration.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composicion, el anticuerpo aislado o el inmunogeno de acuerdo con una cualquiera de las reivindicaciones 1 a 7, en la que dicho epftopo o peptido consiste en:</span>9. The composition, the isolated antibody or the immunogen according to any one of claims 1 to 7, wherein said epitope or peptide consists of:</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">a) GLHGFHVH [DSE7]; o</span>a) GLHGFHVH [DSE7]; or</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">b) un analogo que consiste en GLHGFHVH [DSE7], comprendiendo el analogo una modificacion de un aminoacido por oxidacion o nitracion.</span>b) an analogue consisting of GLHGFHVH [DSE7], the analog comprising a modification of an amino acid by oxidation or nitration.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composicion, el anticuerpo aislado o el inmunogeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, para su uso en el tratamiento de la esclerosis lateral amiotrofica (ALS).</span>10. The composition, the isolated antibody or the immunogen according to any one of claims 1 to 9, for use in the treatment of amyotrophic lateral sclerosis (ALS).</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composicion, el anticuerpo aislado o el inmunogeno para su uso de acuerdo con la reivindicacion 10, en la que la ALS es ALS familiar.</span>11. The composition, the isolated antibody or the immunogen for use according to claim 10, wherein the ALS is familiar ALS.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. La composicion, el anticuerpo aislado o el inmunogeno para su uso de acuerdo con la reivindicacion 10, en la que la ALS es ALS esporadica.</span>12. The composition, the isolated antibody or the immunogen for use according to claim 10, wherein the ALS is sporadic ALS.</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Un metodo para obtener un anticuerpo de acuerdo con la reivindicacion 5, que comprende cultivar dicho hibridoma y aislar dicho anticuerpo.</span>13. A method of obtaining an antibody according to claim 5, comprising culturing said hybridoma and isolating said antibody.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. El hibridoma denominado 5C6 depositado con el numero de acceso 280207-01 en la International Depository 5 Authority of Canada.</span>14. The hybridoma named 5C6 deposited with access number 280207-01 in the International Depository 5 Authority of Canada.</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Un kit para diagnosticar a un sujeto que tiene esclerosis lateral amiotrofica (ALS), comprendiendo dicho kit un anticuerpo de una cualquiera de las reivindicaciones 4, 5, 8 o 9 e instrucciones para su uso.</span>15. A kit for diagnosing a subject having amyotrophic lateral sclerosis (ALS), said kit comprising an antibody of any one of claims 4, 5, 8 or 9 and instructions for its use.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070003977A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070003977A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-20</span>
                    <span class="td style-scope patent-result">2007-01-04</span>
                    <span class="td style-scope patent-result">Amorfix Life Sciences Ltd</span>
                    <span class="td style-scope patent-result">Epitope protection assay and method for detecting protein conformations 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20230051522A/en"><a id="link" href="#" class="style-scope state-modifier">KR20230051522A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-08-18</span>
                    <span class="td style-scope patent-result">2023-04-18</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">
  Testing method for mild cognitive impairment, test reagent for mild cognitive impairment, and screening method for drug candidates for mild cognitive impairment
 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2495327B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2495327B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-09-28</span>
                    <span class="td style-scope patent-result">Methods and compositions to treat and detect misfolded-SOD1 mediated diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7887803B2/en"><a id="link" href="#" class="style-scope state-modifier">US7887803B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-02-15</span>
                    <span class="td style-scope patent-result">Methods and compositions to treat misfolded-SOD1 mediated diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6518727B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6518727B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-05-22</span>
                    <span class="td style-scope patent-result">
  Method of immunologically targeting pathological tau protein
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11905318B2/en"><a id="link" href="#" class="style-scope state-modifier">US11905318B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-02-20</span>
                    <span class="td style-scope patent-result">Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210154315A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210154315A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-05-27</span>
                    <span class="td style-scope patent-result">N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112013008765B1/en"><a id="link" href="#" class="style-scope state-modifier">BR112013008765B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-07-12</span>
                    <span class="td style-scope patent-result">
  ISOLATED HUMAN ANTI-TAU MONOCLONAL ANTIBODIES OR A TAU-BINDING FRAGMENT THEREOF, METHODS OF PREPARATION THEREOF, POLYNUCLEOTIDE OR POLYNUCLEOTIDES, VECTOR OR VECTORS, COMPOSITION, IN VITRO METHOD OF DIAGNOSIS OR MONITORING THE PROGRESSION OF A NEURODEHUMANINATIVE TAUOPATHY , IN VITRO METHOD TO DIAGNOSE A NEURODEGENERATIVE TAUOPATHY IN A HUMAN INDIVIDUAL, AND USEFUL KIT FOR THE DIAGNOSIS OF A NEURODEGENERATIVE TAUOPATHY
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PT2252633E/en"><a id="link" href="#" class="style-scope state-modifier">PT2252633E</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-19</span>
                    <span class="td style-scope patent-result">Anti-trka antibodies and derivatives thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112020001970A2/en"><a id="link" href="#" class="style-scope state-modifier">BR112020001970A2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-08-04</span>
                    <span class="td style-scope patent-result">
  antibody that binds to the active alpha-synuclein
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20160113208A/en"><a id="link" href="#" class="style-scope state-modifier">KR20160113208A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-09-28</span>
                    <span class="td style-scope patent-result">Anti-transthyretin human antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2608002T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2608002T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-04-05</span>
                    <span class="td style-scope patent-result">
  Methods and compositions for treating and detecting SOD1 mediated diseases misfolded
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2625606T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2625606T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-07-20</span>
                    <span class="td style-scope patent-result">
  Prevention and treatment of synucleinopathy and amyloid disease
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (10)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US77837906P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-03-03</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7439324B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/367,609</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-03-03</span>
                    <span class="td style-scope patent-result">ALS-specific peptide composition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US778379P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-03-03</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US367609<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-03-03</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US79872706P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-05-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US79872806P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-05-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US798727P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-05-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US798728P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-05-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US565967<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-12-01</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7794692B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/565,967</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-12-01</span>
                    <span class="td style-scope patent-result">Methods and compositions for detecting amyotrophic lateral sclerosis 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3175347975" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3175347975" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=1136302703" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>